Preparation and Characterisation of Floating

Tablets to Target the Stomach by Rahim, Safwan Abdel
Rahim, Safwan Abdel (2018) Preparation and Characterisation of Floating Tablets 
to Target the Stomach. Doctoral thesis, University of Sunderland. 
Downloaded from: http://sure.sunderland.ac.uk/id/eprint/9233/
Usage guidelines
Please   refer   to   the  usage guidelines  at  http://sure.sunderland.ac.uk/policies.html  or  alternatively 
contact sure@sunderland.ac.uk.
  
Title 
 
 
 
 
 
Preparation and Characterisation of 
Floating Tablets to Target the Stomach 
 
 
 
 
 
 
 
 
 
Safwan Abdel Rahim 
 
 
 
 
 
 
 
PhD March 2018 
 
 II 
 
1 Abstract of Research 
 
Gastroretentive drug delivery systems might enhance bioavailability of some drugs 
formulated in sustained release dosage forms by providing a longer residence time 
in the stomach. The aim of this study was to develop and evaluate a swellable 
floatable gastroretentive drug delivery system utilizing an effervescent mechanism. 
Tablets were based on a binary (1:1) mixture of hydroxyethyl cellulose and sodium 
alginate gel forming polymers, with sodium bicarbonate, calcium carbonate or 
sodium carbonate gas generating agent. The variables affecting drug release and 
floating properties were investigated, such as tablet crushing strength, wet 
granulation (to compare the effects of powders versus those of granules), type and 
ratio of the gas forming agent. The possible interactions between model drug and 
excipients were analysed using differential scanning calorimetry and Fourier 
transform infrared spectroscopy. The drug release characteristics, floating capacity 
and swelling behaviours of drug-loaded matrix tablets were evaluated in 0.1 M HCl 
(pH 1.2) at 37°C ± 0.5°C. Release data were analysed by fitting the power law 
model of Korsmeyer–Peppas, which describes the drug release from polymeric 
systems. The stability of all tablets (stored at 40±2°C and 80±5% RH for 3 months) 
prepared from a granular origin was evaluated for their apparent density, drug 
release rate, and floating capacity. It was found that most tablets prepared through 
wet granulation showed acceptable physical properties. The effect of the 
granulation process on the drug release rate from all formulations at different 
crushing strength levels revealed that the granulation process reduced drug 
release rate. Generally, increasing the tablets‘ crushing strength level of all 
formulations, either prepared from powder or granules, decreased their drug 
release rate. In addition, increasing the gassing agent concentration from 10% to 
20% (w/w) increased the drug release rates of formulations prepared originally 
from a powder mixture at all levels of crushing strength, especially in the case of 
sodium bicarbonate or calcium carbonate. For tablets prepared from granules, 
increasing calcium or sodium carbonate gassing agent increased the drug release 
rate. On the contrary, a decrease in drug release rate was noted when sodium 
bicarbonate level was increased. Generally, increasing the concentration of 
gassing agent decreased the floating lag time for tablets based on sodium 
bicarbonate or calcium carbonate and increased it for those with sodium 
carbonate. However, increasing tablet crushing strength increased the lag time of 
all tablets. Most tablets floated on the surface of the dissolution medium and 
showed an adequate floating lag time (< 30 min) and floated for more than 8 
hours. Tablets containing the model drug pentoxifylline showed better stability 
results in comparison to those of cefalexin monohydrate in either closed or open 
containers. Pentoxifylline tablets manufactured with 20% (w/w) calcium carbonate 
were promising with respect to their floating lag time, floating duration, swelling 
ability, sustained drug release rate, and stability results. An in vivo investigation of 
these promising tablets against a reference solution of pentoxifylline was 
performed by oral administration of 5.75 ± 0.15 mg to rats. Compared with the 
reference solution, the maximum plasma concentration (Cmax) of the tablets 
decreased, while the time to reach this concentration (Tmax) and the t1/2 were 
prolonged. This study shows that a binary mixture of hydroxyethyl cellulose and 
sodium alginate, together with different gassing agents at variable levels, offers an 
exciting opportunity to develop sustained release preparations. 
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1 Chapter One: Introduction
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1.1 Overview 
 
Drug administration through oral route has been reported to be the most 
popular route of drug administration due to safety considerations, patient 
compliance, and flexibility of oral dosage forms design than most other dosage 
forms (Chen et al., 2010a, Gupta and Robinson, 1992). Tablets and capsules are 
the most common marketed oral dosage forms; still, tablets are more widely 
marketed because of patient swallowing convenience, ease of handling, and lower 
manufacturing cost (Ilić et al., 2013). Oral controlled release formulations that are 
able to deliver the drug locally or systemically at predetermined rates for a 
specified period of time have become an integral part of research centers and 
pharmaceutical industry due to their many benefits over conventional dosage 
forms. Such systems can reduce the frequency of dosing which suites patients 
with chronic illnesses and improve their compliance. Also, they can reduce side 
effects due to better control of therapeutic drug concentrations. However, the 
development costs required for some controlled release formulations may be 
expensive, and they should not be crushed or chewed as loss of drug release 
control as well as toxicity may be achieved (Nokhodchi et al., 2012). Despite the 
oral route advantages, it has its own challenges on the controlled drug delivery 
systems. Food and gastric physiological conditions such as transit time, motility, 
ions, pH and enzymes can influence bioavailability of drug loaded in oral controlled 
release systems (Singh et al. 1968; Drewe et al., 1992; Abrahamsson et al. 2004). 
One of the major obstacles is when drugs show variability in absorption throughout 
the gastrointestinal tract (GIT). This can decrease bioavailability as drugs are not 
being fully absorbed once passed the limited area of absorption. Some drugs 
show region specific absorption (absorption window), most commonly from the 
upper part of the small intestine (Harder et al., 1990; Rouge et al., 1996).  
Most drug molecules are absorbed as un-ionized forms by passive diffusion 
but solubility and stability of the drug molecule are of critical value for successful 
biological membrane crossing. Yet, drug molecules experience a wide pH range  
as they pass through the gastrointestinal tract (GIT) which can influence their 
extent of ionization, solubility, and stability. This can lead to variable absorption or 
an absorption window.  
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Polar drug molecules (e.g. cimetidine) generally have good absorption from 
the proximal small intestine, but have poor absorption from the large intestine or 
colon part of the gastrointestinal tract (Adkin et al. 1995; Corrigan, 1997). 
Furthermore, some drugs are substrates of certain enzymes present in a particular 
part of the gastrointestinal tract which can lead to regional variability in these drugs 
absorption (Chungi et al., 1979). Intestinal metabolic enzymes, cytochrome P450 
(CYP3A), are largely present in the intestinal epithelium with levels rising slightly 
from the duodenum to the jejunum and then declining in the ileum and colon. 
Drugs that are substrates of CYP3A enzyme display regional variability in their 
absorption due to the non-uniform enzyme distribution along the gastrointestinal 
tract. Similarly, drugs which depend on certain systems of facilitated transport 
process like carriers and pump systems show higher regional specificity because 
of the dominance of these systems in only certain parts of the gastrointestinal tract 
(Ritschel and Kearns, 1999). For example, angiotensin enzyme inhibitors and β-
lactam antibiotics (e.g. cephalexin) depend on peptide transporters located in the 
small intestine (Zhang et al., 2010).  
Carriers, such as P-glycoprotien, are involved in the secretion of organic 
molecules from the blood back into the intestinal lumen which may affect drug 
absorption (Benet and Cummins, 2001). P-glycoprotien which is located on the 
mucosal surface of intestinal epithelial cells is responsible for low and variable 
bioavailability of various compounds such as propranolol and felodipine 
(Siegmund et al., 2003). Thus drugs with site-specific absorption window are 
difficult to be designed as oral controlled drug delivery systems because time 
available for drug absorption will be limited and after crossing the absorption 
window, the drug will have negligible or no absorption. Accordingly, it has been a 
challenge to develop desirable oral sustained release dosage forms maintained at 
the targeted area inside gastrointestinal tract (GIT). Gastroretentive drug delivery 
systems provide dosage forms with longer residence time in the stomach and 
sustained release behaviour which can improve bioavailability as well as acting 
locally on the stomach (Kagan et al., 2006; Murphy et al., 2009).  
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Many drugs are considered good candidates to be benefit from 
gastroretentive delivery systems. Such drugs include those that a) have narrow 
absorption window such as acyclovir (Bhosale et al., 2012; Ruiz-Caro et al., 2012), 
atenolol (Rouge et al., 1998; Lal and Datta, 2015), furosemide (Klausner et al., 
2003a; Meka et al., 2009), levodopa (Klausner et al., 2003b; Ngwuluka et al., 
2013), metformin (Ali et al., 2007; Ige and Gattani, 2012), metoprolol (Malode et 
al., 2015; Biswas and Sahoo, 2016), and riboflavin (Hamdani et al., 2006; Gröning 
et al., 2007); b) show low solubility within the alkaline environment of the intestine 
such as ofloxacin (Chavanpatil et al., 2006; Qi et al., 2015) verapamil (Dürig and 
Fassihi, 2000; Sawicki, 2002), and diazepam (Sungthongjeen et al., 2008); c) 
unstable in the colonic environment such as captopril (Gröning et al., 2007; 
Jiménez-Martínez et al., 2008); and d) indicate local activity in eradication of the 
stomach Helicobacter pylori such as amoxicillin (Rajinikanth et al., 2007; Badhan 
et al., 2009) and metronidazole (Ishak et al., 2007; Loh and Elkordy, 2015). 
Nevertheless, drugs that have adverse effects on the gastric mucosal lining, are 
unstable in the acidic conditions of the stomach, or are absorbed equally 
throughout the entire GIT are not suitable for use as in gastroretentive delivery 
systems. 
 
1.2 Gastric anatomy and physiology 
1.2.1 Stomach  
 
The stomach is positioned in the left upper part of the abdominal cavity 
immediately under the diaphragm. The stomach size following a meal can swell up 
to 1500 ml; but after emptying food a collapsed state can be obtained with resting 
volume of 25–50 ml (Waugh and Grant, 2001). Anatomically, as shown in 
(Figure ‎1-1), the stomach is divided into four regions: fundus, body, antrum, and 
pylorus. The proximal part of the stomach (fundus) functions as a reservoir. It 
adjusts to the increased volume during eating by relaxation of the fundal muscle 
fiber which results in greater curvature. The proximal stomach controls the gastric 
emptying of liquids by applying basal pressure in the stomach due to slow and 
sustained contractions. Also, a steady pressure is also applied by fundus which 
gradually presses gastric solid contents towards the distal part of the stomach. 
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The distal part (antrum) has a thicker muscular wall to facilitate mechanical 
grinding and homogenisation of food, after which pumping the contents toward the 
pylorus to accomplish gastric emptying. The pylorus is a sphincter located 
between the antrum and the duodenum that functions as a mechanical stricture to 
the transit of large particles into the small intestine (Wilson and Washington, 
1989). The body of the stomach is lined with several types of cells that secrete up 
to 2-3 liters of gastric juice daily. For example, goblet cells secrete mucus, parietal 
(oxytntic) cells secrete acid and intrinsic factor, and peptic (chief) cells secrete the 
precursor of pepsin (pepsinogen) (Dressman et al., 1990). The stomach provides 
barrier to delivery, therefore, very little absorption occurs from this site (Wilson and 
Washington, 1989). More significant absorption occurs outside the stomach where 
the duodenum has epithelial surface with transporters for peptides (Ogihara et al., 
1999) and metals (Cousins and McMahon, 2000; Barley et al., 2001).  
 
 
 
 
Figure ‎1-1: The stomach parts (Wilson and Washington, 1989).  
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1.2.2 Gastric pH  
 
The gastric pH is variable between subjects as well as in the same subject 
where numerous factors such as food, disease, presence of gases, fatty acids, 
and other fermentation products can modify the pH value (Dressman et al., 1990; 
Talukder and Fassihi, 2004). According to food type the gastric pH can be 
increased from 1.8 (at resting time) to 3-5, but milk can raise it to over 6, however 
the pH returns to basal level within approximately 2 h after food ingestion is 
completed (Wilson and Washington, 1989). Age, pathological conditions and drugs 
may influence the gastric pH value. Holt et al. (1989) reported that 20% of elderly 
people show either diminished (hypochlorohydria) or no gastric acid secretion 
(achlorohydria) which elevates the basal pH value above 5.0. Furthermore, 
elevated gastric pH due to significant reduction in the gastric acid secretion was 
reported in some pathological conditions such as pernicious anemia and AIDS 
(Benn and Cooke, 1971; Varis et al., 1979). Drugs like proton pump inhibitors 
significantly reduce gastric acid secretion and elevate the gastric pH over 6.0 
(Laine et al., 2008). Outside the stomach, pH values tends to increase gradually 
due to the bicarbonate secreted by the pancreas and the duodenal mucosa where 
the proximal duodenum pH may rise as high as 4 pH units from the stomach 
(Benn and Cooke, 1971). It is important to take in consideration the gastric pH in 
selecting a drug substance and excipients for designing oral drug delivery 
systems. Nevertheless, the gastric emptying time corresponding to the fast and 
fed states has an enormous influence on the proposed efficacy of such dosage 
forms.  
 
1.2.3 Gastric motility and emptying rate  
 
Gastric emptying occurs during both fasting and fed states, yet, there are 
marked differences between the patterns of motility of both states. During the 
fasting state inter digestive series of electrical events occur, which cycle both 
through the stomach and the intestine every 2 to 3 h (Vantrappen et al., 1979; 
Pawar et al., 2011a). This is called inter digestive myloelectric cycle or migrating 
myloelectric cycle, which can be divided into the following four phases.  
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Phase-I or basal phase, lasts from 40 to 60 min with rare contractions. 
Phase-II or pre burst phase, lasts for 40 to 60 min with intermittent action potential 
and contractions. Phase-III or burst phase, is a short phase of intense (lasts for 4 
to 6 min), and characterized by large regular contractions with a frequency of 4–5 
per min (Rubinstein et al., 1988) and maximal pyloric opening (Ehrlein, 1988). It is 
known as ―house keeper wave‖, and due to that all the undigested material is 
swept out of the stomach down to the small intestine. Phase-IV lasts for 0 to 5 min 
and occurs between phases-III and I of two consecutive cycles.  
In the fed state, the gastric emptying rate is slowed since the onset of 
migrating myloelectric cycle is delayed (Wilson and Washington, 1989). The motor 
activity in the fed state is induced 5–10 min after ingestion of a food and continues 
as long as food remains in the stomach. It can last 2–6 h regarding amount of food 
ingested (Hasler, 1995). Feldman et al. (1984) reported that the time required for 
the stomach to be half emptied from liquid, digestible solid and indigestible solid 
phases (10 oz of soft drink, scrambled egg and radio-opaque markers) was 30 ± 7 
min, 154 ± 11 min and 3.5 ± 0.5 h respectively. Emptying of liquids from the 
stomach is based on slow contractions produced in the proximal stomach. 
However, larger particles require longer time to be milled into a suitable size to 
pass through the pylorus. After emptying digestible materials into the small 
intestine, residues of large undigested solids, which cannot pass through the 
pylorus, will be retro-pulsed from the pylorus and distal antrum to the proximal 
antrum and stomach body (Kelly et al., 1973; Ehrlein, 1980; Shalaby et al., 1992a) 
and will be kept in the stomach till they swept out by house keeper waves of the 
fasted pattern motility (Wilson and Washington, 1989).  
 
1.2.4 Factors influencing gastric emptying rate  
 
Several factors can influence the gastric emptying rate. For example meals 
with balanced content of fat, carbohydrate, and protein, the emptying process will 
depend on its nutritive density (Hunt and Stubbs, 1975). Nonetheless, meals with 
high acidity, osmolarity, calorific value are emptied later than the others (Hunt and 
Knox, 1972). Also, a prolongation in gastric emptying time after a succession of 
meals in comparison to that after a single meal has been reported (Iannuccelli et 
al., 1998a).  
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Fluids temperature and volume can also influence the gastric emptying time. 
Fluids at body temperature are emptied more rapidly in comparison with higher or 
lower temperature ones. Also, large volume fluids can leave the stomach more 
rapidly than smaller volumes (Wilson and Washington, 1989). Stress increases the 
gastric emptying rate, while depression slows it down. In general, women and 
elderly have a slower gastric emptying rate than men and young people 
respectively (Kaus and Fell, 1984; Reddy et al., 1999). Although, Ollerenshaw et 
al. (1987) reported that exercise and body posture may influence the gastric 
emptying, Mojaverian et al. (1988) had observed no significant effect of standing 
or flat on back positions on gastric residence time. Concomitant intake of some 
kinds of drugs acting as anticholinergic agents like atropine and propantheline, 
opiates like codeine and prokinetic agents like metoclopramide, cisapride can alter 
the gastric emptying rate (Kaus et al., 1984). Furthermore, Triantafyllou et al. 
(2007) reported a decrease in the gastric emptying rate of patients with type I and 
type II diabetes, however, a delay in the gastric emptying which may be frequently 
accompanied by constipation was reported in patients with Parkinson‘s disease 
(Krygowska-Wajs et al., 2009). 
 
1.2.5 Gastric emptying time of dosage forms  
 
Presence of food in the stomach can produce a significant effect on dosage 
forms emptying rate. Nonetheless it can increase, decrease, or delay drug 
absorption rate (Heading et al., 1973). For liquid dosage forms, it was reported 
that small volumes (10 to 20 ml) of such dosage forms were emptied from fasted 
volunteers‘ stomach within 1 h (Jenkins et al., 1983), however more than 2 h was 
required to empty them from stomach under fed condition (May et al., 1984). Large 
tablets and capsules are treated by the stomach as an indigestible materials either 
they are intact or in large fragments (Wilson and Washington, 1989). It was 
demonstrated that when non-disintegrating tablets taken before meals they were 
emptied from the stomach within highly variable time ranging from 5 min to 3 h 
depending on the inter digestive myloelectric cycle (Kaus et al., 1984); but when 
taken after meals, the emptying became around 2 to 3 h if the meal was light and 
up to 12 h if the subject was fed in regular intervals (Wilson et al., 1989).  
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In addition to the stomach state (fed or fast), size of the dosage form is 
another parameter that can influence the gastric emptying of non-disintegrating 
tablets. In the fasted state, the gastric emptying of large single unit dosage forms 
is changeable. It depends on the time of arrival in the stomach in relation to activity 
of inter digestive myloelectric cycle. Units larger than 1.9 cm, the pylorus mean 
diameter (Salessiotis, 1972), are retro pulsed in the antrum and several phases of 
myoelectric activity take place when the pyloric opening increases in size during 
the housekeeping wave and allows the sweeping of these solids (Park et al., 
1984). Under the fed state, the gastric waves are delayed and the gastric 
residence time can be significantly increased (Mojaverian et al., 1985). Studies 
revealed that the gastric residence time of tablets in the fed state can also be 
influenced by their size. Although, tablets larger than the pylorus, were retained in 
the stomach for as long as the digestive phase was maintained and emptied 
during the housekeeping waves (Davis et al., 1984), tablets with diameter less 
than 7 mm left the stomach during the digestive phase (Kinget et al., 1998). The 
dosage form density can also alter the gastric emptying rate. Dosage forms with 
densities less than that of the gastric fluids can float and can be kept away from 
the pylorus for a prolonged period of time as they can be protected from the 
peristaltic waves of the stomach.  
A study of effect of size of floating and non-floating capsules on the gastric 
residence time revealed that the floating units were more likely to be kept in the 
stomach compared with the non-floating units. Regarding body posture, the 
upright position enhanced the gastric retention of the low density capsules that 
floated on top of the gastric contents, however, the supine position increased the 
gastric retention time of the non-floating capsules (Timmermans and Möes, 1994). 
Multi-particulate systems or pellets contained in a hard gelatine capsule can also 
be used orally to control the drug release. It was demonstrated that the gastric 
emptying of pellets from fasted subjects was dependent on how quickly they can 
disperse in the small volume of the gastric fluid available in the stomach and they 
tended to empty as a series of boluses (Christensen et al., 1985; Hunter et al., 
1982). In fed conditions, Meyer et al. (1985) reported that spheres emptying rate 
was dependent on their size and density. The smaller the spheres the faster they 
emptied from the stomach.  
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Also, spheres with higher or lower density than that of the gastric fluid, 
tended to sink to the base of the stomach or to float on the gastric content 
respectively. Such spheres emptied more slowly in comparison with spheres of 
similar density to food. Generally, multiple-unit dosage forms such as, beads, 
pellets, and granules have a more predictable and reproducible gastrointestinal 
transit in comparison with single-unit modified-release formulations (Varum et al., 
2010). It is believed that gastric emptying is the major factor controlling the 
absorption of all materials ingested by oral route. As discussed earlier, many 
variables can influence the gastric pH, motility, and emptying rate including 
physiological state of the patient and design of the pharmaceutical dosage form 
which may affect drug bioavailability. Consequently, it is important to design a 
dosage form that can overcome physiological adversities like short residence 
times and unpredictable gastric emptying rates.  
 
1.3 Gastroretentive delivery systems 
 
Over the last three decades, numerous gastroretentive dosage forms have 
been designed and developed by pharmaceutical industry. Increasing gastric 
residence time can be achieved either by expandable systems, mucoadhesive 
systems, high-density systems, superporous hydrogels, magnetic systems, or 
floating systems. 
 
1.3.1 Expandable systems 
 
Such systems can show an increase in their volume and/or shape by 
swelling or unfolding to achieve longer gastric residence time. Swellable systems 
(Figure ‎1-2) are based on hydrophilic polymers such as hydroxypropylmethyl 
cellulose, polyethylene oxide and carbopol which increase in size after hydration 
with the gastric fluids. The swelling is usually results from osmotic absorption of 
water. Unfoldable systems (Figure ‎1-3) are based on biodegradable polymers that 
are folded and encapsulated in a carrier. In the stomach the system unfolds to its 
initial geometrical shape due to carrier degradation and become too large to pass 
through the pylorus (Gardner et al., 1986).   
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Figure ‎1-2: Schematic presentation of gastroretentive delivery systems (Alzaher et 
al., 2016) 
 
 
  
 
Figure ‎1-3: Schematic presentations of gastroretentive unfoldable systems 
(Gardner, 1986) 
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Generally, expandable systems should have convenient size to be easily 
swallowed by patients, and the resulted systems size inside the stomach should 
not be smaller than that of the pylorus. Nevertheless, during fasting, the 
expandable systems can sweep from the stomach by inter digestive myloelectric 
cycle unless they are extremely large in size. Accordingly, in order to prevent 
gastric obstruction either singly or by accumulation, biodegradable polymers 
should facilitate their easy elimination from the stomach at the end of the drug 
delivery process (Klausner et al., 2003c). Expandable systems were investigated 
by researchers. Regarding swellable systems, Mamajek and Moyer, (1980) 
evaluated a device composed of a drug reservoir surrounded by a swellable 
polymer and coated by an elastic outer polymeric permeable membrane to control 
drug release. Also, Urquhart and Theeuwes, (1984) designed and evaluated tiny 
pills coated by wax to control drug release and dispersed in a matrix of polymeric 
hydrogel. The system could swell up to 50-folds of its original size in body fluids. 
Shalaby et al. (1992b) evaluated enzyme-digestible hydrogels based on 
polyvinylpyrrolidone crosslinked with albumin. The system was successful to show 
gastric residence time in dogs more than 24 h under fasted conditions. Gröning et 
al. (2007) developed a drug-loaded collagen freeze-dried sponge which was 
pressed and coated with a thin layer of magnesium stearate to avoid contact with 
saliva. In the stomach, the tablet expanded to almost its original size. El-Zahaby et 
al. (2014) developed swellable tablets (plug-type) loaded with levofloxacin for 
Helicobacter pylori eradication. Tablets were based on in situ gel forming 
polymers, such as gellan gum, sodium alginate, pectin and xanthan gum cross 
linked calcium or aluminum chloride. Results showed that the drug release was 
dependent on nature of the matrix and type of the cross linker used to form the 
plug-type tablets.  
For unfoldable systems, different geometric forms were investigated. 
Caldwell et al. (1988a,b) developed and evaluated tetrahedron, ring and planar 
membrane of bio-erodible polymer enclosed within a capsule. Tetrahedron devices 
had longer gastric residence time than the other tested shapes of similar size. 
Sonobe et al. (1991) patented a ‗‗Y‘‘ shape system, with three erodible arms 
serving as a drug reservoir and whose rate of degradation controlled the gastric 
retention time.  
 13 
 
A spring unfoldable system was evaluated by Curatolo and Lo, (1995) with 
arms fixed by a gelatin band which could dissolve in the stomach, releasing the 
mechanically preferred extended form. Klausner et al. (2003b) developed a 
dosage form based on unfolding polymeric membranes loaded with levodopa. The 
gastroretentive dosage form was able to maintain the drug concentrations within 
the therapeutic level (> 500 ng/ml) over 9 h. Verma et al. (2014) developed and 
evaluated cinnarizine polymeric films of ethylcellulose and hydroxypropylmethyl 
cellulose containing different amounts of stearic acid that were folded into hard 
gelatin capsules. Authors revealed that in the first hour of the in vitro dissolution 
test, the drug had immediate release followed by a gradual release over 12 h. 
Mechanical property of the expanding systems is considered a vital parameter for 
their gastric retention. Although size of the expanding systems is important, 
systems lack high rigidity will not be retained in the stomach (Klausner et al., 
2003b). Moreover, the mechanical shape memory of the unfolding systems, is 
relatively short-lived (Klausner et al., 2003d), they are difficult to industrialize and 
may not be cost-effective (Hwang et al., 1998). 
 
1.3.2 Superporous hydrogels 
 
Superporous hydrogels (Figure ‎1-2) are based on cross-linked hydrophilic 
polymers with average pore size  > 100 μm in comparison with 10 nm to 10 μm 
pore size of conventional swellable systems. Consequently, they can rapidly 
absorb significant volume of aqueous fluids by capillary action to swell and create 
an open channel structure that can avoid premature gastric emptying by house 
keeper waves and increase the gastric residence time (Chavda et al., 2012). 
Superporous hydrogels can be classified according to their swelling and 
mechanical properties into three different generations. The first generation 
(conventional superporous hydrogels) has rapid and high swelling ratio but has 
mechanical fragility. Equilibrium swelling with this generation can be achieved in < 
1 min with an increase in system volume by more than 1000 times in some cases 
(Chen et al., 1999; Chen and Park, 2000a).  
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The second generation (superporous hydrogel composites) has quick and 
moderate swelling ratio (a few hundred times of the original volume) with superior 
mechanical properties (to withstand pressure by the gastric contraction) by adding 
a composite material such as croscarmellose sodium (Chen and Park, 2000b). 
Such systems showed gastric retention in fasted dogs for 2-3 h after which they 
broke into pieces and emptied into the intestine, however, they kept in the 
stomach for > 24 h when dogs were in the fed state (Chen et al., 2000). The 
promising third generation for gastroretention (hybrid superporous hydrogels) has 
a very high mechanical or elastic property. The hybrid superporous hydrogels are 
prepared by adding a hybrid agent such as polysaccharides including sodium 
alginate, pectin, chitosan or synthetic water-soluble hydrophilic polymers such as 
polyvinyl alcohol that can be cross-linked after formation of superporous hydrogel 
(Omidian et al., 2005). For example the synthesis of acrylamide-based 
superporous hydrogel in the presence of sodium alginate which could be cross-
linked by calcium ions. This formulation was able to stretch up to 2–3 times its 
original length showing resilience and a rubbery property in its fully water-swollen 
state (Omidian et al., 2006). Recently, El-Said et al. (2016) evaluated an extended 
release superporous hydrogel hybrid system using gellan gum, guar gum, 
polyvinyl alcohol and gelatin in dogs. Results revealed an increase in baclofen 
bioavailability and the effectiveness of the designed system. Generally, there is a 
lack of information in the literature about superporous systems. 
 
1.3.3 Mucoadhesive systems 
 
Mucoadhesive systems (Figure ‎1-2) are based on natural or synthetic 
mucoadhesive polymers such as poly(acrylic acid), chitosan, cholestyramide, 
tragacanth, sodium alginate, carrageenan, carbopol, sodium carboxymethyl 
cellulose, hydroxypropylmethyl cellulose, sephadex, sucralfate, polyethylene 
glycol, dextran, poly(alkyl cyanoacrylate), and poly-lactic acid that have ability to 
adhere to epithelial surface of the stomach to increase gastric residence time. 
Four different theories exist to explain the adhesion mechanism (Tao et al., 2009). 
First of all is the electronic theory, involving attractive electrostatic forces between 
the glycoprotein mucin network and the mucoadhesive polymers (Derjaguin et al., 
1977).  
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Secondly is the adsorption theory, where secondary forces such as Van der 
Waals forces and hydrogen bonding are responsible for mucoadhesion (Kinloch, 
1980). Thirdly is the wetting theory, as mucoadhesive polymers are able to spread 
and develop close contact with the mucus layers (Kaelbe, 1977). And finally, the 
diffusion theory, which based on a physical entanglement of mucin strands and the 
flexible polymer chain, or an interpenetration of mucin strands into the porous 
structure of the polymer substrate (Voyutskii, 1963).  However, the exact 
mechanism of mucoadhesion is not yet completely understood. Smart and 
Kellaway (1989) reported extended gastric retention time of dosage forms coated 
with carbomer polymer in mice. Akiyama and Nagahara (1999) evaluated 
mucoadhesive microspheres based on a mixture of amoxicillin and carbopol 934P 
which was dispersed within a matrix of polyglycerol esters of fatty acids. After oral 
administration, microspheres were able to adhere to the stomach mucosa in 
Mongolian gerbils and to show higher anti Helicobacter pylori activity in 
comparison with an amoxicillin suspension. Jackson et al. (2000) reported 
extended gastric residence times with ability to coat the gastric mucosa uniformly 
of the positively charged ion-exchange resin colestyramine.  
Hejazi and Amiji (2002) prepared chitosan microspheres loaded with 
tetracycline by ionic precipitation with sodium sulfate. The drug release from the 
microspheres showed dependency on the dissolution medium pH, where ∼ 70 and 
90% of the drug was released after 3 and 8 h at pH 3.5 and 5.0 respectively. Also, 
they investigated the gastric residence time of chitosan-based microspheres 
loaded with tetracycline gerbils (Hejazi and Amiji, 2003). The gastric residence 
time of the microspheres was independent of the gastric pH within the range of 1.0 
– 4.5, but, the drug concentration in the stomach was similar to that of an aqueous 
solution. Later, increased gastric residence time in fasted gerbil stomach was 
reported for chitosan-based microspheres prepared by ionic precipitation followed 
by chemical crosslinking with glyoxal and loaded with tetracycline in comparison 
with non-crosslinked microspheres and tetracycline solutions (Hejazi and Amiji, 
2004). After 2 h, 17% of the crosslinked microspheres remained in the fasted 
stomach, whereas only 10% of the non-crosslinked systems were retained. 
Sakkinen et al. (2003) reported that granules containing microcrystalline chitosan 
and furosemide exhibited slow release characteristic with higher AUC than that of 
the conventional dosage form due to their mucoadhesive properties.  
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Preda and Leucuta (2003) presented significant retardation of gastric 
emptying of a mucoadhesive system based on polyacrylic acid in gelatin 
microspheres in rats. Higo et al. (2004) presented promising mucoadhesive 
properties of tetracycline– sucralfate complex prepared under acidic conditions. 
Higher percentage of the complex was retained on the gastric mucosa in rats 
compared with the physical mixtures of tetracycline and sucralfate after 3 h. 
Schmitz et al. (2005) developed minitablets based on low molecular-weight 
heparin and thiolated polycarbophil was used as the mucoadhesive carrier 
material. Hydroxyethyl cellulose was used as a non-mucoadhesive control. In 
contrast to thiolated polycarbophil-based delivery systems, the control formulations 
were not observed in the gastric lumen of rats at 4 h after administration. Liu et al. 
(2005) developed a promising mucoadhesive microspheres loaded with amoxicillin 
for the treatment of Helicobacter pylori infection. Ethylcellulose was used as matrix 
to control the drug release and carbopol 934P as mucoadhesive polymer. Results 
showed that the system could retain in gastrointestinal tract for an extended period 
of time. Later Tao et al. (2009) evaluated acyclovir mucoadhesive microspheres 
based on similar composition in rats. Results showed prolonged residence time of 
microspheres in the gastrointestinal tract with relatively steady plasma drug 
concentrations within 8 h after oral administration.  
Zate et al. (2010) developed a mucoadhesive tablet loaded with venlafaxine 
hydrochloride using carbopol 971 P as the mucoadhesive agent and Eudragit® 
RS-PO and ethylcellulose as controlled release polymers. Results revealed that 
increasing the carbopol 971 P concentration increased the residence time up to 12 
h and more ethylcellulose retarded the drug release. Jha et al. (2011) 
demonstrated an increase in the absorption, bioavailability and sustained release 
of raloxifene hydrochloride from mucoadhesive microspheres based on 
cyclodextrin(s) and different proportions of carbopol and hydroxypropylmethyl 
cellulose. Pund et al. (2011) developed a biphasic mucoadhesive tablet to deliver 
loading and maintenance dose rifampicin. The tablet was retained in the stomach 
for more than 320 min. Mini-tablets of rosuvastatin calcium with mucoadhesive 
properties using pre-activated thiolated pectin derivative as a mucoadhesive agent 
were formulated (Hauptstein et al., 2013).  
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Results demonstrated improved mucoadhesion with sustained release of 
rosuvastatin calcium over 36 h for the designed system in comparison with mini-
tablets prepared with the pre-activated thiomer, the thiolated intermediate and 
unmodified pectin. Pandey et al. (2013) prepared a bilayer mucoadhesive rate 
controlling film of lercanidipine HCl using a combination of Eudragit® RSPO and 
RLPO, and a mucoadhesion film, combining various hydrophilic polymers. In vivo 
studies in rabbits showed that drug release was controlled for over 12 h, with 
enhanced bioavailability. Jelvehgari et al. (2014) designed multiple unit bilayer 
discs loaded with metformin using carbopol 934P as a mucoadhesive polymer and 
ethylcelullose as a drug retarding polymer. It was found that this system was 
successful to show good drug release properties. Sodium alginate, xanthan and 
karaya gum were used as mucoadhesive polymers to develop a mucoadhesive 
tablet of lafutidine (Patil and Talele, 2015). Results suggested an adequate drug 
release rate was provided with 10 h adhesion in the rabbit stomach.  
An advantage of mucoadhesive systems in the stomach is the short 
pathways due to the close contact with the gastric mucosa for drugs targeting the 
stomach, such as antibiotics against Helicobacter pylori. Although the concept of 
mucoadhesion gains increasing interest, only a few successful approaches to 
develop gastroretentive mucoadhesive systems have been reported. They are 
challenged by the stomach turnover, the mucus layer renewal, and the high 
stomach hydration that decreases the mucoadhesion of polymers (Kockisch et al., 
2003). Also, targeting the gastric mucus with mucoadhesive polymers is difficult 
because they can stick to various surfaces they come in contact with (Khosla and 
Davis, 1987). Regarding safety aspects, oesophageal binding might present a 
challenge for such devices (Wang et al., 2000).  
 
1.3.4 High density systems 
 
These systems (Figure ‎1-2) can sink to the bottom of the stomach (below 
the pylorus) as they have a density higher than that of the gastric fluid (> 1.004 
g/cm3) and tend to withstand the peristaltic movements of the stomach wall (Clarke 
et al., 1993; Bardonnet et al., 2006).  
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High density excipients such as iron powder, barium sulfate, titanium 
dioxide, and zinc oxide could be used to formulate high density systems 
(Devereux et al., 1990). Bechgaard and Ladefoged (1978) evaluated influence of 
density or diameter of pellets on the gastric transit time. An extension of 5.8-25 h 
of the gastric residence time depending more on the pellets density rather than on 
the pellets diameter was reported. Riner et al., (1982) and Cardinal (1985) 
presented promising results of high density systems in ruminants. Also, Devreux et 
al. (1990) reported that pellets with density of at least 1.5 g/cm3 have significantly 
higher gastric residence time either in fasted or fed conditions. Later, it was 
demonstrated that an increase in the gastric residence time of pellets could be 
achieved with density values range 2.4-2.8 g/cm3 (Clarke et al., 1995).  
Simoni et al. (1995) reported a better bioavailability of sinking enteric-
coated tablets loaded with ursodeoxycholic acid in comparison to floating enteric-
coated tablet and hard gelatine capsules in 12 healthy volunteers. Still, Davis et al. 
(1986) showed that in vivo data did not confirm the effectiveness of the high 
density systems in exdending the gastric residence time, as the stomach state at 
time of administration was the main determining factor. Gupta and Robinson 
(1995) reported that these devices did not extend significantly the gastric 
residence time. Furthermore, Rouge et al. (1998) evaluated effect of immediate 
release system, a high density system and a low density system gastric residence 
times. Results indicated that the high density system did not show any significant 
extension of the gastric residence time as results were 0.5, 1, and 2 h respectively. 
Till present, there is a lack in information about successful approach describing a 
gastroretentive device based only on high density.  
 
1.3.5 Magnetic systems 
 
These systems (Figure ‎1-2) are designed to increase the gastric residence 
time because of attractions between the pharmaceutical dosage which contains 
magnetically active elements and a magnet which is placed under the abdomen, 
near the stomach (Lopes et al., 2016). Primarily, magnetic granules were designed 
as a drug delivery system to oesophageal mucosa in oral administration (Ito et al., 
1990).  
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Fujimori et al. (1994) evaluated a magnetic tablet containing 50% w/w ultra-
ferrite with hydroxypropyl cellulose and cinnarizine in beagle dogs by the 
application of a magnetic field. The tablet was successful to remain in the stomach 
for 8 h with sustained drug release. Later, Fujimori et al. (1995) reported a delay 
for 3 h in the gastric emptying time of a bilayer magnetic tablet loaded with 
acetaminophen. Gröning and Berntgen (1996) incorporated a small magnet within 
a drug loaded capsule and guided it with an extracorporeal magnet attached to the 
abdomen. The gastric residence time of the device was effectively delayed. Later, 
Gröning et al. (1998) investigated acyclovir serum concentration after oral 
administration of magnetic depot tablets and the influence of extracorporeal 
magnet to control gastroretentive transit. The drug plasma concentrations showed 
an increase in acyclovir absorption with a gastric residence time of 12 h was 
obtained. Practically, the magnetic field can retain the dosage form and control its 
gastric residence time; however, the external magnet device could decrease the 
patient compliance (Hwang et al., 1998).   
 
1.3.6 Floating systems 
 
The floating drug delivery systems were early described in the literature as 
early as 1968 (Davis, 1968). These systems (Figure ‎1-2) are designed to have a 
bulk density lower than the gastric fluid (< 1.004 g/cm3) so they can remain 
buoyant for prolonged period of time without affecting the gastric emptying rate 
(Whitehead et al., 1998). One of the drawbacks of floating drug delivery systems is 
that they require an adequate level of fluids in the stomach for the system to float 
effectively, but, administration of a glass full of water (200–250 ml) can overcome 
such disadvantage (Pawar et al., 2011b). Floating drug delivery systems can be 
classified into non-effervescent systems or effervescent systems.  
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1.3.6.1 Non-effervescent floating systems 
 
Non-effervescent floating drug delivery systems are based mainly on gel 
forming or highly swellable cellulose type hydrocolloids, polysaccharides, and 
matrix forming polymers such as sodium alginate, polycarbonate, polyacrylate, 
polymethacrylate, and polystyrene. After oral administration, these systems will 
swell in the gastric fluid and maintain a relative stability of shape and a bulk 
density less than that of the gastric fluid. Accordingly, this will assist the floating 
process of these dosage forms, and slow drug release will be achieved by 
diffusion through the formed gel barrier (Sheth and Tossounian, 1984).  
Hydrodynamically Balanced System (HBSTM) is a single unit dosage form 
that was primarily developed by Sheth and Tossounian (1984) as non-effervescent 
floating systems. They are composed of one or more hydrophilic polymers (such 
as hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, 
sodium carboxymethyl cellulose, agar, carrageenan or alginic acid) in which the 
drug is embedded and the mixture is usually enclosed in a gelatin capsule 
(Figure ‎1-4). After administration, the capsule dissolves upon contact with the 
gastric fluid and the polymer (or polymeric mixture) swells to facilitate floating and 
to control the drug release by diffusion and erosion of the gel barrier (Sheth and 
Tossounian, 1984). The HBS maintains surface hydration and buoyancy due to 
continuous erosion of the surface which allows water penetration to the inner 
layers of the system (Reddy and Murthy, 2002). Low density HBS (Madopar ®) was 
developed by incorporation of fatty excipients to reduce water penetration and 
erosion of the system (Erni and Held, 1987; Jansen and Meerwaldtt, 1990). Later, 
a bilayer formulation was developed from swellable polymers and only one of them 
was loaded with misoprostol so that buoyancy and drug release could be 
optimized independently (Oth et al., 1992). Results demonstrated a mean gastric 
residence time > 3 h and > 10 h following a single meal and a succession of meals 
respectively.  
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Figure ‎1-4: Schematic presentation of Hydrodynamic Balanced System (Ushimaru 
et al., 1987) 
 
 
Krogel and Bodmeier (1999) designed a multifunctional drug delivery 
system based on a matrix of hydroxypropylmethyl cellulose loaded with drug and 
placed on both sides of an impermeable polymeric cylinder of polypropylene. The 
system was successful to achieve buoyancy due to the air entrapped in the core of 
the cylinder. Streubel et al. (2003) developed and evaluated floating controlled 
drug delivery systems based on low-density polypropylene foam powder, matrix-
forming polymer, drug and filler. Results showed that foam powder-containing 
tablets could float at least 8 h. Losi et al. (2006) designed a modular technology 
called Dome Matrix® which characterized by the presence of an empty chamber 
between the modules that assists the capacity of floatation. Later, Strusi et al. 
(2008) evaluated the device in healthy volunteers and presented capability of 
reaching up to 5 h of gastric residence time in humans. Hascicek et al. (2011) 
assumed flexibility of Dome Matrix® system as the shape of the module and its 
position in the assembled system could influence the floating and the drug release 
processes. Sauzet et al. (2009) designed and evaluated a low density floating 
tablets using a hydrophobic dusty powder excipient with stearic acid to control the 
drug release. The prepared tablets had a coherent porous structure with good 
ability to retard the drug release, in which the floating capacity was mainly due to 
the high porosity of the system.  
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  Non-effervescent floating multiunit dosage forms were also developed to 
increase gastric residence time. Watanabe et al. (1976) patented a bilayer floating 
coated shell, containing a hollow polystyrene sphere. Talukder and Fassihi (2001) 
developed a multiple unit system using Ca2+ and low methoxylated pectin, or Ca2+, 
low methoxylated pectin and sodium alginate. Drying was done either by air 
convection oven at 40 ˚C for 6 h or by freeze drying. Results showed that the 
freeze dried beads had hollow spaces inside them and were able to float > 12 h, 
while the air-dried beads sank. Also, the drug release was 100% and 50% in 10 h 
from the calcium–pectinate–alginate and the calcium–pectinate beads 
respectively. Calcium alginate beads loaded with riboflavin were successful to be 
considered as a potential gastroretentive dosage form (Stops et al., 2008). Singh 
et al. (2010) developed floating porous beads based on simultaneous ionotropic 
gelation of alginate and sterculia gum using calcium chloride as a cross-linker.  
Another possible approach for multiple unit systems is the use of an air 
compartment that can provide immediate floating process. Iannuccelli et al. 
1998a,b designed floating units composed of a calcium alginate core separated by 
an air compartment from a membrane of calcium alginate: polyvinyl alcohol. Li et 
al. (2014) designed novel gastro-floating multi-layer pellets consisted of a porous 
matrix core with entrapped air, a drug loaded layer (dipyridamole and 
hydroxypropylmethyl cellulose), a sub-coating layer (hydroxypropylmethyl 
cellulose), and a drug release retarding layer (Eudragit® NE 30D).  
 
1.3.6.2 Effervescent floating systems 
 
 Effervescent floating drug delivery systems are classified into raft-forming 
systems, volatile liquid containing systems and gas generating systems. The first 
type is a solution composed of an in situ gel forming polymer such as sodium 
alginate along with a gas forming agent such as carbonates or bicarbonates. It 
tends to form a viscous cohesive gel once swelled with entrapped carbon dioxide 
bubbles upon contact with gastric fluids. Raft-forming systems have a very low 
bulk density due to the entrapped carbon dioxide bubbles that enables them to 
float on the surface of the gastric contents for several hours (Prajapati et al., 
2013).  
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 Due to the ability of such systems to produce a layer over the gastric fluids, 
they are used to deliver antacid drugs such as aluminum hydroxide or calcium 
carbonate to to reduce gastric acidity and treat gastroesophageal reflux as with 
Liquid Gaviscon® and Almagate Flot-Coat® (Washington, 1990; Foldager et al., 
1991; Fabregas et al., 1994; Havelund et al., 1997). Hampson et al. (2010) 
evaluated in vitro and in vivo performance of Gaviscon double action liquid, in 
which calcium carbonate is the main antacid ingredient, in comparison with 
alginate/antacid suspensions. Results showed that the new double action 
formulation was as good as, or better than the other formulations.  Foster et al. 
(2013) developed an in situ gel forming system based on a mixture of 1% sodium 
alginate and 0.625% karaya gum in the presence of a calcium chelator which 
demonstrated a good in vitro / in vivo correlation. Recently, Abou Youssef et al. 
(2015) designed a floating raft system loaded with metronidazole using ion-
sensitive in situ gel forming polymers. Results demonstrated prolonged gastric 
residence time and good release rate of metronidazole. 
The second type of the effervescent floating drug delivery systems is the 
volatile liquid containing systems. They contain a chamber of volatile liquid such 
as ether or cyclopentane that converts into gas at body temperature causing 
inflation of the chamber in the stomach. The drug release control is achieved by an 
outer hydrophilic polymeric layer such as alginate and different types of 
hydroxypropylmethyl cellulose in which the drug is loaded (Sriamornsak et al., 
2007b; Baki et al., 2011). Kawashima et al. (1992) used an emulsion–solvent 
diffusion technique to prepare hollow microspheres of tranilast or ibuprofen. An 
emulsion (o/w) was prepared by adding a solution of drug and Eudragit® S in an 
ethanol/dichloromethane to an aqueous solution of polyvinyl alcohol. Evaporation 
of dichloromethane formed an internal cavity in the microspheres which floated for 
> 12 h on acidic dissolution media containing surfactant. Later, Thanoo et al. 
(1993) presented promising floating on simulated gastric and intestinal fluids of 
hollow polycarbonate microspheres loaded with aspirin, griseofulvin and p-nitro 
aniline, using a solvent evaporation method. Stithit et al. (1998) developed 
theophylline microspheres using a novel emulsion–solvent evaporation process. 
Dispersions of theophylline and polymeric mixture of cellulose acetate butyrate 
and Eudragit® RL 100 were pressurized under carbon dioxide.  
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Upon release of the pressure, bubbles of carbon dioxide generated 
microspheres with round cavities enclosed in the dispersed drug polymer droplets 
with > 24 h floating in pH 1.2 and 7.5 buffers. Streubel et al. (2002) designed 
verapamil HCl foam-based floating microparticles based on polypropylene foam 
powder, Eudragit® RS or polymethyl methacrylate polymers using the solvent 
evaporation method. Results showed in vitro floating for at least 8 h depending on 
the polymer type and initial drug loading of the system. The drug release rate was 
dependent on the type and amount of polymer used in the microspheres. Also, 
Sato et al. (2003) and Dube et al. (2014) prepared floating microballoons (or 
hollow microspheres) containing riboflavin and baclofen respectively. Under fed 
conditions, riboflavin excretion was sustained with the microballoons in 
comparison with other dosage forms (Sato et al., 2003). Moreover, Dube et al. 
(2014) showed that not less than 10 h gastric retention was obtained with baclofen 
floating microspheres. Oh et al. (2013) applied a new approach to improve 
bioavailability of metformin using camphor as a sublimation material and 
polyethylene oxide as a drug retarding agent in formulated floating gastroretentive 
tablets. Camphor sublimation at body temperature resulted in pores formation in 
the matrix that allows floating process.  
Regarding the third type of the effervescent floating drug delivery systems, 
gas generating systems, they are prepared with effervescent components such as 
sodium bicarbonate or calcium carbonate and swellable polymers such as 
methylcellulose, hydroxypropylmethyl cellulose or polysaccharides, such as 
chitosan. Due to the reaction of the carbonate gassing agent, present in these 
formulations, with the stomach gastric acid or with the co-formulated citric acid or 
tartaric acid in the presence of aqueous fluid, carbon dioxide gas is liberated. The 
gas bubbles are entrapped in the gel layer formed by hydrocolloids which causes 
an upward motion of the dosage form and maintains its buoyancy (Baumgartner et 
al., 2000). Involvement of carbonate gassing agents can provide an alkaline 
microenvironment for the polymer to initiate gel formation (Deshpande et al., 
1997). Moreover, the liberation of carbon dioxide can accelerate hydration of the 
polymer which is essential for formation of mucoadhesive hydrogel that can assist 
remaining of the dosage form inside the stomach (Asrani, 1994).  
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The gassing component can be mixed with the polymeric part in case of 
single layer tablets (Hashim and Li Wan Po, 1987; Strübing et al., 2008; Yin et al., 
2013), as well as capsules (Stockwell et al., 1986; Li et al., 2003; Moursy et al. 
2003; Ali et al., 2007). In bilayer tablets, one layer can be formulated for the drug 
release control and the other layer can contain a mixture of the gassing 
component and the polymeric material to promote floating (Ingani et al., 1987; 
Ozdemir et al. 2000; Wei et al., 2001). A special design of multiple unit 
effervescent floating pills was developed by Ichikawa et al. (1991). The system 
was based on pills for retarding p-amino benzoic acid release surrounded by 
double layers (Figure ‎1-5). The inner layer was for the gassing agent component 
containing both sodium bicarbonate and tartaric acid which were also separated 
by sub-layer to avoid direct contact between them. The outer layer was containing 
mainly polyvinyl acetate and purified shellac as swellable membrane layer to 
prevent escape of liberated gas bubbles and to control the drug release.  
Effervescent floating drug delivery systems were successfully prepared as 
multi-particulate or single unit dosage forms. Atyabi et al. (1996) developed 
floating beads using ion exchange resin loaded with sodium bicarbonate which 
were surrounded by a semipermeable membrane to avoid loss of liberated carbon 
dioxide gas. In vivo studies in twelve healthy volunteers of coated and uncoated 
beads showed that the gastric residence time was 24 h and 1-3 h respectively.  
 
 
 
 
 
Figure ‎1-5: Design of multiple unit oral effervescent floating system (Ichikawa et 
al., 1991)  
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Choi et al. (2002) evaluated effects of calcium carbonate and sodium 
bicarbonate as carbon dioxide gas forming agents on floating alginate beads. 
Authors revealed that the size, floating ability, pore structure, morphology, release 
rate, and mechanical strength of the floating beads were affected by type and 
amount of the gassing agent. Although calcium carbonate was less effective as a 
gas forming agent in comparison with sodium bicarbonate, it produced smaller but 
stronger floating beads with enhanced drug release control. Later, Amrutkar et al. 
(2012) developed zolpidem tartarate layered pellets coated with sodium 
bicarbonate effervescent layer and polymeric membrane of Eudragit® NE 30D. 
Results revealed that the floating ability and in vitro drug release of the pellets 
were dependent on amount of sodium bicarbonate and coating level of the 
polymeric membrane. The system showed complete floating within 5 min and 
maintained its floating for > 10 h. 
Multi-particulate effervescent floating formulations were found to be better 
than single unit dosage forms as they reduce the toxicity risk due to the lower 
probability of dose-dumping as well as they reduce dependency on the gastric 
emptying. Multi-particulate formulations were found to be more reliable for gastric 
emptying patterns than single unit formulations, which suffer from ―all or none 
concept‖. Units of multi-particulate systems can be distributed freely throughout 
the stomach and their transport is less affected by the gastric transit time 
compared to single unit formulations. Also, they can minimize the risk of local 
irritation due to avoidance of local high drug concentration (De Brabander et al., 
2000; Dey et al., 2008). However, polymers with rapid swelling rate can overcome 
premature passage of single unit dosage forms through the stomach pylorus 
especially when the gastric fluid level is low (Chen et al., 2013). Penners et al., 
(1997) patented an effervescent expandable tablet based on rapidly swelling 
polymeric mixture of polyvinyl lactams and polyacrylates with gas forming agent. 
Results demonstrated that the density of the system was reduced and 
consequently the system tended to float on the gastric contents. The use of 
hydrophilic matrices has become extremely popular in controlling the release of 
drugs from oral solid dosage forms as they can achieve a desirable drug profile 
and are cost effective (Alderman, 1984).  
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Upon contact with the aqueous medium the hydrophilic polymer swells to 
form a gel layer on the surface of the system from which the drug releases by 
dissolution, diffusion and/or erosion mechanism (Nokhodchi et al., 2012). 
Cellulose derivatives can accommodate tablet formulations due to their ease of 
compression, ability to load high percentage of drugs and processing variables 
show negligible influence on their drug release rates (Ebube and Jones, 2004). 
Hydrophilic polymers, such as cellulose ethers, are probably the most widely 
investigated polymers in literature as matrices for effervescent floating drug 
delivery systems. Yang et al. (1999) used tetracycline, metronidazole and bismuth 
salt (as a triple drug treatment strategy of Helicobacter pylori associated peptic 
ulcers) to design a floating triple layer tablets. Hydroxypropylmethyl cellulose and 
poly(ethylene oxide) were the drug release retarding polymers. Tetracycline and 
metronidazole were formulated for controlled delivery and incorporated into the 
middle layer of the triple-layer tablet. One of the outer layers which was used for 
gas generation contained a mixture of sodium bicarbonate: calcium carbonate (1:2 
ratio) and polymeric mixture of hydroxypropylmethyl cellulose and poly(ethylene 
oxide. The other outer layer was included bismuth salt as an immediate release 
layer. The in vitro drug release results showed continuous tablets floating with 
sustained release of tetracycline and metronidazole over 6–8 h.  
Ozdemir et al, (2000) developed floating bilayer tablets loaded with 
furosemide dispersed in 1:1 ratio with β cyclodextrin and evaluated them by in vitro 
and in vivo studies. The first layer composed of hydroxypropylmethyl cellulose 
(4000 and 100), and carboxymethyl cellulose polymers to retard the drug release. 
The second layer contained a mixture of sodium bicarbonate and citric acid as the 
gas generating agents. Results showed that tablets compressed at 15 MPa floated 
at 20 min whereas at higher force (32 MPa) the floating lag time (the time taken for 
tablets to appear and remain on the dissolution medium surface) was prolonged to 
45 min. The in vivo studies in six healthy male volunteers demonstrated a gastric 
retention for 6 h with higher drug bioavailability in comparison with conventional 
tablets. Baumgartner et al. (2000) developed a matrix-floating tablet containing 
pentoxifylline, hydroxypropylmethyl cellulose K4 M, Avicel® PH 101, and a mixture 
of citric acid and sodium bicarbonate as gas generating agents. The floating lag 
time was 30 seconds and in vivo studies in fasted beagle dogs revealed prolonged 
gastric residence time (240 ± 60 min).  
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Later, a continuous floating monitoring device and statistical experimental 
design were used to evaluate effect of formulation variables on the floating 
properties of gastroretentive drug delivery system based on calcium carbonate as 
a gassing agent (Li et al., 2002). Results showed that the higher viscosity grade of 
hydroxypropylmethyl cellulose improved insignificantly (P<0.05) the floating 
capacity, and different polymers with same viscosity, did not show any significant 
effect (P<0.05) on the floating process. Also, results demonstrated that 
magnesium stearate as a hydrophobic agent could significantly improve the 
floating capacity of the delivery system. Patel et al. (2007) prepared floating tablets 
using hydroxypropylmethyl cellulose, ethylcellulose, and sodium bicarbonate. All 
tablets floated > 12 h and the drug release rate of the optimized batch best fitted to 
the zero order kinetic release model.  Gupta and Aggarwal (2007) developed 
gastroretentive floating delivery system loaded with 5-fluorouracil using 
hydroxypropylmethyl cellulose, carbopol 934P, sodium bicarbonate, citric acid. In 
vitro studies showed sustained drug release for 24 h and floating for 16 h. In 
another work, Jaimini et al. (2007) investigated a gastroretentive drug delivery 
system of famotidine by employing two grades of hydroxypropylmethyl cellulose 
(Methocel® K100 and Methocel® K15M) and sodium bicarbonate. The effect of 
citric acid on floating and drug release properties was also investigated. It was 
reported that a mixture of 130 mg of sodium bicarbonate and 10 mg of citric acid 
was found to achieve optimum in vitro buoyancy; however, decreasing the citric 
acid level increased the floating lag time as well as the floating duration. Methocel 
K100 based tablets were found to float for longer durations in comparison with 
those containing Methocel® K15M.  
One year later, the in vitro controlled release floating matrices of captopril 
formulated with variable proportions of hydroxypropylmethyl cellulose (Metolose 
SH 4000 SR) and sodium bicarbonate, and pressed at different compaction 
pressures  were studied (Jiménez-Martínez et al., 2008). Results indicated that 
matrices without gassing agent floated > 8 h if compacted at 55 MPa, however, 
those compacted at 165 MPa could not float till sodium bicarbonate was included 
in the formulation. The matrices swelling rate increased in the presence of sodium 
bicarbonate in the formulation which reduced the drug release rate with time. 
Authors concluded that gas bubbles of carbon dioxide obstructed the drug 
diffusion path and decreased the matrix coherence.  
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On the contrary, Sungthongjeen et al. (2008) reported that increasing level 
of sodium bicarbonate did not show effect on lag time results; however, it 
increased the drug release rate. They designed floating multi-layer coated tablets 
based on theophylline core coated with a protective layer of hydroxypropylmethyl 
cellulose, a gassing agent layer of sodium bicarbonate and a gas-entrapment 
membrane of Eudragit® RL 30D. Tablet core was prepared either by direct 
compression or by compression after the wet granulation process. Shorter time to 
float (lag time) and faster drug release was reported with direct-compressed cores 
than those using wet-granulated cores. Increasing coating level of gas entrapment 
membrane increased lag time results but it had minimum effect on drug release 
rate. Varshosaz et al. (2006) prepared effervescent ciprofloxacin floating tablets 
based on sodium carboxymethyl cellulose, hydroxypropylmethyl cellulose, 
polyacrylic acid, polymetacrylic acid as drug retarding polymers, and citric acid and 
sodium bicarbonate as gassing components. Results revealed that increasing the 
gassing agent base from 5% to 10% (w/w) decreased the floating lag time; 
however changing the polymer type did not significantly (P<0.05) change the 
floating lag time. Moreover, carboxymethyl cellulose had higher mucoadhesion 
property than that of polyacrylic acid. The most desirable formulation contained 
10% (w/w) effervescent base, 80% (w/w) carboxymethyl cellulose/ 20% (w/w) 
hydroxypropylmethyl cellulose, or 80% (w/w) polyacrylic acid/ 20% (w/w) 
polymetacrylic acid.  
In another study, Bomma et al. (2009) developed floating matrix tablets of 
norfloxacin by the wet granulation technique, using hydroxpropylmethyl cellulose 
(K4M, K100M) and xanthan gum as matrix forming agents and sodium 
bicarbonate as gas generating agent. The tablets showed acceptable floating 
capacity (35 seconds) with extended drug release rate (20-25% in 1 h, 25-45% in 
2 h, 55-75% in 4 h, 65-85% in 6 h and 85% after 8 h). Later, Tadros (2010) 
developed ciprofloxacin gastroretentive controlled release drug delivery system 
with swelling, floating, and adhesive properties using hydroxypropylmethyl 
cellulose (HPMC K15M) and/or sodium alginate as polymeric release retarding 
excipient(s) and sodium bicarbonate or calcium carbonate as a gas generating 
agent.  
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Tablets formulated with 21.42% (w/w) HPMC K15M, 7.14% (w/w) sodium 
alginate and 20% (w/w) sodium bicarbonate or 20% (w/w) calcium carbonate were 
promising according to floating behaviours, extended adhesion periods and 
sustained drug release rate. However, stability studies conducted at 40˚C / 75% 
RH for 3 months showed better physical stability of tablets based on 20% (w/w) 
calcium carbonate. In vivo evaluation of these successful tablets in six healthy 
volunteers fed with a meal of low calorie after overnight fasting presented a mean 
gastric residence time of 5.50 ± 0.77 h. 
Other water-soluble cellulose derivatives rather than hydroxypropylmethyl 
cellulose were also investigated. For example, hydroxypropyl cellulose has been 
formulated in 1:2 ratios with amoxicillin trihydrate to prepare effervescent floating 
tablets based on sodium bicarbonate and sodium bicarbonate as gassing agents 
(Hilton and Deasy, 1992). Tablets kept floating for 6 h with good in vitro drug 
release control. However, in vivo comparative study with conventional capsules in 
fasted volunteers indicated lower relative bioavailability and lack of improved 
efficacy according to other pharmacokinetic parameters. Later, Tokumura and 
Machida (2006), designed floating tablets based on hydroxypropyl cellulose-H 
(HPC-H) as it has neither acidic nor basic functional group in its chemical structure 
and the hydrogel formation is pH independent. Tablets contained 50 mg of 
amoxicillin, 210 mg of HPC-H, 22.8 mg of sodium bicarbonate, and 17.2 mg of 
citric acid and coated with HPC-H. These tablets were buoyant for 24 h and 
showed a sustained-release pattern in water and buffer solutions of pH 1.2 and 
6.8. In another study, optimized floating tablets of ofloxacin were prepared via 
compression coating technique using a mixture of hydroxypropyl cellulose and 
sodium alginate combined with sodium bicarbonate. Tablets were found to float 
within 30 seconds and remain buoyant for > 12 h in simulated gastric fluid (SGF) 
without pepsin. In vivo study in rabbits indicated higher relative bioavailability of 
the ofloxacin after administration of floating tablets in comparison with marketed 
ofloxacin tablets (Qi et al., 2015). 
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Moreover, effervescent floating tablets have been formulated by using 
another water-soluble cellulose derivative. Mixtures of hydroxyethyl cellulose with 
sodium carboxymethyl cellulose (Chen et al., 2010b) and with chitosan (Chen et 
al., 2013) were studied. Chen et al. (2010a) aimed to develop an optimal 
gastroretentive drug delivery system for administering losartan through 
development of swellable and floatable tablets combining the rapidly swellable 
hydroxyethyl cellulose with a fine particle size grade (250HHX), sodium 
carboxymethyl cellulose, and sodium bicarbonate. The best formulation was the 
one based on 91.67% (w/w) hydroxyethyl cellulose, 3.33% (w/w) sodium 
bicarbonate and 8.33% (w/w) losartan as per in vivo characterization. Selected 
promising floating tablets showed that the relative bioavailability was 
approximately 164% in comparison to the immediate-release marketed product 
(Cozaar®). Later, Chen et al. (2013) developed losartan floating swellable tablets 
based on 250HHX hydroxyethyl cellulose, chitosan as swellable floatable 
polymers and sodium bicarbonate as a gassing agent. They evaluated floating lag 
time and duration and swelling characteristics of prepared tablets. Authors 
demonstrated that formulations with 3:7 ratio of hydroxyethyl cellulose: chitosan 
had the best swelling effect, however they had weak structure which is not 
applicable as a gastroretentive drug delivery system, nevertheless, adjusting the 
ratio into 5:5 hydroxyethyl cellulose: chitosan showed preferred properties of 
swelling. Adding sodium bicarbonate assisted the floating ability of all formulations. 
An optimized losartan formulation composed of 1:1 ratio of both polymers with 20 
mg of sodium bicarbonate resulted in the tablets floating for > 16 h and an 
adjustable in vitro drug release rate. 
Other polymers were involved in the development researches of 
effervescent gastroretentive tablets. For example, Talwar et al, (2001) patented a 
once daily ciprofloxacin floating tablet composed of 69.9% drug, 0.34% sodium 
alginate, 1.03% xanthan gum, 12.1% cross-linked polyvinylpyrrolidine, and 13.7% 
sodium bicarbonate. The tablet tended to float and be retained in the stomach or 
upper part of the small intestine with sustained release of the drug. Also, Moursy 
et al. (2003) designed floating capsules of nicardipine hydrochloride based on 
hydrocolloids of high viscosity grades and sodium bicarbonate. In vitro studies 
showed an increase in floating time with increase in proportion of hydrocolloid and 
presence of sodium bicarbonate.  
 32 
 
In vivo studies in rabbit‘s revealed that drug duration after the administration 
of the designed floating capsules significantly exceeded that of the commercially 
available capsules. In another study, Nakagawa et al. (2006) prepared a double 
compressed tablet of 5-Fluorouracil as a core material with outer layer composed 
of povidone, Eudragit® RL, and sodium bicarbonate. Results showed sustained 
drug release by occurrence of a plasma-induced cross-link reaction on the outer 
layer of the tablet. Bani-Jaber et al. (2011) evaluated metronidazole matrix tablets 
made of Eudragit® E PO (EE) and/or Eudragit® L-100-55 (EL) at different weight 
ratios and sodium bicarbonate. The best floating and sustained drug release 
properties in 0.1 M HCl dissolution medium was achieved by effervescent floating 
tablets with 50EE/50EL (w/w); however the related non-floating tablets showed 
significantly faster drug release rate without any floating capacity.  
Loh and Elkordy (2015) studied metronidazole floating tablets using 
hydroxypropylmethyl cellulose K15M, xanthan gum, co-povidone, Eudragit® RL 
PO, Pluronic® F-127 and/or polypropylene foam powder as drug release 
controlling agents and sodium bicarbonate with or without citric acid as 
effervescent agents at different compositions. Results indicated that tablets based 
on 12.5% (w/w) hydroxypropylmethyl cellulose, 25% (w/w) xanthan gum, 12.5% 
(w/w) co-povidone and 31.7% (w/w) sodium bicarbonate showed short floating lag 
time, good floating duration and sustained the drug release for 8 h with a zero 
order drug release kinetic. Authors concluded that the combinations of 
hydroxypropylmethyl cellulose K15M and xanthan gum showed synergistic effect 
in sustaining the drug release. Recently, gastroretentive floating tablets of 
pregabalin model drug were designed and evaluated using different 
concentrations of the gums (xanthan gum and guar gum), carbopol 974P NF, 
hydroxypropylmethyl cellulose K100, and sodium bicarbonate (Kanwar et al., 
2016). The in vitro drug release studies indicated that matrices containing guar 
and xanthan gum had higher drug release rate than those containing carbopol 
974P NF. Abduljabbar (2016) and Yusif et al. (2016) developed gastroretentive 
floating-mucoadhesive tablets using mucoadhesive polymers and sodium 
bicarbonate as a gas forming agent. 
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1.3.7 Commercially available products  
 
Gastroretentive drug delivery systems like expandable, superporous 
hydrogel, mucoadhesive, high density, magnetic, and floating have been widely 
investigated by drug delivery researchers within the last three decades. Many of 
them have been reported to show promising in vitro / in vivo results. Yet, only a 
few of them have been evidenced with clinical trials and proved to be marketed 
commercially as presented in Table ‎1-1.  
AcuFormTM is one of the well-known polymeric swelling monolithic systems 
developed by Depomed, USA.  Possibility of high drug dose loading and the use of 
a classical manufacturing process are considered the main advantages of this 
technology (Prinderre et al., 2011). AcuFormTM platform is a gastric-retentive oral 
delivery technology for a variety of compounds based on polymer technology. 
Following ingestion, it has been shown to promote gastric retention and control 
drug delivery. Chen et al. (2011) reported that in fed state, AcuFormTM gabapentin 
tablet swells up to three to four times in the gastric fluid, with a diameter larger 
than that of the pylorus. This enabled gastric retention for about 8-9 h with 
controlled and prolonged release of gabapentin to the upper intestinal tract. Such 
results support a once- or twice-daily product with potentially less adverse events.  
Another example is Valrelease (15 mg diazepam) which is a slow release 
floating capsule based on hydrodynamically balanced system (HBS) technology. 
Conventional 5 mg diazepam tablets are given three times daily, however, 
Valrelease capsules are given once daily to provide an equivalent plasma 
diazepam concentration. By controlling the rate of release, Cmax is decreased 
relative to that observed when 15 mg is administered as a single dose in tablets. 
The gradual dissolving of Valrelease capsules over an 8-12 h in comparison with 
conventional diazepam tablets which dissolve within 15 min generate a smooth 
onset of action with a prolonged drug release rate (Notari, 1986).  
Also, Madopar HBS is a slow-release floating capsule of L-dopa and 
benserazide based on hydrodynamically balanced system (HBS) technology. 
Malcolm et al. (1987) presented pharmacokinetic studies in parkinsonian patients 
and healthy volunteers to evaluate the effect of food and antacid on the absorption 
of Madopar HBS.  
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In comparison with conventional Madopar, the drug (L-dopa) is released 
and absorbed over a period of 4-5 h. The absorption rate is reduced, providing 
lower peak concentrations of L-dopa but maintaining substantial plasma 
concentrations for 6-8 h after dosing. The bioavailability of L-dopa is reduced in 
comparison with conventional Madopar because of incomplete absorption of the 
drug. No effect of presence or absence of food in the stomach on the drug 
absorption from Madopar HBS is reported; still concomitant administration of 
antacids reduces the drug bioavailability. Another example is liquid Gaviscon® 
which is a raft-forming system with ability to produce a layer over the gastric fluids 
(raft) to deliver antacid drugs to reduce gastric acidity and treat gastroesophageal 
reflux (Washington, 1990). In vitro and in vivo performance of Gaviscon double 
action liquid in comparison with alginate/antacid suspensions showed that the 
double action formulation was as good as, or better than the other formulations 
(Hampson et al., 2010). 
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Table ‎1-1: List of some gastroretentive drug delivery systems commercially available.  
Product Drug Company Technology 
Cytotec Misoprostol Pharmacia/Pfizer, USA Bilayer floating capsules 
Baclofen GRS Baclofen Sun Pharma, India Coated multi-layer floating and swelling system 
Conviron Ferrous sulfate Ranbaxy, India Colloidal gel forming floating system 
Prazopress XL Prazosin HCl Sun Pharma, Japan Effervescent and swelling-based floating system 
Liquid Gaviscon 
Alginic acid and 
sodium bicarbonate 
Reckitt Benckiser 
Healthcare, UK 
Effervescent floating liquid alginate preparation 
Riomet OD Metformin HCl Ranbaxy, India Effervescent floating system 
Zanocin OD Ofloxacin Ranbaxy, India Effervescent floating system 
Cipro XR 
Ciprofloxacin HCl 
and betaine 
Bayer, USA Erodible matrix-based system 
Accordion PillTM 
(In phase II trials) 
Levodopa and 
carbidopa 
Intec Pharma Expandable film filled in capsule 
Valrelease Diazepam 
Hoffmann-LaRoche, 
Switzerland 
Floating capsule 
Eudratec GRS - 
Evonik Industries, 
Germany 
Floating capsulea 
SoctecTM - Vectura Group, UK Floating capsuleb 
Madopar HBS 
Levodopa and 
benserazide 
Hoffmann-LaRoche, 
Switzerland 
Floating CR capsule 
Adapted from: Sheth, and Tossounian, 1984; Washington et al., 1986; Erni and Held, 1987; Fabregas et al., 1994; Pawar et 
al., 2011b; Ishak, 2015. 
a (http://healthcare.evonik.com/product/health-care/en/custom-solutions/oral-drug-delivery/eudratec-grs/pages/default.aspx) 
   Accessed on 10/07/2017 
b (http://www.vectura.com/oral/oral-drug-delivery-technologies/) 
   Accessed on 10/07/2017 
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Table 1-1 (continued): List of some gastroretentive drug delivery systems commercially available.  
Product Drug Company Technology 
Almagate Flotcoat 
Aluminum and 
magnesium antacid 
Laboratorios Almirall, 
Spain 
Floating lipophilic particles 
Topalkan 
Aluminum and 
magnesium antacid 
Pierre Fabre 
Medicament, France 
Floating liquid alginate 
Cifran OD Ciprofloxacin HCl Ranbaxy, India Floating tablets 
Inon Ace Simethicone Sato Pharma, Japan Foam-based floating system 
Coreg CR Carvedilol GlaxoSmithKline Gastro-retention with osmotic system 
Cefaclor LP Cefaclor Galenix, France Minextab Floating® 
Metformin Hcl LP Metformin HCl Galenix, France Minextab Floating® 
Tramadol LP Tramadol Galenix, France Minextab Floating® 
Glumetza Metformin HCl Depomed, USA Polymer-based swelling technology: AcuForm™ 
Gralise Gabapentin Depomed, USA Polymer-based swelling technology: AcuForm™ 
Janumet XR 
Metformine HCl and 
sitagliptin 
Merck, USA Polymer-based swelling technology: AcuForm™ 
Nucynta ER Tapentadol Janssen, Belgium Polymer-based swelling technology: AcuForm™ 
ProQuin XR Ciprofloxacin HCl Depomed, USA Polymer-based swelling technology: AcuForm™ 
Kadian Morphine sulfate 
Sumitomo Pharma, 
Japan 
Stick type capsule type filled with pellets 
Adapted from: Sheth, and Tossounian, 1984; Washington et al., 1986; Erni and Held, 1987; Fabregas et al., 1994; Pawar et 
al., 2011b; Ishak, 2015. 
a (http://healthcare.evonik.com/product/health-care/en/custom-solutions/oral-drug-delivery/eudratec-grs/pages/default.aspx) 
   Accessed on 10/07/2017 
b (http://www.vectura.com/oral/oral-drug-delivery-technologies/) 
   Accessed on 10/07/2017 
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1.4 Formulation development 
 
Despite the proven advantages, through literature, of the gastroretentive 
systems for patients, as a few of them have been evidenced with clinical trials and 
proved to be marketed commercially, it is difficult to identify a single system as the 
best one for all drug candidates. A case by case evaluation for each drug or drug 
combination has to be assessed based on dose and the manufacturability of the 
system. Of all the gastroretentive delivery systems described in the literature, 
floating systems can show promising potential to achieve this goal. Particularly, 
combinations of different gastroretentive concepts, such as mucoadhesion and 
low-density floating, can be expected, for example by using suitable polymers, to 
be promising to have a significant effect on improving the therapeutic effect of the 
drug involved (Streubel et al., 2006). Besides, there is a lack of enough 
information in the literature about floating and drug release rate from pentoxifylline 
or cefalexin monohydrate gastroretentive drug delivery systems based on binary 
mixtures of hydroxyethyl cellulose and sodium alginate as drug retarding 
polymers, and sodium bicarbonate, calcium carbonate, or sodium carbonate as 
gassing components. This made them suitable for the study regarding research 
originality. 
 
1.4.1 Type of polymers 
 
Water-soluble cellulose derivatives can be considered one of the best 
options to design floating tablets with sustained release behaviour (Gerogiannis et 
al., 1993) and are probably the most widely investigated polymers. However, the 
increasing demand of pharmaceutical industry for suitable polymers, to achieve a 
suitable drug release rate, has facilitated screening of a large variety of both 
synthetic and natural polymers for their ability to sustain the drug release process. 
The cost of synthesizing a new polymeric substance and testing their safety are 
highly priced (Ebube and Jones, 2004). An extreme concentration on the use of 
pharmaceutically approved polymeric blends as matrix excipients to control the 
drug release has been widely investigated. This can provide several choices for 
pharmaceutical industry formulators to achieve the best dosage form design.  
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Accordingly, the aim of this work was to design floating gastroretentive drug 
delivery matrix tablets based on pharmaceutically approved binary polymeric 
mixture. Thus, both hydroxyethyl cellulose and sodium alginate were selected to 
design a floating drug delivery system. One of the most important challenges in 
developing gastroretentive single unit dosage forms is to avoid rapid gastric 
emptying and increase the gastric residence time. Polymers with rapid swelling 
rate upon contact with the gastric fluid have rapid reduction in their density, thus 
can overcome premature passage of single unit dosage forms through the 
stomach pylorus especially when the gastric fluid level is low. Cellulose ether 
hydration rate varies according to the nature of the functional group present as 
well as its degree of substitution (Roy and Rohera, 2002). Hydroxyethyl cellulose 
(Figure ‎1-6) is a hydrophilic cellulosic polymer with non-ionic nature which makes 
it a pH independent polymer (Angadi et al., 2010). Hydroxyethyl cellulose 
(Natrosol 250-HHX) has M.W of 1.3x106 which generates viscosity of 3400-5000 
cP at 25˚C at 1% concentration. Additionally, it is well known in the literature as a 
matrix-forming polymer (Chatlapalli and Rohera, 1998; Baumgartner et al., 2002; 
Larsson et al., 2008; Chen et al., 2010b; Chen et al., 2013). It has the advantage 
of more swelling rate than both hydroxypropyl cellulose and hydroxypropylmethyl 
cellulose in purified water (Baumgartner et al., 2006). It also has shown better 
swelling and floating ability than sodium carboxymethyl cellulose (Chen et al., 
2010b). These properties made it suitable over the other cellulose ether 
derivatives for this study.  
Nonetheless, Roy and Rohera (2002) reported that the relatively higher 
hydrophilicity of hydroxyethyl cellulose was the cause for the drug release rate 
from their matrices to be higher than that of hydroxypropyl cellulose matrices. 
Accordingly, sodium alginate with medium viscosity grade (at 25˚C at 1% 
concentration generates 15-25 cP) was selected in this study to be mixed with 
hydroxyethyl cellulose to slow down the drug release rate and to retain carbon 
dioxide gas liberated after acid-base interaction in order to control both floating lag 
time and floating duration capacities. This viscosity grade was chosen to avoid any 
drawbacks on the high swelling rate advantage of hydroxyethyl cellulose.  
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Additionally, sodium alginate is extensively used in the literature, as in situ 
gel forming polymer, in different gastroretentive drug delivery systems such as 
floating tablets (Talwar et al, 2001; Tadros, 2010; Qi et al., 2015), mucoadhesive 
tablets (Patil and Talele, 2015); superporous hydrogel (Omidian et al., 2006), and 
expandable tablets (El-Zahaby et al., 2014). 
Sodium alginate (Figure ‎1-7), is a non-cellulosic water soluble 
polysaccharide derived from brown seaweeds. It consists primarily of sodium salt 
of alginic acid, which is a linear copolymer of 1,4-linked β-D-mannuronic acid (M-
block) and α-L-guluronic acid (G-block) units (Peppas et al., 2006). Sodium 
alginate can be easily cross-linked with other multivalent cations such as calcium 
to form a stable complex assuming the ―egg box‖ model (Gacesa, 1988) 
(Figure ‎1-8). Alginate gel can be created during the formulation process (Miyazaki 
et al., 2000), or in gastric fluids, if suitable conditions of alkaline microenvironment 
and/or calcium ions are available. Accordingly, addition of sodium alginate to 
hydroxyethyl cellulose was expected to enhance drug release retardation 
properties of designed tablets especially in the presence of calcium carbonate. 
This gas forming agent is also a multivalent cations source, hence it was 
suggested to have a role in sodium alginate cross-linking to form a stable complex 
assuming the ―egg box‖ model. Moreover, involvement of carbonate gassing 
agents can provide a microenvironment for the polymer with an alkaline pH to 
initiate gel formation (Deshpande et al., 1997). Consequently, the liberated gas 
bubbles can be entrapped in the formed gel layer to assist an upward motion of 
designed tablets to achieve short lag time and to maintain their buoyancy over the 
gastric fluid. A binary mixture of hydroxyethyl cellulose and sodium alginate in 
(1:1) ratio, which used in the current study, was required to take full advantage of 
both polymers in the formulation. Still, in the future, more ratios of hydroxyethyl 
cellulose and sodium alginate mixture, such as 0:1, 0.25:0.75, 0.75:0.25, and 1:0 
respectively, could be investigated.   
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Figure ‎1-6: Chemical structure of hydroxyethyl cellulose (Zulkifli et al., 2014) 
 
 
 
Figure ‎1-7: Chemical structure of sodium alginate (Steele et al., 2014). 
 
 
 
Figure ‎1-8: Schematic presentation of the ‗egg box‘ model for calcium alginate gel 
(Kühbeck et al., 2015) 
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1.4.2 Method of preparation of floating tablets 
 
Sungthongjeen et al. (2008) designed floating multi-layer coated tablets with 
cores prepared either by direct compression or by compression after the wet 
granulation process. Results revealed shorter floating lag time and faster drug 
release rate with direct-compressed cores than those using wet-granulated cores. 
Ozdemir et al, (2000) showed that bilayer floating tablets compressed at 15 MPa 
floated at 20 min whereas at 32 MPa the floating lag time was prolonged to 45 
min. Also, Jiménez-Martínez et al. (2008) indicated that matrices without gassing 
agent floated > 8 h if compacted at 55 MPa, however, those compacted at 165 
MPa could not float till sodium bicarbonate was included in the formulation. 
Consequently, it was necessary in this research to study the effect of the wet 
granulation process on powder mixture properties and to evaluate the differences 
between application of three crushing strength levels (A: 49–54 N;   B: 54-59 N; 
and C: 59-64 N) on floating capacity of the prepared tablets and their drug release 
rate.  
 
1.4.3 Type of gas-generating agent 
 
Sodium bicarbonate or calcium carbonate is used to react with the stomach 
gastric acid or with the co-formulated citric acid or tartaric acid in the presence of 
aqueous fluid, to liberate carbon dioxide gas. Still, sodium bicarbonate is the 
predominant gassing agent involved in the design and development of 
effervescent floating drug delivery systems. Sodium carbonate has also the ability 
to produce carbon dioxide gas due to acid base reaction (Hapgood, 2009), but, 
available information in the literature about using it within the floating tablets is 
inadequate. Choi et al. (2002) evaluated floated beads based on sodium 
bicarbonate or calcium carbonate. Results showed different porosity percentages, 
bead gel strengths and floating capacities. It was concluded that calcium 
carbonate was better as a gas forming agent in alginate bead preparations in 
comparison with sodium bicarbonate. Additionally, Sriamornsak et al. (2007a) 
evaluated calcium pectinate gel beads containing sodium bicarbonate, calcium 
carbonate, potassium carbonate or sodium carbonate as gas forming agents.  
 42 
 
Beads were successfully produced with sodium bicarbonate or calcium 
carbonate only. Porous beads in comparison with dense beads were resulted due 
to incorporation of sodium bicarbonate and calcium carbonate respectively. 
Therefore, in this study, it is worth testing sodium carbonate and calcium 
carbonate beside sodium bicarbonate to evaluate the effect of gassing agent type 
on the designed system.  
 
1.4.4 Concentration of gas-generating agent 
 
It was reported in the literature that increasing the mass content 
concentration of gas generating agents reduced significantly the floating lag time 
of gastroretentive systems (Varshosaz et al. 2006; Goole et al. 2007; Goole et al., 
2008) and extended their floating duration (Gupta and Aggarwal, 2007; Nama et 
al. 2008), but above a certain limit, a disruption in the system integrity and 
complete loss of floatation capability were noted. A hydrodynamically balanced 
system (HBS) based on sodium bicarbonate at 8% (w/w) along with 
hydroxypropylmethyl cellulose K4M showed an in vitro floating lag time < 3 min, 
floating duration > 12 h, and an in vivo gastric retention time of 220 min (Nama et 
al. 2008). Nonetheless, 20% (w/w) of sodium bicarbonate along with 
hydroxypropylmethyl cellulose K15M and sodium alginate was successful to show 
a mean gastric retention period of 5.5 h (Tadros, 2010). Thus two concentration 
levels (10 and 20% (w/w)) of sodium bicarbonate, calcium carbonate, or sodium 
carbonate were selected (in the current research) beside the control tablets (0% 
(w/w)) to explore the effect of gassing agent concentrations on the designed 
system.   
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1.4.5 Model drug 
 
Two model drugs were selected to be loaded in the designed effervescent 
gastroretentive tablets individually.  
 
1.4.6 Pentoxifylline 
 
Primarily, pentoxifylline (Figure ‎1-9) was used as a model drug. Its 
physicochemical characteristics are presented in Table ‎1-2. Pentoxifylline or 
oxpentifylline (Frampton and Brogden, 1995) is a methylxanthine derivative 
(Steinleitner et al., 1990) that inhibits production of inflammatory cytokines from 
immune cells and treats or prevents fibrosis (Berman and Duncan, 1989; Berman 
et al., 1992). Pentoxifylline inhibits phosphodiesterase through both protein 
kinase_A dependent and independent pathways, which increases intracellular 
levels of cyclic adenosine monophosphate (cAMP). It was reported that 
pentoxifylline can decrease oxidative stress during inflammation and suppress the 
superoxide production of macrophage (Bessler et al., 1986; Costantini et al., 
2009). In humans, pentoxifylline was reported to be effective with peripheral 
vascular disease (Ward and Clissold, 1987), mental dementia (Parnetti et al., 
1986), and alcoholic hepatitis (Haber et al., 2003). Studies showed that 
pentoxifylline at a dosage of 600 to 1200 mg/day, marked overall clinical 
improvements in about 85% in patients with cerebrovascular disorders (Ward and 
Clissold, 1987). 
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Figure ‎1-9: Chemical structure of pentoxifylline (BP, 2015) 
 
 
 
 
 
Table ‎1-2: Physicochemical characteristics of pentoxifylline.  
Parameter Remarks 
Description White or almost white, crystalline powder. 
CAS Number 6493-05-6 
Molecular weight 278.3 g/mole 
Molecular formula C13H18N4O3 
Chemical  
Name 
3,7-dimethyl-1-(5-oxohexyl)-3,7-dihydro-1H-purine-2,6-dione 
Solubility 
Soluble in water (191 mg/ml at 37°C)a, freely soluble in 
methylene chloride, sparingly soluble in ethanol (96 per 
cent). Solubility of pentoxifylline at pH 1.2 was larger than 
that at pH 6.8b.  
Note: The data is adapted from BP, 2015; a Mikac et al., 2010; b Otsuka and 
Matsuda, 1994. 
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After oral administration, pentoxifylline is rapidly absorbed with peak plasma 
level reached between 0.29 and 0.41 h and due to the extensive metabolic 
transformations, pentoxifylline has low and variable bioavailability averaged 20% 
to 30% (Beermann et al. 1985). It has variable plasma clearance from 1.3 to 1.8 
ml/min and less than 1% of the given dose is recovered unchanged from the urine 
(Hinze et al., 1972; Bryce et al., 1989). Hydroxypentoxifylline [1-(5'-hydroxhexyl)-3, 
7-dimethylxanthine] and carboxypentoxifylline [1-(carboxypropy1)-3,7-
dimethylxanthine] are the major circulating metabolites of pentoxifylline in human 
beings. Both pentoxifylline and hydroxypentoxifylline metabolite show the same 
pharmacologic properties and have an equivalent short elimination half-life (t1/2) of 
0.8 to 1.8 h (Hinze et al., 1972; Ings et al., 1982; Aviado and Dettelbach, 1984; 
Beermann et al., 1985). After an oral administration of a sustained-release 
pentoxifylline formulation to healthy volunteers, an increase 3.4 h in pentoxifylline 
terminal half-life (t1/2), with an absolute bioavailability equal to 20% was reported in 
comparison with immediate release pentoxifylline capsule (Beermann et al., 1985).  
The same study showed that pentoxifylline is completely absorbed from the 
gastrointestinal tract (GIT) when given either in the form of sustained release 
tablets or immediate release capsules. Pentoxifylline is a suitable candidate for 
oral sustained release delivery to improve patient compliance and reduce side 
effects due to better control of the therapeutic drug concentration. Sustained-
release 400 mg pentoxifylline tablets (e.g. Trental®) are commercially available in 
the market to avoid frequent dosing and to maintain therapeutic drug plasma 
levels. A pentoxifylline floating tablet based on hydroxypropylmethyl cellulose 
K4M, Avicel® PH 101 as a matrix, and a mixture of citric acid and sodium 
bicarbonate as a gas forming agents was developed (Baumgartner et al., 2000). 
The tablets floated within 30 seconds and prolonged gastric residence time was 
shown in fasted beagle dogs. Pentoxifylline has remarkable properties of high 
density (Baumgartner et al., 2000) and high water solubility (191 mg/ml at 37°C) 
(Mikac et al., 2010) which made it an ideal model drug in this study to challenge 
the ability of the designed gastroretentive tablets to show acceptable floating 
capacity and acceptable retarding of the drug release process. 
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1.4.7 Cefalexin monohydrate 
 
Also in this study, cefalexin monohydrate was selected as a second model 
drug (Figure ‎1-10). Its physicochemical characteristics are presented in Table ‎1-3. 
Cefalexin (BP 2015) or cephalexin (USP, 2012) is a semisynthetic β-lactam first 
generation cephalosporin antibiotic. It causes bacterial cell lysis as it interferes 
with the last step of bacterial cell wall synthesis (transpeptidation or cross-linkage). 
Cefalexin is a broad spectrum antibiotic used for treatment of many bacterial 
infections such as the upper and lower respiratory tract infections except in those 
infections caused by Haemophilus influenzae (Disney, 1983; Raff, 1983). Also, it is 
used for treatment of skin, soft tissues, and the genitourinary tract infections. 
Cefalexin is used in dosages of 1-2 g/day in adults and 20-100 mg/kg/day in 
children (Disney, 1983). After oral administration, cefalexin is completely and 
rapidly absorbed in the upper intestine, therefore, it does not disturb the lower 
bowel flora even with administration of relatively high oral doses, and it has 
minimal toxicity and adverse side effects (Griffith, 1983). It is a lipophilic weak acid 
with 5.2 and 7.3 pKa values, and is stable in gastric conditions but degrades in 
intestinal or alkaline conditions (Marrelli, 1975; Yin et al., 2013). 
Measurement of cefalexin uptake in membrane vesicle preparations or in 
intact enterocytes showed higher uptake in the duodenum than in the jejunum or 
ileum (Kramer et al., 1993; Tomita et al., 1995). Additionally, absorption of β-
lactam antibiotics containing a phenyl-glycine side chain, such as cefalexin, was 
reported to be a carrier mediated process and saturable at high dose (Tsuji et al., 
1979; Tsuji et al., 1981; Nakashima et al., 1984). It has low protein binding to 
human serum proteins and it has rapid distribution to the tissues other than the 
spinal fluid (Griffith, 1983). Cefalexin is not significantly metabolized and is not 
excreted in bile (Barbhaiya, 1996) but it is rapidly cleared from the body by the 
kidneys, and 70-100% of the dose is recovered in the urine within 6-8 h after each 
dose (Griffith, 1983).  
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Figure ‎1-10: Chemical structure of cefalexin monohydrate (BP, 2015) 
 
 
 
 
 
Table ‎1-3: Physicochemical characteristics of cefalexin monohydrate.  
Parameter Remarks 
Description White or almost white, crystalline powder. 
CAS Number 23325-78-2 
Molecular weight 365.4 g/mole 
Molecular formula C16H17N3O4S,H2O 
Chemical name 
(6R,7R)-7-[[(2R)-2-Amino-2-phenylacetyl] amino]-3-methyl-8-
oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylic acid 
monohydrate. 
Solubilitya 
Solubility in water is 13.5 mg/ml at 25 ˚C. 
Solubility in water at pH 2.3 is 120 mg/ml at 37 ˚C.  
Note: The data is adapted from BP, 2015; a Marrelli, 1975. 
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On an empty stomach, cefalexin shows maximal serum concentration 
(Cmax) of 38.8 ± 8.1 mg/L at 65.2 ± 11.1 min (Tmax) after oral capsule administration 
of 1000 mg, however during a standard breakfast the Cmax decreases to 23.1 ± 6.6 
mg/L at 112 ± 23.4 min (Tmax) due to slower oral absorption  (Lode et al., 1979). It 
has a short half-life of approximately 1 h (Davies and Holt, 1972). Therefore, 
conventional cefalexin products should be administered 3–4 times a day to 
maintain drug therapeutic range which make it suitable candidate for sustained 
drug delivery.  
Researchers developed cefalexin controlled release double-layer tablets 
(Martinez-Pacheco et al., 1986), sustained release tablets (Dhopeshwarkar et al., 
1994), and controlled release beads (Agnihotri et al., 2006). No significant 
difference in the clinical responses of sustained release cefalexin granules (L-
Keflex) and regular cefalexin capsules (Keflex) in the field of dental infections were 
reported (Horii et al., 1980). Nonetheless, in vivo study results of optimized 
sustained release tablets along with a fast release capsule showed that the 
relative bioavailability of cefalexin was reduced by about 30% and very little 
absorption was seen after 6-8 h (Dhopeshwarkar et al., 1994).  
Recently, Yin et al. (2013) prepared cefalexin gastroretentive floating 
tablets using hydroxypropylmethyl cellulose K100M as a matrix and sodium 
bicarbonate as a gassing agent. The in vitro studies showed floating lag time 
within 15 seconds and floating duration > 12 h with a satisfactory sustained drug 
release rate for 12 h. An in vivo study was conducted in fed and fasted beagle 
dogs comparing floating tablets with conventional cefalexin capsules and 
sustained release tablets. The gastroretentive formulation enhanced cefalexin 
bioavailability. The relative bioavailability of floating tablets was 99.4% compared 
with the conventional capsules, whereas sustained release tablets showed only 
39.3%.   
Therefore, the cefalexin instability at intestinal pH (Marrelli, 1975; Yin et al., 
2013) and its narrow absorption window at the upper gastrointestinal tract (GIT) 
(Griffith, 1983; Kramer et al., 1993; Tomita et al., 1995) made it an ideal model 
drug in this current study for further investigations regarding gastroretentive 
delivery systems but not ordinary sustained release delivery systems. 
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1.5 Posed research questions 
 
1- What is the effect of using binary mixture (1:1) of hydroxyethyl cellulose and 
sodium alginate on extending the drug release rate of different model drugs 
and floating capacity of tablets? 
2- What is the effect of different formulation parameters (the wet granulation, 
tablet crushing strength, gassing agent type, and gassing agent 
concentration) on drug release rate and floating capacity?  
 
1.6 Aims and objectives: 
 
 To prepare floating tablet compositions containing suitable model drug, 
binary mixture of hydroxyethyl cellulose and sodium alginate gel forming 
polymers, gassing agent, filler (if required), and lubricant. 
 To study the flow properties of different powder mixture formulations and 
the effect of the wet granulation process on powder mixture properties.  
 To investigate the influence of gassing agent type (sodium bicarbonate, 
calcium carbonate, or sodium carbonate) as well as gassing agent level (10 
or 20% w/w) on floating capacity and drug release rate. 
 To evaluate the differences between application of three crushing strength 
levels (A: 49–54 N;   B: 54-59 N; and C: 59-64 N) on floating capacity of the 
prepared tablets and drug release rate from those tablets.  
 To analyse the generated data statistically with the aim to evaluate possible 
significant outcomes of the different formulation parameters on floating and 
drug release rate. 
 To analyse the release kinetics by fitting the generated drug release data to 
different mathematical models (zero order, first order, Hixson-Crowell, 
Higuchi, and Korsmeyer–Peppas). 
 To investigate the most promising formulations by in vivo study to evaluate 
ability to sustain the drug release.  
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The thesis has been presented as following: 
Chapter one  
(Current chapter): 
 
Introduction 
Chapter two: Material and methods. 
Chapter three: Evaluation of the effect of sodium bicarbonate, calcium 
carbonate, and sodium carbonate as gassing agents on 
pentoxifylline floating tablets. 
Chapter four: Evaluation of the effect of sodium bicarbonate, calcium 
carbonate, and sodium carbonate as gassing agents on 
cefalexin monohydrate floating tablets. 
Chapter five: Preliminary In vivo study in rats. 
Chapter six: Conclusions and future work 
Chapter seven: References 
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2 Chapter Two: Materials and methods 
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2.1 Materials 
 
Calcium carbonate, cefalexin monohydrate, sodium carbonate, medium 
viscosity sodium alginate (15-20 cP at 1% at 25˚C), and pentoxifylline were 
supplied by Sigma-Aldrich (UK), silicified microcrystalline cellulose (Prosolv® 90) 
was obtained from JRS Pharma (Germany), magnesium stearate was supplied by 
MEDEX (UK), emitrecitabine, ammonia, formic acid, methanol, and ACE 5 C18 
column were obtained by the Jordan Centre for Pharmaceutical Research (Jordan), 
and hydroxyethyl cellulose (NatrosolTM 250-HHX, 3400-5000 cP at 1% at 25˚C) 
was generously provided by Ashland (USA).  
 
2.2 Methods 
2.2.1 Ultra violet spectroscopy analysis 
 
Spectrophotometric analysis was carried out between 190 and 600 nm to 
determine maximum absorbance wave length of pentoxifylline (Figure 2-1) and 
cefalexin monohydrate (Figure 2-2) in 0.1 M HCl solution using ATI Unicam UV2 
spectrophotometer, UK.  In addition, serial dilutions of 0.5 mg/ml stock solution of 
pentoxifylline or cefalexin monohydrate were carried out to construct calibration 
curves as shown in Figure 2-3 and Figure 2-4 respectively. Each dilution point was 
performed in triplicate and mean values ± standard deviation (SD) are presented. 
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Figure 2-1: UV absorbance spectrum of pentoxifylline in 0.1 M HCl. 
 
 
 
 
Figure 2-2: UV absorbance spectrum of cefalexin monohydrate in 0.1 M HCl. 
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Figure 2-3: Calibration curve of pentoxifylline. 
Note: Error bars cannot be seen because they are very small. 
 
 
 
 
Figure 2-4: Calibration curve of cefalexin monohydrate. 
Note: Error bars cannot be seen because they are very small. 
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2.2.2 Formulation development outline 
 
The formulation development aim, for the gastroretentive floating tablets, 
was to get formulations based on binary mixture of hydroxyethyl cellulose and 
sodium alginate (gel forming polymers); sodium bicarbonate, calcium carbonate, 
or sodium carbonate (gassing agent); filler (if required); and lubricant. The 
formulations should be suitable for the wet granulation process and for pressing at 
three crushing strength levels (A: 49–54 N;   B: 54-59 N; and C: 59-64 N). The 
influence of gassing agent concentration was also considered during the 
formulation development. Several excipients were tried to facilitate manufacturing 
of the required floating tablets using a single-punch tableting machine (Type 3, 
Manesty Machines Ltd, UK) equipped with flat-faced punches (9.60 mm), and the 
compression force was adjusted by decreasing the distance between punches to 
produce tablets with the required crushing strength levels which was measured 
using the crushing strength tester. A turbula mixer with a glass bottle, 250 mL, 
mixing vessel, was used to mix the powders. 
Table 2-1 to Table 2-6 show different trials with excipients used with the 
percentage (%) of each one. In stage I of the formulation development (Table 2-1), 
the binary mixture (1:1) of hydroxylethyl cellulose and sodium alginate was difficult 
to be pressed and resulted crushing strengths were below the required levels. 
Consequently, in stage II (Table 2-2), three different LubriToseTM fillers (MCC, 
mannitol, and lactose), co-processed with stearate lubricant derivatives,  were 
used at 25% (w/w) to improve powder mixture compressibility. The resulted 
crushing strengths were not appropriate; they were in range of 29.5-49 N. In the 
next stage (Table 2-3), the fillers were changed into microcrystalline cellulose 
(MCC) with different particle size property (Avicel® PH101, PH102, PH105, and 
Prosolv 90®). The crushing strength was improved to be > 49 N. Therefore, in 
stage IV of formulation development trials (Table 2-4), wet granulation process 
was processed using water or polyvinylpyrolidone (PVP) at different 
concentrations. Powder mixtures were wetted and mixed for 10 min using a 
Kenwood Chef Kneader before being manually passed through a 1,000 μm sieve. 
The prepared granules were dried using a drying oven at 60°C overnight (~12 h), 
and then dried granules passed through 853 μm sieve and granules ≤ 853 μm 
were used.  
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Resulted crushing strengths of the prepared granules were not appropriate; 
they were in range of 10-41 N. In stage V of the formulation development trials 
(Table 2-5), hydroxyethyl cellulose supplier was changed into Ashland (Natrosol 
250-HHX) which is well known in the literature as a matrix former (Chatlapalli and 
Rohera, 1998; Baumgartner  et al., 2002; Larsson et al., 2008; Chen et al., 2010b; 
Chen et al., 2013). Water as a binder was successful to provide granules with 
promising crushing strength results. Two levels (20 and 25% (w/w)) of filler 
(Avicel® PH102 and Prosolv 90®) were tried to enable maximum drug loading 
ability. At 25% (w/w) filler concentration, both fillers (Avicel® PH102 and Prosolv 
90®) were good, however at 20% (w/w), Prosolv 90® revealed better crushing 
strength results. Finally, in stage VI (Table 2-6), pentoxifylline was successfully 
loaded to the designed floating tablets. Higher quantity of cefalexin monohydrate 
were required to be loaded, thus, the filler (Prosolv 90®) was excluded successfully 
from cefalexin tablets. Water as a binder was effective to provide granules. In 
order to reduce friction during the automatic pressing (of granulated powders) 
using a single-punch tableting machine, 0.5% (w/w) magnesium stearate was 
used. Promising crushing strength results were obtained for the tablets of powder 
mixture or granules origin. 
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Table 2-1: Stage I of formulation development trials. 
Trial HECa Sodium alginateb 
Gassing agent 
Lubricant Model drug 
Sodium bicarbonatef 
1 50% 50% 0% 0% 0% 
2 45% 45% 10% 0% 0% 
3 40% 40% 20% 0% 0% 
a Hydroxyethyl cellulose supplied by Sigma-Aldrich (UK), viscosity at 25˚C at 2% is 4500-6500 cP, molecular weight is 7.2x104 
g/mole. 
b Supplied by Sigma-Aldrich (UK), viscosity at 25˚C at 1% is 15-25 cP (medium viscosity). 
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Table 2-2: Stage II of formulation development trials. 
Trial HECa Sodium alginateb 
Filler Gassing agent 
Lubricant Model drug LubriToseTM 
MCCc 
LubriToseTM 
mannitold 
LubriToseTM 
lactosee 
Sodium bicarbonatef 
4 37.5% 37.5% 25% 0% 0% 0% 0% 0% 
5 33.75% 33.75% 22.5% 0% 0% 10% 0% 0% 
6 30% 30% 20% 0% 0% 20% 0% 0% 
7 37.5% 37.5% 0% 25% 0% 0% 0% 0% 
8 33.75% 33.75% 0% 22.5% 0% 10% 0% 0% 
9 30% 30% 0% 20% 0% 20% 0% 0% 
10 37.5% 37.5% 0% 0% 25% 0% 0% 0% 
11 33.75% 33.75% 0% 0% 25% 10% 0% 0% 
12 30% 30% 0% 0% 25% 20% 0% 0% 
a Hydroxyethyl cellulose supplied by Sigma-Aldrich (UK), viscosity at 25˚C at 2% is 4500-6500 cP, molecular weight is 7.2x104 
g/mole. 
b Supplied by Sigma-Aldrich (UK), viscosity at 25˚C at 1% is 15-25 cP (medium viscosity). 
c Co-processed excipient consisting of NF/EP/JP compliant microcrystalline cellulose (MCC) and glyceryl monostearate NF 
d Co-processed excipient consisting of USP compliant spray dried mannitol and glyceryl monostearate NF 
e Co-processed excipient consisting of NF/EP/JP compliant spray dried monohydrate lactose and glyceryl monostearate NF 
f Supplied by Sigma-Aldrich (UK) 
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Table 2-3: Stage III of formulation development trials. 
Trial HECa 
Sodium 
alginateb 
Filler Gassing agent 
Lubricant Model drug Avicel® 
PH101c 
Avicel® 
PH102d 
Avicel® 
PH105e 
Prosolv 90®f 
Sodium 
bicarbonateg 
13 37.5% 37.5% 25% 0% 0% 0% 0% 0% 0% 
14 33.75% 33.75% 22.5% 0% 0% 0% 10% 0% 0% 
15 30% 30% 20% 0% 0% 0% 20% 0% 0% 
16 37.5% 37.5% 0% 25% 0% 0% 0% 0% 0% 
17 33.75% 33.75% 0% 22.5% 0% 0% 10% 0% 0% 
18 30% 30% 0% 20% 0% 0% 20% 0% 0% 
19 37.5% 37.5% 0% 0% 25% 0% 0% 0% 0% 
20 33.75% 33.75% 0% 0% 22.5% 0% 10% 0% 0% 
21 30% 30% 0% 0% 20% 0% 20% 0% 0% 
22 37.5% 37.5% 0% 0% 0% 25% 0% 0% 0% 
23 33.75% 33.75% 0% 0% 0% 22.5% 10% 0% 0% 
24 30% 30% 0% 0% 0% 20% 20% 0% 0% 
a Hydroxyethyl cellulose supplied by Sigma-Aldrich (UK), viscosity at 25˚C at 2% is 4500-6500 cP, molecular weight is 7.2x104 
g/mole. 
b Supplied by Sigma-Aldrich (UK), viscosity at 25˚C at 1% is 15-25 cP (medium viscosity). 
c Supplied by FMC Biopolymer Corp (USA), particle size is 50 μm. 
d Supplied by FMC Biopolymer Corp (USA), particle size is 100 μm. 
e Supplied by FMC Biopolymer Corp (USA), particle size is 20 μm. 
f Supplied by JRS Pharma (Germany), silicified MCC, particle size is 125 μm. 
g Supplied by Sigma-Aldrich (UK). 
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Table 2-4: Stage IV of formulation development trials. 
Trial HECa 
Sodium 
alginateb 
Filler 
Gassing 
agent 
Lubricant 
Model 
drug 
Liquid binder 
Avicel® 
PH101c 
Avicel® 
PH102d 
Avicel® 
PH105e 
Prosolv 
90®f 
Water 
PVPg 
2.5% 
PVPg 
5.0% 
PVPg 
7.5% 
PVPg 
10% 
25 37.5% 37.5% 25% 0% 0% 0% 0% 0% 0% 
Sufficient liquid was added to 
prepare the wet mass before 
granulation. 
26 37.5% 37.5% 0% 25% 0% 0% 0% 0% 0% 
27 37.5% 37.5% 0% 0% 25% 0% 0% 0% 0% 
28 37.5% 37.5% 0% 0% 0% 25% 0% 0% 0% 
a Hydroxyethyl cellulose supplied by Sigma-Aldrich (UK), viscosity at 25˚C at 2% is 4500-6500 cP, molecular weight is 7.2x104 
g/mole. 
b Supplied by Sigma-Aldrich (UK), viscosity at 25˚C at 1% is 15-25 cP (medium viscosity). 
c Supplied by FMC Biopolymer Corp (USA), particle size is 50 μm. 
d Supplied by FMC Biopolymer Corp (USA), particle size is 100 μm. 
e Supplied by FMC Biopolymer Corp (USA), particle size is 20 μm. 
f Supplied by JRS Pharma (Germany), silicified MCC, particle size is 125 μm. 
g Polyvinylpyrolidone supplied by Sigma-Aldrich (UK), average molecular weight tried was 10,000 and 40,000 g/mole. 
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Table 2-5: Stage V of formulation development trials. 
Trial HECa 
Sodium 
alginateb 
Filler Gassing agent 
Lubricant Model drug 
Liquid binder 
Avicel® 
PH102c 
Prosolv 
90®d 
Sodium bicarbonatee Water 
29 37.5% 37.5% 25% 0% 0% 0% 0% 
Sufficient 
liquid was 
added to 
prepare the 
wet mass 
before 
granulation. 
30 33.75% 33.75% 22.5% 0% 10% 0% 0% 
31 30% 30% 20% 0% 20% 0% 0% 
32 37.5% 37.5% 0% 25% 0% 0% 0% 
33 33.75% 33.75% 0% 22.5% 10% 0% 0% 
34 30% 30% 0% 20% 20% 0% 0% 
35 40% 40% 20% 0% 0% 0% 0% 
36 36% 36% 18% 0% 10% 0% 0% 
37 32% 32% 16% 0% 20% 0% 0% 
38 40% 40% 0% 20% 0% 0% 0% 
39 36% 36% 0% 18% 10% 0% 0% 
40 32% 32% 0% 16% 20% 0% 0% 
a Hydroxyethyl cellulose (Natrosol 250-HHX) was generously supplied by Ashland (USA), viscosity at 25˚C at 1% is 3400-5000 
cP, molecular weight is 1.3x106 g/mole. 
b Supplied by Sigma-Aldrich (UK), viscosity at 25˚C at 1% is 15-25 cP (medium viscosity). 
c Supplied by FMC Biopolymer Corp (USA), particle size is 100 μm. 
d Supplied by JRS Pharma (Germany), silicified MCC, particle size is 125 μm. 
e Supplied by Sigma-Aldrich (UK). 
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Table 2-6: Stage VI of formulation development trials. 
Trial HECa 
Sodium 
alginateb 
Filler Gassing agent Lubricant Model drug Liquid binder 
Prosolv 
90®d 
Sodium 
bicarbonatee 
Magnesium 
stearatef 
Pentoxifyllineg 
Cefalexin 
monohydrateh 
Water 
41 27.86% 27.86% 19.9% 0% 0.5% 23.88% 0% 
Sufficient liquid was 
added to prepare 
the wet mass before 
granulation. 
42 25.10% 25.10% 17.93% 9.87% 0.5% 21.50% 0% 
43 22.28% 22.28% 15.96% 19.87% 0.5% 19.11% 0% 
44 17.66% 17.66% 0% 0% 0.5% 0% 64.18% 
45 15.91% 15.91% 0% 9.85% 0.5% 0% 57.83% 
46 14.13% 14.13% 0% 19.88% 0.5% 0% 51.36% 
a Hydroxyethyl cellulose (Natrosol 250-HHX) was generously supplied by Ashland (USA), viscosity at 25˚C at 1% is 3400-5000 
cP, molecular weight is 1.3x106 g/mole. 
b Supplied by Sigma-Aldrich (UK), viscosity at 25˚C at 1% is 15-25 cP (medium viscosity). 
c Supplied by FMC Biopolymer Corp (USA), particle size is 100 μm. 
d Supplied by JRS Pharma (Germany), silicified MCC, particle size is 125 μm. 
e Supplied by Sigma-Aldrich (UK). 
f Supplied by MEDEX (UK). 
g Supplied by Sigma-Aldrich (UK). 
h Supplied by Sigma-Aldrich (UK).
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To give an outline, Figure 2-5 presents a schematic diagram of this study. 
The aim was to design and evaluate floating gastroretentive drug delivery matrix 
tablets with sustained release behaviours for pentoxifylline and cefalexin 
monohydrate model drugs, using hydroxyethyl cellulose and sodium alginate 
polymers. Effect of different variables such as formulation variables (wet 
granulation, type and ratio of sodium bicarbonate, calcium carbonate, or sodium 
carbonate gas forming agent), and tablet physical properties (tablet crushing 
strength) on floating capacity and drug release rate was investigated. The kinetics 
of drug release were investigated in vitro in relation to these formulations in 0.1 M 
HCl dissolution medium and in vivo for most promising formulations. 
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Figure 2-5: Introduction schematic diagram of the practical work. 
Ingredients 
- Model drug: pentoxifylline, cefalexin monohydrate. 
- Gassing agent: sodium bicarbonate, calcium carbonate, sodium carbonate. 
- Hydrophilic polymer: hydroxyethyl cellulose, sodium alginate. 
- Filler: prosolv
® 
90 
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2.2.3 Preparation of powder mixture and granules containing 
model drugs 
 
Refer to section ‎1.4 and section ‎2.2.2 for the rationale behind selecting the 
ingredients and their amounts. Powder mixture compositions for the preparation of 
tablets are shown in Table 2-7 and Table 2-8. Powder blends were prepared using 
a (1:1) binary mixture of hydroxyethyl cellulose and sodium alginate gel forming 
agents. Sodium bicarbonate, calcium carbonate or sodium carbonate was added 
as a gas forming agent at 0%, 10% or 20% (w/w) concentration of the total tablet 
weight. Pentoxifylline or cefalexin monohydrate was used as a model drug. 
Primarily, the floating tablet formulations (F1-F7) were tested using only 60 mg of 
pentoxifylline to invistigate the ability of the designed tablets to show good floating 
capacity and dug release retardation as pentoxifylline is considered dense and 
highly water soluble. Later, cefalexin monohydrate was loaded in the formulations 
(F8-F14) using the same tablets design principle regarding (1:1) binary mixture of 
the gel forming agents as well as the type and concentration of the gas forming 
agents. 
 However, Prosolv® 90 which was used as a filler to enhance the 
compression process of pentoxifylline formulations was removed from cefalexin 
monohydrate formulations because they were easier to tablet. Additionally, it was 
a target to increase cefalexin monohydrate content in the tablets to simulate the 
effective dose available in the market (500 mg), however because of the tableting 
machine die volume capacity, only 250 mg drug content was achieved. This 
increase in the drug content of cefalexin monohydrate was expected to apply 
further challenge on the properties of the designed floating tablets due to the 
reduction in the polymeric mixture content. All ingredients were passed through a 
180 μm sieve before mixing; sodium alginate was passed through a 350 μm sieve, 
size suitable for tablet compression. A turbula mixer (Glen Creston Ltd, UK) set at 
60 rpm, with a glass bottle, 250 ml, mixing vessel, was used to mix the powders 
for 10 min.  
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The wet granulation process was used to modify powder flowability to 
facilitate automatic compaction of the powder. Powder mixtures were wetted with a 
sufficient quantity of water and mixed for 10 min using a Kenwood Chef Kneader 
(Thorn Domestic Appliances Ltd, UK) before being manually passed through a 
1,000 μm sieve. The prepared granules were dried using a drying oven (SciQuio 
Ltd, UK) at 60°C overnight (~12 h) (Larsson et al., 2008), and then dried granules 
passed through 853 μm sieve and granules ≤ 853 μm were used.   
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Table 2-7: Composition of prepared pentoxifylline tablets 
Ingredients/Formulation 
F1 
(mg) 
F2 
(mg) 
F3 
(mg) 
F4 
(mg) 
F5 
(mg) 
F6 
(mg) 
F7 
(mg) 
Pentoxifylline 60 60 60 60 60 60 60 
Hydroxyethyl cellulose 70 70 70 70 70 70 70 
Sodium alginate 70 70 70 70 70 70 70 
Prosolv® 90 50 50 50 50 50 50 50 
Sodium bicarbonate 27.5 62.5      
Calcium carbonate    27.5 62.5    
Sodium carbonate     27.5 62.5  
Magnesium stearate 
(0.5%) 
1.4 1.6 1.4 1.6 1.4 1.6 1.3 
Total weight 278.9a 314.1a 278.9a 314.1a 278.9a 314.1a 251.3 
a Difference in weight was due to raising gassing agent content from 10% to 20% 
(w/w).                                                                                                                                  
Note: number of moles of the gassing agents used in the formulations is 3.3x10-4 
(F1), 7.4x10-4 (F2), 2.7x10-4 (F3), 6.2x10-4 (F4), 2.6x10-4 (F5), and 5.9x10-4 (F6). 
 
 
 
Table 2-8: Composition of prepared cefalexin monohydrate tablets 
Ingredients/Formulation 
F8 
(mg) 
F9 
(mg) 
F10 
(mg) 
F11 
(mg) 
F12 
(mg) 
F13 
(mg) 
F14 
(mg) 
Cefalexin monohydrate 250 250 250 250 250 250 250 
Hydroxyethyl cellulose 68.8 68.8 68.8 68.8 68.8 68.8 68.8 
Sodium alginate 68.8 68.8 68.8 68.8 68.8 68.8 68.8 
Sodium bicarbonate 42.6 96.8      
Calcium carbonate    42.6 96.8    
Sodium carbonate     42.6 96.8  
Magnesium stearate 
(0.5%) 
2.2 2.4 2.2 2.4 2.2 2.4 1.9 
Total weight 432.4a 486.8a 432.4a 486.8a 432.6a 486.8a 389.5 
a Difference in weight was due to raising gassing agent content from 10% to 20% 
(w/w).       
Note: number of moles of the gassing agents used in the formulations is 5.1x10-4 
(F8), 11.5x10-4 (F9), 4.3x10-4 (F10), 9.7x10-4 (F11), 4.0x10-4 (F12), and 9.1x10-4 
(F13).                            
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2.2.4 Preparation of floating tablets  
 
To evaluate the effect of the gassing agent concentration on tablet porosity, 
floating capacity, swelling, erosion and dissolution behaviours, pentoxifylline or 
cefalexin monohydrate tablets were automatically pressed (from granulated 
powders) using a single-punch tableting machine (Type 3, Manesty Machines Ltd, 
UK) equipped with flat-faced punches (9.60 mm), and the compression speed was 
85 rpm. The compression force was adjusted by decreasing the distance between 
punches to produce tablets with three crushing strength levels (A: 49–54 N;   B: 
54-59 N; and C: 59-64 N), as measured using the crushing strength tester (Model 
2E/205, Schleuniger & Co., Switzerland). Tablets were successfully pressed 
automatically. However, F5 formulation could not be pressed automatically at the 
required crushing strength levels (A: 49–54 N;   B: 54-59 N; and C: 59-64 N), 
hence these were pressed manually; the required granules weight was fed directly 
from the hopper into the die of the single-punch tableting machine and compacted 
manually.  
In order to compare between tablets with same excipient composition 
before and after granulation, in other words to investigate the possible effects of 
the wet granulation process on tablet porosity, floating capacity and dissolution 
behaviour, a group of manually pressed tablets of F1-F14 formulations were 
prepared. These tablets were pressed from powder blends before granulation 
where the required powder mixture was weighed, and fed manually into the die of 
the single-punch tableting machine to produce the desired tablets. Accordingly, 
granulated powders were compacted automatically but un-granulated powder 
mixtures were pressed manually. A flow chart for floating tablets preparation is 
presented in Figure 2-6. 
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Figure 2-6: Flow chart for prepared floating tablets. 
 
2.2.5 Evaluation of the prepared powders and granules 
 
2.2.5.1 Flowability test 
 
Bulk and tapped volumes of 50 g samples of the prepared powder mixture 
and granules were measured by the tapping apparatus (Copley JV1000, UK). Bulk 
and tapped densities were calculated as the ratio of the powder weights to the 
related powder volumes. Carr‘s compressibility index (CI) was calculated using 
equation (1) (Carr, 1965): 
 
 
   (
                           
              
)      
Eq. (1) 
 
Measurements were performed in triplicate and the mean values ± SD are 
presented. 
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2.2.5.2 Moisture content  
 
A Mettler Toledo HG53 Halogen Moisture Analyser (Switzerland) was used 
to measure the moisture content in a 1 g powder mixture before and after 
granulation. Measurements were taken in triplicate and mean values ± SD are 
presented.  
 
2.2.5.3 Differential scanning calorimetry (DSC) study 
 
DSC of model drugs, excipients, and all the formulations (prepared from 
powder mixture and granules) were obtained using a DSC Refrigerated Cooling 
System (Model Q1000, TA Instruments, UK). Samples of pure materials (2–6 mg) 
were weighed and transferred into the equipment for analysis in sealed standard 
aluminum pans, and the calorimetric enthalpy readings were calculated using 
Q1000, TA software (Suliman et al., 2014). The thermal behaviour of the samples 
was investigated at a scanning rate of 10˚C / min, from 0 to 260˚C for 
pentoxifylline and from 0 to 250˚C for cefalexin monohydrate. 
 
2.2.5.4 Fourier-transform infrared (FTIR) spectroscopy 
 
Infrared spectra of model drugs and all the formulations (prepared from 
powder mixture or granules) were obtained using a Perkin Elmer FT-IR system 
Spectrum BX series (Beaconsfield, Buckinghamshire, UK) in the frequency range 
of 4000–620 cm-1 at 4 cm-1 resolution. A few milligrams of each sample were 
placed in the middle of the sample stage using a micro-spatula, before being 
compressed by twisting the top of the arm of the sample stage clockwise (Suliman 
et al., 2014). The data were obtained by Spectrum BX series software version 
5.3.1. 
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2.2.6 Evaluation of floating tablets 
 
Tablets prepared from granules were evaluated for tablet crushing strength, 
friability, weight uniformity, drug content uniformity, apparent density, porosity, 
floating capacity, swelling and erosion, dissolution, release data modeling, and 
stability testing. Tablets prepared from powder mixtures were evaluated only for 
apparent density, porosity, floating capacity, dissolution, and release data 
modeling, as these tablets had been compacted manually. 
 
2.2.6.1 Tablet crushing strength, friability, weight uniformity, drug 
content uniformity 
 
To establish tablet crushing strength, ten tablets were randomly selected, 
their crushing strength examined using a tablet crushing strength tester, and mean 
values ± SD are presented. For friability, twenty tablets were randomly selected 
and tested at 100 revolutions using friability test apparatus (Copley FRV 1000, 
UK). The percentage of weight loss (F) was calculated by equation (2) (BP, 2015): 
 
   
     
  
      Eq. (2) 
     
Where w1 is the tablet weight before friability test, w2 is the tablet weight 
after the test. 
For the weight uniformity test, 20 tablets were randomly selected and 
accurately weighed individually, and the mean weight of all the tablets and 
percentage deviation from the mean for each tablet are presented. Regarding drug 
content uniformity, ten tablets were randomly selected, each individual tablet was 
weighed then crushed, a quantity of the powder was extracted with 100 ml, 0.1 M 
HCl, and the solution was filtered through a cellulose acetate membrane (0.45 
μm). After a suitable dilution in 0.1 M HCl, the absorbance of pentoxifylline and 
cefalexin monohydrate samples were determined using a UV/Vis 
spectrophotometer (Model M501, Camspec Ltd, Cambridge, UK) at 274 nm and 
257 nm respectively.  
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Drug content was calculated using the generated calibration data of each 
model drug (Figure 2-3 and Figure 2-4); the percentages of individual drug content 
were calculated against the average drug content according to the British 
Pharmacopoeia (BP) specifications. 
 
2.2.6.2 Tablet apparent density and porosity  
 
Tablet height (h) and diameter (m) were measured using Vernier caliper 
(Moore and Wright Sheffield England Metric, UK). Tablet weight (w) and the 
circular constant (π) were also used to calculate the apparent density (D) of the 
tablets by equation (3) (Ali et al., 2007): 
 
  (
 
   
)  
 
(
 
 )
 
    
 Eq. (3) 
 
The test was performed in six replicate and mean values ± SD are 
presented. 
Tablet porosity (ε), was calculated using equation (4) ( Sun, 2006): 
 
   [  (            ⁄ )]      Eq. (4) 
 
Where ρtablet is the tablet‘s apparent density and ρtrue is the true density of 
the powder mixture or granule sample measured using a multipycnometer (MVP-
D160-E, Quantachrome Instruments, USA). Five replicate measurements of 
almost 1.8 g and 1.3 g samples of pentoxifylline and cefalexin monohydrate 
respectively were used. The helium pressure was set to 17 psi, and the difference 
in helium pressure before and after sample loading was reported to determine the 
true volume of the samples. Mean values ± SD are presented. 
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2.2.6.3 Tablet floating capacity 
 
Floating capacity was determined under the same conditions and using the 
same apparatus as for the in vitro studies (Section ‎2.2.6.5). The time taken for 
tablets to appear and remain on the dissolution medium surface (floating lag time), 
and the period of time that the tablets constantly floated on the dissolution medium 
surface (floating duration) were determined visually throughout the drug release 
studies (Yin et al., 2013). Measurements were taken in triplicate and mean values 
± SD are presented.  
 
2.2.6.4 Swelling and erosion studies 
 
The initial weights of three randomly chosen tablets were reported. The 
dissolution medium uptake (DMU) and mass loss (ML) percentage of the tablets 
were determined using USP Dissolution Apparatus II (Erweka GmbH, Germany) 
under the same conditions as the drug release study (Section ‎2.2.6.5). Tablets 
were carefully withdrawn using a spoon from the medium at same time intervals 
conditions as the drug release study (at 0.5, 1, 2, 4, 6, 8, 12, and 24 h for 
pentoxifylline and at 0.5, 1, 2, 4, 6, 8, 10 and 12 h for cefalexin monohydrate). 
Excess liquid present on the surface of tablets was removed using a filter paper 
and the tablets were weighed and then dried at 60°C in a drying oven until a 
constant dry weight was achieved.  
Swelling and mass loss percentages were calculated by equations (5) and 
(6) (Roy and Rohera, 2002): 
 
 
     (
     
  
)      
Eq. (5) 
 
 
    (
     
  
)      
Eq. (6) 
 
Where Wi is the initial weight of the tablet, Ww is the wet weight of the 
tablet, and Wd is the dry weight of the tablet and mean values ± SD are presented.  
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2.2.6.5 In vitro drug release studies 
 
Drug release studies of the prepared tablets were carried out using USP 
dissolution apparatus II (Erweka GmbH, Germany) at 37°C ± 0.5°C, and a paddle 
speed of 50 rpm and 100 rpm for pentoxifylline and cefalexin monohydrate 
respectively. Pentoxifylline tablets were tested at 50 rpm rotation speed to meet 
USP dissolution test 6 of pentoxifylline sustained release tablets (USP 2012). For 
cefalexin, no official monograph is available for sustained release tablets; thus the 
paddle rotation speed was adapted from the literature (Agnihotri, et al., 2006; Yin 
et al., 2013). Tablets were placed into 900 ml of 0.1 M HCl (pH 1.2) as a simulated 
gastric fluid without the presence of gastric enzymes (Tadros, 2010; Oh et al., 
2013; Yin et al., 2013; Qi et al., 2015). Samples (10 ml) were withdrawn from the 
dissolution at 0.5, 1, 2, 4, 6, 8, 12, and 24 h for pentoxifylline and at 0.5, 1, 2, 4, 6, 
8, 10 and 12 h for cefalexin monohydrate. Withdrawn samples were replaced with 
fresh medium, and drug content was determined and the cumulative drug release 
percentage was calculated. The test was performed in triplicate and mean values 
± SD are presented. The pH of the dissolution medium at each sampling time 
interval was measured by pH-meter (Hanna Instruments HI 8424N Digital, 
Portable pH Meter, USA). Sink conditions were met for both pentoxifylline and 
cefalexin monohydrate as the concentration of the active substance in the 
saturated medium will be greater than the used concentrations.  
 
2.2.6.6 Release data modeling and analysis  
 
In order to study the release kinetics, data of in vitro drug release studies 
were fitted to different mathematical models. The zero order model equation (7) 
which describes systems where the drug release rate is independent on its 
concentration. However, systems representing a concentration dependent release 
rate are described by the first order model equation (8). The Hixson-Crowell cube 
root law equation (9) describes the release kinetics from systems showing a 
change in surface area and diameter of particles or tablets.  
Moreover, Higuchi kinetic model equation (10) represents the release of 
drugs from insoluble matrix as a square root of time dependent process based on 
Fickian diffusion (Costa and Sousa Lobo, 2001).  
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       Eq. (7) 
 
 
   (     )        
   
     
 
Eq. (8) 
 
 √  
  √  
    t Eq. (9) 
 
     √  Eq. (10) 
 
Where Q is the amount of drug released at time t, Qo is the initial amount of 
the drug in tablet, ko is the zero order release rate constant, k1 is the first order 
release rate constant, kHC is the Hixson-Crowell release rate constant, and kH is 
the Higuchi release rate constant. 
In order to characterise the model drug release mechanism (release data 
modeling and analysis), the power law model of Korsmeyer–Peppas equation (11) 
was fitted to the first 60% release data (Korsmeyer et al., 1983). 
 
   
  
     
  
Eq. (11) 
 
Where Qt/Q∞ represents the fractional drug released at time t, Kp is the 
Korsmeyer–Peppas release rate constant, and n is the release exponent. 
The drug release data were plotted in various kinetic models, including 
zero-order, first order, Hixson Crowell, Higuchi, and Korsmeyer-Peppas equations.  
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2.2.7 Stability studies 
 
Regarding the guidance for industry, Q1A(R2), for stability testing of new 
drug substances and products (ICH, 2003), stress testing of the drug product can 
help identifying the likely changes that can influence quality, safety, and/or 
degradation behaviours of the drug substance. The drug product can be 
maintained under accelerated storage conditions including the effect of elevated 
temperature and humidity (40°C ± 2°C and 75% ± 5% RH) for 6 months while 
stored in suitable container closure system that mimics the appropriate marketing 
package.   
In this work, the stability studies were conducted for shorter period of time 
(3 months) which met those of other gastroretentive dosage form stability studies 
(Tadros 2010; Acharya et al., 2014), however the stability chambers were 
maintained at higher relative humidity level (80% ± 5%) instead of ICH 
requirements (75% ± 5%) to apply further stressful conditions. Furthermore, 
storage in closed containers is reflective to the storage conditions of the packed 
pharmaceutical products; however, storage in open containers will raise the stress 
as the product will be in direct contact with the elevated temperature and humidity. 
Accordingly, granules and tablets prepared from the granules for all the 
formulations were packed in open or closed polyethylene (high density type) 
containers and stored in a stability chamber. Granules were withdrawn after 3 
months and analysed by DSC and FTIR spectroscopy as described in 
sections ‎2.2.5.3, and ‎2.2.5.4 respectively. Also, after 3 months, tablets were 
withdrawn and evaluated for their apparent density, floating capacity, and drug 
release rate as described in sections ‎2.2.6.2, ‎2.2.6.3, and ‎2.2.6.5 respectively. 
 
2.2.8 Preliminary in vivo pharmacokinetic study 
 
Twelve male albino rats weighing 180 ± 20 g were provided by Applied 
Science Private University, Jordan. The animals were kept in the animal house at 
an ambient temperature (25 ± 1 °C) for a 12 h dark and 12 h light cycle. The 
animals were fed a pellet diet and had access to water ad libitum.  
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The experimental protocol was approved by the Research Ethics 
Committee (University of Sunderland), and all methods were conducted according 
to the University of Applied Science Private University guidelines. Pentoxifylline 
tablets (weighing 30 ± 1 mg equivalent to 5.73 mg drug) of F4 formulation were 
pressed manually (for granulated powders) using a single-punch tableting machine 
(Type 3, Manesty Machines Ltd, UK) equipped with concave-faced punches (4.00 
mm), and the compression force was adjusted to produce tablets with a crushing 
strength level of 20 ± 1 N, as measured using the crushing strength tester (Model 
2E/205, Schleuniger & Co., Switzerland). An aqueous solution of pentoxifylline 
(2.88 mg/ml) was prepared as a reference. 
Rats were randomly divided into two groups and fasted for about 12 h prior 
to the experiment with a free access to water. The first group (G1) received the 
oral tablets, and the second group (G2) received the oral reference solution. The 
preparations (tablet and solution) were loaded directly into the stomach by intra-
gastric gavage at a single dose of 5.75 ± 0.15 mg. Blood samples were collected 
using the tail-bleeding technique into a 0.5 ml mini-collect tubes (K3E K3EDTA) at 
0.5, 1, 2, 4, 6, 8, 12 and 24 h, then subjected to centrifugation for 5 min at 13000 
rpm (Model M-24, Boeco, Germany) and aliquots of plasma were frozen at − 20 °C 
before analysis.  
Plasma samples (0.2 ml) mixed with 50 μl of an internal standard (20 μg/ml of 
emitrecitabine) by vortex, before adding 0.55 ml of methanol and mixing, then 
subjecting the mixture to centrifugation for 10 min at 14000 rpm using a centrifuge 
(Model 5417C, Eppendorf - Nrtheler - Hinz GmbH, Germany). The resulting 
supernatant was transferred to a glass insert for analysis, and 2 μl was directly 
injected into a HPLC-MS/MS system (Model 1200, Agilent Technologies Co., Ltd., 
Santa Clara, USA) which was equipped with a mass spectrometer (Model API 
4000, SCIEX, Toronto, Canada).  
Chromatographic separation was based on an ACE 5 C18 column (50 mm x 
2.1 mm, 5µm) with a  mobile phase composed of [0.2% ammonia (10%), 0.04% 
formic Acid (10%)] 50% : methanol 50% pumped at a constant flow rate of 0.6 
ml/min.  
 
 
 78 
 
In this pharmacokinetic study, the maximum plasma concentration (Cmax) 
and the time required to reach this concentration (Tmax) were obtained by actual 
observations of the plasma concentration-time data. The elimination rate constant 
(ke) was calculated from the slope of the linear terminal line of the logarithmic 
plasma concentration-time data, and, the half-life (t1/2) was calculated by equation 
(12) (Jambhekar and Breen, 2009): 
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Eq. (12) 
 
The area under the curve (AUC0-t) was calculated using the trapezoidal rule 
from 0 to 24 h, and the area under the curve from zero to infinity (AUC0-∞) was 
calculated from (AUC0-t) plus the extrapolated portion Cp/ke by equation (13) 
(Kagan et al., 2006):  
 
 
              
   
  
 
Eq. (13) 
 
Where Cpt is the plasma drug concentration observed at time t. All data are 
presented as the mean value ± SD.  
The relative bioavailability values (Frel) were calculated by equation (14) 
(Jambhekar and Breen, 2009): 
 
 
     
         
           
 
            
          
 
Eq. (14) 
 
2.2.9 Statistical analysis 
 
The statistical software package, SPSS 22 (SPSS Inc., Chicago, USA) was 
used to perform the statistical analysis by applying the paired-sample t-test, and 
one-way analysis of variance, depending upon the type of data. Post hoc multiple 
comparisons were applied when necessary, and a P-value of <0.05 was 
considered significant.  
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3 Chapter Three: Evaluation of the effect of 
sodium bicarbonate, calcium carbonate, and 
sodium carbonate as gassing agents on 
pentoxifylline floating tablets 
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In this chapter a swellable, floatable, gastroretentive drug delivery systems 
utilising an effervescent mechanism was developed and evaluated. Tablets were 
based on a binary (1:1) gel forming polymer mixture of hydroxyethyl cellulose and 
sodium alginate, and sodium bicarbonate or calcium carbonate or sodium 
carbonate as a gas generating agent. Pentoxifylline was used as a model drug 
since it has a short half-life (t1/2) of 0.8–1.8 h (Ings et al., 1982), high density 
(Baumgartner et al., 2000), and is highly soluble in water (191 mg/ml at 37°C) 
(Mikac et al., 2010). Consequently, these characteristics made it a suitable 
candidate for oral sustained release delivery to improve patient compliance and 
reduce side effects due to better control of therapeutic drug concentration and also 
made it ideal to challenge the ability of the designed gastroretentive tablets to 
show acceptable floating capacity and acceptable retarding of the drug release 
process. The variables that may affect drug release and floating properties were 
investigated, such as the wet granulation (to compare effects of powder mixtures 
versus those of granules), type and ratio of the gas forming agent (sodium 
bicarbonate, calcium carbonate and sodium carbonate). Only 60 mg of 
pentoxifylline was used in the study to evaluate efficiency of the designed floating 
tablets; however the drug dose could be scaled up in the future.   
 
3.1 Evaluation of the prepared powders and granules (pre-
compression characterisation) 
 
All the prepared powder mixtures and granules of the formulations F1-F7 
were evaluated for flowability CI index, moisture content percentage, DSC, and 
FTIR. The formulations F1-F7 compositions are presented in Table ‎3-1 (and also 
Table 2-7). 
 
 
 
 
  
 
8
1
 
Table ‎3-1: Composition of prepared F1-F7 tablets 
Ingredients/Formulation F1 (mg) F2 (mg) F3 (mg) F4 (mg) F5 (mg) F6 (mg) F7 (mg) 
Pentoxifylline 60 60 60 60 60 60 60 
Hydroxyethyl cellulose 70 70 70 70 70 70 70 
Sodium alginate 70 70 70 70 70 70 70 
Prosolv® 90 50 50 50 50 50 50 50 
Sodium bicarbonate 27.5 62.5      
Calcium carbonate    27.5 62.5    
Sodium carbonate     27.5 62.5  
Magnesium stearate (0.5%) 1.4 1.6 1.4 1.6 1.4 1.6 1.3 
Total weight 278.9a 314.1a 278.9a 314.1a 278.9a 314.1a 251.3 
a Difference in weight was due to raising gassing agent content from 10% to 20% (w/w). 
Note: number of moles of the gassing agents used in the formulations is 3.3x10-4 (F1), 7.4x10-4 (F2), 2.7x10-4 (F3), 6.2x10-4 
(F4), 2.6x10-4 (F5), and 5.9x10-4 (F6). 
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3.1.1 Flowability and moisture content for powders and granules 
 
 It is important for oral solid dosage forms development (such as tablets) to 
investigate powder or granules flow properties by making a correlation between 
rheological test results and manufacturing properties. Many methods are available 
to test the rheology such as angle of repose, compressibility index (Carr‘s index) 
and flow rate through an orifice. Packing studies of powder and granules (bulk 
density measurements) could be carried out with a tapping apparatus where 
powder or granules specific volumes before and after tapping is measured and 
divided by the used masses to calculate bulk and tapped apparent densities to 
give information about sample rheological properties (Yamashiro et al., 1983). It 
has been proposed that a small change in apparent density before and after 
tapping indicates good flow properties (Chan and Heng, 2005). The granulation 
process is one of the agglomeration techniques where fine solid particles are 
converted into larger ones by mixing them in the presence of binding liquids using 
suitable equipment (Wong et al., 2005). It has been reported that the formed 
granules could improve powder flowability and mechanical strength and could also 
narrow bulk density and porosity values (Tardos et al., 1997; Iveson et al., 2001). 
The CI values significantly decreased (P<0.05) following granulation for all the 
prepared formulations (F1-F7, Table ‎3-2) which reveals better flow properties of 
the granules compared to the powder mixture (Gaisford, 2013).  
Results for the moisture content and CI value of the formulations F1-F7 
before and after granulation are shown in Table ‎3-2. It is clear that the moisture 
content percentage significantly decreased (P<0.05) after granulation from 5.37%, 
4.76%, 5.83%, 4.91%, 5.70%, 5.51%, and 5.80% to 4.13%, 3.49%, 4.84%, 4.56%, 
4.53%, 4.11%, and 3.14% in the formulations F1-F7, respectively. It is important to 
control the level of moisture content of powder and granules as it can adversely 
affect on their rheology. Using a drying oven at 60°C overnight (~12 h) until a 
constant dry weight of the granules was achieved simply by evaporating the free 
moisture content (unbound water) resulted from the wet granulation process.  
The CI values significantly decreased (P<0.05) following granulation for all the 
prepared formulations (F1-F7,Table ‎3-2) which reveals better flow properties of the 
granules compared to the powder mixture (Gaisford, 2013). 
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Table ‎3-2: Moisture content and Carr‘s index with statistical analysis (p-value) 
results of the formulations F1-F7 before and after granulation. 
Test Formulation 
Origin of prepared tablets 
P-value Powder 
mixture 
Granules 
Moisture content (%) 
F1 5.37 ± 0.06 4.13 ± 0.17 0.005 
F2 4.76 ± 0.08 3.49 ± 0.14 0.003 
F3 5.83 ± 0.06 4.84 ± 0.05 0.001 
F4 4.91 ± 0.02 4.56 ± 0.04 0.010 
F5 5.70 ± 0.14 4.53 ± 0.19 0.003 
F6 5.51 ± 0.12 4.11 ± 0.16 0.004 
F7 5.80 ± 0.09 3.14 ± 0.93 0.043 
Carr‘s Index (CI) (%) 
F1 27.74 ± 0.46 16.87 ± 0.33 0.001 
F2 28.53 ± 2.81 17.65 ± 0.64 0.016 
F3 26.57 ± 2.53 16.63 ± 1.69 0.011 
F4 29.81 ± 3.09 16.33 ± 0.43 0.015 
F5 31.06 ± 1.58 15.26 ± 1.85 0.003 
F6 27.02 ± 1.32 16.83 ± 2.05 0.014 
F7 29.67 ± 1.60 15.29 ± 1.67 0.010 
Note: The data represents the mean ± SD of three determinations.  
For formulation composition, refer to Table ‎3-1 or Table 2-7.  
 
 
 
 
3.1.2 Differential scanning calorimetry (DSC) 
 
It is important to study the potential interactions between drugs and 
excipients in the pre-formulation stage during the development of all 
pharmaceutical dosage forms. Such interactions can alter chemical nature, 
stability, bioavailability, therapeutic efficacy and safety of drugs. Excipients are 
important to modify the pharmaceutical formulations; however, they might interact 
with drugs causing unwanted degradation. DSC is one of the techniques which 
can screen possible incompatibilities resulting from the appearance, shifts or 
disappearances of peaks and/or changes in the corresponding thermal enthalpies 
(Vueba et al., 2005). 
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Figure ‎3-1 to Figure ‎3-7 represent DSC thermograms of pure pentoxifylline, 
sodium alginate, hydroxyethyl cellulose, Prosolv® 90, sodium bicarbonate, calcium 
carbonate, and sodium carbonate raw materials respectively. As shown in 
(Figure ‎3-1), pure pentoxifylline showed a sharp endothermic peak at 104.80˚C 
due to drug melting. Sodium alginate had a broad endothermic peak around 
114.24˚C and two exothermic peaks at 212.89˚C and 240.02˚C (Figure ‎3-2). 
Hydroxyethyl cellulose, Prosolv® 90, sodium bicarbonate, and sodium carbonate 
presented endothermic peaks at about 94.88˚C (Figure ‎3-3), 94.50˚C (Figure ‎3-4), 
145.81˚C (Figure ‎3-5), and 85.75˚C (Figure ‎3-7) respectively. Calcium carbonate 
as a gassing agent did not show any thermal activity as presented in (Figure ‎3-6). 
The compatibility of pentoxifylline with excipients in the formulations F1-F7 before 
and after granulation was studied using DSC. An overlapping between 
hydroxyethyl cellulose, Prosolv® 90, and pentoxifylline endothermic peaks was 
noted in all the formulations F1-F7. However, the endothermic peak of sodium 
alginate was shifted from 114.24°C (pure sample) to 124.49-146.86°C and to 
120.51-147.26°C in the formulations F1-F7 prepared from the powder mixture and 
the granules respectively. Sodium bicarbonate endothermic peaks at 157.97°C 
and 156.27°C were reported for the powder mixture and the granules, 
respectively: (F1, Figure ‎3-8) and 158.64°C and 171.70°C (F2, Figure ‎3-9). The 
peak of sodium carbonate gassing agent was overlapped with pentoxifylline, 
hydroxyethyl cellulose and Prosolv® 90 in F5 (Figure ‎3-12) and F6 (Figure ‎3-13) 
formulations prepared either from the powder mixture or the granules. 
Although pure pentoxifylline showed a sharp endothermic peak at 
104.80°C, a shift to a lower temperature and a decrease in peak intensity were 
noted for F1 powder mixture and F1 granules with endothermic peaks at 91.84°C 
and 94.64°C, respectively, and enthalpy values were 25.05 J/g and 23.65 J/g 
respectively (Figure ‎3-8). These changes in thermal behaviour of the drug were 
presented in all other formulations (F2-F7).  
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Endothermic peaks at 90.27°C and 94.10°C were reported for the powder 
mixture and granules, respectively: (F2, Figure ‎3-9), 97.60°C and 95.23°C (F3, 
Figure ‎3-10), 95.10°C, and 93.64°C (F4, Figure ‎3-11), 94.06°C, and 92.80°C (F5, 
Figure ‎3-12), 95.34°C, and 97.28°C (F6, Figure ‎3-13), and 95.85°C, and 96.26°C 
(F7, Figure ‎3-14). Moreover, enthalpy for the powder mixture and granules were 
reported respectively 22.76 J/g and 19.15 J/g for F2, 29.09 J/g and 28.21 J/g for 
F3, 27.14 J/g and 20.82 J/g for F4, 32.20 J/g and 20.70 J/g for F5, 32.41 J/g and 
21.66 J/g for F6, and 34.79 J/g and 30.73 J/g for F7. 
These observations reflect the existence of an interaction between the drug 
and the other components; however, it was not due to any of the gassing agents. 
As shown in Figure ‎3-14, the compatibility of pentoxifylline with excipients in the 
control formulation (F7), with 0% (w/w) gassing agent, before and after granulation 
represented also a shift to a lower temperature and a decrease in the peak 
intensity for both F7 powder mixture and F7 granules. Therefore, these changes in 
the thermograms of the formulations F1-F7 may indicate a certain loss of drug 
crystallinity, which means some of pentoxifylline crystals converted into the 
amorphous form during the preparation of both the powder mixture as well as the 
granules (Vueba et al., 2004). No other thermal event occurred and these 
interactions do not necessarily indicate incompatibility, but conclusions based on 
DSC results alone can be often misleading and inconclusive (Mura et al., 1995). 
Therefore results obtained with DSC should always be confirmed with other tests. 
Regarding the ICH (Q6A) guidance for specifications: test procedures and 
acceptance criteria for new drug substances and new drug products, infrared 
spectroscopy is considered one of the specific tests for drug substance 
identification (ICH, 1999). Accordingly, FTIR was used in addition to DSC to 
evaluate potential interactions between the drug and the excipients. Results of 
FTIR (section ‎3.1.3) confirmed presence of pentoxifylline characteristic bands for 
all the formulations F1-F7. Such results approve absence of incompatibility 
between the drug and the formulation excipients (hydroxyethyl cellulose, sodium 
alginate, Prosolv® 90, sodium bicarbonate, calcium carbonate, sodium carbonate, 
and magnesium stearate).  
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Figure ‎3-1: DSC thermogram of pure pentoxifylline. 
 
 
 
Figure ‎3-2: DSC thermogram of sodium alginate. 
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Figure ‎3-3: DSC thermogram of hydroxyethyl cellulose. 
 
 
 
Figure ‎3-4: DSC thermogram of Prosolv® 90. 
. 
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Figure ‎3-5: DSC thermogram of sodium bicarbonate. 
 
 
 
Figure ‎3-6: DSC thermogram of calcium carbonate.  
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Figure ‎3-7: DSC thermogram of sodium carbonate 
 
 
 
Figure ‎3-8: DSC thermograms of pure pentoxifylline, F1 powder mixture and F1 
granules.  
For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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Figure ‎3-9: DSC thermograms of pure pentoxifylline, F2 powder mixture and F2 
granules.  
 
 
 
 
Figure ‎3-10: DSC thermograms of pure pentoxifylline, F3 powder mixture and F3 
granules.  
For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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Figure ‎3-11: DSC thermograms of pure pentoxifylline, F4 powder mixture and F4 
granules. 
 
 
 
 
Figure ‎3-12: DSC thermograms of pure pentoxifylline, F5 powder mixture and F5 
granules.  
For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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Figure ‎3-13: DSC thermograms of pure pentoxifylline, F6 powder mixture and F6 
granules.  
 
 
 
 
Figure ‎3-14: DSC thermograms of pure pentoxifylline, F7 powder mixture and F7 
granules.  
For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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The granules of the formulations F1-F7 were stored for 3 months at 40°C ± 
2°C and 80% ± 5% RH in closed or open containers and evaluated by DSC to 
investigate possible effects of elevated temperature and humidity on the drug. 
Figure ‎3-15 to Figure ‎3-21 represent DSC thermograms of F1-F7 stability samples 
respectively. Endothermic peaks at 89.59°C, and 95.81°C were reported for the 
stability samples in closed and open containers, respectively: (F1, Figure ‎3-15), 
92.44°C, and 95.87°C (F2, Figure ‎3-16), 87.45°C, and 95.23°C (F3, Figure ‎3-17), 
92.97°C, and 97.03°C (F4, Figure ‎3-18), 89.03°C and 96.80°C (F5, Figure ‎3-19), 
92.94°C and 96.25°C (F6, Figure ‎3-20), and 91.89°C and 92.53°C (F7, 
Figure ‎3-21). Moreover, enthalpy for the stability samples in closed and open 
containers were reported respectively 28.41 J/g and 24.09 J/g for F1, 27.20 J/g 
and 25.16 J/g for F2, 26.52 J/g and 22.88 J/g for F3, 20.99 J/g and 20.91 J/g for 
F4, 21.67 J/g and 21.98 J/g for F5, 21.43 J/g and 21.15 J/g for F6, and 25.51 J/g 
and 26.10 J/g for F7. 
Results were almost similar to the endothermic peak temperature and the 
enthalpy of the freshly prepared granules which were respectively: 94.64°C, 23.65 
J/g (F1, Figure ‎3-8) and 94.10°C, 19.15 J/g (F2, Figure ‎3-9), 95.23°C, 28.21 J/g 
(F3, Figure ‎3-10) and 93.64°C, 20.82 J/g (F4, Figure ‎3-11), 92.80°C, 20.70 J/g 
(F5, Figure ‎3-12), 97.28°C, 21.66 J/g (F6, Figure ‎3-13), and 96.26°C, 30.73 J/g 
(F7, Figure ‎3-14). An exception was noted for F3 stability sample in closed 
container where endothermic temperature decreased from 95.23˚C (fresh 
granules) to 87.45˚C. However, the FTIR spectra (section ‎3.1.3) of the stability 
samples confirmed the presence of pentoxifylline characteristic bands in all the 
formulations (F1-F7). Generally, this suggests physical stability of pentoxifylline 
loaded in F1-F7 tablets for 3 months at 40°C ± 2°C and 80% ± 5% RH in either 
closed or open containers. 
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Figure ‎3-15: DSC thermograms of pure pentoxifylline, F1 granules after storage 
for 3 months at 40°C ± 2°C and 80% ± 5% RH in closed or open containers.  
 
 
 
 
Figure ‎3-16: DSC thermograms of pure pentoxifylline, F2 granules after storage 
for 3 months at 40°C ± 2°C and 80% ± 5% RH in closed or open containers. 
For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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Figure ‎3-17: DSC thermograms of pure pentoxifylline, F3 granules after storage 
for 3 months at 40°C ± 2°C and 80% ± 5% RH in closed or open containers.  
 
 
 
 
Figure ‎3-18: DSC thermograms of pure pentoxifylline, F4 granules after storage 
for 3 months at 40°C ± 2°C and 80% ± 5% RH in closed or open containers.  
For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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Figure ‎3-19: DSC thermograms of pure pentoxifylline, F5 granules after storage 
for 3 months at 40°C ± 2°C and 80% ± 5% RH in closed or open containers.  
 
 
 
 
Figure ‎3-20: DSC thermograms of pure pentoxifylline, F6 granules after storage 
for 3 months at 40°C ± 2°C and 80% ± 5% RH in closed or open containers.  
For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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Figure ‎3-21: DSC thermograms of pure pentoxifylline, F7 granules after storage 
for 3 months at 40°C ± 2°C and 80% ± 5% RH in closed or open containers.  
For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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3.1.3 Fourier-transform infrared spectroscopy (FTIR) 
 
Fourier-transform infrared spectroscopy was used to study the compatibility 
of pentoxifylline with excipients (hydroxyethyl cellulose, sodium alginate, Prosolv® 
90, sodium bicarbonate, calcium carbonate, sodium carbonate, and magnesium 
stearate) within the formulations F1-F7 before and after granulation. Figure ‎3-22 to 
Figure ‎3-28 represent the IR spectra of pure pentoxifylline, powder mixture, and 
granules for all the formulations (F1-F7). Indrayanto et al. (1998) reported that the 
spectrum of pentoxifylline shows characteristic bands at 2945, 1701, and 1658 
cm−1 for –CH, –CO, and amide –CO stretching mode, with additional bands 
present at 1433 cm−1 for –CH3 deformation and at 802 cm
−1 for –(CH2)n– skeletal 
vibration. These characteristic bands were presented (almost at the same wave 
numbers) at 2943, 1696, and 1655 cm−1 for –CH, –CO, and amide –CO stretching 
mode, with additional bands presented at 1431 cm−1 for –CH3 deformation and at 
751 cm−1 for –(CH2)n– skeletal vibration in the spectra of drug-loaded powder 
mixture and granules of the formulations F1-F7. This confirms the absence of 
incompatibility between the drug and the formulation excipients. 
 
 
 
 
Figure ‎3-22: FTIR spectra of pure pentoxifylline, F1 powder mixture and F1 
granules.  
For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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Figure ‎3-23: FTIR spectra of pure pentoxifylline, F2 powder mixture and F2 
granules.  
 
 
 
 
Figure ‎3-24: FTIR spectra of pure pentoxifylline, F3 powder mixture and F3 
granules.  
For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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Figure ‎3-25: FTIR spectra of pure pentoxifylline, F4 powder mixture and F4 
granules.  
 
 
 
 
Figure ‎3-26: FTIR spectra of pure pentoxifylline, F5 powder mixture and F5 
granules.  
For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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Figure ‎3-27: FTIR spectra of pure pentoxifylline, F6 powder mixture and F6 
granules.  
 
 
 
 
Figure ‎3-28: FTIR spectra of pure pentoxifylline, F7 powder mixture and F7 
granules.  
For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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Granules of all the formulations (F1-F7) were stored for 3 months at 40°C ± 
2°C and 80% ± 5% RH in closed or open containers and evaluated by FTIR to 
investigate possible effects of the stressed conditions on the drug. The IR spectra 
of (F1-F7) granules after storage are shown in Figure ‎3-29 to Figure ‎3-35. The 
drug characteristic bands of the stability samples (in closed or open containers) of 
the formulations F1-F7 were presented at 2916–2944 cm−1, 1696–1697 cm−1 and 
1654–1657 cm−1 for –CH, –CO, and amide –CO stretching mode respectively. 
Additional bands were presented at 1430–1432 cm−1 for –CH3 deformation and at 
751 cm−1 for –(CH2)n– skeletal vibration. The IR band at 2359 cm
-1 was due to 
carbon dioxide, however, the bands at 3339, 3451, and 3462 cm-1 were for water –
O–H stretching mode (Stuart, 2004). Generally, a slight variation was noted in 
comparison with the freshly prepared samples of the formulations F1-F7 
(Figure ‎3-22 to Figure ‎3-28), still this commonly indicates physical stability of the 
drug loaded in such formulations for 3 months at 40°C ± 2°C and 80% ± 5% RH in 
either closed or open containers. 
 
 
 
Figure ‎3-29: FTIR spectra of F1 granules after storage for 3 months at 40°C ± 2°C 
and 80% ± 5% RH in closed or open containers.  
For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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Figure ‎3-30: FTIR spectra of F2 granules after storage for 3 months at 40°C ± 2°C 
and 80% ± 5% RH in closed or open containers.  
 
 
 
 
Figure ‎3-31: FTIR spectra of F3 granules after storage for 3 months at 40°C ± 2°C 
and 80% ± 5% RH in closed or open containers. 
For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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Figure ‎3-32: FTIR spectra of F4 granules after storage for 3 months at 40°C ± 2°C 
and 80% ± 5% RH in closed or open containers. 
 
 
 
 
 
Figure ‎3-33: FTIR spectra of F5 granules after storage for 3 months at 40°C ± 2°C 
and 80% ± 5% RH in closed or open containers. 
For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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Figure ‎3-34: FTIR spectra of F6 granules after storage for 3 months at 40°C ± 2°C 
and 80% ± 5% RH in closed or open containers. 
 
 
 
 
Figure ‎3-35: FTIR spectra of F7 granules after storage for 3 months at 40°C ± 2°C 
and 80% ± 5% RH in closed or open containers. 
For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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3.2 Evaluation of floating tablets 
 
Tablets prepared from the granules were evaluated for tablet crushing 
strength, friability, weight uniformity, drug content uniformity, apparent density, 
porosity, floating capacity, swelling and erosion, dissolution, release data 
modeling, and stability testing. But, tablets prepared from powder mixtures were 
evaluated only for porosity, floating capacity, dissolution, and release data 
modeling, as these tablets had been compacted manually. 
 
3.2.1 Tablet crushing strength, friability, weight uniformity, and 
drug content 
 
A pharmaceutical dosage form must satisfy certain standards to claim it to 
be a quality product. Thus, the finished product quality characteristics related to its 
manufacturing process such as crushing strength, friability, weight uniformity, and 
drug content should be taken into account. Pharmacopoeias have laid down the 
specified limits within which the specification value should fall in order to be 
compliant as per the standards. 
After granulation, tablets of the formulations F1 and F2 were prepared 
successfully at level A (49–54 N), and level B (54–59 N) of the targeted crushing 
strength as presented in Table ‎3-3. Both the formulations could not be prepared at 
the crushing strength level of 59–64 N; however, this level of crushing strength 
was achieved with tablets prepared from the powder mixture. It has been reported 
that the chemical composition of alginates affects their compression behaviour, 
where alginates with low guluronic acid content behave more elastically than 
alginates with low mannuronic acid content. In this study the ratio of mannuronic 
acid to guluronic acid was 1.56. Furthermore, the plasticity of potassium alginates 
is higher than that of sodium alginates; however, alginates deform elastically 
(Schmid and Picker-Freyer, 2009). Generally, the granulation process may 
enhance elastic recovery of alginate molecules after compression, which could 
explain the inability to prepare tablets of both the formulations F1 and F2 at level 
(C) of crushing strength after granulation.  
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Accordingly, the floating capacity, swelling, and drug release rate of drug-
loaded matrix of F1 and F2 tablets were evaluated at two crushing strength levels 
(A and B) instead of A, B, and C. 
Tablets of the formulations F3-F7 were successfully pressed automatically 
at levels A (49-54 N), B (54-59 N), and C (59-64 N) of crushing strength except 
those of the formulation F5 which were pressed manually. It has been reported in 
some studies that the crushing strength of tablets prepared from a mixture of two 
materials can be predicted from the crushing strength of tablets prepared from 
each of these materials as a linear relationship could be drawn for the composition 
of the mixture (Rubinstein and Jackson, 1987; Sheikh-Salem et al., 1988). In other 
studies, tablet crushing strength exceeds the crushing strength of tablets prepared 
from individual materials (Gren and Nyström, 1996; Olsson et al., 1998), or it 
becomes lower than that of the individual components (Sheikh-Salem et al., 1988; 
Leuenberger, 1982).  
F3 and F4 formulations based on calcium carbonate were pressed 
successfully at all crushing strength levels and the good bonding capacity under 
compression of calcium carbonate (Mattsson and Nyström, 2000) and its role as 
filler in pharmaceutical formulations (Armstrong, 2009) could explain this. Although 
pressing sodium carbonate alone shows a good bonding capacity (Sonnergaard, 
2006); tablets which contain sodium carbonate at 10% (w/w) (F5) could not be 
pressed automatically. Increasing the concentration to 20% (w/w) (F6) overcame 
this issue, and tablets were successfully pressed at levels A, B, and C of crushing 
strength. Generally, this suggests that compressibility of these floating 
formulations (F5 and F6) is dependent by the concentration of sodium carbonate. 
Tablets of F7 formulation without any gassing agent were successfully pressed at 
all required levels of crushing strength. However, the granulation process may 
enhance the elastic recovery of alginate molecules after compression, which could 
explain the inability to prepare tablets based on sodium bicarbonate as a gassing 
agent even at a higher level (59–64 N) of crushing strength following the 
granulation. In addition, it has been reported that sodium bicarbonate has a lower 
bonding capacity than sodium carbonate (Sonnergaard, 2006) and calcium 
carbonate (Mattsson and Nyström, 2000).  
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Hence, it is worth testing sodium carbonate and calcium carbonate as 
gassing agents as per this study, especially as the available information in the 
literature on using them within the floating tablets is inadequate. 
Results of friability (%), average weight (g), and average drug content (mg) 
of prepared matrix tablets of the formulations F1-F7 are presented in Table ‎3-3. 
For the friability test, there were no signs of cracked, split, or broken tablets at the 
end of the test. Additionally, the friability results of the formulations F1, F2, F3, F6, 
and F7 fitted the (BP) limits, as the tablets had friability values < 1% (BP, 2015), 
however, the formulations F4 and F5 exceeded the BP limit of friability as results 
were (1.11% - 1.34%), and (1.14% - 1.16%) respectively. Generally, as the tablet 
crushing strength level increases, the mass loss percentage decreases in all the 
formulations. Consequently, using higher compression force can change the 
friability results to fit BP limits. 
All prepared tablets of the formulations F1-F7 (Table ‎3-3) complied with BP 
specifications (BP, 2015) with respect to weight uniformity test. For content 
uniformity test (Table ‎3-3) results were in the acceptable range, indicating that all 
matrix tablets fitted the (BP) criteria in which each tablet drug content was 
between 85% and 115% of related average content (BP, 2015). 
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Table ‎3-3: Properties of pentoxifylline floating tablets of the formulations F1-F7. 
Formulation 
Crushing 
strength 
level 
Crushing 
strength 
(N)
a
 
Friability 
(%) 
Tablet weight 
(g)
b
 
Drug content 
(mg)
a
 
F1 
(A) 
 
50.99 ± 0.27 0.80 0.297 ± 0.00 57.82 ± 1.63 
(B) 
 
55.90 ± 0.33 0.60 0.292 ± 0.00 57.13 ± 0.64 
F2 
(A) 
 
49.03 ± 0.24 0.88 0.318 ± 0.01 56.63 ± 0.97 
(B) 
 
57.86 ± 0.31 0.66 0.306 ± 0.00 53.43 ± 1.45 
F3 
(A) 
 
51.98 ± 0.16 0.96 0.305 ± 0.00 61.22 ± 0.57 
(B) 
 
55.90 ± 0.24 0.94 0.302 ± 0.00 60.89 ± 0.93 
(C) 
 
59.82 ± 0.17 0.82 0.302 ± 0.00 63.24 ± 1.51 
F4 
(A) 
 
53.94 ± 0.40 1.34 0.343 ± 0.00 61.78 ± 1.28 
(B) 
 
55.90 ± 0.34 1.28 0.342 ± 0.00 63.99 ± 1.57 
(C) 
 
62.76 ± 0.23 1.11 0.343 ± 0.00 65.69 ± 1.53 
F5 
(A) 
 
50.03 ± 0.27 1.16 0.299 ± 0.00 58.34 ± 1.81 
(B) 
 
55.90 ± 0.69 1.15 0.300 ± 0.00 59.74 ± 2.13 
(C) 
 
59.82 ± 0.85 1.14 0.298 ± 0.00 58.57 ± 2.90 
F6 
(A) 
 
52.96 ± 0.80 0.89 0.315 ± 0.00 56.91 ± 2.12 
(B) 
 
57.86 ± 0.35 0.57 0.335 ± 0.01 57.55 ± 1.89 
(C) 
 
63.74 ± 0.44 0.56 0.349 ± 0.00 56.95 ± 1.77 
F7 
(A) 
 
49.03 ± 0.52 0.79 0.296 ± 0.00 69.15 ± 0.80 
(B) 
 
54.13 ± 0.36 0.57 0.296 ± 0.01 69.38 ± 1.15 
(C) 
 
59.04 ± 0.23 0.47 0.305 ± 0.02 69.47 ± 0.76 
Notes: aThe data represents the mean ± SD of 10 determinations. bThe data 
represents the mean ± SD of 20 determinations. The compression force of the 
prepared tablets was adjusted to give two crushing strength levels: A (49–54 N), 
and B (54–59 N) for F1 and F2 formulations, and three crushing strength levels: A 
(49–54 N), B (54–59 N), and C (59-64 N) for F3-F7 formulations. For formulation 
composition, refer to Table ‎3-1 or Table 2-7. 
 
 110 
 
3.2.2 Tablet apparent density and porosity 
 
For floating drug delivery systems it is important to have a density < 1.004 
g/cm3 in order to initiate buoyancy on the release medium (Whitehead et al., 1998; 
Bardonnet et al., 2006). Upon water uptake, chains of hydrophilic polymers move 
apart from each other resulting in both weight and volume increases. Although, 
this will reduce the density of the swollen matrix, the rate of medium uptake 
depends upon the matrix porosity level. Therefore, the apparent density and 
porosity results of the tablets were used to evaluate the magnitude of the different 
formulation factors (crushing strength, the wet granulation, type and ratio of gas 
forming agents) on the prepared tablets. 
The apparent density of the prepared tablets of the formulations F1-F7 were 
calculated by equation (3) (Chapter ‎2, section ‎2.2.6.2), and the results are shown 
in Figure ‎3-36 (for F1 and F2), Figure ‎3-37 (for F3 and F4), Figure ‎3-38 (for F5 and 
F6), and Figure ‎3-39 (for F7). Generally, increasing tablet crushing strength level 
increased significantly (p<0.05) the apparent density of all the tablets prepared 
from the powder mixture or the granules of the formulations F1, F2, F3, F4 and F7. 
However, the effect was not significant (P>0.05) for those of the formulations F5 
and F6 except between the extreme margins of the crushing strength (levels A and 
C). This may be explained by the reduction in tablet thicknesses as particles 
became more adjacent to each other by increasing the compression force as 
shown in Table ‎3-4. 
The granulation process caused a significant (P<0.05) decrease in tablet 
apparent density of F1 formulation at both crushing strength levels. In addition, a 
significant (P=0.001) decrease was noted in tablet apparent density results of F2 
formulation prepared at crushing strength level (A); however, a non-significant 
(P=0.363) decrease was noted at level (B) of crushing strength. A non-significant 
(P>0.05) decrease in the apparent density results was observed in the 
formulations F6 and F7. In contrast, the granulation process caused a significant 
(P<0.05) increase in tablet apparent density of the formulations F3, F4, and F5 at 
all crushing strength levels.  
 
 
 111 
 
For the formulations F1 and F2 (based on sodium bicarbonate gassing 
agent), as shown in Table ‎3-4, tablet thicknesses after the granulation process 
were increased in comparison to those before the granulation process which agree 
with the effect of the granulation process on alginate molecules elastic recovery 
after compression. This tablet thickness difference was reduced when sodium 
bicarbonate level was increased to 20% (w/w) (for F2 formulation) especially at 
crushing strength level (B). This indicates that the elastic recovery effect of sodium 
alginate (after the granulation process) was reduced. The high true density of 
sodium bicarbonate (Cable, 2009), which is 2.173 g/cm3, in addition to the high 
compression pressure of level (B) may inverse the elastic recovery effect of the 
granulation process on the apparent density results of F2 formulation 
(Figure ‎3-36). The enhancement of sodium alginate molecules elastic recovery 
after compression following the granulation also explains the results of the 
formulation F7 (0% (w/w) gassing agent), where tablet thicknesses after 
granulation increased (Table ‎3-4) whilst the apparent densities decreased 
(Figure ‎3-39). This also explains the apparent density results of F6 (20% (w/w) 
sodium carbonate) (Figure ‎3-38).   
The apparent density of F5 (10% (w/w) sodium carbonate) tablets 
(Figure ‎3-38) increased after the granulation. It has been reported that the amount 
of stress developed at the points of local deformation depend upon several factors 
such as physical properties of the material, force magnitude, rate of application, 
and contact time (Wray, 1992). F5 formulation was pressed manually after the 
granulation; therefore, the longer contact time between the granules and the 
punches of the tableting machine may overcome the alginate elastic recovery and 
explains the increase in the apparent density results.     
The tablet thicknesses of F3 (10% (w/w)) and F4 (20% (w/w)) calcium 
carbonate based tablets decreased after the granulation (Table ‎3-4) which 
increased their apparent densities (Figure ‎3-37). This may be explained by the 
good compressibility of calcium carbonate that may overcome the effect of sodium 
alginate elastic recovery after compression following the granulation process; this 
also explains the benefits of using calcium carbonate in effervescent floating 
tablets.   
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Changing calcium carbonate concentration from 10% to 20% (w/w) 
significantly (P<0.05) increased the apparent density of all the tablets prepared 
from the powder mixture or the granules. Raising sodium carbonate concentration 
to 20% (w/w) significantly (P<0.05) increased the apparent densities of those 
tablets prepared from the powder mixture only. This may be explained by the high 
specific gravities of calcium carbonate and sodium carbonate which are 2.70 
(Armstrong, 2009) and 2.53 (Hapgood, 2009) respectively, which also agrees with 
the results of sodium bicarbonate based tablets discussed earlier. 
A non-significant (P>0.05) decrease in the apparent densities of tablets 
prepared from granules due to changing sodium carbonate concentration from 
10% to 20% (w/w) was noted. As stated above, the manual pressing of F5 (10% 
(w/w) sodium carbonate) formulation could enhance the reduction of their tablet 
thicknesses with a higher ratio than that of F6 (20% (w/w) sodium carbonate) 
tablets which could explain this reduction in their densities. 
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Figure ‎3-36: Apparent density of F1 and F2 tablets before granulation, after 
granulation, and after stability (tablets prepared from granules stored at 40°C ± 
2°C and 80% ± 5% RH for 3 months in closed or open container).  
Note: The data represents the mean ± SD of six determinations. The compression 
force of the prepared tablets was adjusted to give two crushing strength levels: A 
(49–54 N), and B (54–59 N).  
 
 
 
 
Figure ‎3-37: Apparent density of F3 and F4 tablets before granulation, after 
granulation, and after stability (tablets prepared from granules stored at 40°C ± 
2°C and 80% ± 5% RH for 3 months in closed or open container).  
Note: The data represents the mean ± SD of six determinations. The compression 
force of the prepared tablets was adjusted to give three crushing strength levels: A 
(49-54 N), B (54-59 N), and C (59-64 N).   
For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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Figure ‎3-38: Apparent density of F5 and F6 tablets before granulation, after 
granulation, and after stability (tablets prepared from granules stored at 40°C ± 
2°C and 80% ± 5% RH for 3 months in closed or open container).  
Note: The data represents the mean ± SD of six determinations. The compression 
force of the prepared tablets was adjusted to give three crushing strength levels: A 
(49-54 N), B (54-59 N), and C (59-64 N). 
 
 
 
 
Figure ‎3-39: Apparent density of F7 tablets before granulation, after granulation, 
and after stability (tablets prepared from granules stored at 40°C ± 2°C and 80% ± 
5% RH for 3 months in closed or open container).  
Note: The data represents the mean ± SD of six determinations. The compression 
force of the prepared tablets was adjusted to give three crushing strength levels: A 
(49-54 N), B (54-59 N), and C (59-64 N). 
For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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Table ‎3-4: F1-F7 tablets thickness before granulation, after granulation, and after stability (tablets prepared from granules 
stored at 40°C ± 2°C and 80% ± 5% RH for 3 months in closed or open container). 
Formulation 
Crushing 
strength level 
Tablet thickness (cm) 
Origin of prepared tablets 
Before granulation After granulation 
After stability 
(closed container) 
After stability 
(open container) 
F1 
(A) 0.294 ± 0.01 0.303 ± 0.01 0.323 ± 0.01 0.326 ± 0.03 
(B) 0.289 ± 0.01 0.298 ± 0.02 0.315 ± 0.01 0.326 ± 0.02 
F2 
(A) 0322 ± 0.01 0.327 ± 0.00 0.345 ± 0.00 0.366 ± 0.01 
(B) 0.316 ± 0.01 0.318 ± 0.02 0.340 ± 0.02 0.357 ± 0.03 
F3 
(A) 0.299 ± 0.01 0.285 ± 0.02 0.317 ± 0.01 0.342 ± 0.03 
(B) 0.293 ± 0.01 0.282 ± 0.01 0.312 ± 0.01 0.336 ± 0.02 
(C) 0.290 ± 0.01 0.282 ± 0.01 0.307 ± 0.01 0.323 ± 0.02 
F4 
(A) 0.326 ± 0.01 0.311 ± 0.01 0.334 ± 0.02 0.369 ± 0.03 
(B) 0.319 ± 0.01 0.307 ± 0.01 0.331 ± 0.01 0.363 ± 0.04 
(C) 0.317 ± 0.01 0.304 ± 0.01 0.326 ± 0.03 0.357 ± 0.02 
F5 
(A) 0.298 ± 0.00 0.286 ± 0.01 0.332 ± 0.02 0.351 ± 0.01 
(B) 0.295 ± 0.00 0.283 ± 0.04 0.327 ± 0.02 0.350 ± 0.04 
(C) 0.292 ± 0.01 0.282 ± 0.04 0.327 ± 0.01 0.347 ± 0.03 
F6 
(A) 0.326 ± 0.01 0.329 ± 0.08 0.365 ± 0.02 0.421 ± 0.04 
(B) 0.322 ± 0.02 0.324 ± 0.01 0.354 ± 0.02 0.412 ± 0.02 
(C) 0.319 ± 0.01 0.320 ± 0.01 0.347 ± 0.01 0.405 ± 0.02 
F7 
(A) 0.305 ± 0.01 0.318 ± 0.02 0.342 ± 0.01 0.358 ± 0.02 
(B) 0.301 ± 0.01 0.313 ± 0.01 0.336 ± 0.01 0.353 ± 0.05 
(C) 0.297 ± 0.02 0.303 ± 0.01 0.326 ± 0.01 0.350 ± 0.01 
Note: The data represents the mean ± SD. of three determinations. The compression force of the prepared tablets was adjusted to 
give two crushing strength levels: A (49–54 N), and B (54–59 N) for F1 and F2 formulations, and three crushing strength levels: A 
(49–54 N), B (54–59 N), and C (59-64 N) for F3-F7 formulations. For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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A statistical analysis of the tablets apparent density after storage for 3 
months at 40°C ± 2°C and 80% ± 5% RH in closed or open containers was 
undertaken. Generally, storage in closed containers is reflective to the storage 
conditions of the packed pharmaceutical products; however, storage in open 
containers may apply further harsh conditions on the pharmaceutical dosage 
forms as they become in direct contact with an elevated level of heat and humidity 
which may accelerate degradation of unstable ingredients. Consequently, it is 
worth to study samples physical stability in both closed and open containers. As 
discussed earlier (Chapter ‎2, section ‎2.2.4), tablets were compacted manually 
using the powder mixtures and automatically using the granules. The good flow 
properties of the granules which facilitate their automatic pressing made them 
more suitable to benefit the pharmaceutical industry, therefore, only the tablets 
prepared from the granules were subjected to stability studies. 
Tablet apparent densities after stability (in closed or open container) are 
presented in Figure ‎3-36 to Figure ‎3-39. The tablets apparent densities decreased 
significantly (P<0.001) in all the formulations (F1-F7) in either open or closed 
containers in comparison to the freshly prepared samples. This is also explained 
by the increase in tablets thicknesses after 3 months storage as presented in 
Table ‎3-4. It has been reported that the crushing strength, disintegration and 
dissolution rate of tablets could change with time as part of the aging process of 
pharmaceutical tablets (Lowenthal, 1972; Karehill and Nystrom, 1990; Babu and 
Pandit, 1999). Tablets stress relaxation after compression which depends upon 
the deformation mechanism could enhance this aging process (Hwang et al., 
2001). Moreover, an elastically deformed material usually possesses a significant 
internal pressure following compression, and this internal pressure will be released 
over time (Rubinstein and Jackson, 1987). Consequently, during storage, this 
excess internal pressure may reach equilibrium with the external conditions such 
as temperature and humidity resulting in various physicomechanical 
characteristics. Hwang et al. (2001) studied tablet relaxation and 
physicomechanical stability of lactose, microcrystalline cellulose, and dibasic 
calcium phosphate directly compressed tablets by evaluating the percentage of 
change in thickness, crushing strength, and friability of freshly prepared tablets 
and those stored for one month at 25°C and 60% RH and 40°C and 75% RH.  
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In this work, the resulted change in the tablets thickness was used to 
evaluate the stress relaxation effect by calculating tablet apparent density values. 
The reduction of the apparent density results was higher in open containers than 
those of closed ones. A study by Aljaberi et al (2013) suggested that the direct 
exposure to a stressful humidity level (75% RH) causes a higher increase in 
tablet‗s dimensions when compared to those stored in closed containers. 
Regarding porosity, tablet porosity percentages of the formulations F1-F7 
are presented in Figure ‎3-40. Generally, increasing tablet crushing strength level 
decreased the porosity percentages of all the formulations F1-F7. This effect was 
significant (P<0.05) in F1 and F2 formulations and non-significant (P>0.05) in F3-
F7 formulations except between the extreme levels of crushing strength (A and C). 
This reduction in the tablet porosity percentages may be explained by the tablet 
thickness results presented in Table ‎3-4, where increasing the tablet crushing 
strength level reduced the tablet thicknesses as particles became strongly bonding 
due to being closer which agrees with a previous study of effect of the tablet radial 
tensile strength to the tablet porosity (Sebahatu and Alderborn, 1999). 
The granulation process decreased the tablet porosity significantly (P<0.05) 
in the formulations F1, F5, and F7, and non-significantly (P>0.05) in F2 
formulation. In contrast, the porosity significantly increased (P<0.05) in the 
formulations F3 and F6, and non-significantly (P>0.05) in F4 formulation following 
the granulation process (Figure ‎3-40).   
The effect of different treatment conditions on the production of cross-linked 
drug alginate granules has been reported by (Mukhopadhyay et al., 2008). This 
study demonstrated that increasing the water binder volume decreases porosity 
during the wet massing stage and this reduction in porosity could delay dissolution 
medium entrapment through the matrix at an early stage of the dissolution test.  
This may explain the results of F7 (0% w/w gassing agent) formulation where the 
granulation reduced the tablet porosity. However, tablet porosity of calcium 
carbonate based formulations (F3 and F4) increased after the granulation. This 
may be related to calcium carbonate insolubility in water (Armstrong, 2009) which 
could enhance the formation of voids between adjacent molecules during the wet 
massing stage with water. 
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In contrast, sodium carbonate as a gassing agent is a water-soluble 
material (Hapgood, 2009) which may form a homogenous mass with the 
hydrophilic polymeric (1:1) binary mixture of hydroxyethyl cellulose and sodium 
alginate during the wet massing process. This could explain the tablets porosity 
reduction at 10% (w/w) level for F5 formulation after the granulation. This complies 
with the results of the formulations F1 and F2 based on sodium bicarbonate which 
is also water-soluble (Cable, 2009). However, the significant (P<0.05) elevation in 
porosity results of F6 tablets could be explained by  the hygroscopic properties of 
sodium carbonate, where one mole of sodium carbonate could gradually absorb 
one mole of water on exposure to air (Hapgood, 2009). Raising sodium carbonate 
concentration means more water molecules may be absorbed during the wet 
massing step and evaporated easily due to the drying step of the granulation 
process. Therefore the granules porosity will be increased. This agrees with the 
moisture content (%) results before and after the granulation (Table ‎3-2). The 
moisture content (%) for the formulations F5 (10% (w/w)) and F6 (20% (w/w)) 
based on sodium carbonate gassing agent were 5.70% ± 0.14 and 5.51% ± 0.12 
before granulation and became 4.53% ± 0.19 and 4.11% ± 0.16 after the 
granulation respectively. Obviously, the moisture content (%) decreased in both 
formulations after the granulation, but more moisture lost was noted in F6 
formulation based on 20% (w/w) sodium carbonate. 
Increasing calcium carbonate concentration from 10% (w/w) (F3) to 20% 
(w/w) (F4) significantly (P<0.05) increased the porosity percentage of the tablets 
prepared either from the powder mixture or the granules (Figure ‎3-40). It has been 
reported that calcium carbonate mainly undergoes fragmentation when 
compressed (Roberts and Rowe, 1985); fragmentation establishes a large number 
of bonding points between calcium carbonate molecules during volume reduction, 
which will maintain the porosity of such tablets relatively high (Mattsson and 
Nyström, 2000). This may explain the increase in the tablet porosity results due to 
the change in calcium carbonate concentration in tablets prepared from either the 
powder mixture or the granules. 
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A significant (P<0.05) increase in porosity was noted when sodium 
carbonate concentration was raised from 10% (w/w) (F5) to 20% (w/w) (F6) in the 
tablets prepared from the granules, nonetheless, the porosity significantly (P<0.05) 
decreased for the tablets prepared from the powder mixture (Figure ‎3-40). 
Regarding the tablets prepared from the powder mixture, raising sodium carbonate 
concentration from 10% (w/w) (F5) to 20% (w/w) (F6) could enhance more voids 
between molecules being filled after compression, which may reduce the porosity. 
This also conforms to the results of sodium bicarbonate based tablets as 
increasing the level of sodium bicarbonate from 10% (w/w) (F1) to 20% (w/w) (F2) 
significantly (P<0.05) decreased all the tablet porosity results prepared from the 
powder mixture or the granules. However, the significant (P<0.05) increase in the 
porosity values of the tablets prepared from the granules may be explained by the 
hygroscopic properties of sodium carbonate as discussed earlier.  
 
 
 
 
Figure ‎3-40: Porosity percentage of the formulations F1-F7 before and after 
granulation. 
Note: The data represents the mean ± SD. of three determinations. The 
compression force of the prepared tablets was adjusted to give two crushing 
strength levels: A (49–54 N), and B (54–59 N) for F1 and F2 formulations, and 
three crushing strength levels: A (49–54 N), B (54–59 N), and C (59-64 N) for F3-
F7 formulations. 
For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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3.2.3 Tablet floating capacity 
 
Floating drug delivery systems, as shown in (Figure ‎3-41), aim to maintain 
floating for a long period of time on the release medium of the stomach without 
affecting the gastric emptying time. Normally in human, the gastric emptying of 
large single unit dosage forms is changeable in the fasted state. It depends on the 
time of arrival in the stomach in relation to activity of inter digestive myloelectric 
cycle, but a longer time is required for the gastric emptying in the fed conditions. 
All undigested materials are normally emptied out of the stomach and down the 
small intestine at the end of the gastric emptying process (Wilson and Washington, 
1989). It is important for floating tablets to avoid premature sweeping from their 
major absorption zone of the stomach and upper intestine, which could be 
managed by achieving the least possible lag time, and longer floating duration. 
All the tablets (F1-F7) were tested for the floating capacity under the same 
conditions and using the same apparatus for the in vitro studies. F7 tablets had no 
floating capacity, as they do not contain any gassing agent. Sodium bicarbonate, 
calcium carbonate and sodium carbonate as gassing agents enhanced the floating 
behaviour of the formulated tablets. Carbon dioxide is generated by reaction with 
the acidic dissolution medium (0.1 M HCl) and entrapped in the formed gel layer 
around the swollen tablets. Figure ‎3-42 reveals the floating of F4 tablets prepared 
at 49–54 N crushing strength, as an example, a floating lag time was ~ 7 min and 
tablets kept floating for > 24 h. Table ‎3-5 and Table ‎3-6 represent all the prepared 
tablets floating lag time and floating duration results respectively. 
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Figure ‎3-41: Schematic presentation of gastroretentive floating system.  
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Figure ‎3-42: Floating process of F4 tablet prepared at 49–54 N crushing strength 
(marked with a circle) during drug release. 
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Table ‎3-5: Floating lag-time of the formulations F1-F7 at different crushing strength levels before granulation, after granulation, 
and after stability (tablets prepared from granules stored at 40°C ± 2°C and 80% ± 5% RH for 3 months in closed or open 
container). 
Formulation 
Crushing 
strength level 
Floating lag time (min) 
Origin of prepared tablet 
Before granulation After granulation 
After stability 
(closed container) 
After stability 
(open container) 
F1 
(A) 0.84 ± 0.08 6.54 ± 1.19 2.14 ± 0.13 3.51 ± 1.31 
(B) 1.81 ± 0.25 9.78 ± 1.77 5.91 ± 1.68 4.91 ± 1.72 
F2 
(A) 0.44 ± 0.03 4.13 ± 0.35 2.17 ± 0.24 0.48 ± 0.04 
(B) 0.92 ± 0.05 4.48 ± 0.67 2.42 ± 0.04 1.06 ± 0.39 
F3 
(A) 0.32 ± 0.07 21.81 ± 4.00 7.49 ± 1.19 5.40 ± 0.44 
(B) 0.81 ± 0.03 24.17 ± 1.62 17.06 ± 4.94 28.18 ± 0.31 
(C) 7.19 ± 0.57 27.46 ± 4.42 23.92 ± 4.81 30.33 ± 1.86 
F4 
(A) 0.21 ± 0.04 6.93 ± 1.03 4.18 ± 0.58 6.71 ± 0.18 
(B) 0.26 ± 0.03 9.99 ± 1.36 5.57 ± 0.85 6.82 ± 0.24 
(C) 0.31 ± 0.01 13.11 ± 1.38 6.65 ± 0.71 7.69 ± 1.83 
Notes: The data represents the mean ± SD of three determinations. The compression force of the prepared tablets was 
adjusted to give two crushing strength levels: A (49–54 N), and B (54–59 N) for F1 and F2 formulations, and three crushing 
strength levels: A (49–54 N), B (54–59 N), and C (59-64 N) for F3-F7 formulations. 
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Table 3-5 (continued): Floating lag-time of the formulations F1-F7 at different crushing strength levels before granulation, 
after granulation, and after stability (tablets prepared from granules stored at 40°C ± 2°C and 80% ± 5% RH for 3 months in 
closed or open container). 
Formulation 
Crushing 
strength level 
Floating lag time (min) 
Origin of prepared tablet 
Before granulation After granulation 
After stability 
(closed container) 
After stability 
(open container) 
F5 
(A) 1.88 ± 0.65 6.95 ± 0.91 9.08 ± 0.84 0.41 ± 0.44 
(B) 3.46 ± 0.21 7.43 ± 0.70 10.82 ± 0.45 0.91 ± 0.62 
(C) 3.74 ± 0.21 10.09 ± 0.96 12.72 ± 1.06 1.55 ± 0.21 
F6 
(A) 4.20 ± 0.73 8.27 ± 1.25 9.49 ± 0.65 0.19 ± 0.04 
(B) 5.44 ± 1.33 11.09 ± 1.19 11.73 ± 1.12 0.20 ± 0.02 
(C) 7.19 ± 0.24 12.38 ± 1.86 12.83 ± 1.55 0.20 ± 0.02 
F7 
(A) 
Complete disintegration 
(within 30 min) 
No floating No floating No floating 
(B) No floating No floating No floating No floating 
(C) No floating No floating No floating No floating 
Notes: The data represents the mean ± SD of three determinations. The compression force of the prepared tablets was 
adjusted to give two crushing strength levels: A (49–54 N), and B (54–59 N) for F1 and F2 formulations, and three crushing 
strength levels: A (49–54 N), B (54–59 N), and C (59-64 N) for F3-F7 formulations. 
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Table ‎3-6: Floating duration of the formulations F1-F7 at different crushing strength levels before granulation, after 
granulation, and after stability (tablets prepared from granules stored at 40°C ± 2°C and 80% ± 5% RH for 3 months in closed 
or open container). 
Formulation 
Crushing 
strength level 
Total floating duration (h) 
Origin of prepared tablet 
Before granulation After granulation 
After stability 
(closed container) 
After stability 
(open container) 
F1 
(A) > 12 > 8 > 24 > 24 
(B) > 12 > 8 > 24 > 24 
F2 
(A) > 24 > 24 > 24 > 24 
(B) > 24 > 24 > 24 > 24 
F3 
(A) 
Complete disintegration 
(within 30 min) 
> 5 > 8 > 8 
(B) 
Complete disintegration 
(within 30 min) 
> 5 > 8 > 8 
(C) > 4 > 8 > 12 > 8 
F4 
(A) 
Complete disintegration 
(within 30 min) 
> 24 > 24 > 24 
(B) 
Complete disintegration 
(within 30 min) 
> 24 > 24 > 24 
(C) 
Complete disintegration 
(within 30 min) 
> 24 > 24 > 24 
Notes: The compression force of the prepared tablets was adjusted to give two crushing strength levels: A (49–54 N), and B 
(54–59 N) for F1 and F2 formulations, and three crushing strength levels: A (49–54 N), B (54–59 N), and C (59-64 N) for F3-
F7 formulations. For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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Table 3-6 (continued): Floating duration of the formulations F1-F7 at different crushing strength levels before granulation, 
after granulation, and after stability (tablets prepared from granules stored at 40°C ± 2°C and 80% ± 5% RH for 3 months in 
closed or open container). 
Formulation 
Crushing 
strength level 
Total floating duration (h) 
Origin of prepared tablet 
Before granulation After granulation 
After stability 
(closed container) 
After stability 
(open container) 
F5 
(A) > 12 > 12 > 24 > 24 
(B) > 12 > 12 > 24 > 24 
(C) > 12 > 12 > 24 > 24 
F6 
(A) > 24 > 24 > 24 > 24 
(B) > 24 > 24 > 24 > 24 
(C) > 24 > 24 > 24 > 24 
F7 
(A) 
Complete disintegration 
(within 30 min) 
No floating No floating No floating 
(B) No floating No floating No floating No floating 
(C) No floating No floating No floating No floating 
Notes: The compression force of the prepared tablets was adjusted to give two crushing strength levels: A (49–54 N), and B 
(54–59 N) for F1 and F2 formulations, and three crushing strength levels: A (49–54 N), B (54–59 N), and C (59-64 N) for F3-
F7 formulations. For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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Increasing the crushing strength level of the floating tablets (F1-F6) 
increased the floating lag time results. Regarding the formulations prepared from 
the powder mixture, a significant (P<0.05) increase in the floating lag time was 
noted for F1 and F2 formulations. A non-significant (P>0.05) effect was shown in 
all the other formulations except those of F3 where a significant (P<0.05) increase 
was noted at level C of crushing strength. Additionally, a non-significant (P>0.05) 
increase in the lag time results was seen in all the floating tablets (F1-F6) 
prepared from granules, except between the extreme margins of crushing strength 
(level A and C) of F3-F6 tablets (Table ‎3-5). These results could be explained by 
the porosity results (Section ‎3.2.2) where reducing the tablet porosity, as a result 
of increased compaction force, delayed the penetration of the acidic medium and 
hence delayed the gas generation process. 
The granulation process caused a significant (P<0.05) increase in the 
floating lag time of all the tablet (F1-F6) compared to that of the tablets prepared 
from the powder mixture before the granulation (Table ‎3-5).  A complete 
disintegration effect (within 30 min) was seen in the tablets prepared from the 
powder mixture based on calcium carbonate as a gassing agent (F3 and F4). 
These tablets rapidly moved in an upward motion and disintegrated on the surface 
of the dissolution medium. All the tablets based on sodium bicarbonate (F1 and 
F2) or sodium carbonate (F5 and F6) as a gassing agent either prepared from the 
powder mixture or the granules did not show any disintegration behaviour. This 
disintegration behaviour may be explained by the stronger effervescent activity of 
calcium carbonate compared to sodium bicarbonate and sodium carbonate, which 
ruptured the tablet structure of the formulations F3 and F4 prepared from powder 
mixture (Table ‎3-5). During the granulation process, liquid bridges of adhesives 
such as hydroxyethyl cellulose are formed between particles during the wet 
massing step and these harden due to the drying step (Summers and Aulton, 
2007). This could make the internal structure of the tablets much more resistant to 
the disintegration effect of calcium carbonate effervescent reaction, and provide 
sufficient time for swelling and gel layer formation.  
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It has been reported that carbonates could generate an alkaline 
microenvironment for pH sensitive polymers to initiate gel formation (Deshpande 
et al., 1997). The absence of the disintegration behaviour for F5 and F6 tablets 
prepared from powder mixture could be explained by the better ability of sodium 
carbonate compared to calcium carbonate to provide a suitable microenvironment 
for the polymer to start gelling as 1% (w/v) aqueous solution of sodium carbonate 
generates a pH of 11.4 at 25°C (Hapgood, 2009) while 10% (w/v) aqueous 
dispersion of calcium carbonate produces a pH of 9.0 (Armstrong, 2009).  
The increase in the lag time results of F1 and F2 (10% and 20% (w/w) 
sodium bicarbonate respectively), and F5 (10% (w/w) sodium carbonate) tablets 
after the granulation (Table ‎3-5) may be due to the reduction in the porosity 
(Section ‎3.2.2). Although the porosity level of F6 (20% (w/w) sodium carbonate) 
formulation increased following the granulation process, its floating lag time also 
increased. The increase in the porosity level may enhance rapid contact between 
the gassing agent and the acidic medium, but it also could accelerate the escape 
of liberated gas bubbles from the matrix structure before the formation of a 
coherent gel layer around the tablet, which may delay the floating process.  
Changing sodium bicarbonate concentration from 10% (w/w) (F1) to 20% 
(w/w) (F2) caused a significant (P<0.05) decrease in the lag time data of the 
tablets prepared from the powder mixture at both crushing strength levels. 
However, the reduction in the lag time values was not significant (P>0.05) in the 
tablets prepared from the granules. Increasing calcium carbonate concentration 
from 10% (w/w) (F3) to 20% (w/w) (F4) in tablets prepared from the powder 
mixture decreased the lag time non-significantly (P>0.05) except at level C of 
crushing strength. Moreover, a significant (P<0.05) reduction in the floating lag 
time was noted in the tablets prepared from the granules when calcium carbonate 
level was increased from 10% to 20% (w/w). Increasing the gassing agent content 
available for an acidic medium enhanced the efficiency of the effervescent 
reaction, which was represented by a shorter floating lag time. Changing sodium 
carbonate concentration from 10% (F5) to 20% (w/w) (F6), increased the lag time 
non-significantly (P>0.05) in all the tablets.  
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The ability of sodium carbonate to generate an alkaline microenvironment 
to accelerate swelling and gel formation may reduce the dissolution medium 
entrapment rate and the quantity of acidic medium available for the effervescent 
reaction. Moreover, raising sodium carbonate level to 20% (w/w) increased tablets 
density (Section ‎3.2.2), and more time was taken for the floating process. 
Regarding the floating duration (Table ‎3-6), although, F1 tablets prepared 
from the powder mixture floated for > 12 h, there were 4 h reduction in their 
floating duration after the granulation process. In addition, there was no difference 
in the floating duration of F2 formulation before and after the granulation, where 
they floated for > 24 h. It is clear that 20% (w/w) concentration was more effective 
than 10% (w/w) concentration to maintain tablets on the surface of the dissolution 
medium for a longer duration of time.  
As stated above, tablets based on calcium carbonate as a gassing agent of 
the formulations F3 and F4 prepared from the powder mixture showed complete 
disintegration behaviour within short time (30 min) after floating. However, 
following the granulation process, the tablets of F3 (10% (w/w)) formulation floated 
for > 5 h, while F4 (20% (w/w)) formulation floated for > 24 h due to the high 
gassing agent reservoir available for the floating process. The granulation process 
did not cause any difference in the floating duration results of F5 and F6 tablets 
based on sodium carbonate as a gassing agent, as > 12 h and > 24 h were 
reported, respectively. This may be related to the absence of the disintegration 
effect due to the ability of sodium carbonate to generate an alkaline 
microenvironment to accelerate gel formation; however the longer floating duration 
could be related to the high gassing agent reservoir during the test for F6. 
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Regarding stability studies, the effect of storage at 40°C ± 2°C and 80% ± 
5% RH for 3 months on the tablets floating lag time and floating duration has been 
evaluated and presented in Table ‎3-5 and Table ‎3-6 respectively. The floating lag 
time results of both the formulations based on sodium bicarbonate F1 (10% (w/w) 
and F2 (20% w/w) decreased after storage in closed and open containers. In 
closed containers, the effect was significant (P<0.05) for F1 tablets at both 
crushing strength levels, however it was not significant (P>0.05) for F2 tablets. 
Furthermore, in open containers, a significant (P<0.05) effect was only noted for 
F1 tablets at crushing strength level (B) and F2 tablets at crushing strength level 
(A). The floating lag time results of the tablets based on 10% (w/w) calcium 
carbonate as a gassing agent (F3) in closed containers decreased at all crushing 
strength levels. The effect was non-significant (P>0.05) except at level A of 
crushing strength. In contrast, storage in open containers increased the floating 
lag time non-significantly (P>0.05) in comparison with freshly prepared ones. But, 
at level A of crushing strength the floating lag time was significantly (P<0.05) 
decreased. For F4 (20% (w/w) calcium carbonate) tablets, the floating lag time 
non-significantly decreased (P>0.05) after storage in either closed or open 
containers at all crushing strength levels. An exception was reported at level C of 
crushing strength in open containers where the effect was significant (P<0.05) 
(Table ‎3-5).  
The decrease in floating lag time may be explained by the increase in the 
tablet thicknesses due to the aging process which facilitated dissolution medium 
entrapment at early stages of the dissolution process. This means rapid contact 
between the gassing agent and the acidic medium to start the effervescent and the 
floating processes. For calcium carbonate based tablets, the reduction in the lag 
time results was higher in closed containers than in open ones. The storage in 
open containers caused a direct exposure to a stressful humidity level (80% RH) 
which caused a higher increase in tablets‘ dimensions when compared to those 
stored in closed containers (Table ‎3-4). Even calcium carbonate has a higher 
effervescent activity; it has less ability to generate an alkaline microenvironment. 
Therefore, this may lead to escape of generated carbon dioxide bubbles at early 
stages of contact with the acidic medium and delay the floating process which 
explains the higher reduction in the floating lag time values in closed containers 
than that in open ones.  
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The lag time results of the formulations F5 and F6 based on sodium 
carbonate non-significantly (P>0.05) increased after a storage in closed 
containers. Conversely, a significant (P<0.05) decrease was noted after storage in 
the open ones. This increase in the lag time results of the tablets of F5 and F6 
formulation may be related to the high hygroscopic properties of sodium carbonate 
(Section ‎3.2.2). The relatively high moisture level during the storage may decrease 
the concentration of sodium carbonate molecules available for the effervescent 
reaction at the commencement of the dissolution test which was reflected by the 
increase in the floating lag time results. Even storage in open containers 
stressfully caused a direct exposure to humidity, however the lag time results were 
sharply decreased. This could be explained by the sharp reduction in their 
apparent density results at levels A, B, and C of crushing strength where 0.92, 
0.97, and 0.98 g/cm3 were respectively reported (Figure ‎3-38) which enhanced 
rapid floating. 
Additionally, in both closed and open containers, the floating duration was 
sharply increased from > 8 h to > 24 h for F1 formulation (10% (w/w) sodium 
bicarbonate); but, it did not change for F2 formulation (20% (w/w) sodium 
bicarbonate) where results remained > 24 h. Additionally, the floating duration was 
increased from > 5 h to > 8 h for F3 (10% (w/w) calcium carbonate) tablets and 
sharply increased from > 12 h to > 24 h for F5 (10% (w/w) sodium carbonate) 
tablets after storage in either closed or open containers. Yet, the floating duration 
of the formulations F4 (20% (w/w) calcium carbonate) and F6 (20% (w/w) sodium 
carbonate) did not change after the storage and they continued to float for > 24 h 
(Table ‎3-6). This agrees with the tablet relaxation behaviour during the storage 
which could enhance faster dissolution medium entrapment through the dilated 
inter-particulate voids of the relaxed tablet structure. This enhanced a rapid 
reaction with the superficial gassing agent molecules and shortened the lag time 
results of the formulations F1-F6. However, the gassing agent was also uniformly 
distributed all over the tablet matrix. Consequently, a sufficient deep penetration of 
the acidic medium through the relaxed matrix voids would be expected to make a 
contact with the deeply impeded gassing agent molecules. Extra bubbles of 
carbon dioxide would be generated to maintain the floating process for longer 
floating time duration. Moreover, 20% (w/w) of the gassing agents was already 
enough for the tablets to float > 24 h.    
 131 
 
3.2.4 Swelling and erosion studies 
 
The hydration layer plays a key role in the controlled drug release of gel 
forming tablets. Also, drug solubility plays a major role in the release mechanism. 
Water soluble drugs are released by diffusion through the formed gel layer, 
nonetheless, for poor water-soluble drugs, matrix erosion is considered as the rate 
limiting step for the drug release. Since the designed floating tablets based on gel 
forming polymeric mixture (hydroxyethyl cellulose and sodium alginate), it was 
important to evaluate swelling and erosion data. Swelling studies were conducted 
according to the method described earlier (Chapter 2, section 2.2.6.4). Results 
were utilized to make a correlation with the drug release rate and the release 
mechanism. Only the tablets prepared from the granules were subjected to 
swelling studies due to the good flow properties that facilitate their automatic 
pressing by the single-punch tableting machine which made them more suitable to 
benefit the pharmaceutical industry.  
The % of dissolution medium uptake (DMU) for all the tablets prepared from 
the granules (F1-F7) in 0.1 M HCl medium was calculated by equation (5) 
(Chapter ‎2, section ‎2.2.6.4), and data is presented in Figure ‎3-43 to Figure ‎3-46. 
For all the tablets the percentage of dissolution medium uptake (DMU), in 0.1 M 
HCl medium, showed a continuous increase until 12 h of the experiment time 
except for the control tablets (F7) where the increase continued till 8 h only. 
Increasing the tablet crushing strength in all the formulations (F1-F7) did not cause 
a significant (P>0.05) effect in the swelling rate results at majority of the time 
points. Viridén et al. (2009) showed that the tablet strength had only a small effect 
on the swelling rate of hydrophilic tablets. Tablets of F2 formulation showed a 
significant (P<0.05) decrease in DMU (compared to F1 formulation) at most of the 
time points (Figure ‎3-43). When a tablet floats on the dissolution medium, its upper 
surface does not come in contact with the medium, while other surfaces are 
placed under the dissolution medium surface. Once it sinks after a period of time, 
all surfaces of this tablet becomes completely available for DMU. Accordingly, the 
surface area available for water uptake and the floating duration could explain the 
lower swelling rate of F2 tablets in comparison with F1 tablets. As stated 
previously, tablets of F2 formulation floated for > 24 h while F1 tablets floated for 
only > 8 h and then sank for the rest of the experiment time.  
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This means that the upper tablet surface of F1 formulation became 
available for DMU after sinking and the tablet showed higher swelling rate by the 
end of the experiment. As presented in Figure ‎3-46, F7 control tablets that 
remained under the surface of the dissolution medium throughout the experiment 
time showed an almost similar swelling rate profile of those of F1 tablets 
(Figure ‎3-43) and the difference was not significant (P>0.05) at majority of the time 
points. Nevertheless, F2 tablets showed a significant (P<0.05) lower swelling rate 
results (Figure ‎3-43) than those of F7 tablets at larger part of the time points.  
Raising calcium carbonate levels from 10% (w/w) (F3) to 20% (w/w) (F4) 
caused a significant (P<0.05) decrease in the tablet swelling at most of the time 
points (Figure ‎3-44). However, increasing sodium carbonate level did not cause a 
significant (P>0.05) effect on the swelling of F5 and F6 tablets at majority of the 
time points (Figure ‎3-45). F4 tablets floated for > 24 h while F3 tablets floated for 
only > 5 h. This means that the upper tablet surface of F3 sample became 
available for DMU after sinking and the tablet showed great swelling by the end of 
the experiment. Although, tablets of F5 (10% (w/w)) and F6 (20% (w/w)) 
formulations, based on sodium carbonate as a gassing agent, floated for > 12 and 
> 24 h respectively (Table ‎3-6), the DMU results were almost the same. Data of 
the formulations F5 and F6 (Figure ‎3-45) showed a continuous increase in 
swelling rate until 12 h only which could explain the absence of a significant 
(P>0.05) difference between the formulations F5 and F6 at bulk of the time points.  
Pentoxifylline control tablets of F7 formulation (Figure ‎3-46) that remained 
under the surface of the dissolution medium for the entire period of the experiment 
and demonstrated a significantly (P<0.05) higher swelling rate profile compared to 
the formulations F3 and F4 based on calcium carbonate as a gassing agent at 
most of the time points. However, this difference was not significant (P>0.05) in 
comparison to the formulations F5 and F6 which were based on sodium carbonate 
at larger part of the time points. Sodium carbonate is a stronger alkaline material 
than calcium carbonate (Section ‎3.2.3) which may explain the ability of the 
formulations F5 and F6 to swell at an almost similar rate to F7 formulation even 
after the long period of floating. Figure ‎3-47 reveals images of F4 and F7 tablets 
prepared at 49-54 N crushing strength (as examples) during their swelling 
characterization test for 24 h.  
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Figure ‎3-43: Percentage of medium uptake for the formulations F1 and F2 
(prepared from granules) in 0.1 M HCl medium. 
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give two crushing 
strength levels: A (49–54 N), and B (54–59 N).  
 
 
 
 
Figure ‎3-44: Percentage of medium uptake for the formulations F3, and F4 
(prepared from granules) in 0.1 M HCl medium.  
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N). 
For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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Figure ‎3-45: Percentage of medium uptake for the formulations F5, and F6 
(prepared from granules) in 0.1 M HCl medium.  
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  
 
 
 
 
Figure ‎3-46: Percentage of medium uptake for F7 formulation (prepared from 
granules) in 0.1 M HCl medium.  
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N). 
For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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Figure ‎3-47: Images of F4 and F7 tablets during their swelling for 24 hours.  
For formulation composition, refer to Table ‎3-1 or Table 2-7. 
 
 
 
Regarding erosion studies, they were accomplished according to the 
method described earlier (Chapter ‎2, section ‎2.2.6.4). Only the tablets prepared 
from the granules were subjected to erosion studies due to the good flow 
properties that facilitate their automatic pressing by the single-punch tableting 
machine. The % of mass loss for all the tablets was calculated by equation (6) 
(Chapter ‎2, section ‎2.2.6.4). Figure ‎3-48 to Figure ‎3-51 represent the percentage 
of the mass loss of all the tablets (F1-F7) prepared from the granules where all the 
tablets showed gradual loss in their masses up to almost half of their original 
weight at the end of 24 h. Increasing crushing strength levels did not cause a 
significant (P>0.05) effect on the mass loss values of all the formulations (F1-F7) 
at majority of the time points. Increasing the gassing agent concentration of 
sodium bicarbonate (Figure ‎3-48), calcium carbonate (Figure ‎3-49) and sodium 
carbonate (Figure ‎3-50) from 10% to 20% (w/w) significantly (P<0.05) increased 
the mass loss values at most of the time points. Pentoxifylline control tablets (F7) 
demonstrated the lowest mass loss percentage profile as shown in (Figure ‎3-51) 
and their results were significantly (P<0.05) lower than all the other formulations at 
larger part of the time points. This may be explained by the higher effervescent 
effect due to the higher gassing agent level, which liberates more carbon dioxide 
bubbles. This means more mass loss from the tablet matrix due to the 
effervescent process.  
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Figure ‎3-48: Percentage of mass loss for the formulations F1 and F2 (prepared 
from granules) in 0.1 M HCl medium.  
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give two crushing 
strength levels: A (49–54 N), and B (54–59 N).  
 
 
 
 
Figure ‎3-49: Percentage of mass loss for the formulations F3, and F4 (prepared 
from granules) in 0.1 M HCl medium.  
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  
For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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Figure ‎3-50: Percentage of mass loss for the formulations F5, and F6 (prepared 
from granules) in 0.1 M HCl medium.  
Notes: The data represents the mean ± SD of three determinations. The compression 
force of the prepared tablets was adjusted to give three crushing strength levels: A (49-54 
N), B (54-59 N), and C (59-64 N). 
 
 
 
 
Figure ‎3-51: Percentage of mass loss for F7 formulation (prepared from granules) 
in 0.1 M HCl medium.  
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  
For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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3.2.5 In vitro drug release studies 
 
In vitro drug release study is an important analytical method to investigate 
and develop product behaviour during various stages of new drug product 
development. Moreover, the resulted release profile can reveal essential 
information regarding the release mechanism and kinetics, enabling a rational and 
scientific approach to drug product development. Dissolution profiles of all the 
tablets (F1-F7) prepared from the powder mixtures are presented in Figure ‎3-52 to 
Figure ‎3-55.  
Statistically, the tablets of F1 (10% (w/w) sodium bicarbonate) and F2 (20% 
(w/w) sodium bicarbonate) showed a significant (P<0.05) decrease in their drug 
release rate when their crushing strength level increased from level (A) to level (B) 
at majority of the time points (Figure ‎3-52). Additionally, a significant (P<0.05) 
difference was found between the release profiles of pentoxifylline control tablets 
(F7) at different crushing strength levels at most of the time points (Figure ‎3-55). 
The tablets of F3 (10%) and F4 (20%) based on calcium carbonate as a gassing 
agent showed only a small difference between their drug release rate due to their 
complete disintegration. An exception was noted in those of F3 at level C of 
crushing strength where a significant (P<0.05) slower release rate occurred up to 
12 h at bulk of the time points (Figure ‎3-53). The tablets of F5 and F6 which 
contained sodium carbonate as a gassing agent did not disintegrate and the 
difference between their drug release rate was not significant (P>0.05) at larger 
part of the time points (Figure ‎3-54).  
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Figure ‎3-52: Percentage of drug release of F1 and F2 floating tablets pressed at 
levels (A) and (B) of crushing strength in 0.1 M HCl medium before granulation. 
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give two crushing 
strength levels: A (49–54 N), and B (54–59 N).  No significant change in the 
dissolution medium, macroenvironment, pH was recorded through the experiment 
time.   
 
 
 
Figure ‎3-53: Percentage of drug release of F3, and F4 floating tablets pressed at 
levels (A), (B), and (C) of crushing strength in 0.1 M HCl medium before 
granulation. 
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  No significant change 
in the dissolution medium, macroenvironment, pH was recorded through the 
experiment time.   
For formulation composition, refer to Table ‎3-1 or Table 2-7 
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Figure ‎3-54: Percentage of drug release of F5, and F6 floating tablets pressed at 
levels (A), (B), and (C) of crushing strength in 0.1 M HCl medium before 
granulation. 
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  No significant change 
in the dissolution medium, macroenvironment, pH was recorded through the 
experiment time.   
 
 
 
Figure ‎3-55: Percentage of drug release of F7 control tablets pressed at levels 
(A), (B), and (C) of crushing strength in 0.1 M HCl medium before granulation. 
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  No significant change 
in the dissolution medium, macroenvironment, pH was recorded through the 
experiment time. 
For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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Figure ‎3-56: Percentage of drug release of F1, and F2 floating tablets pressed at 
levels (A), and (B) of crushing strength in 0.1 M HCl medium after granulation. 
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give two crushing 
strength levels: A (49-54 N) and B (54-59 N).  No significant change in the 
dissolution medium, macroenvironment, pH was recorded through the experiment 
time. 
 
 
 
Figure ‎3-57: Percentage of drug release of F3, and F4 floating tablets pressed at 
levels (A), (B), and (C) of crushing strength in 0.1 M HCl medium after granulation. 
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  No significant change 
in the dissolution medium, macroenvironment, pH was recorded through the 
experiment time. 
For formulation composition, refer to Table ‎3-1 or Table 2-7 
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Figure ‎3-58: Percentage of drug release of F5, and F6 floating tablets pressed at 
levels (A), (B), and (C) of crushing strength in 0.1 M HCl medium after granulation. 
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  No significant change 
in the dissolution medium, macroenvironment, pH was recorded through the 
experiment time. 
 
 
 
Figure ‎3-59: Percentage of drug release of F7 control tablets pressed at levels 
(A), (B), and (C) of crushing strength in 0.1 M HCl medium after granulation. 
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  No significant change 
in the dissolution medium, macroenvironment, pH was recorded through the 
experiment time. 
For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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Although Liew et al (2006) proposed that both gel layer generation around a 
matrix tablet as well as the gel layer porosity can control the drug release process, 
but not the dry matrix porosity; however, Mandal et al (2009) reported a significant 
difference in drug release from highly compressed tablets, indicating that there is a 
limit of crushing strength above which the porosity of a dry matrix will affect the 
penetration of the dissolution medium inside the tablet. This agrees with the 
porosity results of F1, F2, and F7 tablets (Section ‎3.2.2), where increasing the 
compression force made the powder mixture particles closer to each other and 
reduced the porosity percentage significantly (P<0.05). Therefore, the penetration 
of the dissolution medium into the matrix to dissolve pentoxifylline was more 
difficult, and the drug release process was delayed. Calcium carbonate may show 
higher effervescent behaviour compared to sodium carbonate (Section ‎3.2.3), but 
the ability of sodium carbonate to generate an alkaline microenvironment to 
accelerate swelling and gel formation is better than that of calcium carbonate. 
Thus, an insufficient gel layer formation may lead to partial or complete tablet 
disintegration in case of calcium carbonate based tablets. 
The drug release rate of (F1-F7) tablets prepared from the granules is 
shown in Figure ‎3-56 to Figure ‎3-59. Increasing the tablets crushing strength level 
in all the formulations (F1-F7) caused a non-significant (P>0.05) difference in their 
drug release rate at majority of the time points. This comes in agreement with 
DMU results (Section ‎3.2.4) where the tablet strength had only a small effect on 
the tablets swelling rate behaviour. In addition, Ebube and Jones (2004) 
concluded a minimal effect of compression force on acetaminophen release rate 
from either hydroxypropylmethyl cellulose or hydroxypropyl cellulose matrices 
prepared from granules. Consequently, this gives an advantage to control other 
formulation parameters such as high friability percentages by raising the 
compression force without disturbing the drug release rate. 
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The effect of the granulation process on the drug release rate from the 
formulations F1-F7 reveals that the granulation extended the drug release rate of 
all the prepared tablets. A significant (P<0.05) decrease at larger part of the time 
points was noted in the release profiles in both the formulations F1 and F2 except 
at level (B) of crushing strength for F1 formulation which was not significant 
(P>0.05) at bulk of the time points. Additionally, the granulation effect was 
significant (P<0.05) in the formulations F3, F4, and F7, yet, it was not significant 
(P>0.05) in the formulations F5 and F6 at most of the time points. A lower 
standard deviation (SD) values were reported for the formulations F5, F6, and F7 
following the granulation which reveals a homogenous drug release rate in 
comparison with tablets prepared from the powder mixtures.  
The granulation process enhanced the internal structure resistance of the 
formulations F3 and F4 to rupture due to calcium carbonate effervescent 
behaviour and gave enough time for swelling and gel layer formation to control the 
drug release process. Results of the tablets based on sodium bicarbonate as a 
gassing agent (F1 and F2) and the control tablets (F7) may be explained by 
results of Mukhopadhyay et al. (2008) study where increasing the water binder 
volume decreased the porosity during the wet massing stage, and this reduction 
decreased the dissolution medium entrapment rate through the matrix at an early 
stage of the dissolution test, which decreased the drug release process. The 
insignificant (P>0.05) effect of the granulation process on F5 and F6 tablets at 
most of the time points may be explained by the high alkalinity of sodium 
carbonate as a gassing agent which may explain the ability of the tablets either 
before or after the granulation to swell at a similar rate. Although the porosity of F6 
formulation increased after the granulation as discussed earlier (Section ‎3.2.2), it 
has been proposed that dissolution medium can pass through tablet surface pores 
to initiate gel layer formation through the swelling process (Alderman, 1984). 
Within the formed gel blocks, the liquid can fill pores in less than 15 min, after 
which water can be primarily transported through the created coherent gel layer 
(Bajwa et al., 2006). Accordingly, swelling rate may control the drug release rate 
and explain the insignificant (P>0.05) effect of granulation. 
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Increasing the concentration of sodium bicarbonate from 10% to 20% (w/w) 
increased significantly (P<0.05) the drug release rates of the formulations 
prepared from the powder mixture at majority of the time points (Figure ‎3-52). 
More pore formation in the wet matrix structure due to the effervescent process 
and the liberation of more carbon dioxide bubbles explains the higher drug release 
rate. In contrast, increasing sodium bicarbonate concentration significantly 
(P<0.05) decreased the drug release rate of the formulations prepared from the 
granules at bulk of the time points (Figure ‎3-56). This conforms to the DMU results 
(Section ‎3.2.4), where the swelling rate of F1 formulation was higher than that of 
F2 (Figure ‎3-43). Accordingly, a higher swelling rate indicates more dissolution 
medium entrapment in the matrix structure, which may dissolve and release more 
drug molecules. A non-significant (P>0.05) effect of raising the concentration of 
calcium carbonate as a gassing agent on the drug release rate of the tablets 
prepared from the powder mixture at larger part of the time points was noted 
except at level C of crushing strength as shown in (Figure ‎3-53). This may be 
explained by the complete disintegration behaviour of the tablets (within 30 min). 
However, the effect was significant (P<0.05) in the tablets prepared from the 
granules at majority of the time points (Figure ‎3-57). Increasing calcium carbonate 
concentration from 10% to 20% (w/w) increased pore formation in the formed gel 
layer around the tablets due to the entrapped gas bubbles, and this caused a 
higher drug release rate. Increasing sodium carbonate concentration produced a 
non-significant (P>0.05) increase in the rate of drug release from the tablets 
prepared either from the powder mixture (Figure ‎3-54) or the granules 
(Figure ‎3-58) at most of the time points. This agrees with the effect of sodium 
carbonate alkalinity on the swelling behaviour of tablets (Section ‎3.2.4).  
The effect of adding a gassing agent on the drug release rate of the tablets 
prepared from the powder mixture or the granules was evaluated by comparing F7 
(0% w/w gassing agent) results with all the other formulations. As presented in 
Figure ‎3-55 and Figure ‎3-59, pentoxifylline control tablets (F7) prepared from the 
powder mixture or the granules respectively, showed a drug release rate almost 
similar (P>0.05) to that of F1 formulation, but significantly (P<0.05) higher than 
that of F2 formulation at bulk of the time points.  
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This also agrees with the swelling study results (Section ‎3.2.4), where the 
swelling rate of F7 formulation (Figure ‎3-46) was almost similar (P>0.05) to that of 
F1 formulation and significantly (P<0.05) higher than that of F2 formulation at 
majority of the time points (Figure ‎3-43). Adding calcium carbonate at both 
concentrations caused a higher drug release rate due to liberation of carbon 
dioxide bubbles. Generally, the effect was significant (P<0.05) at larger part of the 
time points for the tablets prepared from the powder mixture  following the 
disintegration behaviour in most of F3 and F4 tablets (Figure ‎3-53) except at level 
A of crushing strength where F7 tablets also showed complete disintegration 
(Figure ‎3-55). For the tablets prepared from the granules, the effect was not 
significant (P>0.05) at 10% (w/w) (F3) but significant (P<0.05) at 20% (w/w) (F4) of 
calcium carbonate (Figure ‎3-57) compared to F7 tablets (Figure ‎3-59) at most of 
the time points. In contrast, adding sodium carbonate (gassing agent) at 10% (F5) 
and 20% (w/w) (F6) decreased the release rate compared to that of pentoxifylline 
control tablets (F7) of both the powder mixture (Figure ‎3-54 and Figure ‎3-55) and 
the granules origin (Figure ‎3-58 and Figure ‎3-59) respectively. Generally, the 
effect was not significant (P>0.05) at majority of the time points except for the 
tablets prepared from the powder mixture at level A of crushing strength where F7 
tablets showed complete disintegration behaviour (within 30 min). Although, the 
tablets of the formulations F5 and F6 floated for > 12 and > 24 h respectively 
(Table ‎3-6); their DMU results (Section ‎3.2.4) were almost similar to that of F7 
formulation due to the alkalinity of sodium carbonate which may explain the non-
significant (P>0.05) difference in their drug release rate. 
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Regarding the stability studies, storage for 3 months at 40°C ± 2°C and 
80% ± 5% RH in closed containers slightly (P>0.05) decreased the drug release 
rate of all the tablets of F1 (Figure ‎3-60) and F2 (Figure ‎3-61) formulations in 
comparison with the freshly prepared tablets at majority of the time points. 
However, storage in open containers increased the drug release rate non-
significantly (P>0.05) for F1 tablets and significantly (P<0.05) for F2 tablets at both 
crushing strength levels at most of the time points. The in vitro drug release results 
of the stability studies in open containers agrees with the reduction in the lag time 
results after storage (Section ‎3.2.3) where the dissolution medium easily 
penetrated the relaxed tablet matrices to dissolve the drug and release it at a 
higher rate in comparison to the freshly prepared tablets. 
Storage for 3 months at 40°C ± 2°C and 80% ± 5% RH in closed containers 
caused a decrease in the drug release rate of tablets based on calcium carbonate 
(gassing agent) as presented in Figure ‎3-62 and Figure ‎3-63. Although the effect 
was not significant (P>0.05) at bulk of the time points for F3 (10% (w/w) calcium 
carbonate) formulation, it was significant (P<0.05) for F4 (20% (w/w) calcium 
carbonate) formulation at majority of the time points. Storage for three months in 
the open containers caused a significant (P<0.05) increase in the drug release rate 
of F3 (10% (w/w) calcium carbonate) formulation at larger part of the time points. A 
significant (P<0.05) decrease in the in vitro drug release results of F4 (20% (w/w) 
calcium carbonate) formulation at bulk of the time points was noted except at level 
C of crushing strength where the effect was not significant (P>0.05) at most of the 
time points. These results support the later proposal (Section ‎3.2.6) that the in situ 
ability of anionic alginate molecules to form a gel in the presence of multivalent 
cations such as calcium ions in aqueous medium especially under a relatively high 
moisture level during storage will generate an insoluble gel that may decrease the 
drug release rate. Nevertheless, the cross linking process with 10% (w/w) (F3) 
calcium carbonate may be insufficient to overcome the increase in the tablets 
dimensions due to tablet aging behaviour.     
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The stability drug release rate of sodium carbonate (gassing agent) 
formulations (F5, 10% (w/w) and F6, 20% (w/w)) were presented in Figure ‎3-64 
and Figure ‎3-65 respectively. Storage for three months in either closed or open 
containers significantly increased (P<0.05) the in vitro drug release rate of both F5 
and F6 at all crushing strength levels at bulk of the time points. An exception was 
reported at the lower gassing agent concentration (F5) in the closed containers 
where the effect was not significant (P>0.05) at majority of the time points.   
For F7 formulation (0% gassing agent), a significant (P<0.05) increase in 
the drug release rate was reported at levels A, B, and C of crushing strength at 
larger part of the time points (Figure ‎3-66). This increase in the drug release rate 
of F5, F6, and F7 tablets may be explained by the tablet relaxation during the 
storage process which enhanced more entrapment of the dissolution medium in 
the matrices, leading to dissolve more pentoxifylline molecules and generating 
higher dissolution profiles. 
Generally, tablets stored in the closed containers showed an increase in 
their dimensions; still a lower change in their drug release rate was noted in 
comparison to those stored in the open containers. This may indicate a better 
physical stability of such formulations in closed containers rather than under the 
harsh storage conditions (open containers). Generally, solid oral dosage forms, 
such as tablets, needs protection from moisture, and sometimes from light or 
reactive gases. Because moisture may enhance the drug substance 
decomposition rate or the dissolution rate of the dosage form, a typical container 
closure system for such drug products should have low moisture permeation rate 
such as plastic bottle with a screw-on or snap-off closure or a flexible packaging 
system, like a pouch or a blister package. Essentially, a suitable eye-catching label 
to direct patients for good practice should be recommended for floating tablet 
formulations. 
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Figure ‎3-60: Percentage of drug release of F1 floating tablets pressed at levels 
(A) and (B) of crushing strength in 0.1 M HCl medium after storage for 3 months at 
40°C ± 2°C and 80% ± 5% RH in closed or open containers. 
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give two crushing 
strength levels: A (49–54 N), and B (54–59 N).  No significant change in the 
dissolution medium, macroenvironment, pH was recorded through the experiment 
time. 
 
 
 
Figure ‎3-61: Percentage of drug release of F2 floating tablets pressed at levels 
(A) and (B) of crushing strength in 0.1 M HCl medium after storage for 3 months at 
40°C ± 2°C and 80% ± 5% RH in closed or open containers. 
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give two crushing 
strength levels: A (49–54 N), and B (54–59 N).  No significant change in the 
dissolution medium, macroenvironment, pH was recorded through the experiment 
time. 
For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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Figure ‎3-62: Percentage of drug release of F3 floating tablets pressed at levels 
(A) and (B) of crushing strength in 0.1 M HCl medium after storage for 3 months at 
40°C ± 2°C and 80% ± 5% RH in closed or open containers. 
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  No significant change 
in the dissolution medium, macroenvironment, pH was recorded through the 
experiment time. 
 
 
 
Figure ‎3-63: Percentage of drug release of F4 floating tablets pressed at levels 
(A) and (B) of crushing strength in 0.1 M HCl medium after storage for 3 months at 
40°C ± 2°C and 80% ± 5% RH in closed or open containers. 
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  No significant change 
in the dissolution medium, macroenvironment, pH was recorded through the 
experiment time. 
For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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Figure ‎3-64: Percentage of drug release of F5 floating tablets pressed at levels 
(A) and (B) of crushing strength in 0.1 M HCl medium after storage for 3 months at 
40°C ± 2°C and 80% ± 5% RH in closed or open containers. 
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  No significant change 
in the dissolution medium, macroenvironment, pH was recorded through the 
experiment time. 
 
 
 
Figure ‎3-65: Percentage of drug release of F6 floating tablets pressed at levels 
(A) and (B) of crushing strength in 0.1 M HCl medium after storage for 3 months at 
40°C ± 2°C and 80% ± 5% RH in closed or open containers. 
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  No significant change 
in the dissolution medium, macroenvironment, pH was recorded through the 
experiment time. 
For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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Figure ‎3-66: Percentage of drug release of F7 control tablets pressed at levels (A) 
and (B) of crushing strength in 0.1 M HCl medium after storage for 3 months at 
40°C ± 2°C and 80% ± 5% RH in closed or open containers. 
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  No significant change 
in the dissolution medium, macroenvironment, pH was recorded through the 
experiment time. 
For formulation composition, refer to Table ‎3-1 or Table 2-7. 
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Regarding the ICH (Q6A), any change in the qualitative characteristics of 
the dosage form, such as the colour, during storage should be investigated 
appropriately (ICH, 1999). The morphological changes due to storage for 3 months 
at 40°C ± 2°C and 80% ± 5% RH in closed or open containers had been observed 
(Figure ‎3-67). Pictures of the tablets based on sodium bicarbonate (F1 and F2) 
gave an impression that the tablets became pink and spotted after the storage, 
however they were not. Pictures were taken at different time intervals during the 
study and it was difficult to have the same quality of the pictures at each time 
interval. Additionally, no change in the tablets colour of the formulations based on 
calcium carbonate (F3 and F4) was observed after the storage neither in the 
closed nor in the open containers. This agrees with earlier results of DSC 
(Section ‎3.1.2) and FTIR (Section ‎3.1.3) that confirmed stability of pentoxifylline in 
the formulations F1-F4 after storage for 3 months at 40°C ± 2°C and 80% ± 5% 
RH in closed or open containers. In contrast, small spots with brown colour were 
shown on the surface of F5 (10% sodium carbonate) and F6 (20% sodium 
carbonate) tablets only after storage in open containers. Although, both DSC 
(Section ‎3.1.2) and FTIR results (Section 3.1.3) indicates stability of pentoxifylline 
in such formulations, this is not acceptable and needs further investigations in the 
future using a specific stability-indicating assay method such as HPLC to 
determine the drug content and any possible degradation products.  
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Figure ‎3-67: Pictures of F1-F7 tablets freshly prepared and after storage for 3 
months at 40°C ± 2°C and 80% ± 5% RH in closed or open containers.  
For formulation composition, refer to Table ‎3-1or Table 2-7. 
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3.2.6 Release data modeling and analysis  
 
Hydrophilic polymers such as hydroxyethyl cellulose, hydroxypropyl 
cellulose, hydroxypropylmethyl cellulose, methylcellulose, sodium carboxymethyl 
cellulose, and alginates are commonly used to fabricate three dimensional 
networks (matrices) to extend the drug release. Within these systems, drug and 
other substances like excipients required for the formulation are embedded 
(Kydonieus, 1992; Wise, 2000). On contact with aqueous media, water penetrates 
the polymer network inducing stresses within the matrix polymer causing 
relaxation shown as swelling by converting the hydrated polymer from a glassy 
state (or crystalline phase) to a rubbery state (Kararli et al., 1990; Ju et al., 1995; 
Linder et al., 1996). The resulted gel layer will control further diffusion of water into 
the matrix as well as diffusion of the drug out of the matrix. With time, this gel layer 
will dissolve (erode) in the medium by slow disentanglement of the polymer 
chains. After erosion, the new matrix surface will again be hydrated to form a new 
gel layer. In general, polymer dissolution (erosion) and diffusion of drug molecules 
across the gel layer have been identified as the rate-controlling mechanisms (Li 
and Jasti, 2006). 
Presence of cross-links between the polymeric chains enhances swelling of 
the network and delays its dissolution in the liquid medium. In case of strong 
cross-links between polymeric chains, covalent bonds are present, and the 
network is not modifying with time. However, in case of weak cross-links, van der 
Waals, dipole–dipole, hydrophobic and hydrogen bonding exist; and this kind of 
network can easily undergo erosion due to polymer-polymer junction weakness. 
Further complicated situation is present in matrices based on two different 
polymers as two interpenetrating structures (networks) are created. Normally, 
these systems are created by an early swelling of a monomer and reacting to form 
a second intermeshing network structure (Aso et al. 1999, Xuequan et al., 2000).  
Matrices can be classified regarding their porosity into macroporous, 
microporous and non-porous systems. In macroporous and microporous systems, 
drug diffusion occurs essentially through pores ranging in size between 0.1-1 mm 
and between 50-200 Å respectively. Conversely, in non-porous systems drug 
molecules diffuse through network meshes as only the polymeric phase exists and 
no pores are present (Kydonieus, 1992).  
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Figure ‎3-68 represent polymer swelling/erosion and drug delivery process 
from matrix systems. During the drug release process, eroding, swelling, and 
diffusion fronts can be shown (Lee and Kim, 1991). The eroding front separates 
the release environment (dissolution medium) from the matrix. Position of the 
eroding front depends on hydrodynamic conditions of the release environment and 
on cross-linking strength of the matrix. It moves outwards when swelling kinetics is 
predominant on the erosion process, and moves inwards in the opposite situation. 
The swelling front separates the swollen matrix layer from the dry glassy core. It 
moves inward with a speed depends on the viscoelastic properties of the polymer / 
solvent couple of non-porous matrices, while it depends additionally on matrix 
porosity for porous systems. 
Drug release kinetics can be influenced by drug / polymer ratio, drug 
distribution inside the matrix, drug dissolution / diffusion characteristics, polymer 
swelling and erosion characteristics, and system geometry (Conte et al., 1988; 
Colombo et al., 1999). Drug solubility plays a major role in the release mechanism. 
Soluble drugs are released by diffusion through the formed gel layer, while 
insoluble drug release is done by erosion followed by dissolution and diffusion of 
drug molecules. 
 
 
Figure ‎3-68: Polymer swelling/erosion and drug delivery process from matrix 
systems (Lopes et al., 2005) 
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Extended drug release systems such as matrices are able to control drug 
release rate and its duration of action by maintaining drug concentration in the 
blood or in targeted tissues at a desired level as long as possible (Langer and 
Wise, 1984, Robinson and Lee, 1987). Newly developed pharmaceutical products 
are extensively evaluated by the pharmaceutical industry and the registration 
authorities to ensure that drug release / dissolution occurs in an appropriate 
manner (Costa and Sousa Lobo, 2001). Drug is released continuously from most 
oral sustained drug release systems in a linear or non-linear release fashion 
(Bussemer and Bodmeier, 2003) as drug cristallinity, polymorphic form, particle 
size, solubility and amount in the dosage form can influence the release kinetics 
(Salomon and Doelker, 1980; El-Arini and Leuenberger, 1995). Thus, the 
quantitative analysis of the drug release data obtained from in vitro dissolution 
tests is easier when mathematical models are applied. This approach enables 
prediction of the drug delivery system release kinetics and consequently has a 
very important role in the drug delivery systems optimisation. Well-defined drug 
release kinetics is required in order to supply the drug maintenance dose to 
achieve the desired therapeutic level (Grassi and Grassi, 2005). In this work, zero 
order, first order, Hixson-Crowell, Higuchi, and Korsmeyer–Peppas mathematical 
release models were used to describe drug release process from the designed 
floating systems. 
Pharmaceutical dosage forms that do not disaggregate (assuming that area 
does not change) and release the drug slowly can be represented by zero order 
models. This model can be used to describe the drug dissolution of some 
transdermal systems, as well as matrix tablets with low soluble drugs, coated 
forms, and osmotic systems (Varelas et al., 1995). The same amount of drug by 
unit of time can be achieved by this order of release and it is the ideal method of 
drug release in order to achieve a pharmacological prolonged action (Costa and 
Sousa Lobo, 2001). Release of water-soluble drugs loaded in porous matrices can 
be fitted into first order release model in which the drug is released in a way that is 
proportional to the amount of drug remaining in its interior (Costa and Sousa Lobo, 
2001). Higuchi (1963) developed another mathematical model using an equation 
to describe the drug release from an insoluble matrix as the square root of a time-
dependent process based on Fickian diffusion.  
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Several types of modified release pharmaceutical dosage forms can be 
fitted into this model such as some transdermal systems (Costa et al., 1996) and 
matrix tablets with water soluble drugs (Desai et al., 1966a,b; Schwartz et al., 
1968a,b). The Hixson-Crowell model is a cube root law describes the drug release 
from delivery systems where there is a change in surface area and diameter of 
particles or tablets (Hixson and Crowell, 1931). Korsmeyer-pepas model is used to 
describe the release of polymeric pharmaceutical dosage forms, when the release 
mechanism is not well known or when more than one type of release phenomena 
could be involved (Korsmeyer et al., 1983). Drug release mechanism could be 
predicted from values of exponent (n). For a cylindrical tablet, a value of n ≤ 0.45 
indicates Case I transport or Fickian release (release by diffusion), 0.45 < n < 0.89 
indicates anomalous or non-Fickian release (release by diffusion and polymer 
relaxation), n = 0.89 indicates Case II transport (release by polymer erosion and 
zero-order kinetics), and n > 0.89 indicates Super Case II transport (release by 
polymer erosion) (Peppas, 1985; Mura et al., 1995). 
Table ‎3-7 summarizes the release rate constants (k), and correlation 
coefficients (R2) calculated after fitting the release profiles of the formulations F1-
F7 into zero order, first order, Hixson-Crowell, and Higuchi drug release 
mathematical models. Due to the rapid dissolution profiles of the tablets prepared 
from the powder mixtures at levels A of crushing strength of F2 (Figure ‎3-52), at 
levels A and B of F3 (Figure ‎3-53), at levels A, B, and C of F4 (Figure ‎3-53), and at 
level A of F7 (Figure ‎3-55) their profiles were excluded from Table ‎3-7 evaluation.  
The in vitro drug release rate of the formulations F1-F7 were best explained 
by first order, Hixson-Crowell, and Higuchi‗s equations, as greater than 0.98 
linearity (R2) values were obtained. Results indicates a concentration dependent 
drug release process and a change in diameter and surface area of the matrices 
with the progressive dissolution process as a function of time. Additionally, the 
release of pentoxifylline from the evaluated floating matrices (F1-F7) as a square 
root of time dependent process was based on Fickian diffusion. 
The drug release data were fitted into Korsmeyer–Peppas equation 
(Equation 11, chapter ‎2, section ‎2.2.6.6), which describes the drug release from 
polymeric systems, to evaluate the effect of different variables such as tablet 
crushing strength, the granulation process, and gassing agent concentration on 
the drug release mechanism of the prepared tablet (F1-F7).  
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Table ‎3-7: Release rate constants (k), and correlation coefficients (R2) calculated after fitting the release profiles of F1-F7 into 
of zero order, first order, Hixson-Crowell, and Higuchi drug release mathematical models. 
Formulation 
Origin of 
prepared 
tablets 
Crushing 
strength 
Level 
Drug release mathematical model 
Zero order First order Hixson-Crowell Higuchi 
R2 
K0 
(mg*h-1) 
R2 
K1 
(h-1) 
R2 
KHC 
(mg1/3*h-1) 
R2 
KH 
(mg1/2*h-1) 
F1 
Powder 
(A) 0.9363 5.0306 0.9988 0.1564 0.9905 0.1617 0.9925 21.582 
(B) 0.9569 6.3404 0.9885 0.1810 0.9982 0.1908 0.9974 26.974 
Granules 
(A) 0.9350 6.3000 0.9980 0.1451 0.9860 0.1670 0.9930 27.050 
(B) 0.9440 6.7200 0.9970 0.1773 0.9960 0.1920 0.9960 28.760 
F2 
Powder 
(A) 0.6237 0.8232 0.6670 0.0712 0.6539 0.0533 0.7917 3.865 
(B) 0.9719 3.5910 0.9985 0.1092 0.9952 0.1153 0.9923 15.120 
Granules 
(A) 0.9870 5.9810 0.9930 0.1152 0.9980 0.1410 0.9870 24.910 
(B) 0.9850 5.6540 0.9960 0.1082 0.9990 0.1330 0.9900 23.610 
The compression force of the prepared tablets was adjusted to give two crushing strength levels: A (49–54 N), and B (54–59 
N) for F1 and F2 formulations, and three crushing strength levels: A (49–54 N), B (54–59 N), and C (59-64 N) for F3-F7 
formulations. For formulation composition, refer to Table ‎3-1 or Table 2-7. Figure ‎3-69 shows the release kinetic plots with 
equations. 
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Table 3-7 (continued): Release rate constants (k), and correlation coefficients (R2) calculated after fitting the release profiles 
of F1-F7 into of zero order, first order, Hixson-Crowell, and Higuchi drug release mathematical models. 
Formulation 
Origin of 
prepared 
tablets 
Crushing 
strength 
Level 
Drug release mathematical model 
Zero order First order Hixson-Crowell Higuchi 
R2 
K0 
(mg*h-1) 
R2 
K1 
(h-1) 
R2 
KHC 
(mg1/3*h-1) 
R2 
KH 
(mg1/2*h-1) 
F3 
Powder 
(A) 0.5492 -0.3801 0.5058 -0.0560 0.5199 -0.0349 1.0000 1.000 
(B) 0.5623 -0.3834 0.5172 -0.0617 0.5337 -0.0376 0.4637 -1.450 
(C) 0.9193 5.4102 0.9832 0.2229 0.9760 0.2061 0.9795 23.270 
Granules 
(A) 0.9768 6.4900 0.9632 0.1891 0.9933 0.1968 0.9985 27.342 
(B) 0.9671 6.2208 0.9803 0.1670 0.9938 0.1802 0.9986 26..34 
(C) 0.9682 6.2580 0.9718 0.1614 0.9912 0.1768 0.9973 26.466 
F4 
Powder 
(A) 0.3708 0.9083 0.3764 0.0949 0.3823 0.0658 0.5424 4.578 
(B) 0.4099 0.6645 0.4778 0.0903 0.4577 0.0580 0.5787 3.290 
(C) 0.6909 1.2145 0.8202 0.1004 0.7843 0.0808 0.8178 5.506 
Granules 
(A) 0.9781 5.7699 0.9311 0.2250 0.9829 0.2085 0.9977 24.283 
(B) 0.9657 5.8074 0.9552 0.2054 0.9901 0.1987 0.9984 24.604 
(C) 0.9730 6.3913 0.9450 0.2351 0.9909 0.2215 0.9978 26.969 
The compression force of the prepared tablets was adjusted to give two crushing strength levels: A (49–54 N), and B (54–59 
N) for F1 and F2 formulations, and three crushing strength levels: A (49–54 N), B (54–59 N), and C (59-64 N) for F3-F7 
formulations. For formulation composition, refer to Table ‎3-1 or Table 2-7. Figure ‎3-69 shows the release kinetic plots with 
equations. 
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Table 3-7 (continued): Release rate constants (k), and correlation coefficients (R2) calculated after fitting the release profiles 
of F1-F7 into of zero order, first order, Hixson-Crowell, and Higuchi drug release mathematical models. 
Formulation 
Origin of 
prepared 
tablets 
Crushing 
strength 
Level 
Drug release mathematical model 
Zero order First order Hixson-Crowell Higuchi 
R2 
K0 
(mg*h-1) 
R2 
K1 
(h-1) 
R2 
KHC 
(mg1/3*h-1) 
R2 
KH 
(mg1/2*h-1) 
F5 
Powder 
(A) 0.9722 6.5091 0.9943 0.1462 0.9974 0.1691 0.9918 27.394 
(B) 0.9674 6.5549 0.9964 0.1492 0.9979 0.1718 0.9939 27.686 
(C) 0.9705 6.3234 0.9983 0.1303 0.9980 0.1557 0.9954 26.686 
Granules 
(A) 0.9968 6.5989 0.9523 0.1490 0.9831 0.1712 0.9818 27.290 
(B) 0.9849 6.3283 0.9864 0.1333 0.9983 0.1578 0.9950 26.505 
(C) 0.9804 6.2525 0.9848 0.1327 0.9963 0.1565 0.9955 26.255 
F6 
Powder 
(A) 0.9627 5.1328 0.9944 0.1343 0.9913 0.1483 0.9906 21.695 
(B) 0.9780 5.6887 0.9884 0.1557 0.9979 0.1680 0.9912 23.864 
(C) 0.9800 5.8058 0.9910 0.1446 0.9993 0.1615 0.9934 24.358 
Granules 
(A) 0.9848 6.4070 0.9687 0.1416 0.9900 0.1643 0.9919 26.794 
(B) 0.9784 6.2527 0.9926 0.1315 0.9994 0.1559 0.9969 26.300 
(C) 0.9789 5.9492 0.9922 0.1195 0.9979 0.1443 0.9963 25.010 
F7 
Powder 
(A) 0.6161 -0.1697 0.4580 -0.0707 0.5119 -0.0311 0.5679 -0.679 
(B) 0.9280 4.9154 0.9327 0.3222 0.8799 0.3822 0.9924 21.187 
(C) 0.9352 6.1052 0.9858 0.2126 0.9970 0.2069 0.9946 26.236 
Granules 
(A) 0.9313 5.5089 0.9873 0.1124 0.9734 0.1355 0.9910 23.680 
(B) 0.9718 5.7306 0.9963 0.1207 0.9973 0.1434 0.9974 24.192 
(C) 0.9749 5.6694 0.9950 0.1207 0.9971 0.1430 0.9958 23.880 
The compression force of the prepared tablets was adjusted to give two crushing strength levels: A (49–54 N), and B (54–59 
N) for F1 and F2 formulations, and three crushing strength levels: A (49–54 N), B (54–59 N), and C (59-64 N) for F3-F7 
formulations. For formulation composition, refer to Table ‎3-1 or Table 2-7. Figure ‎3-69 shows the release kinetic plots with 
equations. 
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Figure ‎3-69: Mathematical model plots of F2 floating tablets (as an example) 
pressed at level (A) of crushing strength in 0.1 M HCl medium after granulation. 
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As shown in Table ‎3-8, drug release results of F1-F7 tablets fitted into 
Korsmeyer–Peppas equation as correlation coefficients (R2) greater than 0.98 
were obtained in most cases except for those tablets prepared from the powder 
mixture of F1 formulation (10% (w/w) sodium bicarbonate) at crushing strength 
level (A), F2 formulation (20% (w/w) sodium bicarbonate) at crushing strength 
level (B), and F3 formulation (10% (w/w) calcium carbonate) at crushing strength 
level (C) where (R2) values were 0.9710, 0.9459, and 0.9392 respectively. There 
were insufficient data points on the release profile ≤ 60% drug release in order to 
provide accurate values for tablets prepared from the powder mixture of F2 
(Figure ‎3-52), F3, F4 (Figure ‎3-53), and F7 (Figure ‎3-55) due to their rapid drug 
release rate.  
The values of release rate constant (KP) conforms to the in vitro drug 
release results discussed earlier (Section ‎3.2.5). Generally, increasing tablet 
crushing strength showed a decrease in KP values of the tablets prepared from the 
powder mixture but slightly changed those of the granules origin. This complies 
with in vitro drug release studies, where increasing the compression force made 
the powder mixture particles closer to each and reduced the porosity percentage 
values. This also delayed penetration of the dissolution medium into the matrix to 
dissolve the drug, which decreased the drug release rates. 
The granulation process decreased the release rate constant (KP) of all the 
formulations (F1-F7). This agrees with previous discussion for the effect of the 
granulation process on the drug release process (Section ‎3.2.5), where the 
granulation decreased porosity during the wet massing stage, and this reduction 
delayed the dissolution medium entrapment through the matrix at an early stage of 
the dissolution test, and decreased the drug release rate. 
It has been noted that as sodium bicarbonate concentration increased from 
0% to 20% (w/w), drug release rate (Kp) decreased in all the tablets prepared from 
the granules. This complies with the drug release rate (Section ‎3.2.5) as 
increasing sodium bicarbonate concentration increased the floating duration, 
which decreased the available surface area of tablets for DMU. Consequently, a 
lower swelling rate was obtained (Section ‎3.2.4), which means less dissolution 
medium entrapment in matrix tablet bodies, which was presented by reduction in 
the drug release rate.  
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Regarding the other formulations (F3-F6), increasing gassing agent 
concentration from 0% (w/w) to 20 % (w/w) increased KP values of all the tablets 
except those based on sodium carbonate as a gassing agent (F5 and F6) 
prepared from the powder mixture or the granules which obeys with the drug 
release rate discussed earlier (Section ‎3.2.5). 
The effect of the tablet crushing strength, the granulation process, and the 
gassing agent concentration on the drug release mechanism of the prepared tablet 
(F1-F7) was also evaluated through the release exponent (n) values. As shown in 
Table ‎3-8, increasing tablet crushing strength for F1 formulation prepared from 
powder mixture changed the release exponent (n) values from 0.2532 to 0.5057. 
This indicates a change in the mechanism of the drug release from Fickian to non-
Fickian, which means involvement of polymer swelling or relaxation in the release 
process beside drug diffusion. However, the results of F2 formulation were not 
clear regarding release kinetics due to the insufficient data points at level (A) of 
crushing strength. Changing the crushing strength level in the tablets prepared 
from the granules slightly changed the exponent (n) values in both the 
formulations F1 and F2, where values were in the range of 0.5799 - 0.6822, which 
indicates anomalous or non-Fickian release mechanism. Regarding the 
formulations F3-F7, changing the crushing strength level slightly changed (n) 
values but without changing the release mechanism of all the prepared tablets. An 
exception was noted in those of F7 (0% gassing agent) formulation prepared from 
the powder mixture where (n) values indicates a change from Fickian to non-
Fickian release. This reveals involvement of polymer swelling or relaxation in the 
release beside drug diffusion.  
Generally, as presented in Table ‎3-8, the granulation process changed the 
exponent (n) values for both the formulations F1 and F2 at both crushing strength 
levels from Fickian to a non-Fickian release mechanism, which suggests the 
involvement of polymer relaxation in the release process in addition to drug 
diffusion.  
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Effect of the granulation process on the release kinetics of F3, F4 and F7 
tablets was not clear because of insufficient data points. For the tablets based on 
sodium carbonate as a gassing agent (F5 and F6), the granulation process 
changed the drug release mechanism only for F6 (20% (w/w) sodium carbonate) 
formulation from Fickian to non-Fickian release, however the release mechanism 
for F5 (10% (w/w) sodium carbonate) formulation remained non-Fickian release.     
The effect of increasing the gassing agent concentration from 0% to 20% 
(w/w) on the release kinetics was not clear in the tablets prepared from the powder 
mixture due to the insufficient data points. However, for the tablets prepared from 
the granules the effect was much clearer. It was noted that at the absence of a 
gassing agent, the drug release was through diffusion and polymer relaxation 
(non-Fickian release). The addition of gassing agents (sodium bicarbonate, 
calcium carbonate, or sodium carbonate) slightly increased the exponent (n) 
values, which reveals a little more contribution of polymer relaxation and erosion to 
release mechanism (Jiménez-Martinez et al., 2008). This may be related to the 
movement of generated carbon dioxide bubbles from internal to peripheral sides of 
floating tablets, which increased the mass loss or polymer erosion behaviour. The 
release mechanism did not change on the addition of gassing agents, but, adding 
calcium carbonate at 20% (w/w) level changed the release mechanism to diffusion 
mechanism (Fickian release). This may be explained by the in situ ability of the 
anionic alginate molecules to form a gel in the presence of multivalent cations 
such as calcium ions in aqueous medium, which fit in to the guluronate block 
structure like eggs in an egg box (Gacesa, 1988; Grant et al., 1973). In addition, 
theophylline release from polymeric matrices contained calcium ions was studied 
by Nokhodchi and Tailor (2004). They proposed that when calcium ions 
concentration increases the drug release rate increases to an optimum level 
before declining due to insufficient calcium ions being available to cross-link with 
the anionic alginate molecules to form an insoluble gel. This explain the change in 
the drug release mechanism from diffusion and polymer relaxation (F3) to diffusion 
only (F4) which may be due to better and stronger gel formation. 
 
 
 
 166 
 
Table ‎3-8: Korsmeyer-Peppas kinetic parameters of the formulations F1-F7 
pentoxifylline tablet formulations. 
Formulation 
Origin of 
prepared 
tablets 
Crushing 
strength 
Level 
Korsmeyer-Pepas 
R2 n 
Kp 
(h-n) 
F1 
Powder 
(A) 0.9710 0.2532 0.3809 
(B) 0.9969 0.5057 0.2512 
Granules 
(A) 0.9989 0.5799 0.1907 
(B) 0.9990 0.6690 0.1990 
F2 
Powder 
(A) N.A N.A N.A 
(B) 0.9459 0.1503 0.4747 
Granules 
(A) 0.9921 0.6822 0.1359 
(B) 0.9907 0.6113 0.1566 
F3 
Powder 
(A) N.A N.A N.A 
(B) N.A N.A N.A 
(C) 0.9392 0.2310 0.4161 
Granules 
(A) 0.9993 0.5280 0.2336 
(B) 1 0.5441 0.2319 
(C) 0.9995 0.5800 0.2144 
F4 
Powder 
(A) N.A N.A N.A 
(B) N.A N.A N.A 
(C) N.A N.A N.A 
Granules 
(A) 0.9910 0.3355 0.3522 
(B) 0.9927 0.3768 0.3342 
(C) 0.9880 0.4202 0.2949 
F5 
Powder 
(A) 0.9929 0.6470 0.1662 
(B) 0.9944 0.6656 0.1673 
(C) 0.9982 0.7289 0.1410 
Granules 
(A) 0.9995 0.7032 0.1359 
(B) 0.9997 0.7210 0.1397 
(C) 0.9969 0.7083 0.1458 
F6 
Powder 
(A) 0.9899 0.3012 0.3246 
(B) 0.9881 0.3458 0.2928 
(C) 0.9835 0.4379 0.2534 
Granules 
(A) 0.9980 0.7116 0.1452 
(B) 0.9972 0.7005 0.1481 
(C) 0.9979 0.6739 0.1487 
F7 
Powder 
(A) NA NA NA 
(B) 0.9986 0.2511 0.5098 
(C) 0.9963 0.4564 0.3163 
Granules 
(A) 0.9985 0.5859 0.1994 
(B) 0.9961 0.5889 0.1855 
(C) 0.9980 0.5457 0.1968 
Notes: N.A: There are insufficient data points on the release profiles ≤ 60% drug 
release in order to provide accurate values. The compression force of the 
prepared tablets was adjusted to give two crushing strength levels: A (49–54 N), 
and B (54–59 N) for F1 and F2 formulations, and three crushing strength levels: A 
(49–54 N), B (54–59 N), and C (59-64 N) for F3-F7 formulations. For formulation 
composition, refer to Table ‎3-1 or Table 2-7.  
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3.3 Conclusions 
 
In this chapter, floating tablets of pentoxifylline were prepared using a (1:1) 
ratio of hydroxyethyl cellulose and sodium alginate polymeric mixture based on 
sodium bicarbonate, calcium carbonate or sodium carbonate gas forming agent. 
The granulation process may enhance elastic recovery of alginate molecules after 
compression, which explains the inability to prepare tablets of both the 
formulations F1 (10% (w/w) sodium bicarbonate) and F2 (20% (w/w) sodium 
bicarbonate) at 59-64 N, (level C), crushing strength after the granulation. All the 
prepared tablets (F1-F7) through the granulation showed acceptable physical 
properties via complying with the BP requirements of friability, weight and drug 
content uniformity. The results of the formulations F4 (20% (w/w) calcium 
carbonate) and F5 (10% (w/w) sodium carbonate) exceeded the BP limit of 
friability (< 1%), however, as the tablet crushing strength level increased as the 
mass loss percentage decreased. Increasing the compression force showed 
negligible influence on the drug release rate after the granulation. This gives an 
advantage to control the other formulation parameters such as high friability 
percentages by raising the compression force without disturbing the drug release 
rate.  
The effect of the granulation process on the drug release rate from all the 
formulations F1-F7 reveals that the granulation extended the drug release rate of 
all the prepared tablets. Increasing the concentration of the gassing agent 
decreased the floating lag time results of the tablets based on sodium bicarbonate 
or calcium carbonate due to the higher effervescent efficiency. In contrast, the lag 
time results increased in the tablets based on sodium carbonate due to increasing 
the tablets apparent densities. Raising sodium bicarbonate concentration in the 
tablets prepared after the granulation increased the floating duration which 
decreased the available surface area for the dissolution medium uptake. 
Consequently, a decrease in the swelling and the drug release rates were noted. 
In contrast, an increase in the drug release rate was noted in calcium carbonate 
based tablets when its concentration was increased due to the amplified pore 
formation in the generated gel layer around the tablets.  
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However, sodium carbonate, regardless its concentration, generated an 
alkaline microenvironment which accelerated the swelling and the gel formation 
rate. Hence, altering sodium carbonate concentration did not change the drug 
release rate from the prepared tablets.  
The drug release rate of all the formulations (F1-F7) fitted into non-Fickian 
release mechanism except F4 tablets, containing 20% (w/w) calcium carbonate as 
a gassing agent, which fitted into Fickian release mechanism due to the in situ 
ability of the anionic alginate molecules to be cross linked in the presence of 
enough concentration of calcium ions. The tablets could float on the surface of 
dissolution medium and sustain the drug release over 24 h. F4 tablets prepared 
with 20% (w/w) calcium carbonate showed satisfactory results with respect their 
quality control tests, floating lag time, total floating duration, swelling ability, and 
sustained drug release rate. Stability studies point to suitability of closed 
containers for such formulations. Generally, from the results, calcium carbonate 
was the most effective gassing agent to produce efficient floating tablets and this 
can add to the pharmaceutical filed as there is sparse literature about calcium 
carbonate application in floating gastroretentive drug delivery systems. Therefore, 
calcium carbonate containing formulation, F4, was chosen for preliminary in vivo 
studies (Chapter ‎5).   
In the following chapter (Chapter 4), another model drug, cefalexin 
monohydrate, which can be better to benefit from the gastroretentive systems, was 
loaded in floating tablet dosage forms using the gassing agents used with 
pentoxifylline floating tablets.   
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4 Chapter Four: Evaluation of the effect of sodium 
bicarbonate, calcium carbonate, and sodium 
carbonate as gassing agents on cefalexin 
monohydrate floating tablets 
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In this chapter, tablets based on a gel forming polymeric mixture of (1:1) ratio 
of hydroxyethyl cellulose and sodium alginate, and a gassing component based on 
sodium bicarbonate, calcium carbonate or sodium carbonate were developed and 
evaluated as an effervescent gastroretentive drug delivery system. Cefalexin 
monohydrate was used as a model drug since it has a short half-life of 
approximately 1 h (Davies and Holt, 1972). Consequently, it is suitable for 
sustained drug delivery. Still, its instability at intestinal pH and its narrow 
absorption window at the upper gastrointestinal tract (GIT) made it ideal model 
drug for the gastroretentive delivery systems but not the ordinary sustained 
release delivery systems (Yin et al., 2013). The variables that may affect drug 
release and floating properties were evaluated, such as the wet granulation (to 
compare effects of powders versus those of granules), and type and ratio of the 
gas forming agent.  
In order to increase the challenge level over the designed floating tablets, the 
(1:1) binary mixture of hydroxyethyl cellulose and sodium alginate content was 
reduced by almost 36% (w/w) in cefalexin monohydrate tablets compared to 
pentoxifylline tablets (Chapter ‎3) due to the change in their drug content. In 
chapter 3, the dose of pentoxifylline was only 60 mg to evaluate the designed 
floating tablets, but in this chapter cefalexin monohydrate dose was raised up to 
250 mg.  
 
4.1 Evaluation of the prepared powders and granules (pre-
compression characterisation) 
 
All the prepared powder mixtures and granules of the formulations F8-F14 
were evaluated for flowability CI index, moisture content percentage, DSC, and 
FTIR. The formulations F8-F14 compositions are presented in Table ‎4-1 (and also 
Table 2-8). 
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Table ‎4-1: Composition of prepared F8-F14 tablets 
Ingredients/Formulation F8 (mg) F9 (mg) F10 (mg) F11 (mg) F12 (mg) F13 (mg) F14 (mg) 
Cefalexin monohydrate 250 250 250 250 250 250 250 
Hydroxyethyl cellulose 68.8 68.8 68.8 68.8 68.8 68.8 68.8 
Sodium alginate 68.8 68.8 68.8 68.8 68.8 68.8 68.8 
Sodium bicarbonate 42.6 96.8      
Calcium carbonate    42.6 96.8    
Sodium carbonate     42.6 96.8  
Magnesium stearate (0.5%) 2.2 2.4 2.2 2.4 2.2 2.4 1.9 
Total weight 432.4a 486.8a 432.4a 486.8a 432.6a 486.8a 389.5 
a Difference in weight was due to raising gassing agent content from 10% to 20% (w/w). 
Note: number of moles of the gassing agents used in the formulations is 5.1x10-4 (F8), 11.5x10-4 (F9), 4.3x10-4 (F10), 9.7x10-4 
(F11), 4.0x10-4 (F12), and 9.1x10-4 (F13).   
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4.1.1 Flowability and moisture content for powders and granules 
 
The results of the moisture content and the CI value of the formulations F8- 
F14 before and after granulation are shown in Table ‎4-2. The granulation process 
caused a significant (P<0.05) decrease in the percentage of the moisture content 
of all the formulations except F13 where p=0.380.  
 Moreover, CI decreased following the granulation in all the formulations 
(F8-F14, Table ‎4-2) which reveals better flow properties of the granules compared 
to the powder mixture (Gaisford, 2013). The effect was significant (P<0.05) in the 
formulations based on sodium bicarbonate (F8 and F9) and sodium carbonate 
(F12 and F13) as gassing agents, but not significant (P>0.05) in all the other 
formulations (F10, F11, and F14). 
The water solubility of sodium bicarbonate (Chapter ‎3, section ‎3.2.2) could 
enhance formation of a homogenous mass with the hydrophilic polymeric binary 
mixture of hydroxyethyl cellulose and sodium alginate during the wet massing 
process. This could assist agglomeration techniques of the granulation process 
where fine solid particles are converted into larger ones by mixing them in the 
presence of water binding liquid. This acts in accordance with the significant 
(P<0.05) decrease in CI results of F12 and F13 based on sodium carbonate as a 
gassing agent which is also water-soluble (Chapter ‎3, section ‎3.2.2). Additionally, 
this may explain the non-significant (P>0.05) effect of the granulation process on 
the formulations F10 and F11 based on calcium carbonate which is less water-
soluble (Chapter ‎3, section ‎3.2.2). Hamed et al. (2005) proposed that changing 
proportions of water soluble excipients in formulations could significantly modify 
granules‘ properties which may explain the absence of significant effect of the 
granulation on the CI results of cefalexin monohydrate control formulation (F14).  
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Table ‎4-2: Moisture content and Carr‘s index with statistical analysis (p-value) 
results of the formulations F8-F14 before and after granulation. 
Test Formulation 
Origin of prepared tablets 
P-value 
Powder mixture Granules 
Moisture content (%) 
F8 6.25 ± 0.20 4.36 ± 0.13 0.001 
F9 5.68 ± 0.12 4.95 ± 0.16 0.013 
F10 6.74 ± 0.08 5.31 ± 0.42 0.023 
F11 5.97 ± 0.17 4.28 ± 0.08 0.001 
F12 6.80 ± 0.12 5.09 ± 0.13 0.004 
F13 6.17 ± 0.17 6.02 ± 0.11 0.380 
F14 7.20 ± 0.14 5.02 ± 0.26 0.001 
Carr‘s Index (CI) (%) 
F8 43.09 ± 0.78 23.67 ± 0.32 0.001 
F9 38.37 ± 1.87 22.34 ± 0.57 0.003 
F10 37.14 ± 4.89 30.97 ± 1.09 0.194 
F11 38.79 ± 1.83 33.97 ± 0.31 0.052 
F12 39.89 ± 1.54 28.02 ± 1.10 0.016 
F13 40.39 ± 2.26 18.92 ± 1.48 0.001 
F14 37.46 ± 4.29 31.72 ± 1.70 0.066 
Note: The data represents the mean ± SD of three determinations.  
For formulation composition, refer to Table ‎4-1 or Table 2-8.    
 
 
 
4.1.2 Differential scanning calorimetry (DSC) 
 
The compatibility of cefalexin monohydrate with excipients within the 
formulations F8-F14 before and after the granulation was studied using DSC. 
Cefalexin melting point and decomposition temperature was not clearly defined in 
literature. El-Shattawy et al. (1982) reported that cefalexin showed exothermic 
peaks at 178°C and at 198°C when it decomposed. Also, Doadrio et al. (2004) 
presented that samples containing cefalexin had an endothermic melting peak at 
50°C and an exothermic decomposition peak at 200°C. However, Agnihotri, et al. 
(2006) stated that for pure cefalexin, an endothermic peak appeared at 194°C due 
to the melting of the drug. Recently, Chuong et al., (2016) concluded that the 
melting of cefalexin is atypical, and cefalexin monohydrate had ability to absorb 
energy from 31.5 to 121.9°C to permit both free and bound water to evaporate, 
and more enthalpy to assist degradation ranging from 176.2 to 200.3°C. 
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As shown in Figure ‎4-1, pure cefalexin monohydrate showed a broad 
endothermic peak at about 102.72˚C due to water evaporation, and a sharper 
positive transition (heat release) at 192.57˚C due to the drug degradation. Sodium 
alginate had a broad endothermic peak around 114.24˚C and two exothermic 
peaks at 212.89˚C and 240.02˚C (Chapter ‎3, Figure ‎3-2). Hydroxyethyl cellulose, 
sodium bicarbonate, and sodium carbonate showed endothermic peaks at about 
94.88˚C (Chapter ‎3, Figure ‎3-3), 145.81˚C (Chapter ‎3, Figure ‎3-5), and 85.80˚C 
(Chapter ‎3, Figure ‎3-7) respectively. However, calcium carbonate as a gassing 
agent did not show any thermal activity as presented in (Chapter ‎3, Figure ‎3-6). 
Figure ‎4-2 and Figure ‎4-3 show DSC thermograms of placebo powder mixtures 
and placebo granules samples of F12 and F13 formulations respectively. 
The DSC thermograms of the powder mixture and the granules of the 
formulations F8-F14 are shown in Figure ‎4-4 to Figure ‎4-10 respectively. A slight 
shift was noted in the drug exothermic peak to a lower temperature in the powder 
mixture samples (192.26˚C, 192.34˚C, 192.07˚C, and 192.15˚C), and to a higher 
temperature in the granules samples (194.35˚C, 194.68˚C, 194.42˚C and 
193.95˚C) of the formulations F8 (Figure ‎4-4) and F9 (Figure ‎4-5) based on 
sodium bicarbonate as a gassing agent and the formulations F12 (Figure ‎4-8) and 
F13 (Figure ‎4-9) based on sodium carbonate respectively. Additionally, the DSC 
thermograms of the powder mixtures and the granules of F10, F11 (based on 
calcium carbonate), and the control formulation (F14) are shown in Figure ‎4-6, 
Figure ‎4-7, Figure ‎4-10 respectively. A slight shift in the drug exothermic peak to a 
lower temperature in the powder mixture samples (192.24˚C, 192.52˚C, and 
191.94˚C), and the granules samples (191.91˚C, 191.66˚C, and 191.24˚C) was 
noted in the formulations F10, F11, and F14 respectively. This could be due to 
minor morphological changes of cefalexin monohydrate that took place after 
physical mixing and the granulation process (Agnihotri et al., 2006). 
An overlapping between the broad endothermic peaks of cefalexin 
monohydrate, and the binary polymeric mixture (hydroxyethyl cellulose and 
sodium alginate) was shown at about 103.34˚C, 106.15˚C, 102.74˚C, 100.18˚C, 
104.28˚C, 103.15˚C, and 106.27˚C for the powder mixture samples and a round 
99.20˚C, 97.61˚C, 103.13˚C, 101.93˚C, 115.77˚C, 106.06˚C, and 104.43˚C for the 
granules samples of the formulations F8-F14 respectively.  
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The gassing agent (sodium bicarbonate) endothermic peak was noted at 
156.62˚C, and 154.81˚C for the powder mixture samples and at 153.34˚C and 
151.40˚C for the granules samples of the formulations F8 and F9 respectively. 
However, the gassing agent (calcium carbonate) was not involved in the thermal 
changes of the formulations F10 and F11 as it did not show any thermal activity as 
discussed earlier. Regarding F12 and F13 formulations based on sodium 
carbonate, thermograms presented more thermal activities especially after the 
granulation process. The endothermic peaks presented at 101.30˚C, 142.69˚C for 
F12 granules (Figure ‎4-8) and at 136.92˚C for F13 granules (Figure ‎4-9) were not 
related to the drug-excipient interactions. These thermal activities were related to 
the physical interaction between the formulation excipients as shown in Figure ‎4-2 
for F12 and Figure ‎4-3 for F13 placebo samples. Moreover, sodium alginate 
exothermic peak noted at 205.40˚C for F12 and at 205.72˚C for F13 granules 
samples was related to the formulation excipients interactions.  
Moreover, these thermal changes were not due to the gassing agents 
(sodium bicarbonate, calcium carbonate, or sodium carbonate) as the thermogram 
of cefalexin monohydrate with the excipients in the control formulation (F14) 
before and after the granulation displayed a slight decrease in the drug exothermic 
peak, from 192.57˚C (Figure ‎4-1), to 191.94˚C and 191.24˚C in the powder mixture 
and the granules samples respectively. Additionally, a broad endothermic peak 
due to overlapping between the endothermic peaks of the drug and the hydrophilic 
polymers was noted at 106.27˚C and 104.43˚C (Figure ‎4-10).  
No additional thermal changes were reported in the DSC thermograms of 
the formulations F8-F14, but results obtained with DSC should always be 
confirmed with other tests, like IR, to avoid misleading conclusions (Chapter ‎3, 
section ‎3.1.2). The FTIR spectra (Section ‎4.1.3) confirmed presence of cefalexin 
monohydrate characteristic bands for the formulations F8-F14 indicating absence 
of incompatibility between the drug, the gassing agents (sodium bicarbonate, 
calcium carbonate, or sodium carbonate) and the formulation excipients 
(hydroxyethyl cellulose, sodium alginate, and magnesium stearate). 
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Figure ‎4-1: DSC thermogram of pure cefalexin monohydrate. 
 
 
 
Figure ‎4-2: DSC thermogram of F12 formulation placebo powder mixture and 
placebo granules. 
For formulation composition, refer to Table ‎4-1 or Table 2-8.    
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Figure ‎4-3: DSC thermogram of F13 formulation placebo powder mixture and 
placebo granules. 
 
 
 
Figure ‎4-4: DSC thermograms of F8 powder mixture and F8 granules. 
For formulation composition, refer to Table ‎4-1 or Table 2-8.    
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Figure ‎4-5: DSC thermograms of F9 powder mixture and F9 granules. 
 
 
 
Figure ‎4-6: DSC thermograms of F10 powder mixture and F10 granules. 
For formulation composition, refer to Table ‎4-1 or Table 2-8. 
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Figure ‎4-7: DSC thermograms of F11 powder mixture and F11 granules. 
 
 
 
Figure ‎4-8: DSC thermograms of F12 powder mixture and F12 granules. 
For formulation composition, refer to Table ‎4-1 or Table 2-8. 
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Figure ‎4-9: DSC thermograms of F13 powder mixture and F13 granules. 
 
 
 
Figure ‎4-10: DSC thermograms of F14 powder mixture and F14 granules. 
For formulation composition, refer to Table ‎4-1 or Table 2-8. 
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The granules of all the formulations (F8-F14) were stored for 3 months at 
40°C ± 2°C and 80% ± 5% RH in closed or open containers and evaluated by DSC 
to investigate possible effects of the stressed conditions on the drug. Figure ‎4-11 
to Figure ‎4-17 represent DSC thermograms of F8-F14 stability samples.  
For the closed container stability samples, all characteristic peaks of 
cefalexin monohydrate and excipients used in the formulations F8-F14 showed 
almost similar thermal behaviour in comparison with the related freshly prepared 
granules (Figure ‎4-4 to Figure ‎4-10). The exothermic peak of cefalexin 
monohydrate was presented at 192.46°C, 196.45°C, 192.09°C, 192.03°C, 
196.79°C, 196.03°C, and 191.31°C, and the overlapping endothermic peak of the 
drug and the hydrophilic polymers was noted at 120.45°C, 107.75°C, 102.71°C, 
97.94°C, 110.67°C, 110.82°C, and 106.60°C for the formulations F8-F14 
respectively (Figure ‎4-11 to Figure ‎4-17). Moreover, the endothermic peak of 
sodium bicarbonate and sodium carbonate gassing agents was shown at 
170.52°C, 160.22°C, 142.18°C and 141.10°C for the formulations F8 
(Figure ‎4-11), F9 (Figure ‎4-12), F12 (Figure ‎4-15) and F13 (Figure ‎4-16) 
respectively. 
Similar behaviour was reported in the open container stability samples of 
the formulations F10 (Figure ‎4-13) and F11 (Figure ‎4-14) based on calcium 
carbonate gassing agent, and the control formulation (F14) (Figure ‎4-17) with 
exothermic degradation peak presented at 191.90°C, 192.08°C, and 190.77°C, 
and overlapping endothermic peak at 103.13°C, 100.85°C, and 113.26°C 
respectively. This represents the stability indicating effect of calcium carbonate. 
Thermogram of open container stability sample of F8 (10% (w/w) sodium 
bicarbonate) showed the drug exothermic peak and the endothermic overlapping 
peak of the drug and the polymeric mixture with lower peaks intensity. Moreover, a 
complete disappearance of the characteristic endothermic peak of sodium 
bicarbonate was noted (Figure ‎4-11). In contrast, as shown in Figure ‎4-12, 
thermogram of F9 (20% (w/w) sodium bicarbonate) open container sample 
showed complete disappearance of the drug exothermic peak and sharp reduction 
in the endothermic peak of sodium bicarbonate, however the overlapping 
endothermic peak was still present.  
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Thermograms of sodium carbonate based formulations (F12 (Figure ‎4-15) 
and F13 (Figure ‎4-16)) stored in open container at 40°C ± 2°C and 80% ± 5% RH 
showed complete disappearance of both the drug exothermic peak and the 
endothermic peak of sodium carbonate, however the overlapping endothermic 
peak was still present.  
The changes in the thermal behaviour of sodium carbonate in the open 
container stability samples agrees with its water solubility (Chapter ‎3, 
section ‎3.2.2) where direct exposure to the stressful humidity level (80%) for 3 
months caused complete loss of its crystallinity where an increase in the matrix 
microenvironment pH resulted in degradation of cefalexin monohydrate as noted in 
the FTIR results (Section ‎4.1.3). Nevertheless, calcium carbonate insolubility in 
water (Chapter ‎3, section ‎3.2.2) and absence of the gassing agent in the control 
formulation explain the physical stability of cefalexin monohydrate in the 
formulations F10 (10% (w/w) calcium carbonate), F11 (20% (w/w) calcium 
carbonate), and F14 stored under same stressful conditions. 
Generally, the results of DSC suggest dependency of cefalexin 
monohydrate physical stability in open containers for 3 months at 40°C ± 2°C and 
80% ± 5% RH on the gassing agent water solubility and the resulted matrix 
microenvironment pH. Thus, better physical stability of cefalexin monohydrate 
loaded in sodium bicarbonate or sodium carbonate floating tablets for 3 months at 
40°C ± 2°C and 80% ± 5% RH in closed containers than that in open ones was 
noted. This suggests that, all cefalexin monohydrate floating systems based on 
such gas forming agents should be packaged by pharmaceutical companies in 
tightly closed containers with an eye-catching label to direct patients for good 
practice. 
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Figure ‎4-11: DSC thermograms of F8 granules after storage for 3 months at 40°C 
± 2°C and 80% ± 5% RH in closed or open containers.  
 
 
  
Figure ‎4-12: DSC thermograms of F9 granules after storage for 3 months at 40°C 
± 2°C and 80% ± 5% RH in closed or open containers.  
For formulation composition, refer to Table ‎4-1 or Table 2-8.    
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Figure ‎4-13: DSC thermograms of F10 granules after storage for 3 months at 
40°C ± 2°C and 80% ± 5% RH in closed or open containers. 
 
 
 
Figure ‎4-14: DSC thermograms of F11 granules after storage for 3 months at 
40°C ± 2°C and 80% ± 5% RH in closed or open containers. 
For formulation composition, refer to Table ‎4-1 or Table 2-8. 
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Figure ‎4-15: DSC thermograms of F12 granules after storage for 3 months at 
40°C ± 2°C and 80% ± 5% RH in closed or open containers. 
 
 
 
Figure ‎4-16: DSC thermograms of F13 granules after storage for 3 months at 
40°C ± 2°C and 80% ± 5% RH in closed or open containers.  
For formulation composition, refer to Table ‎4-1 or Table 2-8. 
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Figure ‎4-17: DSC thermograms of F14 granules after storage for 3 months at 
40°C ± 2°C and 80% ± 5% RH in closed or open containers.  
For formulation composition, refer to Table ‎4-1 or Table 2-8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 187 
 
4.1.3 Fourier-transform infrared spectroscopy (FTIR) 
 
The Fourier-transform infrared spectroscopy was used to study the 
compatibility of cefalexin monohydrate with excipients (hydroxyethyl cellulose, 
sodium alginate, sodium bicarbonate, calcium carbonate, sodium carbonate, and 
magnesium stearate) within the formulations F8-F14 before and after the 
granulation. Figure ‎4-18 to Figure ‎4-24 represent the IR spectra of pure cefalexin 
monohydrate, the powder mixtures, and the granules of all the formulations F8-
F14. The spectrum of cefalexin monohydrate shows characteristic bands at 3037 
and 1280 cm−1 for carboxylic acid –O–H, and carboxylic acid –C–O stretching 
mode respectively. Bands presented at 1803 and 1686 cm−1 are due to the four-
membered lactam –C=O and secondary amide –C=O stretching mode 
respectively.  Bending of both primary amide –NH2, and secondary amide –N–H 
as well as secondary amide –C–N stretching are shown at 1578 cm−1. In addition 
bands at 1454 and 953 cm−1 are for carboxylic acid –C–O–H in and out of plan 
bending respectively (Stuart, 2004, Agnihotri et al., 2006).  
The drug peaks were also presented at the same wave numbers in the 
spectra of the drug-loaded powder mixtures and granules of all the formulations F8 
F14. A slight shift in the bands due the four-membered lactam –C=O and 
secondary amide –C=O stretching mode were noted at 1753 and 1687 cm−1 
respectively, and the bending of both primary amide –NH2, and secondary amide –
N–H as well as secondary amide –C–N stretching were shifted to 1572 cm−1. 
Characteristic peaks representing primary amide –NH2 asymmetric and symmetric 
stretching modes were shown only in the granules of F8 and F9 formulations near 
3671, 2985, and 2900 cm−1. The IR peak at 2358 cm−1 was due to carbon dioxide 
(Stuart, 2004). Accordingly, FTIR results suggest the absence of incompatibility 
between the drug and the formulation excipients. 
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Figure ‎4-18: FTIR spectra of pure cefalexin monohydrate, F8 powder mixture and 
F8 granules.  
 
 
 
Figure ‎4-19: FTIR spectra of pure cefalexin monohydrate, F9 powder mixture and 
F9 granules.  
For formulation composition, refer to Table ‎4-1 or Table 2-8.   
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Figure ‎4-20: FTIR spectra of pure cefalexin monohydrate, F10 powder mixture 
and F10 granules. 
 
 
 
Figure ‎4-21: FTIR spectra of pure cefalexin monohydrate, F11 powder mixture 
and F11 granules.  
For formulation composition, refer to Table ‎4-1 or Table 2-8.   
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Figure ‎4-22: FTIR spectra of pure cefalexin monohydrate, F12 powder mixture 
and F12 granules. 
 
 
 
Figure ‎4-23: FTIR spectra of pure cefalexin monohydrate, F13 powder mixture 
and F13 granules. 
For formulation composition, refer to Table ‎4-1 or Table 2-8.   
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Figure ‎4-24: FTIR spectra of pure cefalexin monohydrate, F14 powder mixture 
and F14 granules. 
For formulation composition, refer to Table ‎4-1 or Table 2-8. 
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The granules of all the formulations (F8-F14) were stored for 3 months at 
40°C ± 2°C and 80% ± 5% RH in closed or open containers and evaluated by 
FTIR to investigate possible effects of the stressed conditions on the drug. 
Figure ‎4-25 to Figure ‎4-31 represent after the storage (in closed or open 
containers) IR spectra of F8-F14 granules respectively. Generally, the drug 
characteristic bands of the stability samples (in closed or open containers) were 
presented at almost the same wave numbers of the freshly prepared granules of 
the formulations F8-F14 (Figure ‎4-18 to Figure ‎4-24). Cefalexin monohydrate 
characteristic bands were presented at 3040–3368 cm−1 and 1249–1280 cm−1 for 
carboxylic acid –O–H, and carboxylic acid –C–O stretching mode respectively. 
Bands presented at 1753–1755 cm−1 and 1654–1688 cm−1 were due to the four-
membered lactam –C=O and secondary amide –C=O stretching mode 
respectively. Bending of both primary amide –NH2, and secondary amide –N–H as 
well as secondary amide –C–N stretching were shown at 1570–1598 cm−1. In 
addition bands at 1450–1491 cm−1 and 862–1004 cm−1 were for carboxylic acid –
C–O–H in and out of plan bending respectively (Figure ‎4-25 to Figure ‎4-31). For 
F9 (20% (w/w) sodium bicarbonate) open container samples the four-membered 
lactam –C=O band was completely disappeared (Figure ‎4-26).  
As discussed earlier (Section ‎4.1.2), the change in the formulation F8 
(disappearance of sodium bicarbonate melting peak) in the open container stability 
samples agrees with sodium bicarbonate water solubility (Chapter ‎3, section ‎3.2.2) 
where direct exposure to the stressful humidity level (80%) for 3 months caused 
complete (Figure ‎4-11) or incomplete (Figure ‎4-12) loss of sodium bicarbonate 
crystallinity depending upon its reservoir (10% or 20% (w/w)). This may increase 
the pH of the matrix microenvironment in a concentration dependent rhythm and 
may cause degradation for cefalexin monohydrate which was represented by the 
loss of the four-membered lactam –C=O band (Figure ‎4-26). This also complies 
with the results of the open container samples of sodium carbonate based 
formulations (F12 and F13), which is water soluble, where the four-membered 
lactam –C=O band was completely disappeared (Figure ‎4-29 and Figure ‎4-30 
respectively). On the other hand, FTIR data (Figure ‎4-27 and Figure ‎4-28) confirm 
the physical stability of the drug within F10 and F11 calcium carbonate as a gas 
forming agent in the gastroretentive drug delivery systems with cefalexin 
monohydrate as well as with pentoxifylline (Chapter ‎3, section ‎3.1.3).  
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Overall, the results of the FTIR suggest better physical stability of cefalexin 
monohydrate floating tablets for 3 months at 40°C ± 2°C and 80% ± 5% RH in 
closed containers rather than that in open ones. Still, cefalexin monohydrate 
physical stability in open containers for 3 months at 40°C ± 2°C and 80% ± 5% RH 
is suggested to be reliant on the gassing agent water solubility and the resulted 
matrix microenvironment pH. 
 
 
 
 
 
 
 
Figure ‎4-25: FTIR spectra of F8 granules after storage for 3 months at 40°C ± 2°C 
and 80% ± 5% RH in closed or open containers.  
For formulation composition, refer to Table ‎4-1 or Table 2-8.    
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Figure ‎4-26: FTIR spectra of F9 granules after storage for 3 months at 40°C ± 2°C 
and 80% ± 5% RH in closed or open containers.  
 
 
 
 
Figure ‎4-27: FTIR spectra of F10 granules after storage for 3 months at 40°C ± 
2°C and 80% ± 5% RH in closed or open containers. 
For formulation composition, refer to Table ‎4-1 or Table 2-8.    
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Figure ‎4-28: FTIR spectra of F11 granules after storage for 3 months at 40°C ± 
2°C and 80% ± 5% RH in closed or open containers. 
 
 
 
 
Figure ‎4-29: FTIR spectra of F12 granules after storage for 3 months at 40°C ± 
2°C and 80% ± 5% RH in closed or open containers. 
For formulation composition, refer to Table ‎4-1 or Table 2-8.    
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Figure ‎4-30: FTIR spectra of F13 granules and storage for 3 months at 40°C ± 
2°C and 80% ± 5% RH in closed or open containers. 
 
 
 
 
Figure ‎4-31: FTIR spectra of F14 granules after storage for 3 months at 40°C ± 
2°C and 80% ± 5% RH in closed or open containers. 
For formulation composition, refer to Table ‎4-1 or Table 2-8.    
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4.2 Evaluation of floating tablets 
 
Tablets prepared from the granules were evaluated for tablet crushing 
strength, friability, weight uniformity, drug content uniformity, apparent density, 
porosity, floating capacity, swelling and erosion, dissolution, release data 
modeling, and stability testing. Tablets prepared from the powder mixtures were 
evaluated only for porosity, floating capacity, dissolution, and release data 
modeling, as these tablets had been compacted manually. 
 
4.2.1 Tablet crushing strength, friability, weight uniformity, and 
drug content 
 
All the prepared tablets‘ results of crushing strength (N), friability (%), 
average weight (g), and average drug content (mg) are presented in Table ‎4-3. All 
the tablets of the formulations F8-F14 were successfully pressed automatically at 
levels A (49-54 N), B (54-59 N), and C (59-64 N) of crushing strength. 
For the friability test, although there were no signs of cracked, split, or 
broken tablets at the end of the test, results at 59-64 N crushing strength were 
1.10% (F8), 1.67% (F9), 1.10% (F10), 1.67% (F11), and 1.23% (F14) which did 
not fit the (BP) limit, as the friability values were slightly more than 1% (BP, 2015). 
However, the results of both F12 and F13 formulations fit the BP limit of friability 
except at level A of crushing strength (Table ‎4-3). Generally, as the tablet crushing 
strength level increased as the friability percentage decreased in all the 
formulations. Consequently, formulators can use higher compression force to 
change the friability results to fit the BP limit (< 1%). All the prepared tablets of the 
formulations F8-F14 (Table ‎4-3) complied with BP specifications (BP, 2015) with 
respect to weight uniformity test. With regards to content uniformity test, Table ‎4-3, 
results were in the acceptable range, indicating that all matrix tablets fitted the 
(BP) criteria in which each tablet drug content was between 85% and 115% of 
related average content (BP, 2015). 
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Table ‎4-3: Properties of cefalexin monohydrate floating tablets of the formulations 
F8-F14. 
Formulation 
Crushing 
strength 
level 
Crushing 
strength 
(N)
a
 
Friability 
(%) 
Tablet weight 
(g)
b
 
Drug content 
(mg)
a
 
F8 
(A) 
 
50.99 ± 0.61 3.68 0.439 ± 0.01 273.13 ± 5.11 
(B) 
 
56.88 ± 0.79 2.16 0.455 ± 0.01 232.04 ± 6.67 
(C) 
 
63.74 ± 0.81 1.10 0.457 ± 0.01 280.61 ± 5.92 
F9 
(A) 
 
50.99 ± 0.45 3.44 0.518 ± 0.01 274.03 ± 5.49 
(B) 
 
57.86 ± 0.49 2.03 0.526 ± 0.00 272.91 ± 5.47 
(C) 
 
62.76 ± 0.69 1.67 0.523 ± 0.01 273.55 ± 6.39 
F10 
(A) 
 
50.99 ± 0.61 3.68 0.439 ± 0.01 273.13 ± 5.11 
(B) 
 
56.88 ± 0.79 2.16 0.455 ± 0.01 232.04 ± 6.67 
(C) 
 
63.74 ± 0.81 1.10 0.457 ± 0.01 280.61 ± 5.91 
F11 
(A) 
 
50.99 ± 0.45 3.44 0.518 ± 0.01 274.03 ± 5.49 
(B) 
 
57.86 ± 0.49 2.03 0.526 ± 0.00 272.91 ± 5.47 
(C) 
 
62.76 ± 0.69 1.67 0.523 ± 0.01 273.55 ± 6.39 
F12 
(A) 
 
50.01 ± 0.20 1.02 0.468 ± 0.01 277.77 ± 7.84 
(B) 
 
56.88 ± 0.18 0.85 0.472 ± 0.00 280.93 ± 8.53 
(C) 
 
63.74 ± 0.28 0.69 0.464 ± 0.01 283.40 ± 8.21 
F13 
(A) 
 
49.03 ± 0.21 1.11 0.515 ± 0.01 287.99 ± 4.98 
(B) 
 
54.92 ± 0.22 0.96 0.518 ± 0.01 285.07 ± 6.30 
(C) 
 
60.80 ± 0.25 0.85 0.520 ± 0.01 284.18 ± 8.02 
F14 
(A) 
 
49.03 ± 0.36 1.50 0.420 ± 0.01 273.78 ± 8.59 
(B) 
 
54.92 ± 0.24 1.33 0.423 ± 0.00 273.98 ± 9.15 
(C) 
 
63.74 ± 0.30 1.23 0.417 ± 0.00 269.32 ± 8.44 
Notes: aThe data represents the mean ± SD of 10 determinations. bThe data 
represents the mean ± SD of 20 determinations. The compression force of the 
prepared tablets was adjusted to give three crushing strength levels: A (49-54 N), 
B (54-59 N), and C (59-64 N). For formulation composition, refer to Table ‎4-1 or 
Table 2-8.    
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4.2.2 Tablet apparent density and porosity 
 
In order to evaluate the magnitude of different formulation factors (crushing 
strength, the wet granulation, type and ratio of gas forming agents) on the 
prepared tablets the apparent density and porosity results of the tablets were 
used. The apparent density of all the prepared tablets F8-F14 were calculated by 
equation (3) (Chapter ‎2, section ‎2.2.6.2), and the results are shown in Figure ‎4-32 
to Figure ‎4-35 respectively. Generally, increasing the tablet crushing strength level 
in the tablets prepared from the powder mixtures of F8-F13, significantly (P<0.05) 
increased their apparent density results. Exceptionally, the effect was not 
significant (P>0.05) between the crushing strength levels A and B of F8, F10, F12, 
and F13 tablets, and between the crushing strength levels B and C of F9 and F11 
tablets where the effect was not significant (P>0.05). Neither the effect was 
significant (P>0.05) for F14 tablets between all the crushing strength levels. For 
the tablets prepared from the granules, changing the crushing strength level 
increased tablet apparent density. Mostly the effect was significant (P<0.05) in all 
the formulations except for F12 tablets (at all crushing strength levels), for tablets 
of F8 and F10 (at levels B and C), and for F9 and F13 tablets (at levels A and B) 
where P>0.05. This agrees with the reduction in the tablet thicknesses (Table ‎4-4) 
as particles became more adjacent to each other by increasing the compression 
force. Also, these results are similar to that of pentoxifylline tablets (Chapter ‎3, 
section ‎3.2.2) based on sodium bicarbonate (F1 and F2), calcium carbonate (F3 
and F4), sodium carbonate (F5 and F6), and the control ones (F7). 
The granulation process decreased significantly (P<0.001) the apparent 
density values of all the prepared tablets of the formulations F8-F14 (Figure ‎4-32 
to Figure ‎4-35 respectively). These results were similar to the related apparent 
density results of pentoxifylline floating tablet F1, F2 (10% and 20% (w/w) sodium 
bicarbonate respectively), F6 (20% (w/w) sodium carbonate), and F7 (the control 
tablets) (Chapter ‎3, section ‎3.2.2) where the enhancement of sodium alginate 
elastic recovery after compression following the granulation explains their 
apparent density reduction as the tablet thicknesses after the granulation 
increased (Chapter ‎3, Table ‎3-4).  
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It is clear that the drug content was increased from 60 mg of pentoxifylline 
(F1-F7) to 250 mg of cefalexin monohydrate (F8-F14), and the binary (1:1) mixture 
level of hydroxyethyl cellulose and sodium alginate was kept at almost 140 mg 
(Chapter ‎2, For formulation composition, refer to Table 2-7 and Table 2-8) in all 
the formulations (F1-F14). Although, this should decrease the elastic recovery 
effect of alginate following the granulation because the polymeric content was 
reduced by almost 36% (w/w), Kaneniwa et al. (1984) reported that pressing 
cefalexin powder with small diameter punch (0.7 cm) showed greater elastic 
behaviour than pressing it with larger diameter one (2.0 cm). This suggests 
additional elastic recovery effect to that of sodium alginate as the tablet 
thicknesses of the formulations F8-F14 increased after the granulation (Table ‎4-4). 
Changing the concentration of the gassing agent (sodium bicarbonate 
(Figure ‎4-32), calcium carbonate (Figure ‎4-33), or sodium carbonate (Figure ‎4-34)) 
from 10% (w/w) to 20% (w/w) significantly (P<0.05) increased the apparent density 
results of all the tablets either prepared from the powder mixtures or the granules. 
An exception was noted in the tablets prepared from the powder mixture of the 
formulations based on sodium bicarbonate at level C of crushing strength where 
the effect was not significant (P>0.05) (Figure ‎4-32). The high specific gravity of 
sodium bicarbonate (2.173 g/cm3), calcium carbonate (2.70 g/cm3) and sodium 
carbonate (2.53 g/cm3) may explain such increased density results which also 
agree with the related results of pentoxifylline floating tablets based on same 
gassing agents. An exception was noted in pentoxifylline floating tablets prepared 
from the granules where increasing sodium carbonate concentration from 10% 
(w/w) (F5) to 20% (w/w) (F6) decreased the apparent density results. This may be 
explained by the manual pressing of F5 tablets that enhanced higher reduction of 
their tablet thicknesses in comparison with the automatically pressed F6 tablets 
(Chapter ‎3, section ‎3.2.2).  
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Figure ‎4-32: Apparent density of F8 and F9 tablets before granulation, after 
granulation, and after stability (tablets prepared from granules stored at 40°C ± 
2°C and 80% ± 5% RH for 3 months in closed or open container).   
Note: The data represents the mean ± SD of six determinations. The compression 
force of the prepared tablets was adjusted to give three crushing strength levels: A 
(49-54 N), B (54-59 N), and C (59-64 N).   
 
 
 
 
Figure ‎4-33: Apparent density of F10 and F11 tablets before granulation, after 
granulation, and after stability (tablets prepared from granules stored at 40°C ± 
2°C and 80% ± 5% RH for 3 months in closed or open container).   
Note: The data represents the mean ± SD of six determinations. The compression 
force of the prepared tablets was adjusted to give three crushing strength levels: A 
(49-54 N), B (54-59 N), and C (59-64 N).   
For formulation composition, refer to Table ‎4-1 or Table 2-8.    
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Figure ‎4-34: Apparent density of F12 and F13 tablets before granulation, after 
granulation, and after stability (tablets prepared from granules stored at 40°C ± 
2°C and 80% ± 5% RH for 3 months in closed or open container).   
Note: The data represents the mean ± SD of six determinations. The compression 
force of the prepared tablets was adjusted to give three crushing strength levels: A 
(49-54 N), B (54-59 N), and C (59-64 N).   
 
 
 
 
Figure ‎4-35: Apparent density of F14 tablets before granulation, after granulation, 
and after stability (tablets prepared from granules stored at 40°C ± 2°C and 80% ± 
5% RH for 3 months in closed or open container).   
Note: The data represents the mean ± SD of six determinations. The compression 
force of the prepared tablets was adjusted to give three crushing strength levels: A 
(49-54 N), B (54-59 N), and C (59-64 N). 
For formulation composition, refer to Table ‎4-1 or Table 2-8.   
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Table ‎4-4: F8-F14 tablets thickness before granulation, after granulation, and after stability (tablets prepared from granules stored at 40°C 
± 2°C and 80% ± 5% RH for 3 months in closed or open container).  
Formulation 
Crushing 
strength level 
Tablet thickness (cm) 
Origin of prepared tablets 
Before granulation After granulation 
After stability 
(closed container) 
After stability 
(open container) 
F8 
(A) 0.482 ± 0.00 0.507 ± 0.03 0.513 ± 0.02 0.550 ± 0.01 
(B) 0.471 ± 0.01 0.500 ± 0.02 0.509 ± 0.04 0.549 ± 0.03 
(C) 0.467 ± 0.03 0.496 ± 0.01 0.505 ± 0.01 0.537 ± 0.03 
F9 
(A) 0.533 ± 0.01 0.559 ± 0.03 0.565 ± 0.02 0.550 ± 0.06 
(B) 0.521 ± 0.01 0.552 ± 0.02 0.558 ± 0.02 0.550 ± 0.05 
(C) 0.517 ± 0.01 0.543 ± 0.02 0.549 ± 0.03 0.547 ± 0.09 
F10 
(A) 0.483 ± 0.01 0.552 ± 0.01 0.557 ± 0.01 0.571 ± 0.01 
(B) 0.469 ± 0.01 0.545 ± 0.01 0.550 ± 0.00 0.565 ± 0.04 
(C) 0.463 ± 0.01 0.544 ± 0.01 0.550 ± 0.01 0.562 ± 0.01 
F11 
(A) 0.531 ± 0.01 0.589 ± 0.01 0.594 ± 0.01 0.612 ± 0.03 
(B) 0.519 ± 0.01 0.576 ± 0.01 0.582 ± 0.01 0.602 ± 0.03 
(C) 0.516 ± 0.00 0.566 ± 0.01 0.572 ± 0.01 0.593 ± 0.02 
F12 
(A) 0.481 ± 0.01 0.521 ± 0.02 0.528 ± 0.02 0.559 ± 0.02 
(B) 0.472 ± 0.01 0.520 ± 0.01 0.525 ± 0.01 0.560 ± 0.02 
(C) 0.470 ± 0.00 0.516 ± 0.01 0.522 ± 0.02 0.558 ± 0.05 
F13 
(A) 0.531 ± 0.01 0.568 ± 0.02 0.620 ± 0.01 0.638 ± 0.06 
(B) 0.526 ± 0.00 0.559 ± 0.01 0.611 ± 0.01 0.631 ± 0.15 
(C) 0.517 ± 0.01 0.554 ± 0.01 0.606 ± 0.02 0.625 ± 0.15 
F14 
(A) 0.443 ± 0.02 0.490 ± 0.01 0.499 ± 0.01 0.523 ± 0.04 
(B) 0.441 ± 0.03 0.485 ± 0.01 0.491 ± 0.02 0.517 ± 0.02 
(C) 0.437 ± 0.01 0.471 ± 0.02 0.481 ± 0.03 0.503 ± 0.02 
Note: The data represents the mean ± SD. of three determinations. The compression force of the prepared tablets was adjusted to 
give three crushing strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  
For formulation composition, refer to Table ‎4-1 or Table 2-8.    
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Tablets apparent density after storage for 3 months at 40°C ± 2°C and 80% 
± 5% RH in closed or open containers was analysed statistically. Figure ‎4-32 to 
Figure ‎4-35 show tablets apparent densities of the formulations F8-F14 
respectively after stability studies in closed or open containers. Generally, the 
tablets apparent density of all the formulations F8-F14 decreased after storage at 
40°C ± 2°C and 80% ± 5% RH in both closed and open containers.   
A significant (P<0.05) decrease in the tablets apparent density was noted 
for F8 formulation in both container types. Nevertheless, a non-significant (P>0.05) 
decrease was reported for F9 tablets in both storage conditions except at level C 
of crushing strength in the open containers where P=0.07. Additionally, tablets 
apparent density non-significantly (P>0.05) decreased in all the other formulations 
(F10-F14) after storage at 40°C ± 2°C and 80% ± 5% RH in the closed containers 
and significantly (P<0.05) after storage in the open ones. An exception was noted 
for F13 (20% (w/w) sodium carbonate) tablets where the effect was not significant 
(P>0.05) after storage in the closed containers except at level A of crushing 
strength (P=0.006) and significant (P<0.05) after storage in the open ones at all 
the crushing strength levels. This conforms to the increase in the tablet thickness 
results after 3 months storage as shown in Table ‎4-4.  
The reduction in the apparent density results was higher in the open 
containers than that in the closed ones for all the formulations except for F13 (20% 
sodium carbonate) tablets where the effect was reversed. Although F13 tablets 
had higher tablet thicknesses after storage in the open containers than that in the 
closed ones, their apparent densities were also higher (Figure ‎4-34). This may be 
explained by the decrease in the tablet diameter (Figure ‎4-60) which may be 
caused due to the presence of the hygroscopic sodium carbonate under stressful 
humidity (80%) conditions. Additionally, such decrease in tablets diameters were 
absent in case of F12 (10% (w/w) sodium carbonate) tablets which suggests a 
concentration dependent effect of sodium carbonate. Generally, the results of all 
the formulations except those of F13 (20% sodium carbonate) tablets agrees with 
the related results of pentoxifylline tablets (F1-F7) (Chapter ‎3, section ‎3.2.2) where 
the tablets stress relaxation during storage and the direct exposure to the stressful 
humidity level (80% RH) induced these apparent density changes.   
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The tablet porosity percentages of the formulations F8-F14 are presented in 
Figure ‎4-36. Increasing the crushing strength level of all the tablets prepared from 
the powder mixtures or the granules decreased their porosity results. However, the 
effect was not significant (P>0.05) for the tablets prepared from the powder 
mixture (at levels A and B of F8 (10% (w/w)), and at levels B and C of F9 (20% 
(w/w)), and of the tablets prepared from granules (at levels B and C of F8, and at 
levels A and B of F9). Moreover, the porosity percentages were decreased non-
significantly (P>0.05) for the tablets based on calcium carbonate (F10 (10% (w/w) 
and F11 (20% (w/w)) and sodium carbonate (F12 (10% (w/w) and F13 (20% 
(w/w)) prepared from the powder mixture or the granules except between the 
extreme levels of crushing strength (A and C) of F10, F12, and F13 prepared from 
the powder mixtures and F13 prepared from the granules where the effect was 
significant (P<0.05). For cefalexin monohydrate control tablets (F14), the effect 
was not significant (P>0.05) in the tablets prepared from the powder mixture, but it 
was significant (P<0.05) in those prepared from the granules (Figure ‎4-36). This 
reduction in the porosity data complies with the reduction in the tablet thicknesses 
presented in Table ‎4-4, where increasing the tablet crushing strength made the 
particles to become strongly bonding due to being closer. This also, complies with 
the related results of pentoxifylline tablets (Chapter ‎3, section ‎3.2.2) based on 
sodium bicarbonate (F1 and F2), calcium carbonate (F3 and F4), sodium 
carbonate (F5 and F6), and the control ones (F7). 
The granulation process increased the porosity levels of the formulations 
F9, F10, F13, and F14, and decreased the porosity of F8, F11, and F12 tablets 
(Figure ‎4-36). Regarding the control tablets of pentoxifylline (F7) and the tablets 
based on sodium bicarbonate as a gassing agent (F1 and F2) (Chapter ‎3, 
section ‎3.2.2), their porosity percentages decreased following the granulation 
process because increasing the water binder volume decreases porosity during 
the wet massing stage (Mukhopadhyay et al., 2008).  
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Nevertheless, Gokhale et al. (2005) proposed that the drug loading and the 
amount of excipients could affect the rate and the final degree of densification of 
the resulted granules. As discussed earlier, the polymeric content was reduced by 
almost 36% (w/w) in cefalexin monohydrate formulations due to the increase in 
their drug content (Chapter ‎2, for formulation composition, refer to Table 2-7 and 
Table 2-8). Therefore, the difference in the effect of the wet granulation process on 
the porosity levels of the control formulations of pentoxifylline (F7) and cefalexin 
monohydrate (F14) may be explained. It is clear as presented in Figure ‎4-36 that 
adding 10% (w/w) sodium bicarbonate (F8) counter acted the effect of the high 
drug loading (250 mg cefalexin monohydrate) on the granulation process by 
decreasing the porosity level. The water solubility of sodium bicarbonate 
(Chapter ‎3, section ‎3.2.2) may enhance the formation of a homogenous mixture 
with the hydrophilic polymers to assist voids filling of F8 matrices, which reduced 
their final porosity levels. But, the tablet porosity results of F9 (20% (w/w) sodium 
bicarbonate) formulation increased following the granulation process which agrees 
with Gokhale et al. (2005) discussion above. The presence of sodium bicarbonate 
at a higher level (20% (w/w)) compared to that used in F8 formulation (10% (w/w) 
during the granulation process may dilute the concentration of the (1:1) binary 
mixture of hydroxyethyl cellulose and sodium alginate and may reduce the efficacy 
of decreasing porosity levels during the wet massing stage of the granulation.  
For the tablets based on calcium carbonate (F10 and F11), the porosity 
percentages increased after the granulation for F10 (10% (w/w)) (Figure ‎4-36). 
This may be related to calcium carbonate water insolubility, as explained also in 
chapter ‎3, section ‎3.2.2, that enhanced voids formation between adjacent 
molecules during the wet massing stage. This complies with the related results of 
F3 (10% (w/w)) and F4 (20% (w/w)) pentoxifylline tablets based calcium carbonate 
(Chapter ‎3, section ‎3.2.2). In contrast, the porosity level decreased after the 
granulation in F11 (20% (w/w) calcium carbonate) tablets. The good bonding 
capacity under compression of calcium carbonate and its role as a filler in the 
pharmaceutical formulations in addition to the granulation process improvement 
role on tablets mechanical properties (Summers and Aulton, 2007) explain the 
decrease in the porosity level of F11 formulation.    
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Porosity results (after granulation) of the tablets based on sodium 
carbonate as a gassing agent (F12 and F13) were consistent with the results of 
pentoxifylline tablets (Chapter ‎3, section ‎3.2.2) based on the relevant gassing 
agent (F5 and F6). Water solubility of sodium carbonate (Chapter ‎3, section ‎3.2.2) 
especially at the lower concentration (F12) assisted a homogeneous mixture 
formation with the hydrophilic polymers during the wet massing stage of the 
granulation that reduced the final porosity percentages. However, at 20% (w/w) 
concentration (F13), the hygroscopicity of sodium carbonate may support more 
water molecules loss through the granulation drying step which increased their 
porosity percentages (Figure ‎4-36). 
Raising the concentration of sodium bicarbonate from 10% (w/w) (F8) to 
20% (w/w) (F9) in the tablets prepared from granules significantly (P<0.05) 
increased the porosity levels except at level C of crushing strength which was not 
significant (P>0.05). Regarding the tablets prepared from the powder mixture, 
raising sodium bicarbonate concentration significantly (P<0.001) decreased the 
tablet porosity percentages (Figure ‎4-36). This fits into the related pentoxifylline 
tablet results of F1 (10% (w/w)) and F2 (20% (w/w)) formulations (Chapter ‎3, 
section ‎3.2.2) where sodium bicarbonate enhanced voids filling between 
molecules to reduce the percentage of porosity. 
Increasing calcium carbonate concentration from 10% (w/w) (F10) to 20% 
(w/w) (F11) increased significantly (P<0.001) the porosity percentages of the 
tablets prepared either from the powder mixtures or the granules (Figure ‎4-36). 
This also conforms to the related pentoxifylline tablet results based on 10% (w/w) 
(F3) and 20% (w/w) (F4) calcium carbonate (Chapter ‎3, section ‎3.2.2) where 
fragmentation behaviour under compression of calcium carbonate maintained the 
porosity of such tablets relatively high. In contrast, a significant (P<0.05) decrease 
in the porosity levels was noted when sodium carbonate concentration raised from 
10% (w/w) (F12) to 20% (w/w) (F13) in the tablets prepared from the powder 
mixtures or the granules. An exception was noted at level A of crushing strength in 
the tablets prepared from the granules where P=0.378 (Figure ‎4-36).  
The results of F12 and F13 tablets prepared from the powder mixtures were 
consistent with the related results of pentoxifylline tablets prepared with 10% (w/w) 
(F5) and 20% (w/w) (F6) sodium carbonate (Chapter ‎3, section ‎3.2.2) where ability 
of sodium carbonate to fill voids between molecules after compression clarifies the 
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reduction in the tablets porosity due to increasing its concentration. For the tablets 
prepared from the granules, raising sodium carbonate concentration from 10% 
(F12) to 20% (F13) (w/w) decreased the porosity of cefalexin monohydrate tablets 
(Figure ‎4-36), however, it increased the porosity of pentoxifylline tablets 
(Chapter ‎3, section ‎3.2.2). The hygroscopic behaviour of sodium carbonate 
especially at the higher concentration (20% (w/w)) explains the results of 
pentoxifylline tablets where higher water loss due to granules drying leads to 
higher porosity levels.  Nevertheless, the results of cefalexin monohydrate tablets 
were different. As shown in (Table ‎4-2), the percentage of moisture content of F13 
(20% (w/w) sodium carbonate) formulation slightly decreased after the granulation 
from 6.17% to 6.02% which could be related to the mono-hydration nature of 
cefalexin molecules. This may inverse the hygroscopicity effect of sodium 
carbonate during the granulation where higher moisture content was kept inside 
the granules of F13 formulation (after drying till reaching a constant weight). This 
high moisture content clarifies the decrease in the porosity due to raising sodium 
carbonate concentration in the granules origin tablets. 
 
 
 
 
Figure ‎4-36: Porosity percentage of the formulations F8-F14 before and after 
granulation.  
The compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  
For formulation composition, refer to Table ‎4-1 or Table 2-8. 
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4.2.3 Tablet floating capacity 
 
It is vital for floating tablets to avoid premature evacuation from their major 
absorption area of the stomach and upper intestine, which could be accomplished 
by achieving the least possible lag time, and longer floating duration. Gassing 
agents such as sodium bicarbonate, calcium carbonate and sodium carbonate 
enhanced the floating behaviour of tablets due to the release of carbon dioxide 
gas, which entrapped in the formed gel layer around the tablets and results in 
reducing tablet density to facilitate the floating process (Chapter ‎3, section ‎3.2.3). 
Table ‎4-5 and Table ‎4-6 represent floating lag time and floating duration results of 
all prepared tablets respectively. All the formulations (F8-F14) were tested for 
floating capacity under the same conditions and using the same apparatus for the 
in vitro studies.  
A statistical analysis (P-value) of changing the crushing strength level on 
the tablet floating lag time of the formulations F8-F13 prepared from the powder 
mixture or the granules revealed that changing the crushing strength level in all the 
prepared tablets caused generally a non-significant (P>0.05) increase in the 
floating lag time. An exception was noted between the extreme level of crushing 
strength (A and C) of F10 and F11 prepared from the granules where P<0.05 
(Table ‎4-5). This agrees with the related results of pentoxifylline tablets 
(Chapter ‎3, section ‎3.2.3) based on sodium bicarbonate (F1 and F2), calcium 
carbonate (F3 and F4) and sodium carbonate (F5 and F6) where reducing the 
tablet porosity, as a result of increased compaction force, delayed the penetration 
of the acidic medium and hence delayed the gas generation process. 
The granulation process increased the floating lag time results of all the 
tablets F8-F13 compared to that of the tablets prepared from the powder mixture 
before the granulation (Table ‎4-5). The effect of the granulation process was 
significant (P<0.05) for F8, F10, and F12 tablets and non-significant (P>0.05) for 
F9, F11, and F13 tablets except at level C of crushing strength of F9 and F11 
where P<0.05.  
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Table ‎4-5: Floating lag-time of the formulations F8-F14 at different crushing strength levels before granulation, after 
granulation, and after stability (tablets prepared from granules stored at 40°C ± 2°C and 80% ± 5% RH for 3 months in closed 
or open container).  
Formulation 
Crushing 
strength level 
Floating lag time (min) 
Origin of prepared tablet 
Before granulation After granulation 
After stability 
(closed container) 
After stability 
(open container) 
F8 
(A) 0.02 ± 0.01 8.29 ± 3.18 2.67 ± 0.54 No floating 
(B) 0.03 ± 0.01 10.76 ± 2.81 5.18 ± 1.01 No floating 
(C) 0.05 ± 0.02 12.71 ± 3.56 6.46 ± 1.89 No floating 
F9 
(A) 0.02 ± 0.00 3.05 ± 0.49 2.56 ± 0.27 
complete disintegration 
within 30 min 
(B) 0.03 ± 0.02 4.03 ± 0.85 2.92 ± 0.12 
complete disintegration 
within 30 min 
(C) 0.04 ± 0.01 4.69 ± 0.48 5.27 ± 0.74 
complete disintegration 
within 30 min 
F10 
(A) 0.12 ± 0.03 1.01 ± 0.06 0.29 ± 0.06 0.16 ± 0.03 
(B) 0.13 ± 0.05 1.58 ± 0.41 0.34 ± 0.06 0.18 ± 0.08 
(C) 0.15 ± 0.08 2.28 ± 0.59 0.38 ± 0.08 0.18 ± 0.01 
F11 
(A) 0.08 ± 0.03 0.34 ± 0.06 0.20 ± 0.03 0.15 ± 0.03 
(B) 0.12 ± 0.04 0.69 ± 0.09 0.30 ± 0.03 0.16 ± 0.01 
(C) 0.13 ± 0.04 1.17 ± 0.22 0.35 ± 0.09 0.18 ± 0.01 
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Table 4-5 (continued): Floating lag-time of the formulations F8-F14 at different crushing strength levels before granulation, after 
granulation, and after stability (tablets prepared from granules stored at 40°C ± 2°C and 80% ± 5% RH for 3 months in closed or open 
container). 
Formulation 
Crushing 
strength level 
Floating lag time (min) 
Origin of prepared tablet 
Before granulation After granulation 
After stability 
(closed container) 
After stability 
(open container) 
F12 
(A) 1.78 ± 0.25 8.19 ± 3.92 No floating No floating 
(B) 1.81 ± 0.30 10.28 ± 3.16 No floating No floating 
(C) 1.87 ± 0.16 10.92 ± 1.80 No floating No floating 
F13 
(A) 4.72 ± 0.20 3.63 ± 0.55 No floating No floating 
(B) 4.79 ± 0.19 5.30 ± 0.92 No floating No floating 
(C) 4.83 ± 0.14 7.22 ± 1.41 No floating No floating 
F14 
(A) No floating 12.43 ± 3.81 No floating No floating 
(B) 
complete 
disintegration 
within 30 min 
14.43 ± 3.02 No floating No floating 
(C) 
complete 
disintegration 
within 30 min 
17.57 ± 1.96 No floating No floating 
Notes: The data represents the mean ± SD of three determinations. The compression force of the prepared tablets was 
adjusted to give three crushing strength levels: A (49-54 N), B (54-59 N), and C (59-64 N). For formulation composition, refer 
to Table ‎4-1 or Table 2-8.   
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Table ‎4-6: Floating duration of the formulations F8-F14 at different crushing strength levels before granulation, after 
granulation, and after stability (tablets prepared from granules stored at 40°C ± 2°C and 80% ± 5% RH for 3 months in closed 
or open container).  
Formulation 
Crushing 
strength level 
Total floating duration (h) 
Origin of prepared tablet 
Before granulation After granulation 
After stability 
(closed container) 
After stability 
(open container) 
F8 
(A) > 8 > 4 > 2 No floating 
(B) > 8 > 4 > 2 No floating 
(C) > 8 > 4 > 2 No floating 
F9 
(A) > 8 > 10 
complete disintegration 
within 30 min 
complete disintegration 
within 30 min 
(B) > 8 > 10 
complete disintegration 
within 30 min 
complete disintegration 
within 30 min 
(C) > 8 > 10 
complete disintegration 
within 30 min 
complete disintegration 
within 30 min 
Notes: The compression force of the prepared tablets was adjusted to give three crushing strength levels: A (49-54 N), B (54-
59 N), and C (59-64 N). For formulation composition, refer to Table ‎4-1 or Table 2-8. 
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Table 4-6 (continued): Floating duration of the formulations F8-F14 at different crushing strength levels before granulation, after 
granulation, and after stability (tablets prepared from granules stored at 40°C ± 2°C and 80% ± 5% RH for 3 months in closed or open 
container). 
Formulation 
Crushing 
strength level 
Total floating duration (h) 
Origin of prepared tablet 
Before granulation After granulation 
After stability 
(closed container) 
After stability 
(open container) 
F10 
(A) 
complete 
disintegration 
within 30 min 
> 8 Partial disintegration Partial disintegration 
(B) 
complete 
disintegration 
within 30 min 
> 8 Partial disintegration Partial disintegration 
(C) 
complete 
disintegration 
within 30 min 
> 8 Partial disintegration Partial disintegration 
F11 
(A) 
complete 
disintegration 
within 30 min 
> 12 
complete disintegration 
within 30 min 
complete disintegration 
within 30 min 
(B) 
complete 
disintegration 
within 30 min 
> 12 
complete disintegration 
within 30 min 
complete disintegration 
within 30 min 
(C) 
complete 
disintegration 
within 30 min 
> 12 
complete disintegration 
within 30 min 
complete disintegration 
within 30 min 
Notes: The compression force of the prepared tablets was adjusted to give three crushing strength levels: A (49-54 N), B (54-
59 N), and C (59-64 N). For formulation composition, refer to Table ‎4-1 or Table 2-8. 
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Table 4-6 (continued): Floating duration of the formulations F8-F14 at different crushing strength levels before granulation, after 
granulation, and after stability (tablets prepared from granules stored at 40°C ± 2°C and 80% ± 5% RH for 3 months in closed or open 
container). 
Formulation 
Crushing 
strength level 
Total floating duration (h) 
Origin of prepared tablet 
Before granulation After granulation 
After stability 
(closed container) 
After stability 
(open container) 
F12 
(A) > 8 > 10 
complete disintegration 
within 30 min 
No floating 
(B) > 8 > 10 
complete disintegration 
within 30 min 
No floating 
(C) > 8 > 10 
complete disintegration 
within 30 min 
No floating 
F13 
(A) > 8 > 12 
complete disintegration 
within 30 min 
complete disintegration 
within 30 min 
(B) > 8 > 12 
complete disintegration 
within 30 min 
complete disintegration 
within 30 min 
(C) > 8 > 12 
complete disintegration 
within 30 min 
complete disintegration 
within 30 min 
F14 
(A) No floating > 12 
complete disintegration 
within 30 min 
complete disintegration 
within 30 min 
(B) 
complete 
disintegration 
within 30 min 
> 12 
complete disintegration 
within 30 min 
complete disintegration 
within 30 min 
(C) 
complete 
disintegration 
within 30 min 
> 12 
complete disintegration 
within 30 min 
complete disintegration 
within 30 min 
Notes: The compression force of the prepared tablets was adjusted to give three crushing strength levels: A (49-54 N), B (54-
59 N), and C (59-64 N). For formulation composition, refer to Table ‎4-1 or Table 2-8.   
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The results of F8 (10% (w/w) sodium bicarbonate) tablets may be explained 
by the decrease in their porosity levels after the granulation process, which also 
conforms to the results of F1 (10% (w/w) sodium bicarbonate) formulation based 
on pentoxifylline (Chapter ‎3, section 3.2.3). The floating lag time of F9 (20% w/w 
sodium bicarbonate tablets increased after the granulation (Table ‎4-5) which also 
complies with the results of F2 (20% (w/w) sodium bicarbonate) tablets. But, unlike 
F2 tablets, the porosity of F9 tablets increased by the granulation process 
(Figure ‎4-36). This may be explained by the higher swelling ability of F9 tablets 
compared to that of F8 tablets (Section ‎4.2.4, Figure ‎4-37) which may counteract 
the increase in F9 tablets porosities by decreasing the acidic media penetration 
rate inside their matrices and delaying the effervescent reaction and their floating 
process. Hodsdon et al. (1995) explained the faster release of chlorpheniramine 
maleate (highly soluble model drug) from alginate matrices in the simulated gastric 
fluid (SGF) than in the simulated intestinal fluid (SIF) by difference in the formed 
internal microscopic structure of the alginate hydrated surface layer and by 
different hydration kinetics of the polymer in these two media. They concluded that 
the highly hydrated continuous gel layer formed by alginate in SIF in comparison 
to the particulate and porous hydrated layer formed in SGF was responsible for 
retarding the drug release. Furthermore, 0.1 M aqueous solution of sodium 
bicarbonate generates pH=8.3 at 25°C (Cable, 2009), which suggests better ability 
of the higher concentration of sodium bicarbonate (F9) than that of the lower 
concentration (F8) to provide an alkaline microenvironment for sodium alginate 
molecules to initiate a stronger hydrated gel. This clarifies the slower drug release 
results of F9 tablets compared to that of F8 tablets (Section ‎4.2.5) and explains 
the increase in their floating lag time results following the granulation process. 
The results of F10 (10% (w/w)) and F11 (20% (w/w)) tablets based on 
calcium carbonate as a gassing agent were similar to the related results of 
pentoxifylline tablets (F3 and F4) (Chapter ‎3, section ‎3.2.3). The absence of the 
disintegration behaviour due to strengthening the tablets internal structure after the 
granulation delayed the entrapment of the acidic medium and increased their lag 
time results.  
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Moreover, the increase in the lag time values of the tablets based on 
sodium carbonate as a gassing agent (F12 (10% (w/w) and F13 (20% (w/w)) 
complies with the relevant pentoxifylline tablets (F5 and F6) (Chapter ‎3, 
section ‎3.2.3). Although, the decrease in F12 porosity percentages following the 
granulation (Figure ‎4-36) hindered the initiation of the effervescent process, the 
increase in F13 porosity percentages (after the granulation) reduced their matrices 
ability to retain the liberated gas bubbles and delayed their floating process. 
Changing the concentration of sodium bicarbonate from 10% (F8) to 20% 
(w/w) (F9) and calcium carbonate from 10% (F10) to 20% (w/w) (F11) decreased 
the lag time results significantly (P<0.05) for the tablets prepared from the 
granules, nonetheless, the effect was not significant (P>0.05) for the tablets 
prepared from the powder mixtures (Table ‎4-5). This complies with the related 
results of pentoxifylline tablets based on sodium bicarbonate (F1 and F2) and 
calcium carbonate (F3 and F4) (Chapter ‎3, section ‎3.2.3) where increasing the 
gassing agent content available for the acidic medium enhanced the rate as well 
as the efficiency of the effervescent reaction, which was represented by the 
shorter floating lag time values.  
Regarding sodium carbonate gassing agent, changing its concentration 
from 10% (F12) to 20% (w/w) (F13), increased the lag time values non-
significantly (P>0.05) in the tablets prepared from the powder mixtures (Table ‎4-5). 
This is similar to the related results of F5 (10% (w/w)) and F6 (20% (w/w)) 
pentoxifylline tablets (Chapter ‎3, section ‎3.2.3) where the alkalinity of sodium 
carbonate enhanced the swelling rate (at 20% w/w) and delayed the effervescent 
process due to the reduction in the dissolution medium entrapment rate. 
Additionally, the apparent density of F13 tablets increased due to raising the 
concentration of sodium carbonate (Figure ‎4-34) which hindered their floating 
process. Concerning the tablets prepared from the granules, increasing sodium 
carbonate concentration from 10% (F12) to 20% (w/w) (F13) decreased the lag 
time values non-significantly (P>0.05) except at level B of crushing strength where 
P=0.037 (Table ‎4-5). This did not agree with the related pentoxifylline tablet results 
of F5 (10% (w/w)) and F6 (20% (w/w)) where the lag time values increased by 
changing sodium carbonate concentration.  
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More time was taken for the floating process due to sodium carbonate 
alkalinity effect on the dissolution medium entrapment rate and due to the increase 
in the tablet apparent density at the higher concentration level (20% (w/w)) of 
sodium carbonate (Chapter ‎3, section ‎3.2.3).     
As discussed earlier, the polymeric content was reduced by almost 36% 
(w/w) in cefalexin monohydrate formulations due to the increase in their drug 
content (Chapter ‎2, for formulation composition, refer to Table 2-7 and Table 2-8). 
This changed the gassing agent: polymeric mixture ratio from (4.5:10) for 
pentoxifylline based formulations to (7:10) for cefalexin monohydrate formulations. 
Consequently, more sodium carbonate molecules became available alongside the 
hydrophilic polymeric mixture to accelerate the swelling process, and also to 
generate better effervescent process efficiency for cefalexin formulations. Upon 
quicker water uptake, chains of the polymeric mixture moved apart from each 
other resulted in both weight and volume growth which rapidly reduced the density 
of the swollen matrix and decreased their floating lag time values.  
Table ‎4-6 shows floating duration results of all the formulations F8-F14. 
Although, F8 (10% (w/w) sodium bicarbonate) tablets prepared from the powder 
mixture at all crushing strength levels floated for > 8 h, their floating duration after 
the granulation process was reduced by half. In contrast, the floating duration of 
F9 (20% (w/w) sodium bicarbonate) formulation increased from > 8 h before the 
granulation to > 10 h after the granulation at all crushing strength levels. This is 
also similar to the related results of the formulations F1 and F2 based on 
pentoxifylline (Chapter ‎3, section ‎3.2.3). Obviously, the higher concentration of 
sodium bicarbonate (20% (w/w)) was more effective than the lowest one (10% 
(w/w)) to maintain the tablets from the granules origin on the surface of the 
dissolution medium for a longer duration of time. Increasing sodium bicarbonate 
level in the tablets prepared from the powder mixture did not cause a difference in 
the floating duration results where both the formulations (F8 and F9) floated for > 8 
h. Although the porosity percentages decreased by increasing the gassing agent 
reservoir (Figure ‎4-36), the increase in their apparent density values (Figure ‎4-32) 
may inverse the effect of both the porosity reduction and the high gassing agent 
reservoir, and maintain the floating duration > 8 h.     
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The tablets based on calcium carbonate as a gassing agent of the 
formulations F10 and F11 prepared from the powder mixtures showed complete 
disintegration behaviour within short time (30 min) after the floating process. 
Following the granulation process, F10 (10% (w/w)) tablets floated for > 8 h and 
the tablets of F11 (20% (w/w)) floated for > 12 h (Table ‎4-6). This complies with 
the related results of F3 (10% (w/w)) and F4 (20% (w/w)) pentoxifylline based 
tablets (Chapter ‎3, section ‎3.2.3) where the higher calcium carbonate reservoir 
available for the floating process increased the floating duration. 
For the tablets based on sodium carbonate as a gassing agent, the 
granulation process increased the floating duration results for F12 (10% (w/w)) 
from > 8 to > 10 h and for F13 (20% (w/w)) from > 8 to > 12 h (Table ‎4-6). Still, 
pentoxifylline tablets based on sodium carbonate presented better floating duration 
where F5 (10% (w/w)) tablets floated for > 12 h and F6 (20% (w/w)) tablets floated 
for > 24 h without a difference between the results before or after the granulation 
(Chapter ‎3, section ‎3.2.3). The reduction (by almost 36% (w/w)) in the polymeric 
content of cefalexin monohydrate tablets (F12 and F13) reduced their swelling rate 
(Section ‎4.2.4) in comparison to that of pentoxifylline tablets (F5 and F6) 
(Chapter ‎3, section ‎3.2.4) which affected the ability of such tablets to hold the 
generated gas bubbles for longer time. Raising sodium carbonate concentration 
increased the floating duration from > 10 h (F12) to > 12 h (F13) for the tablets 
prepared from the granules and kept the floating duration without change (> 8 h) 
for the tablets prepared from the powder mixtures (Table ‎4-6). This is similar to the 
related results of F5 (10% (w/w)) and F6 (20% (w/w)) pentoxifylline tablets based 
on sodium carbonate where the higher gassing agent concentration (20% (w/w)) 
was more effective than the lower one (10% (w/w)) to maintain the tablets floated 
on the surface of the dissolution medium for longer duration of time (Chapter ‎3, 
section ‎3.2.3). 
As shown in Table ‎4-6, the control tablets of cefalexin monohydrate (F14) 
prepared from the powder mixture did not show any floating behaviour which 
agrees with the related results of pentoxifylline control tablets (F7) where absence 
of gassing agents explains this. Moreover, the complete disintegration of F14 
tablets was noted within short time (30 min) after immersion in to the dissolution 
medium except for those compacted at level A of crushing strength which kept 
sinking through the experiment time.  
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The reported elastic behaviour of cefalexin under compression with 
elevated pressure (Kaneniwa et al., 1984) may justify the disintegration behaviour 
of F14 tablets pressed at levels B and C of crushing strength. Although cefalexin 
monohydrate control tablets (F14) prepared from the granules had 0% (w/w) 
content of gassing agents, those tablets compacted at the levels A, B, and C of 
crushing strength floated at 12.43, 14.43, and 17.57 min. respectively (Table ‎4-5) 
and all of them kept floating for > 12 h on the surface of the dissolution medium 
(Table ‎4-6). This did not agree with the related results of F7 control tablets of 
pentoxifylline prepared from the granules. The granulation process improved F14 
tablets internal structure, decreased their apparent density results (Figure ‎4-35) 
and increased their porosity percentages (Figure ‎4-36). This may entrap more 
dissolution medium and consequently enhanced rapid swelling rate behaviour 
(Section ‎4.2.4) which further reduced their tablets density to initiate and to 
maintain the floating process. In contrast, the granulation process decreased the 
porosity level of F7 control tablets (Chapter ‎3, Figure ‎3-40). Moreover, although 
the granulation process decreased F7 tablets apparent density results (Chapter ‎3, 
Figure ‎3-39); their values were higher than the apparent density results of F14 
tablets (Figure ‎4-35). This clarifies the better floating ability of F14 tablets in 
comparison with F7 tablets. 
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Regarding stability studies, the effect of storage at 40°C ± 2°C and 80% ± 
5% RH for 3 months on the tablets floating lag time and the floating duration was 
evaluated and presented in Table ‎4-5 and Table ‎4-6 respectively. For the tablets 
based on sodium bicarbonate as a gassing agent, storage in closed containers 
significantly decreased (P<0.05) the floating lag time of F8 (10% (w/w)) tablets and 
non-significantly (P>0.05) decreased the floating lag time of F9 (20% (w/w)) tablets 
(Table ‎4-5). Tablets of F8 formulation floated for only > 2 h, but F9 tablets 
completely disintegrated after short time (within 30 min) of the floating process 
(Table ‎4-6). The increase in the tablet thicknesses after the storage (Table ‎4-4) 
may cause a rapid contact between the gassing agent (sodium bicarbonate) and 
the acidic medium to start rapidly the effervescent and the floating processes 
which was consistent with the floating lag time results of the related pentoxifylline 
tablets (F1 and F2) (Chapter ‎3, section ‎3.2.3). Nevertheless the floating duration 
results of F8 and F9 tablets were different from those of F1 and F2 tablets. The 
reduction by almost 36% (w/w) in the polymeric content of cefalexin monohydrate 
formulations (F8 and F9) in addition to the tablet relaxation behaviour due the 
aging process decreased the matrices ability to hold the liberated gas baubles for 
longer time. Moreover, the higher content of sodium bicarbonate for F9 tablets 
(20% (w/w)) assisted rupturing of the relaxed tablets which clarifies the floating 
duration results of F8 and F9 formulations after storage at 40°C ± 2°C and 80% ± 
5% RH for 3 months in the closed containers.   
In the open containers, the tablets of F8 (10% (w/w)) formulation lost their 
ability to float, however, the tablets of F9 (20% (w/w)) disintegrated after a short 
period of time (within 30 min) of immersion inside the dissolution medium 
(Table ‎4-5) and (Table ‎4-6). These results were different from the related results of 
F1 and F2 pentoxifylline based formulations (Chapter ‎3, section ‎3.2.3). The loss in 
the floating ability of F8 tablets complies with its open container DSC stability 
thermogram (Figure ‎4-11) where the complete loss of sodium bicarbonate 
crystallinity affected its role in the effervescent reaction. Moreover, the open 
container DSC stability results of F9 formulation (Figure ‎4-12) showed partial 
presence of sodium bicarbonate in the crystalline form which was responsible for 
the complete disintegration behaviour of the relaxed aged tablets. 
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Concerning the tablets based on calcium carbonate as a gassing agent 
(F10 and F11), storage in closed or open containers decreased their floating lag 
time results significantly (P<0.05) for F10 (10% (w/w)) at all crushing strength 
levels in comparison with the freshly prepared tablets. Conversely, the effect was 
not significant (P>0.05) for F11 (20% (w/w)) except at level C of crushing strength 
where P<0.05 (Table ‎4-5). Moreover, both F10 and F11 tablets could not maintain 
the floating on the surface of the dissolution medium as both formulations showed 
partial and complete disintegration behaviour respectively after short time (30 min) 
of their floating process (Table ‎4-6).  This decrease in the stability floating lag time 
results is similar to the related stability results of F3 and F4 tablets based on 
pentoxifylline (Chapter ‎3, section ‎3.2.3) where the increase in the tablet 
thicknesses after the storage (Table ‎4-4) caused a rapid contact between the 
gassing agent and the acidic medium to start the effervescent and the floating 
processes rapidly. The absence of the significance effect for F11 (20% (w/w) 
calcium carbonate) tablets could be the related to their higher gassing agent 
reservoir. The floating duration results of F10 and F11 tablets (Table ‎4-6) were 
different from those of F3 and F4 tablets (Chapter ‎3, section ‎3.2.3). This because 
of the reduction in the polymeric content of cefalexin monohydrate formulations 
(F10 and F11) in addition to the high effervescent activity of calcium carbonate 
caused the partial or complete rupture of the aged relaxed tablets according to 
calcium carbonate concentration. However, calcium carbonate is still the most 
effective gassing agent to keep floating integrity compared to other gassing agents 
(sodium bicarbonate and sodium carbonate).  
 A complete loss of the floating ability was noted in sodium carbonate based 
formulations (F12 and F13) after storage at 40°C ± 2°C and 80% ± 5% RH for 3 
months in either closed or open containers (Table ‎4-5). This was accompanied 
with a complete disintegration behaviour in all the tablets except those of F12 
(10% (w/w)) formulation stored in the open containers (Table ‎4-6) which sank till 
the end of the experiment. This did not agree with the related results of 
pentoxifylline tablets (F5 and F6) based on sodium carbonate which kept their 
floating properties after storage under the same conditions (Chapter ‎3, 
section ‎3.2.3). Storage under the stressful humidity conditions may decrease the 
available sodium carbonate molecules (due to hygroscopicity) for the effervescent 
process and consequently delayed the floating process.  
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This also clarifies the absence of the floating behaviour in the closed 
container stability samples of F12 (10% (w/w) sodium carbonate) and F13 (20% 
(w/w) sodium carbonate) tablets which could not float, and their relaxed aged 
structure completely ruptured within a short time (30 min) of immersion in the 
dissolution medium. Moreover, the aged matrices of the formulations F12 and F13 
were weaker (due to their polymeric content) than those of F5 (10% (w/w) sodium 
carbonate) and F6 (20% (w/w) sodium carbonate) pentoxifylline tablets. The loss 
in the floating ability of F12 tablets complies with its open container DSC stability 
thermogram (Figure ‎4-15) which indicates absence of sodium carbonate crystals 
and its role in the effervescent reaction. Although the open container DSC stability 
thermogram of F13 formulation (Figure ‎4-16) also indicates absence of the 
crystallinity of sodium carbonate, F13 tablets completely disintegrated while F12 
tablets did not. This may be explained by the morphological changes in F13 
tablets after storage under the stressful conditions which suggests a concentration 
dependent interaction of sodium carbonate.     
Results of the control tablets (F14) stored either in closed or open 
containers presented complete disintegration behaviour within a short period of 
time (30 min) of starting the test. This is not similar to the related results of 
pentoxifylline control tablets (F7) which conform the effect of their polymeric 
content on their ability to control the drug release rate (Section ‎4.2.5).    
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4.2.4 Swelling and erosion studies 
 
Swelling and erosion studies were carried out to make a correlation with the 
drug release rate and the release mechanisms. The percentage of dissolution 
medium uptake and the percentage of mass loss of all the tablets prepared from 
the granules (F8-F14) in 0.1 M HCl medium are presented in Figure ‎4-37 to 
Figure ‎4-40 and in Figure ‎4-41 to Figure ‎4-44 respectively. Increasing the tablet 
crushing strength in all the formulations did not cause a significant (P>0.05) effect 
neither in the swelling rate results nor in the mass loss ones at majority of the time 
points. This is similar to the related results of pentoxifylline tablets based on 
sodium bicarbonate (F1 and F2), calcium carbonate (F3 and F4), sodium 
carbonate (F5 and F6), and the control tablets (F7) where the tablet strength had 
only a small effect on the swelling rate and the mass loss percentage of the 
hydrophilic tablets (Chapter ‎3, section ‎3.2.4).  
Raising the level of calcium carbonate from 10% (w/w) (F10) to 20% (w/w) 
(F11) caused a significant (P<0.05) decrease in the tablet swelling rate at most of 
the time points (Figure ‎4-38) and a significant (P<0.05) increase in the mass loss 
percentages at bulk of the time points (Figure ‎4-42). This complies with the related 
pentoxifylline tablets results (F3 and F4) (Chapter ‎3, section ‎3.2.4) where the 
swelling rate was inversely proportional with the floating duration of F10 and F11 
tablets (Table ‎4-6). Moreover, the high effervescent activity of calcium carbonate 
explains the higher erosional behaviour in 20% (w/w) tablets in comparison with 
that in 10% (w/w) concentration.   
In contrast, changing the concentration of the gassing agent from 10% 
(w/w) to 20% (w/w) in the formulations based on sodium bicarbonate (F8 and F9) 
and the formulations based on sodium carbonate (F12 and F13) significantly 
(P<0.05) increased the DMU results at majority of the time points (Figure ‎4-37 and 
Figure ‎4-39 respectively). A non-significant (P>0.05) decrease in the percentage of 
the mass loss was noted for the formulations based on sodium bicarbonate at 
larger part of the time points (Figure ‎4-41), nevertheless, a non-significant 
(P>0.05) increase except at the level C of crushing strength where P<0.05 was 
noted for the formulations based on sodium carbonate at bulk of the time points 
(Figure ‎4-43).  
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These results are not similar to those of the related pentoxifylline tablets 
based on sodium bicarbonate (F1 and F2), where the DMU decreased and the 
mass loss percentage increased as the concentration of the gassing agent 
increased. Regarding the tablets based sodium carbonate gassing agent, the 
results were statistically different from those of the related pentoxifylline tablets (F5 
and F6), yet, the effect was similar (Chapter ‎3, section ‎3.2.4).  Alginates have 
better ability to swell in a higher pH environment, hence, the higher sodium 
bicarbonate or sodium carbonate concentration may influence the swelling rate 
behaviour. Besides, the strength of the hydrated microstructure of the swollen 
matrix tablets may be altered by the concentration of the gassing agent available 
in the gassing agent: polymeric mixture ratio (Section ‎4.2.3). Therefore, the 
coherent gel layer formed around F9 (20% (w/w) sodium bicarbonate) and F13 
(20% (w/w) sodium carbonate) matrices may assist a higher swelling rate 
(Figure ‎4-37 and Figure ‎4-39 respectively) and a better resistance to the erosional 
behaviour due to the effervescent reaction (Figure ‎4-41 and Figure ‎4-43 
respectively) in comparison with 10% (w/w) gassing agent based formulations.  
Regarding cefalexin monohydrate control tablets (F14), their swelling rate at 
majority of the time points (Figure ‎4-40) was significantly (P<0.05) the highest at 
bulk of the time points in comparison with all the other formulations except with 
F13 (20% (w/w) sodium carbonate) tablets where P>0.05 at most of the time 
points. Additionally, their mass loss percentages were almost the lowest 
(Figure ‎4-44), but the difference was not significant (P>0.05) at larger part of the 
time points in comparison with all the other tablets except with F11 (20% (w/w) 
calcium carbonate) tablets where P<0.05 at most of the time points. Although, 
cefalexin monohydrate control tablets (F14) floated on the surface of the 
dissolution medium for all the experiment time, they had the highest swelling rate 
(Figure ‎4-40). The absence of the gassing agents in such tablets may explain their 
highest swelling rate and lowest mass loss results as it excluded additional 
accelerated erosional process by the gas bubbles (liberated through the 
effervescent reaction) and enhanced normal polymeric swelling process.    
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Figure ‎4-37: Percentage of medium uptake for the formulations F8 and F9 
(prepared from granules) in 0.1 M HCl medium. 
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  
 
 
 
 
Figure ‎4-38: Percentage of medium uptake for the formulations F10 and F11 
(prepared from granules) in 0.1 M HCl medium. 
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  
For formulation composition, refer to Table ‎4-1 or Table 2-8. 
 
 
 226 
 
 
 
Figure ‎4-39: Percentage of medium uptake for the formulations F12 and F13 
(prepared from granules) in 0.1 M HCl medium. 
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  
 
 
 
 
Figure ‎4-40: Percentage of medium uptake for the formulation F14 (prepared from 
granules) in 0.1 M HCl medium. 
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  
For formulation composition, refer to Table ‎4-1 or Table 2-8. 
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Figure ‎4-41: Percentage of mass loss for the formulations F8, and F9 (prepared 
from granules) in 0.1 M HCl medium.  
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  
 
 
 
 
Figure ‎4-42: Percentage of mass loss for the formulations F10, and F11 (prepared 
from granules) in 0.1 M HCl medium.  
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N). 
For formulation composition, refer to Table ‎4-1 or Table 2-8.  
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Figure ‎4-43: Percentage of mass loss for the formulations F12, and F13 (prepared 
from granules) in 0.1 M HCl medium.  
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N). 
 
 
 
 
Figure ‎4-44: Percentage of mass loss for the formulation F14 (prepared from 
granules) in 0.1 M HCl medium.  
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N). 
For formulation composition, refer to Table ‎4-1 or Table 2-8.  
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4.2.5 In vitro drug release studies 
 
The dissolution profiles of all the tablets (F8-F14) prepared from the powder 
mixtures are presented in Figure ‎4-45 to Figure ‎4-48 respectively. Generally, 
increasing the tablet crushing strength level increased the drug release rate of F8 
(10% w/w) and F9 (20% w/w) tablets based on sodium bicarbonate (Figure ‎4-45). 
Statistically, a significant (P<0.05) effect at majority of the time points was noted 
except between the tablets prepared at the levels A and B of F8, and at the levels 
B and C of F9 where the effect was not significant (P>0.05) at most of the time 
points. This does not agree with the related results of pentoxifylline tablets (F1 and 
F2) as a significant (P<0.05) decrease in their drug release rate when their 
crushing strength level increased from level (A) to level (B) was noted at bulk of 
the time points (Chapter ‎3, section ‎3.2.5). Increasing the tablet crushing strength 
decreased the porosity percentage of both F8 and F9 tablets prepared from the 
powder mixture (Figure ‎4-36) which should reduce the penetration of the 
dissolution medium inside their matrices and decrease their drug release rate. But 
their dissolution profiles were not clear enough to match them with the porosity 
results.  
Kaneniwa et al. (1984) reported that cefalexin showed elastic behaviour on 
high compression pressure which may clarify inability of the relaxed dry matrices 
to reduce the drug release rate at the higher crushing strength levels. Increasing 
the tablet crushing strength level did not show any significant (P>0.05) effect on 
both the formulations F10 (10%) and F11 (20%) at larger part of the time points 
because the high effervescent activity of the gassing agent (calcium carbonate) 
facilitated the disintegration process of these tablets (Figure ‎4-46), which complies 
with the related results of F3 and F4 pentoxifylline tablets (Chapter ‎3, 
section ‎3.2.5). Regarding the formulations based on sodium carbonate as a 
gassing agent (F12 and F13), neither disintegration behaviour nor significant 
difference (P>0.05) between their drug release rate was noted (Figure ‎4-47). This 
also agrees with the related results of pentoxifylline tablets (F5 and F6) 
(Chapter ‎3, section ‎3.2.5) where the ability of sodium carbonate to generate an 
alkaline microenvironment in the swelled matrices protected their tablets from the 
disintegration process due to the rapid gel formation.  
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Figure ‎4-45: Percentage of drug release of F8, and F9 floating tablets pressed at 
levels (A), (B), and (C) of crushing strength in 0.1 M HCl medium before 
granulation. 
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  No significant change 
in the dissolution medium, macroenvironment, pH was recorded through the 
experiment time. 
 
 
 
Figure ‎4-46: Percentage of drug release of F10, and F11 floating tablets pressed 
at levels (A), (B), and (C) of crushing strength in 0.1 M HCl medium before 
granulation.  
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  No significant change 
in the dissolution medium, macroenvironment, pH was recorded through the 
experiment time. 
For formulation composition, refer to Table ‎4-1 or Table 2-8. 
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Figure ‎4-47: Percentage of drug release of F12, and F13 floating tablets pressed 
at levels (A), (B), and (C) of crushing strength in 0.1 M HCl medium before 
granulation.  
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  No significant change 
in the dissolution medium, macroenvironment, pH was recorded through the 
experiment time. 
 
 
 
Figure ‎4-48: Percentage of drug release of F14 control tablets pressed at levels 
(A), (B), and (C) of crushing strength in 0.1 M HCl medium before granulation.  
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  No significant change 
in the dissolution medium, macroenvironment, pH was recorded through the 
experiment time. 
For formulation composition, refer to Table ‎4-1 or Table 2-8. 
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Figure ‎4-49: Percentage of drug release of F8, and F9 floating tablets pressed at 
levels (A), (B), and (C) of crushing strength in 0.1 M HCl medium after granulation.  
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  No significant change 
in the dissolution medium, macroenvironment, pH was recorded through the 
experiment time. 
 
 
 
Figure ‎4-50: Percentage of drug release of F10, and F11 floating tablets pressed 
at levels (A), (B), and (C) of crushing strength in 0.1 M HCl medium after 
granulation.  
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  No significant change 
in the dissolution medium, macroenvironment, pH was recorded through the 
experiment time. 
For formulation composition, refer to Table ‎4-1 or Table 2-8. 
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Figure ‎4-51: Percentage of drug release of F12, and F13 floating tablets pressed 
at levels (A), (B), and (C) of crushing strength in 0.1 M HCl medium after 
granulation.  
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  No significant change 
in the dissolution medium, macroenvironment, pH was recorded through the 
experiment time. 
 
 
 
Figure ‎4-52: Percentage of drug release of F14 control tablets pressed at levels 
(A), (B), and (C) of crushing strength in 0.1 M HCl medium after granulation.  
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  No significant change 
in the dissolution medium, macroenvironment, pH was recorded through the 
experiment time. 
For formulation composition, refer to Table ‎4-1 or Table 2-8. 
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Cefalexin monohydrate control tablets (F14), showed a significant (P<0.05) 
difference between the release profiles of the tablets pressed at the levels A and B 
and the levels A and C of crushing strength at majority of the time points 
(Figure ‎4-48). This may be explained by the complete disintegration behaviour of 
F14 tablets compacted at the levels B and C of crushing strength. However, for 
pentoxifylline control tablets (F7), only those tablets compacted at the level A of 
crushing strength showed a disintegration behaviour while those compacted at the 
levels B and C did not (Chapter ‎3, section ‎3.2.5). The elastic behaviour of 
cefalexin powder (Kaneniwa et al., 1984) may explain the disintegration behaviour 
of those tablets pressed at the higher compression force.   
For the tablets prepared from the granules, the dissolution profiles of all the 
tablets (F8-F14) are presented in Figure ‎4-49 to Figure ‎4-52 respectively. 
Generally, increasing the tablets crushing strength level in all the formulations (F8-
F14) caused a non-significant (P>0.05) difference in their drug release rate at bulk 
of the time points. This fits into the DMU results (Section ‎4.2.4) as well as the 
related pentoxifylline tablet results based on sodium bicarbonate (F1 and F2), 
calcium carbonate (F3 and F4), sodium carbonate (F5 and F6), and the control 
tablets (F7) (Chapter ‎3, section ‎3.2.5) where the tablet strength had only a small 
effect on the in vitro drug release rate. This negligible influence of increasing the 
compression force on the drug release rate following the granulation gives an 
advantage to control the high tablet friability percentages (Section ‎4.2.1) without 
disturbing the drug release rate.  
The effect of the granulation process on drug release rate from the tablets 
(F8-F14) revealed that the granulation extended the drug release rate of all the 
prepared tablets significantly (P<0.05) at most of the time points (Figure ‎4-49 to 
Figure ‎4-52 respectively). Results of F8 (10% (w/w) sodium bicarbonate) tablets 
were consistent with the reduction in their porosity percentages following the 
granulation (Figure ‎4-36). Additionally, this agrees with the related results of F1 
(10% (w/w)) formulation based on pentoxifylline (Chapter ‎3, section ‎3.2.5). The 
decrease in their porosity levels occurred during the wet massing stage of the 
granulation process could delay the dissolution medium entrapment through the 
matrix at an early stage of the dissolution test and decreased the drug release 
process.  
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Although the porosity levels of F9 (20% (w/w) sodium bicarbonate) tablets 
increased after the granulation (Figure ‎4-36), their dissolution profiles decreased. 
The better gel hydration ability of F9 tablets because of their higher sodium 
bicarbonate content (Section ‎4.2.3) may inverse the increase in their porosity 
percentages and decrease their drug release rate. The granulation process made 
the formulations F10 (10% (w/w)) and F11 (10% (w/w)) more resistant to rupture 
due to calcium carbonate effervescent behaviour and gave sufficient time for 
swelling and gel layer formation to control the drug release process (Figure ‎4-50) 
which is similar to the related results of F3 and F4 pentoxifylline tablets (Chapter ‎3, 
section ‎3.2.5). For the tablets based on sodium carbonate (F12 and F13), the 
decrease in their drug release rate following the granulation complies with the 
reduction in their porosity percentages after the granulation (Figure ‎4-36) where 
penetration rate of the dissolution medium inside these tablets decreased as well 
as drug release rate (Figure ‎4-51).  
In comparison with the related results of pentoxifylline tablets, although the 
granulation process decreased the porosity levels of F5 (10% (w/w) sodium 
carbonate) tablets and increased the porosity of F6 (20% (w/w) sodium carbonate) 
tablets based on pentoxifylline, the difference in their drug release rate before and 
after the granulation was not significant (P>0.05) at majority of the time points 
(Chapter ‎3, section ‎3.2.5). For F14 tablets, after the granulation, their porosity 
level increased (Figure ‎4-36) and their internal structure became stronger. This 
rapidly initiated a gel layer (due to more dissolution medium entrapment rate) that 
prevented the tablet rupture by the disintegration and reduced the drug release 
rate (Figure ‎4-52) in comparison with the tablets prepared from the powder 
mixture. The drug release rate of pentoxifylline control tablets (F7) also decreased 
following the granulation (Chapter ‎3, section ‎3.2.5); however, this effect was 
explained by the reduction in their porosity levels in comparison with the tablets 
prepared from the powder mixture (Chapter ‎3, Figure ‎3-40). The (1:1) binary 
mixture of hydroxyethyl cellulose and sodium alginate content was reduced by 
almost 36% (w/w) in cefalexin monohydrate tablets (F8-F14) compared to 
pentoxifylline tablets (F1-F7) due to the change in their drug content (Chapter ‎2, 
Table 2-7 and Table 2-8) which made the lower polymeric content tablets (F8-F14) 
more sensitive to the effect of granulation process and explain these differences. 
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Increasing the concentration of sodium bicarbonate from 10% (w/w) (F8) to 
20% (w/w) (F9) increased the drug release rates of the tablets prepared from the 
powder mixture (Figure ‎4-45). At majority of the time points, the effect was not 
significant (P>0.05) except at the level B of crushing strength where P<0.05. This 
is similar to the related results of F1 (10% (w/w)) and F2 (20% (w/w)) tablets 
(Chapter ‎3, section ‎3.2.5) where increasing the gassing agent level increased the 
pore formation in the wet matrix tablets due to liberation of more carbon dioxide 
bubbles, which caused higher drug release rate. In contrast, for tablets prepared 
from the granules, increasing the concentration of sodium bicarbonate significantly 
(P<0.05) decreased their dissolution behavior at bulk of the time points 
(Figure ‎4-49). This conforms to the related results of F1 and F2 tablets based on 
pentoxifylline. F1 tablets (10% (w/w)) demonstrated a higher swelling rate in 
comparison with F2 (20% (w/w)) tablets (Chapter ‎3, section ‎3.2.4) which indicates 
more entrapment of the dissolution medium in their matrices that dissolves and 
releases more drug molecules. In contrast, the swelling rate of F9 (20% (w/w) 
sodium bicarbonate) formulation was higher than that of F8 (10% (w/w) sodium 
bicarbonate) (Section ‎4.2.4). As discussed earlier (Section ‎4.2.3), a coherent 
microstructure of the swollen gel layer may be formed due to the higher gassing 
agent level which explains the lower drug release rate of F9 tablets prepared from 
the granules.  
As shown in Figure ‎4-46, increasing the concentration of calcium carbonate 
from 10% (w/w) (F10) to 20% (w/w) (F11) in the tablets prepared from the powder 
mixture did not affect significantly (P>0.05) on their drug release rate at most of 
the time points because of the complete disintegration behavior. This is similar to 
the related pentoxifylline tablet results of the formulations F3 (10% (w/w)) and F4 
(20% (w/w)) (Chapter ‎3, section ‎3.2.5). Yet, at larger part of the time points for the 
tablets prepared from the granules, increasing calcium carbonate concentration 
caused a significant (P<0.05) increase in the drug release except at level C of 
crushing strength where P>0.05 (Figure ‎4-50). This also conforms with the related 
results of pentoxifylline tablets (Chapter ‎3, section ‎3.2.5) where increasing the 
concentration of calcium carbonate from 10% (F3) to 20% (w/w) (F4) increased 
pore formation in the formed gel layer due to the entrapped gas bubbles, and this 
resulted in the higher drug release rate.  
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Increasing sodium carbonate concentration from 10% (F12) to 20% (w/w) 
(F13) caused a non-significant (P>0.05) decrease in the drug release rate from the 
tablets prepared from the powder mixtures at majority of the time points 
(Figure ‎4-47) and a non-significant (P>0.05) increase from the tablets prepared 
from the granules at larger part of the time points (Figure ‎4-51). This agrees with 
the related results of the formulations F5 (10% (w/w) sodium carbonate) and F6 
(20% (w/w) sodium carbonate) based on pentoxifylline  (Chapter ‎3, section ‎3.2.5) 
where the ability of sodium carbonate to generate an alkaline microenvironment 
enhanced pentoxifylline tablets (F5 and F6) to swell and to release the drug in 
almost similar rate. Nevertheless, as discussed earlier (Section ‎4.2.4), a higher 
swelling rate was noted with cefalexin monohydrate tablets based on 20% (w/w) 
sodium carbonate (F13) compared to 10% (w/w) (F12). This agrees with the 
increase in the number of parts of sodium carbonate available for the hydrophilic 
polymeric mixture in these formulations (Section ‎4.2.4) which enhanced their 
swelling rate behaviour. This difference in the swelling rate did not cause a 
difference in the drug release rate of F12 and F13 tablets suggesting that the 
coherent hydrated gel microstructure that was formed at 10% (w/w) sodium 
carbonate (F12) reached a point of strength after which no further decrease in the 
drug release rate can be noted.  
The effect of adding a gassing agent on the drug release rate of the tablets 
prepared from the powder mixture or the granules was evaluated by comparing 
the control formulation (F14) results with all the other formulations (F8-F13). A 
significant (P<0.05) higher release rate at bulk of the time points of cefalexin 
monohydrate from F14 control tablets prepared from the powder mixture 
(Figure ‎4-48) or the granules (Figure ‎4-52) compared to both the formulations F8 
(10% (w/w)) and F9 (20% (w/w) was noted. This conforms to the related results of 
pentoxifylline tablets based on sodium bicarbonate (F1 and F2) and the control 
ones (F7) where the swelling rate of the control tablets (F14) showed a higher 
swelling rate compared to the tablets of F8 and F9 formulations.  
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Conversely, increasing the number of parts of sodium bicarbonate available 
for the hydrophilic polymeric mixture in the formulations based on cefalexin 
monohydrate (Section ‎4.2.4) could alter the strength of the hydrated 
microstructure of the swollen matrix tablets due to the prospected difference in the 
microenvironment alkalinity level generated during the dissolution process. 
Accordingly, absence of the gassing agent (sodium bicarbonate) from F14 tablets 
generated thicker but weaker gel structure that could not retard the drug molecules 
as those of the formulations F8 and F9.  
Regarding the addition of calcium carbonate, a significant (P<0.05) lower 
dissolution rate of cefalexin monohydrate from F14 control tablets prepared from 
the powder mixture at most of the time points was noted (Figure ‎4-48) compared 
to both the formulations F10 (10% (w/w)) and F11 (20% only at the level A of 
crushing strength as F14 tablets did not disintegrate). But, at the levels B and C of 
crushing strength the effect was not significant (P>0.05) at majority of the time 
points due to the complete disintegration behaviour of the tablets F10, F11, and 
F14. Nonetheless, for the tablets prepared from the granules, the drug release rate 
significantly (P<0.05) decreased at larger part of the time points on the addition of 
10% (w/w) calcium carbonate and non-significantly (P>0.05) decreased on the 
addition of 20% (w/w) of it. 
This was not similar to the related results of pentoxifylline tablets prepared 
from the granules where adding calcium carbonate at 10% (w/w) (F3) or at 20% 
(w/w) (F4) increased the drug release rate due to the liberation of the gas bubbles 
that enhanced more pore formation (Chapter ‎3, section ‎3.2.5).  Changing the 
(gassing agent: polymeric mixture) ratio in cefalexin monohydrate tablets 
facilitated the formation of a more cohesive hydrated gel microstructure. This 
explains the significant decrease in the drug release rate upon addition of 10% 
(w/w) calcium carbonate. Still, the absence of the significance effect at the higher 
level (20 % w/w) suggests that the effervescent activity of calcium carbonate 
increased the pore formation in the hydrated gel layer which may inverse the effect 
of the (gassing agent: polymeric mixture) ratio.  
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Adding sodium carbonate as a gassing agent at 10% (w/w) (F12) or at 20% 
(w/w) (F13) decreased significantly (P<0.05), at majority of the time points, the 
drug release rate from the tablets either prepared from the powder mixture or the 
granules, which is similar to the related results of pentoxifylline tablets but the 
effect was generally not significant (Chapter ‎3, section ‎3.2.5). Although (sodium 
carbonate: polymeric mixture) ratio was higher in cefalexin monohydrate 
formulations than that used in pentoxifylline formulations, the drug release rate 
decreased on addition of sodium carbonate in both formulations. This complies 
with the earlier suggestion that sodium carbonate may form a coherent gel 
microstructure regardless of the used concentration. Generally, it is worth in the 
future to do further evaluation regarding the swollen gel microenvironment pH, 
strength, and morphology which will support the previously mentioned 
explanations. 
Cefalexin monohydrate tablets (F8-F14) generally showed faster drug 
release rate in comparison with pentoxifylline tablets (F1-F7). Changing the drug 
content from 60 mg (pentoxifylline) to 250 mg (cefalexin monohydrate) changed 
the (polymeric mixture: tablet weight) ratio. For example, it was changed from 
(5.0:10) for F1 and (4.5:10) for F2 to (3.2:10) for F8 and (2.8:10) for F9. This 
reduction (by almost 36% (w/w)) in the polymeric content reduced ability of the 
later tablet matrices to sustain the drug release process. Still, further investigations 
on cefalexin monohydrate floating tablets based on higher polymeric mixture 
content could be tried in the future to enhance their dissolution profiles. 
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Concerning the stability studies of the formulations F8-F14, effect of the 
storage for 3 months at 40°C ± 2°C and 80% ± 5% RH in closed or open 
containers is shown in Figure ‎4-53 to Figure ‎4-59 respectively. A significant 
(P<0.05) increase in the drug release rate of the tablets F8 (10% (w/w) sodium 
bicarbonate) and F9 (20% (w/w) sodium bicarbonate) at bulk of the time points in 
comparison to the freshly prepared ones was noted after storage in the closed 
containers (Figure ‎4-53 and Figure ‎4-54 respectively). This rapid drug release rate 
of F8 and F9 tablets complies with reduction in their floating lag time results after 
storage. The dissolution medium easily penetrated the relaxed tablet matrices to 
dissolve the drug and release it in a higher rate than that of the freshly prepared 
tablets. In contrast, the stability results of F8 formulation in the open containers 
showed a significant (P<0.05) reduction in their dissolution profiles at majority of 
the time points (Figure ‎4-53) in comparison with their freshly prepared samples. 
Almost 80% of the drug was released after 12 h; however, after 24 h a complete 
drug release was reported. Moreover, these tablets (F8) lost their ability to float 
and kept sinking during the experiment time. As discussed earlier (Section ‎4.1.3), 
the stressful humidity level (80%) may generate a concentration dependent 
alkaline microenvironment, which may facilitate a rapid generation of a coherent 
gel microstructure around the tablets once they contacted the dissolution medium 
to retard the drug release rate. Also, the loss of the effervescent activity of sodium 
bicarbonate, after the storage, decreased the erosional behaviour of these 
tablets which may explain the sharp decrease in the drug release process.  
For F9 tablets, storage for 3 months at 40°C ± 2°C and 80% ± 5% RH in the 
open containers (Figure ‎4-54) indicates cefalexin monohydrate degradation as 
presented in the related DSC thermogram (Figure ‎4-12) and the IR spectra 
(Figure ‎4-26). Accordingly, the release profiles of F9 tablets after storage in the 
open containers may be related to degradation product(s). Also, sodium carbonate 
based formulations (F12 (10% (w/w) and F13 (20% (w/w)), as shown respectively 
in their DSC thermograms (Figure ‎4-15 and Figure ‎4-16) and their IR spectra 
(Figure ‎4-29 and Figure ‎4-30), storage for 3 months at 40°C ± 2°C and 80% ± 5% 
RH in the open containers indicates degradation of cefalexin monohydrate. 
Accordingly, the related release profiles (Figure ‎4-57 and Figure ‎4-58) could 
represent degradation product(s). 
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Conversely, the stability studies of the tablets based on calcium carbonate 
as a gassing agent (F10 and F11) and the control tablets (F14) stored either in the 
closed or the open containers showed a significant (P<0.05) increase in their drug 
release rate at majority of the time points. This complies with earlier discussion 
about the relaxation behaviour of the tablets during the storage time where a 
complete disintegration was reported. An exception was noted for F10 tablets 
(10% calcium carbonate) which presented a partial control of the drug release 
(Figure ‎4-55). This conforms to the in situ ability of the anionic alginate molecules 
to form a gel in the presence of multivalent cations such as calcium ions in 
aqueous medium. During the storage process, especially under a relatively high 
moisture level (80%), this may generate an insoluble gel that could decrease the 
drug release rate. But, the lower polymeric content in cefalexin monohydrate 
based tablets and the higher calcium carbonate level for F11 (20% (w/w)) tablets 
counteracted the in situ cross linking effect and resulted in a complete 
disintegration behaviour (Figure ‎4-56). 
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Figure ‎4-53: Percentage of drug release of F8 floating tablets pressed at levels 
(A), (B), and (C) of crushing strength in 0.1 M HCl medium after storage for 3 
months at 40°C ± 2°C and 80% ± 5% RH in closed or open containers. 
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  No significant change 
in the dissolution medium, macroenvironment, pH was recorded through the 
experiment time. 
For formulation composition, refer to Table ‎4-1 or Table 2-8. 
 
 
 
Figure ‎4-54: Percentage of drug release of F9 floating tablets pressed at levels 
(A), (B), and (C) of crushing strength in 0.1 M HCl medium after storage for 3 
months at 40°C ± 2°C and 80% ± 5% RH in closed or open containers. 
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  No significant change 
in the dissolution medium, macroenvironment, pH was recorded through the 
experiment time. 
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Figure ‎4-55: Percentage of drug release of F10 floating tablets pressed at levels 
(A), (B), and (C) of crushing strength in 0.1 M HCl medium after storage for 3 
months at 40°C ± 2°C and 80% ± 5% RH in closed or open containers. 
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  No significant change 
in the dissolution medium, macroenvironment, pH was recorded through the 
experiment time. 
For formulation composition, refer to Table ‎4-1 or Table 2-8. 
This makes this formulation with calcium carbonate successful and confirms the 
feasibility of using calcium carbonate as an stability indicating gassing agent within 
floating drug delivery systems. 
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Figure ‎4-56: Percentage of drug release of F11 floating tablets pressed at levels 
(A), (B), and (C) of crushing strength in 0.1 M HCl medium after storage for 3 
months at 40°C ± 2°C and 80% ± 5% RH in closed or open containers. 
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  No significant change 
in the dissolution medium, macroenvironment, pH was recorded through the 
experiment time. 
 
 
 
Figure ‎4-57: Percentage of drug release of F12 floating tablets pressed at levels 
(A), (B), and (C) of crushing strength in 0.1 M HCl medium after storage for 3 
months at 40°C ± 2°C and 80% ± 5% RH in closed or open containers. 
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  No significant change 
in the dissolution medium, macroenvironment, pH was recorded through the 
experiment time. 
For formulation composition, refer to Table ‎4-1 or Table 2-8. 
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Figure ‎4-58: Percentage of drug release of F13 floating tablets pressed at levels 
(A), (B), and (C) of crushing strength in 0.1 M HCl medium after storage for 3 
months at 40°C ± 2°C and 80% ± 5% RH in closed or open containers. 
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  No significant change 
in the dissolution medium, macroenvironment, pH was recorded through the 
experiment time. 
 
 
 
Figure ‎4-59: Percentage of drug release of F14 floating tablets pressed at levels 
(A), (B), and (C) of crushing strength in 0.1 M HCl medium after storage for 3 
months at 40°C ± 2°C and 80% ± 5% RH in closed or open containers. 
Notes: The data represents the mean ± SD of three determinations. The 
compression force of the prepared tablets was adjusted to give three crushing 
strength levels: A (49-54 N), B (54-59 N), and C (59-64 N).  No significant change 
in the dissolution medium, macroenvironment, pH was recorded through the 
experiment time. 
For formulation composition, refer to Table ‎4-1 or Table 2-8. 
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In order to investigate morphological changes of all the tablets (F8-F14) 
before and after storage for 3 months at 40°C ± 2°C and 80% ± 5% RH in closed 
or open containers, pictures were evaluated (Figure ‎4-60). Concerning the tablets 
based on sodium bicarbonate as a gassing agent, a change in the colour from 
white to yellow (F8) or dark brown (F9) was observed in the open container 
tablets. However a very slight change in the colour was noted in the tablets stored 
in the closed ones. The formulations which were loaded with sodium carbonate 
showed a change in the colour from white to yellow (F12) or dark brown (F13) in 
the open container tablets, and a very slight change in colour was seen in tablets 
stored in closed ones. The intensity of the colour was proportional to both sodium 
bicarbonate and sodium carbonate concentrations in the related formulations. This 
agrees with the results of DSC (Section ‎4.1.2) and FTIR (Section ‎4.1.3) that an 
interaction occurred between these gassing agents and cefalexin monohydrate 
after storage in the open containers. Since sodium bicarbonate and sodium 
carbonate are water soluble, direct exposure to a stressful humidity level (80%) for 
3 months could increase the pH of the matrix microenvironment in a concentration 
dependent rhythm causing degradation for cefalexin monohydrate as it is unstable 
in such conditions (Marrelli, 1975; Yin et al., 2013). F10 and F11 calcium 
carbonate based formulations and F14 control formulation did not show change in 
colour which approves that calcium carbonate is a promising gassing agent. 
According to the ICH guidelines, a specific stability-indicating assay method such 
as HPLC to determine the drug content and any possible degradation products in 
the formulations will be required in the future to do more investigations (ICH, 
1999). Consequently, it is suggested that all cefalexin monohydrate floating 
systems based on such gas forming agents should be packaged by the 
pharmaceutical companies in tightly closed containers with an eye-catching label 
to direct patients for good practice. 
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Figure ‎4-60: Pictures of F8-F14 tablets freshly prepared and after storage for 3 
months at 40°C ± 2°C and 80% ± 5% RH in closed or open containers.  
For formulation composition, refer to Table ‎4-1 or Table 2-8.   
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4.2.6 Release data modeling and analysis  
 
Table ‎4-7 shows the release rate constants (k), and the correlation 
coefficients (R2) calculated after fitting the dissolution profiles of the formulations 
F8-F14 into zero order, first order, Hixson-Crowell, and Higuchi drug release 
mathematical models. Because of the rapid dissolution profiles of F8, F9 
(Figure ‎4-45) F10, F11 (Figure ‎4-46), and F14 (Figure ‎4-48) tablets, prepared from 
the powder mixtures, only their drug release rate of the tablets prepared from the 
granules were considered beside those of F12, and F13 tablets prepared from 
either the powder mixtures or the granules for Table ‎4-7 evaluation. 
The in vitro drug release rate of the formulations F8-F14 were best 
explained by Higuchi‘s and Hixson-Crowell equations, as the highest linearity (R2) 
values were obtained. This indicates that the release of cefalexin monohydrate 
from the evaluated floating matrices (F8-F14) as a square root of time was 
dependent process based on Fickian diffusion alongside with a change in diameter 
and surface area of the matrices with the progressive dissolution process as a 
function of time. Korsmeyer–Peppas equation (Equation 11, chapter ‎2, 
section ‎2.2.6.6) was used, as it describes the drug release from polymeric 
systems, to evaluate the effect of tablet crushing strength, the granulation process, 
and the gassing agent concentration on the drug release mechanism of the 
prepared tablet formulations (F8-F14).  
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Table ‎4-7: Release rate constants (k), and correlation coefficients (R2) calculated after fitting the release profiles of F8-F14 
into of zero order, first order, Hixson-Crowell, and Higuchi drug release mathematical models. 
Formulation 
Origin of 
prepared tablets 
Crushing 
strength 
level 
Drug release mathematical model 
Zero order First order Hixson-Crowell Higuchi 
R2 
K0 
(mg*h-1) 
R2 
K1 
(h-1) 
R2 
KHC 
(mg1/3*h-1) 
R2 
KH 
(mg1/2*h-1) 
F8 
Powder 
(A) 0.8863 3.9990 0.9465 0.5048 0.9977 0.2882 0.9686 16.307 
(B) 0.8343 4.4056 0.8208 0.4115 0.6709 0.3711 0.9308 18.152 
(C) 0.7018 2.0625 0.3286 0.4021 0.6056 0.2742 0.8360 8.781 
Granules 
(A) 0.9449 8.9962 0.9681 0.3554 0.9819 0.3240 0.9856 35.839 
(B) 0.9301 9.1435 0.9687 0.3986 0.9804 0.3461 0.9818 36.642 
(C) 0.9797 9.4911 0.8994 0.4178 0.8179 0.5362 0.9994 37.392 
F9 
Powder 
(A) 0.8460 2.9198 0.8595 0.3547 0.8800 0.2226 0.9354 11.976 
(B) 0.7878 2.3566 0.9581 0.8012 0.8746 0.4919 0.9003 9.826 
(C) 0.6743 1.4251 0.8802 0.4599 0.7616 0.3289 0.8041 6.070 
Granules 
(A) 0.9934 9.0537 0.8716 0.3314 0.9601 0.3052 0.9913 35.279 
(B) 0.9896 9.1997 0.8466 0.4016 0.8228 0.4717 0.9950 35.982 
(C) 0.9905 8.6846 0.8860 0.3051 0.9632 0.2887 0.9861 33.801 
The compression force of the prepared tablets was adjusted to give three crushing strength levels: A (49-54 N), B (54-59 N), 
and C (59-64 N). For formulation composition, refer to Table ‎4-1 or Table 2-8. 
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Table 4-7 (continued): Release rate constants (k), and correlation coefficients (R2) calculated after fitting the release profiles 
of F8-F14 into of zero order, first order, Hixson-Crowell, and Higuchi drug release mathematical models. 
Formulation 
Origin of 
prepared tablets 
Crushing 
strength 
level 
Drug release mathematical model 
Zero order First order Hixson-Crowell Higuchi 
R2 
K0 
(mg*h-1) 
R2 
K1 
(h-1) 
R2 
KHC 
(mg1/3*h-1) 
R2 
KH 
(mg1/2*h-1) 
F10 
Powder 
(A) 0.9551 -0.5019 0.4439 0.1573 0.7697 -0.1805 0.4109 0.566 
(B) 0.7933 -0.6129 0.1798 -0.0242 0.5346 -0.2081 0.8333 -2.451 
(C) 0.8903 -0.4031 N.A N.A 0.8770 -0.0856 0.8780 -1.561 
Granules 
(A) 0.9610 8.1567 0.9872 0.2642 0.9998 0.2640 0.9965 32.400 
(B) 0.9588 8.1645 0.9438 0.3332 0.9940 0.2986 0.9979 32.490 
(C) 0.9605 8.3348 0.9030 0.3763 0.9850 0.3179 0.9981 33.142 
F11 
Powder 
(A) 0.9315 -0.6329 N.A N.A 0.8798 -0.0952 0.8998 -2.426 
(B) 0.9121 -0.6109 N.A N.A 0.9137 -0.0715 0.9392 -2.418 
(C) 0.9171 -0.5527 N.A N.A 0.8955 -0.0874 0.9291 -2.170 
Granules 
(A) 0.9672 6.4713 0.9838 0.2589 0.9994 0.2415 0.9967 25.624 
(B) 0.9734 6.6079 0.9315 0.3079 0.9881 0.2661 0.9984 26.105 
(C) 0.9781 7.0334 0.9311 0.3022 0.9869 0.2691 0.9972 27.702 
The compression force of the prepared tablets was adjusted to give three crushing strength levels: A (49-54 N), B (54-59 N), 
and C (59-64 N). For formulation composition, refer to Table ‎4-1 or Table 2-8. 
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Table 4-7 (continued): Release rate constants (k), and correlation coefficients (R2) calculated after fitting the release profiles 
of F8-F14 into of zero order, first order, Hixson-Crowell, and Higuchi drug release mathematical models. 
Formulation 
Origin of 
prepared tablets 
Crushing 
strength 
level 
Drug release mathematical model 
Zero order First order Hixson-Crowell Higuchi 
R2 
K0 
(mg*h-1) 
R2 
K1 
(h-1) 
R2 
KHC 
(mg1/3*h-1) 
R2 
KH 
(mg1/2*h-1) 
F12 
Powder 
(A) 0.8232 6.9840 0.9120 0.8749 0.9628 0.5901 0.9265 28.902 
(B) 0.8433 7.0862 0.9900 0.5576 0.8010 0.4668 0.9397 29.178 
(C) 0.8477 7.0778 0.9777 0.4670 0.9500 0.3441 0.9406 29.082 
Granules 
(A) 0.9709 8.6529 0.8518 0.4058 0.9680 0.3306 0.9994 34.245 
(B) 0.9606 8.4918 0.9389 0.3284 0.9919 0.2999 0.9981 33.764 
(C) 0.9809 8.0994 0.9436 0.2692 0.9884 0.2646 0.9995 31.972 
F13 
Powder 
(A) 0.8593 7.3927 0.9665 0.6243 0.9893 0.4883 0.9504 30.327 
(B) 0.8618 7.4746 0.9808 0.5852 0.9698 0.6097 0.9535 30.668 
(C) 0.8560 7.4062 0.9204 0.6941 0.9916 0.4969 0.9501 30.436 
Granules 
(A) 0.9799 7.9649 0.9769 0.2388 0.9968 0.2467 0.9954 31.313 
(B) 0.9658 8.0112 0.9847 0.2658 0.9991 0.2635 0.9962 31.736 
(C) 0.9674 7.8763 0.9840 0.2671 0.9965 0.2632 0.9945 31.151 
F14 
Powder 
(A) 0.7257 3.4234 0.9045 0.4210 0.5643 0.2860 0.8580 14.520 
(B) 0.7384 -0.3480 0.1798 0.0520 0.4553 -0.1451 0.6525 -1.274 
(C) 0.7387 -0.4828 0.5993 0.0811 0.6453 -0.2584 0.8332 -2.000 
Granules 
(A) 0.9428 6.8051 0.9859 0.3047 0.9987 0.2689 0.9900 27.002 
(B) 0.9427 7.4179 0.9137 0.4928 0.9937 0.3490 0.9915 29.680 
(C) 0.9419 7.4527 0.9236 0.4459 0.9957 0.3343 0.9919 29.832 
The compression force of the prepared tablets was adjusted to give three crushing strength levels: A (49-54 N), B (54-59 N), 
and C (59-64 N). For formulation composition, refer to Table ‎4-1 or Table 2-8.  
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As shown in Table ‎4-8, the drug release results of F8-F14 tablets fitted into 
Korsmeyer–Peppas equation as the correlation coefficients (R2) greater than 0.98 
were obtained in all the tablets except for the tablets prepared from the granules of 
the formulations F9 (20% (w/w) sodium bicarbonate) at the crushing strength level 
C, F11 (20% (w/w) calcium carbonate) at all the crushing strength levels, and F14 
(the control tablets) at the crushing strength level A. But, there were insufficient 
data points on the release profile ≤ 60% drug release in order to provide accurate 
values for the tablets prepared from the powder mixture of the formulations F8, F9 
(Figure ‎4-45), F10, F11 (Figure ‎4-46), and F14 (Figure ‎4-48). The values of the 
release rate constant (KP) were consistent with the in vitro drug release results 
(Section ‎4.2.5). Generally, increasing the tablet crushing strength, slightly changed 
KP values of the tablets prepared from the powder mixtures or the granules. The 
granulation process decreased the release rate constant (KP) of the tablets F12 
and F13 based on sodium carbonate as a gassing agent, however the effect was 
not clear for the other formulations due to the insufficient data points.  
For the tablets prepared form the powder mixtures, the effect of increasing 
the gassing agent concentration from 0% to 20 % (w/w) on the release kinetics 
was not clear due to the rapid drug release rate; but, increasing sodium carbonate 
concentration from 10% to 20% (w/w) decreased their KP values (Table ‎4-8). 
Regarding the tablets prepared from the granules the effect was much clearer. 
Raising sodium bicarbonate concentration decreased the release rate constant 
(Kp). For calcium carbonate, increasing its level decreased the release rate 
constant (KP) at 10% (w/w) concentration (F10), but, at 20% (w/w) concentration 
(F11), it increased KP values up to almost similar level of the control tablets (F14, 
0% (w/w)). Additionally, raising sodium carbonate content decreased the drug 
release rate constant (KP) at 10% (w/w) level (F12) and slightly increased it at the 
higher level (F13).  
The effect of these factors on the drug release mechanism was also 
evaluated through the release exponent (n) values. As shown in Table ‎4-8 
changing the crushing strength level slightly changed (n) values but without 
changing the release mechanism of all the prepared tablets (with sufficient data 
points). 
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The granulation process changed the drug release mechanism for the 
formulation F12 (10% (w/w) sodium carbonate) from release by diffusion (Fickian) 
to release by diffusion and polymer relaxation (non-Fickian) and retained it by non-
Fickian release for the formulation F13 (20% (w/w) sodium carbonate). This is 
almost similar to the related results of pentoxifylline tablets (F5 and F6) where 
more involvement of polymer relaxation in addition to drug diffusion was 
predominant in the release process from such matrices (Chapter ‎3, section ‎3.2.6). 
The effect of raising the gassing agent concentration (sodium bicarbonate, 
calcium carbonate or sodium carbonate) from 10% to 20% (w/w) was also 
evaluated in all the tablets with sufficient data points (Table ‎4-8). Regarding 
sodium bicarbonate, no change in the release mechanism was reported by raising 
its concentration which agrees with the related results of F1 and F2 tablets based 
on pentoxifylline where release by diffusion and polymer relaxation (non-Fickian) 
was reported (Chapter ‎3, section ‎3.2.6). Increasing calcium carbonate 
concentration in the tablets of the granules origin changed the release mechanism 
from non-Fickian at 10% (w/w) (F10) to Fickian release at 20% (w/w) (F11). This 
conforms to the related results of F3 (10% (w/w)) and F4 (20% (w/w)) tablets of 
pentoxifylline based on calcium carbonate (Chapter ‎3, section ‎3.2.6). Although the 
(calcium carbonate: polymeric mixture) ratio was different between these 
formulations, where it was (2:10) for F3, (4.5:10) for F4, (3.1:10) for F10, and 
(7:10) for F11 (Chapter ‎2, Table 2-7 and Table 2-8), the release mechanism 
results of pentoxifylline tablets (F3 and F4) were similar to the related ones of 
cefalexin monohydrate tablets (F10 and F11). This suggests that calcium ion 
concentration available in the formulations F3 and F11 (10% (w/w)) was 
insufficient to properly cross-link with the anionic alginate molecules of the 
polymeric mixture. Still, the concentration was enough in the formulations F4 and 
F12 (20% (w/w)) as only diffusion mechanism became the controller of the drug 
release.  
For the tablets based on sodium carbonate as a gassing agent (F12 and 
F13), a change in the drug release mechanism from Fickian to non-Fickian release 
was noted by increasing its concentration from 10% to 20% (w/w) in the tablets 
prepared from the powder mixtures. In contrast, the release mechanism changed 
in the related results of pentoxifylline tablets from non-Fickian at 10% (w/w) (F5) to 
Fickian release at 20% (w/w) (F6) (Chapter ‎3, section ‎3.2.6).  
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Concerning the tablets prepared from the granules, no change in the 
release mechanism was reported by raising sodium carbonate concentration 
which agrees with the related results of F5 and F6 tablets based on pentoxifylline 
where release was by diffusion and polymer relaxation (non-Fickian) (Chapter ‎3, 
section ‎3.2.6). Accordingly the change in the (gassing agent: polymeric mixture) 
ratio suggests that the role of sodium carbonate in the tablets of the powder 
mixture origin was concentration dependent. As sodium carbonate concentration 
increased the coherency of the hydrated gel microstructure increased to an 
optimum level (release by diffusion) after which polymer relaxation started to 
involve in the release mechanism due to more gas bubbles liberation. However, 
following the granulation, the matrices became less sensitive to the change in 
sodium carbonate concentration and more contribution of polymeric relaxation in 
the release mechanism was noted. 
Fickian release mechanism (release by diffusion) was reported in the 
control tablets (F14) prepared from the granules. Nonetheless, non-Fickian 
release mechanism (release by diffusion and polymer relaxation) was noted in 
pentoxifylline control tablets (F7) (Chapter ‎3, section ‎3.2.6). Adding the gassing 
agents (sodium bicarbonate, calcium carbonate, or sodium carbonate) changed 
the release mechanism from release by diffusion (F14) to release by diffusion and 
polymer relaxation in the tablets prepared from the granules (F8-F13 respectively). 
This could be related to the movement of the generated carbon dioxide bubbles 
from the internal to the peripheral sides of the floating tablets, which increased the 
mass loss or the polymeric erosional behaviour (Section ‎4.2.4). This does not 
agree with the related results of pentoxifylline tablets (F1-F7) where the release 
mechanism was kept by diffusion and polymer relaxation, but, adding calcium 
carbonate at 20% (w/w) level changed the release mechanism to diffusion 
mechanism (Chapter ‎3, section ‎3.2.6). The reduction by almost 36% (w/w) in the 
polymeric content of cefalexin monohydrate control tablets (F14) compared to 
pentoxifylline control tablets (F7) explains this difference in their drug release 
mechanisms. 
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Table ‎4-8: Korsmeyer-Peppas kinetic parameters of F8-F14 cefalexin 
monohydrate tablet formulations. 
Formulation 
Origin of 
prepared 
tablets 
Crushing 
strength 
level 
Korsmeyer-Pepas 
R
2
 n 
Kp 
(h
-n
) 
F8 
Powder 
(A) N.A N.A N.A 
(B) N.A N.A N.A 
(C) N.A N.A N.A 
Granules 
(A) 0.9995 0.655 0.2424 
(B) 0.9997 0.7257 0.2444 
(C) 0.9949 0.7136 0.2294 
F9 
Powder 
(A) N.A N.A N.A 
(B) N.A N.A N.A 
(C) N.A N.A N.A 
Granules 
(A) 0.999 0.6986 0.1884 
(B) 0.9985 0.6674 0.2138 
(C) 0.9528 0.6199 0.2104 
F10 
Powder 
(A) N.A N.A N.A 
(B) N.A N.A N.A 
(C) N.A N.A N.A 
Granules 
(A) 0.9986 0.5937 0.2582 
(B) 0.9999 0.5637 0.2888 
(C) 0.9978 0.5837 0.2831 
F11 
Powder 
(A) N.A N.A N.A 
(B) N.A N.A N.A 
(C) N.A N.A N.A 
Granules 
(A) 0.9718 0.2637 0.4115 
(B) 0.9772 0.2709 0.4166 
(C) 0.9492 0.3107 0.376 
F12 
Powder 
(A) 0.9947 0.4172 0.4683 
(B) 0.9971 0.4315 0.4506 
(C) 0.9995 0.4052 0.4341 
Granules 
(A) 0.9934 0.6457 0.2486 
(B) 0.9905 0.6587 0.2501 
(C) 0.9945 0.6009 0.2505 
F13 
Powder 
(A) 1 0.4673 0.4221 
(B) 0.9984 0.5214 0.4327 
(C) 0.9999 0.5267 0.4198 
Granules 
(A) 0.9997 0.5301 0.2514 
(B) 0.9985 0.5324 0.2807 
(C) 0.9961 0.4877 0.2924 
F14 
Powder 
(A) N.A N.A N.A 
(B) N.A N.A N.A 
(C) N.A N.A N.A 
Granules 
(A) 0.952 0.3015 0.4138 
(B) 0.999 0.3793 0.3948 
(C) 0.991 0.3985 0.3856 
Notes: N.A: There are insufficient data points on the release profiles ≤ 60% drug 
release in order to provide accurate values. The compression force of the prepared 
tablets was adjusted to give three crushing strength levels: A (49-54 N), B (54-59 N), 
and C (59-64 N). For formulation composition, refer to Table ‎4-1 or Table 2-8.  
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4.3 Conclusions 
 
In this chapter, effervescent floating tablets of cefalexin monohydrate were 
successfully compacted using sodium bicarbonate, calcium carbonate, or sodium 
carbonate as a gas forming agent and a (1:1) binary mixture of hydroxyethyl 
cellulose and sodium alginate as a drug retarding polymeric matrix. All the 
prepared tablets through the granulation showed acceptable physical properties 
regarding weight and drug content uniformity tests. Friability results of sodium 
bicarbonate based formulations F8 (10% (w/w)) and F9 (20% (w/w)), calcium 
carbonate based formulations F10 (10% (w/w)) and F11 (20% (w/w)), and 
cefalexin monohydrate control tablets F14 exceeded the BP limit of friability (< 
1%), however, as the tablet crushing strength level increased as the mass loss 
percentage decreased in all the formulations.  
Increasing the compression force showed minor influence on the drug 
release rate of the tablets prepared after the granulation. Raising the gassing 
agent (sodium bicarbonate, calcium carbonate, or sodium carbonate) 
concentration, in the tablets prepared from the granules, decreased their floating 
lag time results and increased their floating duration time. Cefalexin monohydrate 
control tablets prepared following the granulation showed acceptable floating 
capacity behaviour due to the rapid swelling rate profiles which reduced their 
tablets density to initiate and to maintain the floating process. The drug release 
rate indicates a release by non-Fickian mechanism except for F11 tablets based 
on 20% (w/w) calcium carbonate as a gassing agent and the control tablets of 
cefalexin monohydrate (F14) which fitted to Fickian release mechanism. The 
addition of the gassing agents enhanced the movement of the generated carbon 
dioxide bubbles from the internal to the peripheral sides of the floating tablets 
which influenced the polymer erosional behaviour and changed cefalexin 
monohydrate release mechanism from release by diffusion (Fickian) to release by 
diffusion and polymer relaxation (non-Fickian). However 20% (w/w) concentration 
of calcium carbonate was enough to influence the in situ ability of the anionic 
alginate molecules to be cross linked and changed the drug release mechanism to 
release by diffusion (Fickian). The tablets could float on the surface of the 
dissolution medium and the drug release was sustained over 10 h.  
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DSC and FTIR indicates instability of the formulation based on sodium 
bicarbonate (F8 and F9) or sodium carbonate (F12 and F13) after storage for 3 
months at 40°C ± 2°C and 80% ± 5% RH in the open containers. Still, the closed 
containers showed better physical stability of cefalexin monohydrate loaded in 
such formulations. A specific stability-indicating assay method such as HPLC to 
determine the drug content and any possible degradation products in the 
formulations will be required in the future to do more investigations. The tablets 
prepared with 10% (w/w) calcium carbonate (F10) at 59-64 N crushing strength 
were promising with respect to their floating lag time, floating duration, swelling 
ability, sustained drug release rate, and physical stability results. Accordingly, 
calcium carbonate revealed promising results not only with cefalexin monohydrate 
but also with pentoxifylline and this makes the chosen ingredients (for this 
research)and their quantities feasible to be applied with other drugs intend for 
gastroretentive delivery systems.  
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5 Chapter Five: preliminary in vivo study in rats  
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5.1 Preliminary in vivo pharmacokinetic study  
 
Tablets manufactured from the granules with 20% (w/w) calcium carbonate 
(F4) were promising with respect to their floating lag time (~ 7 min), floating 
duration (> 24 h), swelling ability, sustained drug release rate and physical stability 
(Chapter ‎3). As in vitro studies remain largely inadequate to evaluate the 
complexities of human gastrointestinal tract (GIT) physiology, in vivo evaluation is 
required. But, it is not easy to run in vivo in human for this research as ethical 
approval will not be approved, so animal model was used. Small rodents such as 
mouse, rat, guinea pig, and rabbit; and larger mammals like dog, pig, and monkey 
are commonly used in clinical studies. Primarily, it was required to test the in vivo 
ability of the designed F4 tablets to sustain the drug release. Rats were chosen for 
the preliminary in vivo evaluation as rodents are more popular choice in 
biomedical research (Hatton et al., 2015). Nevertheless, using small rodents is not 
suitable to evaluate the gastric retention capability of the promising F4 tablets. 
Therefore, in vivo studies in appropriate larger mammals are essential in the 
future. Rats‘ duodenum diameter is 2.5 - 3 mm (Kararli, 1995), their stomach fluid 
volume is 2.29 ± 1.59 g (Hatton et al., 2015), and their gastric pH (3.9 and 3.2 in 
fasted and fed state respectively (McConnell et al., 2008)). It is obvious that rats‘ 
gastric anatomy and physiology is not similar to that of human (Chapter ‎1, 
section ‎1.2), yet, the taken F4 tablet (4 mm) will be retained in the rats‘ stomach 
not because of the floating process which may be exist but because of the 
duodenum diameter. Additionally, rats‘ gastric pH is enough to initiate the acid 
base reaction with the loaded calcium carbonate (gassing agent) in F4 tablets. 
This can further challenge the drug release rate of the tested tablets, thus, it was 
worth to evaluate the in vivo behaviour of the selected formulation (F4) preliminary 
in rats. 
It was a challenge to use pentoxifylline, highly soluble model drug (191 
mg/ml at 37°C), to investigating the ability of the formulation for improvements to 
pentoxifylline pharmacokinetic parameters as a controlled release dosage form. 
Pentoxifylline is completely absorbed from the gastrointestinal tract (GIT) when 
given either in the form of sustained release tablets or immediate release 
capsules; however, its bioavailability averages only 20% to 30% due to extensive 
first pass metabolism (Beermann et al., 1985).  
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No advantage was expected from a comparative in vivo evaluation between 
non-floating sustained release tablets (F7) and the selected floating tablets (F4), 
therefore pentoxifylline solution, as a reference, was selected for the study.        
In this study F4 floating tablets and a reference solution of pentoxifylline were 
investigated following oral administration of 5.75 ± 0.15 mg in rats. Drug plasma 
levels were determined by HPLC-MS/MS, and the regression equation was y = 
0.0251x - 0.000893 (r=0.9993) for pentoxifylline with a linear concentration of 4 - 
400 ng/ml. The retention time was 0.45 and 0.29 min for pentoxifylline and the 
internal standard (Emitrecitabine), respectively.  
The individual pentoxifylline plasma concentration-time curves following oral 
administration of F4 floating tablets (G1) and reference solution (G2) in rats are 
shown in Figure ‎5-1 to Figure ‎5-12. Unusual (outlier) data points were shown 
following oral administration of F4 floating tablets in rat 1, G1, thus it was excluded 
from the statistical evaluation.The average plasma concentration-time profiles for 
the two formulations are shown in Figure ‎5-13, and the pharmacokinetic 
parameters are shown in Table ‎5-1. The maximum plasma concentrations (Cmax) 
of F4 tablets and the reference solution were 982.24 ± 484.71 and 2552.30 ± 
110.85 ng/ml, respectively, and these were achieved at 1.80 ± 0.45 and 0.50 ± 
0.00 h (Tmax), respectively. Compared to the reference solution, the Cmax of the 
tablets decreased significantly (P<0.05), and the Tmax was prolonged significantly 
(P<0.05). The half-life (t1/2) value significantly increased (P<0.05) from 0.29 ± 0.03 
to 0.65 ± 0.24 h in F4 tablets in comparison with the reference solution; thus 
indicating relatively sustained-release behaviour of F4 tablets.   
The relative bioavailability (Frel) of the tablets compared to the reference 
solution was 80.86%. This can be explained by the significant (P<0.05) reduction 
in the AUC0-∞ value of F4 tablets in comparison with the reference solution which 
were 2371.25 ± 797.54 and 2932.53 ± 351.23 ng h/ml respectively. Although 
pentoxifylline is completely absorbed from the gastrointestinal tract, drug 
absorption is highly variable in the individuals (Davis, 2005) and it depends on the 
administered dosage form. Beermann et al. (1985) evaluated the kinetics of 
intravenous and oral pentoxifylline capsules and tablets in healthy subjects.  
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Results revealed a significant difference between Cmax levels of pentoxifylline 
after 400 mg oral dosing of capsules and tablets where mean values of 1218 and 
248 ng/ml was noted respectively. Moreover, absolute bioavailability of the 
capsules was 30.7 ± 19.1% and of the tablets was 19.4% ± 12.7% due to higher 
AUC value of the capsules in comparison to that of the tablets. 
It is difficult to evaluate the gastric retention along with bioavailability for a 
regular size tablet dosage form by using small animals like mice, rats, guinea pigs 
or rabbits (Turner et al., 2011). Still, a well-designed in vivo studies in appropriate 
animal model such as dogs or healthy human volunteers are essential in the future 
to verify the in vivo efficacy of the promising floating tablets.  
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Figure ‎5-1: Pentoxifylline plasma concentration-time curve following oral 
administration of F4 floating tablets in rat 1, G1. 
Note: HPLC chromatograms are shown in Figure A 1 and Figure A 2.  
 
 
 
 
 
 
Figure ‎5-2: Pentoxifylline plasma concentration-time curve following oral 
administration of F4 floating tablets in rat 2, G1. 
Note: HPLC chromatograms are shown in Figure A 3 and Figure A 4.  
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Figure ‎5-3: Pentoxifylline plasma concentration-time curve following oral 
administration of F4 floating tablets in rat 3, G1. 
Note: HPLC chromatograms are shown in Figure A 5 and Figure A 6.  
 
 
 
 
 
Figure ‎5-4: Pentoxifylline plasma concentration-time curve following oral 
administration of F4 floating tablets in rat 4, G1. 
Note: HPLC chromatograms are shown in Figure A 7and Figure A 8.  
 
 264 
  
 
 
 
Figure ‎5-5: Pentoxifylline plasma concentration-time curve following oral 
administration of F4 floating tablets in rat 5, G1. 
Note: HPLC chromatograms are shown in Figure A 9 and Figure A 10.  
 
 
 
 
 
 
Figure ‎5-6: Pentoxifylline plasma concentration-time curve following oral 
administration of F4 floating tablets in rat 6, G1. 
Note: HPLC chromatograms are shown in Figure A 11 and Figure A 12.  
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Figure ‎5-7: Pentoxifylline plasma concentration-time curve following oral 
administration of reference solution in rat 1, G2. 
Note: HPLC chromatograms are shown in Figure A 13 and Figure A 14.  
 
 
 
 
 
 
Figure ‎5-8: Pentoxifylline plasma concentration-time curve following oral 
administration of reference solution in rat 2, G2. 
Note: HPLC chromatograms are shown in Figure A 15 and Figure A 16.  
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Figure ‎5-9: Pentoxifylline plasma concentration-time curve following oral 
administration of reference solution in rat 3, G2. 
Note: HPLC chromatograms are shown in Figure A 17 and Figure A 18. 
 
 
 
 
 
 
Figure ‎5-10: Pentoxifylline plasma concentration-time curve following oral 
administration of reference solution in rat 4, G2. 
Note: HPLC chromatograms are shown in Figure A 19 and Figure A 20.  
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Figure ‎5-11: Pentoxifylline plasma concentration-time curve following oral 
administration of reference solution in rat 5, G2. 
Note: HPLC chromatograms are shown in Figure A 21 and Figure A 22.  
 
 
 
 
 
 
Figure ‎5-12: Pentoxifylline plasma concentration-time curve following oral 
administration of reference solution in rat 6, G2. 
Note: HPLC chromatograms are shown in Figure A 23 and Figure A 24.  
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Figure ‎5-13: Average pentoxifylline plasma concentration-time curves following 
oral administration of F4 floating tablets and reference solution in rats.  
The data represents the mean ± SD of six determinations. 
Note: The plasma drug profile of rat 1, G1 was excluded due to the outlier data 
points. 
 
 
 
 
Table ‎5-1: Pharmacokinetic parameters of pentoxifylline F4 tablets and a 
reference solution.  
Formulation 
Ke 
(h-1) 
t1/2 
(h) 
Cmax 
(ng/ml) 
Tmax 
(h) 
AUC0-∞ 
(ng h/ml) 
F4 floating tablets 
1.21 
± 0.52 
0.65 
± 0.24 
982.24 
± 484.71 
1.80 
± 0.45 
2371.25 
± 797.54 
Reference solution  
2.42 
± 0.21 
0.29 
± 0.03 
2552.30 
± 110.85 
0.50 
± 0.00 
2932.53 
± 351.23 
The data represents the mean ± SD of six determinations.  
Note: The plasma drug profile of rat 1, G1 was excluded due to the outlier data 
points.F4 floating tablets composed of pentoxifylline, hydroxyethyl cellulose, 
sodium alginate, Prosolv® 90, calcium carbonate, and magnesium stearate. 
Reference solution composed of pentoxifylline and water. 
For formulation composition, refer to Table ‎3-1or Table 2-7 
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5.2 Conclusions 
 
F4 tablets prepared with 20% (w/w) calcium carbonate were promising with 
respect to their quality control tests, floating lag time, floating duration, swelling 
ability, sustained drug release rate, and physical stability results. A preliminary in 
vivo study of tablets of F4 formulation and a reference solution of pentoxifylline 
were tested following oral administration of 5.75 ± 0.15 mg in rats. The Cmax of F4 
tablets and the reference solution were 982.24 ± 484.71 and 2552.30 ± 110.85 
ng/ml, respectively, and these were achieved at Tmax 1.80 ± 0.45 and 0.50 ± 0.00 
h, respectively. The t1/2 value significantly increased (P<0.05) from 0.29 ± 0.03 to 
0.65 ± 0.24 h in F4 tablets in comparison with the reference solution; thus 
indicating relatively sustained-release behaviour of the tablets. Although 
pentoxifylline is completely absorbed from the gastrointestinal tract, the relative 
bioavailability (Frel) of the tablets compared to the reference solution was 80.86% 
because drug absorption is highly variable in the individuals.  
The preliminary data presented are valuable as they provide insight to the 
sustained effect of the novel formulations prepared. Although there are sustained 
formulations in the market but the prepared may offer less side effects to patients 
and save money to industry. Research is not stopping if the drug is available as 
sustained release medicine in the market hence many drugs are available in more 
than one sustained release brand in the market so that is why this research. 
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6 Chapter Six: Conclusions and future work 
 
 271 
 
6.1 Conclusions 
 
In this study, floating tablets of pentoxifylline or cefalexin monohydrate were 
prepared using a (1:1) ratio of hydroxyethyl cellulose and sodium alginate 
polymeric mixture based on sodium bicarbonate, calcium carbonate or sodium 
carbonate gas forming agent. The variables affecting the drug release and the 
floating properties, such as tablet crushing strength, wet granulation, type and ratio 
of the gas forming agent, were examined.  
Tablets prepared through the wet granulation process showed acceptable 
physical properties via complying with the BP requirements of friability, weight and 
drug content uniformity. Some of the formulations exceeded the BP limit of friability 
(< 1%), nonetheless, as the tablet crushing strength level increased as the mass 
loss percentage decreased in all the formulations. Increasing the compression 
force showed minor influence on the drug release rate of the tablets prepared after 
the granulation. This gives an advantage to control the other formulation 
parameters, such as high friability percentages, by raising the compression force 
without disturbing the drug release rate. 
Effect of the granulation process on the drug release rate from all the 
formulations at different crushing strength levels revealed that the granulation 
process reduced the drug release rate. The decrease in the porosity levels due to 
the wet massing stage of the granulation process delayed the dissolution medium 
entrapment through the matrix at an early stage of the dissolution test and 
decreased the drug release process. However, the better gel hydration ability of 
cefalexin monohydrate tablets because of their higher sodium bicarbonate content 
probably inversed the increase in their porosity percentages after the granulation 
and decreased their drug release rate. Also, calcium carbonate formulations 
became more resistant to rupture due to strengthening of the tablets internal 
structure following the granulation which gave sufficient time for swelling and gel 
layer formation to control the drug release process. 
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Regarding the tablets prepared from the granules, increasing the gassing 
agent concentration from 10% to 20% (w/w) influenced the drug release rate. 
Raising sodium bicarbonate level decreased the drug release rate depending on 
the microstructure of the swollen gel layer formed around the tablets. In contrast, 
increasing calcium carbonate concentration increased the drug release rate 
because of pore formation in the swollen gel layer resulted from the entrapped gas 
bubbles. A slight increase in the drug release rate was noted because of 
increasing sodium carbonate concentration. The ability of sodium carbonate, 
regardless the concentration, to generate an alkaline microenvironment enhanced 
the tablets to swell and to release the drug in almost similar rate. Noticeably, the 
higher gassing agent concentration was more effective than the lower one to 
maintain the tablets, from the granules origin, on the surface of the dissolution 
medium for a longer duration of time. Most tablets floated on the surface of the 
dissolution medium and showed an adequate floating lag time (< 30 min) and 
floated for more than 8 h. Cefalexin monohydrate control tablets (0% (w/w) 
gassing agent) prepared following the granulation showed acceptable floating 
capacity behaviour because of their rapid swelling rate which reduced their 
apparent densities to initiate and to maintain the floating process. 
The granulation process increased the floating lag time results of all the 
floating tablets compared to that of the tablets prepared from the powder mixture 
before the granulation. Similarly, increasing the tablet crushing strength increased 
the lag time of all the tablets designed to float. However, increasing the 
concentration of the gassing agent decreased the floating lag time results of the 
tablets based on sodium bicarbonate or calcium carbonate due to the higher 
effervescent efficiency. In contrast, the lag time results increased in the tablets 
based on sodium carbonate due to increasing their apparent densities. 
The drug release rate of all the prepared tablets fitted into non-Fickian 
release mechanism. An exception was seen in the tablets containing 20% (w/w) 
calcium carbonate gassing agent. They fitted into Fickian release mechanism due 
to the in situ ability of the anionic alginate molecules to be cross-linked in the 
presence of enough concentration of calcium ions. Generally, addition of the 
gassing agents enhanced movement of the generated carbon dioxide bubbles 
from the internal to the peripheral sides of the floating tablets which influenced 
more of the polymer erosional behaviour.  
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Tablets loaded with pentoxifylline showed better stability results in 
comparison to those of cefalexin monohydrate in either closed or open containers. 
DSC and FTIR indicated instability of the formulation based on sodium 
bicarbonate or sodium carbonate after storage for 3 months at 40°C ± 2°C and 
80% ± 5% RH in the open containers. Still, the closed containers showed better 
physical stability of cefalexin monohydrate formulations.  
Pentoxifylline tablets manufactured with 20% w/w calcium carbonate were 
promising with respect to their floating lag time, floating duration, swelling ability, 
sustained drug release rate, and stability results. A preliminary in vivo investigation 
of these promising tablets against a reference solution of pentoxifylline was 
performed by oral administration of 5.75 ± 0.15 mg to rats. Compared with the 
reference solution, the maximum plasma concentration (Cmax) of the tablets 
decreased, while the time to reach this concentration (Tmax) and the t1/2 were 
prolonged.  
This study shows that a binary mixture of hydroxyethyl cellulose and sodium 
alginate, together with different gassing agents at variable levels, offers a 
promising opportunity to develop sustained release preparations.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 274 
 
6.2 Suggestions for future work 
 
Formulations based on calcium carbonate as a gas generating agent, are 
suggested to be promising through this study. However, further formulation 
development studies are worth to be accomplished in the future to achieve a 
suitable floating tablet dosage form to benefit the pharmaceutical industry. For 
example, friability results of these formulations exceeded the accepted BP limit (< 
1%), and tablets showed relaxation through the stability studies. Yet, increasing 
the compression force presented negligible influence on the drug release rate after 
the granulation. This gives an advantage to reduce the high friability percentages 
and tablet relaxation during storage without affecting the drug release rate.  
Furthermore, it would be useful to increase pentoxifylline content of the 
designed floating tablets from 60 mg up to the therapeutic dose (400 mg). 
Primarily, increasing the tablet weight will increase its drug content, but almost 2 g 
tablet weight will be required to contain 400 mg pentoxifylline. This may be not 
convenient for patients‘ oral administration, thus, reducing the polymeric mixture 
level of hydroxyethyl cellulose and sodium alginate to increase the drug content 
may be helpful. Moreover, the in vitro drug release rate of cefalexin monohydrate 
floating tablets based on calcium carbonate was successfully controlled over 12 h, 
however, due to the tablet relaxation through the stability studies, the in vitro drug 
release was sharply increased. It would be useful to increase the polymeric 
mixture content of such formulations to control the drug release rates of fresh and 
stability samples. Generally, applying factorial design would be valuable to extend 
the study to cover more suitable model drugs for gastroretentive dosage forms; 
more ratios of hydroxyethyl cellulose: sodium alginate mixture such as (0:1), 
(0.25:0.75), (0.75:0.25), and (1:0); and more concentrations of gassing agents 
such as 5, 15, and 25% to achieve the best possible combination. This also could 
benefit exploring different mechanisms governing the release kinetics. 
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It has been reported that carbonates could generate an alkaline 
microenvironment for pH sensitive polymers to initiate gel formation, but, no 
significant change in the dissolution medium (macroenvironment) pH was 
recorded through the experiment time. Therefore, it is worth doing further 
investigations regarding the effect of the gassing agents (sodium bicarbonate, 
calcium carbonate, and sodium carbonate) on the swollen gel microenvironment 
pH and morphology. The microenvironment pH can be tested by adding a pH 
indicator, such as methyl red, to the matrix and visually monitor the pH within the 
tablets during drug release process as the indicator is red at acidic pH and 
converts into yellow at pH values > 5.8 (Streubel et al., 2000). Morphology of the 
gel structure can be evaluated using the scanning electron microscopy (SEM) 
technique.  
Regarding the stability results, a specific stability-indicating assay method 
such as HPLC is critically required to do more evaluation. The study suggested 
that sodium bicarbonate and sodium carbonate, the gas forming agents loaded in 
the floating tablets, under stressful humidity conditions may affect the formulation 
stability. Consequently, it is important to apply such stability-indicating methods to 
determine the drug content and any possible degradation products in the 
formulations.  
According to literature, a critical challenge for floating gastroretentive 
systems is their requirement for an adequate level of fluids in the stomach to float 
effectively. Combinations of different gastroretentive concepts, such as low-density 
floating and mucoadhesion can be expected to be particularly promising to have a 
significant influence on improving the therapeutic effect of drugs involved. Ability of 
sodium alginate to adhere to epithelial surface of the stomach could benefit the 
designed floating tablets. Tablet adhesion retention period could be investigated 
by using suitable methods such as modified balance tensiometer to quantify the 
mucoadhesive properties of the prepared tablets (Kast and Bernkop-Schnürch, 
2011). 
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Furthermore, in vitro drug release tests in simulated gastric fluids with 
enzymes would be more representative to the gastric medium conditions at fed 
and fasted state in order to simulate the influence of meal digestion on the 
solubility of drugs (Freire and Basit, 2013). In this study, the prepared tablets were 
able to float on the surface of the dissolution medium due to the ability of the 
swelled matrices to retain the liberated gas bubbles. The tablets might become 
weaker due to swelling and floating processes. Hence, it is worth linking this to the 
mechanical destructive force in the human stomach by evaluating the tablets‘ 
mechanical strength.  
A computer-controlled dynamic gastric model, which simulate the 
mechanical grinding forces (by gentle contractions) and gastric secretions (acid 
and enzymes) occurring in the fundus, body and antrum parts of the stomach and 
lead to food digestion, could be used for this purpose (Vardakou et al, 2011). But, 
this system is unlikely to give a widespread estimation of the tablet performance in 
the gastrointestinal tract. Thus, using the most complete simulator of the 
gastrointestinal tract (TIM-1) could benefit the development of the best selected 
formulations before the in vivo studies. This system is composed of interconnected 
segments representing the stomach, duodenum, jejunum and ileum with 
simulation to most physiological gastrointestinal tract parameters (Blanquet et al, 
2004). Although it simulates passive absorption of water and small molecules via 
dialysis membranes, which can be considered a unique advantage for oral 
pharmaceutical dosage forms development, active transport, efflux and intestinal 
wall metabolism are also existing (Freire and Basit, 2013). Therefore, a well-
designed in vivo study in healthy human volunteers is essential in the future to 
verify the in vivo efficacy of the most promising floating tablets.  
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Figure A 1: HPLC chromatograms of rat 1, G1 plasma sample at 0.5, 1, 2, and 4 h.  
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Figure A 2: HPLC chromatograms of rat 1, G1 plasma sample at 6, 8, 12, and 24 h. 
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Figure A 3: HPLC chromatograms of rat 2, G1 plasma sample at 0.5, 1, 2, and 4 h. 
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Figure A 4: HPLC chromatograms of rat 2, G1 plasma sample at 6, 8, 12, and 24 h. 
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Figure A 5: HPLC chromatograms of rat 3, G1 plasma sample at 0.5, 1, 2, and 4 h. 
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Figure A 6: HPLC chromatograms of rat 3, G1 plasma sample at 6, 8, 12, and 24 h. 
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Figure A 7: HPLC chromatograms of rat 4, G1 plasma sample at 0.5, 1, 2, and 4 h. 
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Figure A 8: HPLC chromatograms of rat 4, G1 plasma sample at 6, 8, 12, and 24 h. 
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Figure A 9: HPLC chromatograms of rat 5, G1 plasma sample at 0.5, 1, 2, and 4 h. 
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Figure A 10: HPLC chromatograms of rat 5, G1 plasma sample at 6, 8, 12, and 24 h. 
 319 
 
3
1
9 
 
 
  
Figure A 11: HPLC chromatograms of rat 6, G1 plasma sample at 0.5, 1, 2, and 4 h. 
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Figure A 12: HPLC chromatograms of rat 6, G1 plasma sample at 6, 8, 12, and 24 h. 
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Figure A 13: HPLC chromatograms of rat 1, G2 plasma sample at 0.5, 1, 2, and 4 h. 
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Figure A 14: HPLC chromatograms of rat 1, G2 plasma sample at 6, 8, 12, and 24 h. 
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Figure A 15: HPLC chromatograms of rat 2, G2 plasma sample at 0.5, 1, 2, and 4 h. 
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Figure A 16: HPLC chromatograms of rat 2, G2 plasma sample at 6, 8, 12, and 24 h. 
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Figure A 17: HPLC chromatograms of rat 3, G2 plasma sample at 0.5, 1, 2, and 4 h. 
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Figure A 18: HPLC chromatograms of rat 3, G2 plasma sample at 6, 8, 12, and 24 h. 
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Figure A 19: HPLC chromatograms of rat 4, G2 plasma sample at 0.5, 1, 2, and 4 h. 
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Figure A 20: HPLC chromatograms of rat 4, G2 plasma sample at 6, 8, 12, and 24 h. 
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Figure A 21: HPLC chromatograms of rat 5, G2 plasma sample at 0.5, 1, 2, and 4 h. 
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Figure A 22: HPLC chromatograms of rat 5, G2 plasma sample at 6, 8, 12, and 24 h. 
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Figure A 23: HPLC chromatograms of rat 6, G2 plasma sample at 0.5, 1, 2, and 4 h. 
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Figure A 24: HPLC chromatograms of rat 6, G2 plasma sample at 6, 8, 12, and 24 h. 
 
